{"meta":{"query_hash":"5b6606e725da","filters":{"venue":"Advances in Therapy"},"cohort_total":352,"direct_labels_cover":1,"predictions_cover":352,"exported":352,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/5b6606e725da","api":"https://metacan.xera.ac/api/v1/cohort?venue=Advances+in+Therapy"},"results":[{"id":"W1582892440","doi":"10.1007/s12325-015-0224-2","title":"Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study","year":2015,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Fingolimod; Medicine; Tolerability; Adverse effect; Internal medicine; Discontinuation; Multiple sclerosis; Expanded Disability Status Scale; Immunology","score_opus":0.03442763743359083,"score_gpt":0.28378565897330327,"score_spread":0.24935802153971243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1582892440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99597895,0.0031731,0.00009138496,0.00003504112,0.000059110374,0.0005593417,0.0000083651985,0.0000037677903,0.00009092735],"genre_scores_gemma":[0.99758846,0.0011516064,0.0010646301,0.00010156384,0.000030672938,0.00003353056,0.000010105465,0.000014187406,0.0000052714613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896455,0.0001323136,0.00030071338,0.00030472863,0.0001282394,0.00016945094],"domain_scores_gemma":[0.9993296,0.00007732095,0.00017812884,0.0003092929,0.00006823459,0.0000374242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006069123,0.0001275436,0.00025639636,0.000028351067,0.00006295069,0.000020157322,0.0002722053,0.000031185373,8.348908e-7],"category_scores_gemma":[0.00018872134,0.000086070315,0.000011548933,0.00020933816,0.00014756301,0.00002535946,0.00012999531,0.00009797558,1.01911574e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012704695,0.00052165386,0.9679755,0.000004580857,0.000013482526,1.9900126e-7,0.001740145,0.0011017509,0.0013987749,0.00000778422,0.0000020110979,0.025963627],"study_design_scores_gemma":[0.013506062,0.0011695914,0.9770029,0.000082977094,0.000006260135,2.5680853e-7,0.0022879306,0.0002664827,0.0030849776,0.00006132161,0.0023254137,0.00020582322],"about_ca_topic_score_codex":0.0004857996,"about_ca_topic_score_gemma":0.0017163035,"teacher_disagreement_score":0.025757805,"about_ca_system_score_codex":0.000013493754,"about_ca_system_score_gemma":0.00003152295,"threshold_uncertainty_score":0.35098457},"labels":[],"label_agreement":null},{"id":"W1963508707","doi":"10.1007/bf02849799","title":"Evaluation of the comfort of Alphagan® P compared with Alphagan® in irritated eyes","year":2003,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AGE-WELL; Allergan; American Glaucoma Society","keywords":"Brimonidine; Medicine; Tolerability; Eye drop; Crossover study; Anesthesia; Regimen; Ophthalmology; Adverse effect; Glaucoma; Internal medicine","score_opus":0.02132787291849239,"score_gpt":0.32099683399051654,"score_spread":0.2996689610720241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963508707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809625,0.013342282,0.000022253524,0.00011594428,0.00006917345,0.00059564534,0.0000014904717,0.000005582575,0.0048851417],"genre_scores_gemma":[0.99831927,0.0011874614,0.0003350854,0.00008981454,0.0000034132606,0.000020843652,0.000003969185,0.000009752385,0.000030417206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988381,0.00018881593,0.0002689592,0.00012043324,0.0004598561,0.00012380409],"domain_scores_gemma":[0.9994359,0.00006093028,0.00012832021,0.00020199399,0.00015487464,0.000017994404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057564245,0.00009292606,0.00025423756,0.000079048514,0.000014982206,0.000001318228,0.000083610175,0.000033808683,0.00005865913],"category_scores_gemma":[0.000064920496,0.000053713477,0.000038595324,0.00043285184,0.00016785233,0.00007525121,0.0000044546614,0.00009563626,5.110991e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074342394,0.00056868186,0.96934974,0.00005779409,0.00005126893,0.0000032986104,0.0014441144,0.0012334823,0.0069202906,0.00067634095,0.00001770916,0.018933836],"study_design_scores_gemma":[0.012125346,0.000669195,0.9338324,0.0004546987,0.00006328792,0.000016350172,0.0020943186,0.0012152105,0.041872058,0.0050514783,0.0024670516,0.00013862466],"about_ca_topic_score_codex":0.000053448657,"about_ca_topic_score_gemma":0.00045099002,"teacher_disagreement_score":0.03551738,"about_ca_system_score_codex":0.000033755634,"about_ca_system_score_gemma":0.00011184041,"threshold_uncertainty_score":0.2190372},"labels":[],"label_agreement":null},{"id":"W1970194363","doi":"10.1007/s12325-015-0189-1","title":"Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users","year":2015,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Rivaroxaban; Medicine; Warfarin; Atrial fibrillation; Propensity score matching; Internal medicine; Pharmacy; Cohort; Anticoagulant; Emergency medicine; Family medicine","score_opus":0.05419746696597991,"score_gpt":0.36244004818528847,"score_spread":0.3082425812193086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970194363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993511,0.0031866047,0.00006095329,0.0006136149,0.0008943906,0.0014717007,0.000030415067,0.000065082124,0.00016621544],"genre_scores_gemma":[0.99596703,0.002265138,0.00075842266,0.000097234486,0.0004180788,0.0000049347354,0.00042504014,0.000035104284,0.00002901483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818176,0.00024811842,0.0005086766,0.00036506445,0.000450233,0.00024612455],"domain_scores_gemma":[0.9984624,0.00061293243,0.00032769525,0.0003417222,0.00010888444,0.00014640825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034139332,0.00025420642,0.0005969043,0.00019254723,0.000072272946,0.00002101851,0.000096356474,0.000104633895,0.000011652376],"category_scores_gemma":[0.00030732775,0.00021613602,0.00015041347,0.00034792506,0.00007949888,0.00044492987,0.000041750725,0.0001295299,0.0000048061897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071996776,0.000007963742,0.9348966,0.0000504238,0.00009634174,0.0000013038865,0.00159715,0.0025202292,0.000025051753,0.00010887668,0.000049622402,0.053446755],"study_design_scores_gemma":[0.03664626,0.0052804695,0.94107527,0.00022168056,0.000088819936,1.7270177e-7,0.000883796,0.0006020133,0.00075660646,0.00018564661,0.013933904,0.00032535594],"about_ca_topic_score_codex":0.0011522268,"about_ca_topic_score_gemma":0.00034979847,"teacher_disagreement_score":0.0531214,"about_ca_system_score_codex":0.0004184354,"about_ca_system_score_gemma":0.00005798025,"threshold_uncertainty_score":0.8813771},"labels":[],"label_agreement":null},{"id":"W1970541415","doi":"10.1007/s12325-013-0067-7","title":"Obesity and Bipolar Disorder: Synergistic Neurotoxic Effects?","year":2013,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Medicine; Bipolar disorder; Obesity; Rheumatology; Neurology; Internal medicine; Psychiatry; Lithium (medication)","score_opus":0.0172866482341123,"score_gpt":0.3286273825403722,"score_spread":0.3113407343062599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970541415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023190712,0.9964561,0.00004618367,0.00003261321,0.0002235152,0.002716619,0.000010614496,0.00005847082,0.00022401781],"genre_scores_gemma":[0.000109829845,0.9985579,0.00016687675,0.00012361191,0.000056525078,0.0007122141,0.000053489322,0.00007346584,0.00014603641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984855,0.0001704106,0.00035400243,0.00051111146,0.0001688854,0.0003100861],"domain_scores_gemma":[0.9989703,0.00030074213,0.00014269154,0.0004536552,0.00001770266,0.00011489702],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008393307,0.00048666642,0.001511104,0.00018562902,0.00006118085,0.000021161286,0.00012549154,0.00017772944,0.00005348513],"category_scores_gemma":[0.000034520388,0.00032598263,0.00022346989,0.0002719338,0.000116057105,0.00013120624,0.00003929262,0.00041255544,0.00006833321],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010899699,0.00033776643,0.00406002,0.0072960095,0.000102452184,0.000021390757,0.000019026622,1.1162351e-7,0.0000010947124,0.000103542974,0.000011594737,0.9880361],"study_design_scores_gemma":[0.001109731,0.00046006695,0.0009421434,0.0037789282,0.00023654518,0.00005330796,0.000002492386,0.0000027387546,0.0000030238743,0.00027199875,0.9928709,0.00026810347],"about_ca_topic_score_codex":0.00005400558,"about_ca_topic_score_gemma":0.000051578885,"teacher_disagreement_score":0.9928593,"about_ca_system_score_codex":0.00006117084,"about_ca_system_score_gemma":0.00006233863,"threshold_uncertainty_score":0.99991924},"labels":[],"label_agreement":null},{"id":"W1975674908","doi":"10.1007/s12325-010-0033-6","title":"Systematic review on evidence of the effectiveness of cholesterol-lowering drugs","year":2010,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regina Qu'Appelle Health Region","funders":"","keywords":"Medicine; Intensive care medicine; MEDLINE; Coronary heart disease; Diabetes mellitus; Disease; Population; Internal medicine; Environmental health; Endocrinology","score_opus":0.024738024962558287,"score_gpt":0.3738771809146772,"score_spread":0.3491391559521189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975674908","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014414561,0.99215645,0.000013803224,0.00000982656,0.00033053066,0.0071722483,0.000003059389,0.000008586627,0.00016133815],"genre_scores_gemma":[0.0006360652,0.99844253,0.000020312682,0.00010203917,0.000058085618,0.00068994425,0.0000017504492,0.000037527534,0.000011754288],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9967687,0.00123342,0.0009694153,0.00029215403,0.0005724198,0.0001638981],"domain_scores_gemma":[0.99658644,0.0009368224,0.0007722369,0.0015785538,0.00008760916,0.000038314134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004242352,0.00029302877,0.0040758224,0.00008659802,0.000020248104,0.0000030870337,0.00038838582,0.00015380759,0.0000048075512],"category_scores_gemma":[0.000539014,0.00014320167,0.0010849524,0.00045021359,0.00008915195,0.00008551762,0.000036352947,0.00055898767,0.000003095755],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022884798,0.000031602885,0.0000037883824,0.6410847,0.000084107094,9.613804e-7,0.000012165114,3.6439704e-7,0.000003074114,0.000020433681,1.4426944e-7,0.35873583],"study_design_scores_gemma":[0.00031949225,0.00020165618,0.000027204245,0.9536014,0.00058793783,0.00003225051,0.0000028874251,8.462941e-8,0.00014658186,0.000020267664,0.044955842,0.000104349914],"about_ca_topic_score_codex":0.000015149077,"about_ca_topic_score_gemma":0.00000271501,"teacher_disagreement_score":0.3586315,"about_ca_system_score_codex":0.00008876191,"about_ca_system_score_gemma":0.00019771908,"threshold_uncertainty_score":0.58395946},"labels":[],"label_agreement":null},{"id":"W1975715092","doi":"10.1007/s12325-013-0040-5","title":"Obesity and Mental Illness: Implications for Cognitive Functioning","year":2013,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diet and metabolism studies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Obesity; Cognition; Rheumatology; Mental illness; Mental health; Psychiatry; Gerontology; Clinical psychology; Internal medicine","score_opus":0.054945110803057286,"score_gpt":0.40239120352450813,"score_spread":0.3474460927214508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975715092","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012439121,0.9959255,0.00014870337,0.000060233182,0.0003945135,0.0020887859,0.00005481807,0.000023370805,0.0011797018],"genre_scores_gemma":[0.000058009286,0.99682033,0.00039344557,0.00010325588,0.00020732266,0.001835842,0.00011703773,0.000024370713,0.0004403627],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992915,0.000023519056,0.00022582526,0.0002531161,0.00004934212,0.00015674067],"domain_scores_gemma":[0.9994562,0.00021530883,0.00012221187,0.00010269217,0.00006521039,0.00003834663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008592111,0.00019876113,0.00085717184,0.00008399746,0.00011633144,0.000011347949,0.000040437906,0.000073535586,0.000016499862],"category_scores_gemma":[0.000042890606,0.00013905502,0.0001260048,0.00012351299,0.00009058156,0.000140258,0.000020594323,0.00011228203,0.0000055528826],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018745424,0.000056116758,0.00047535522,0.0013923716,0.00010037137,1.5760233e-7,0.0001692337,7.021597e-9,6.2741674e-7,0.0003690398,0.000119334945,0.99729866],"study_design_scores_gemma":[0.0008254924,0.000088690125,0.0010391751,0.0023749622,0.00018781274,0.000005949488,0.0002995851,1.7320929e-7,0.0000010987167,0.00067667814,0.99434894,0.00015144143],"about_ca_topic_score_codex":0.000003411226,"about_ca_topic_score_gemma":0.0000055470773,"teacher_disagreement_score":0.9971472,"about_ca_system_score_codex":0.000027381942,"about_ca_system_score_gemma":0.000039183833,"threshold_uncertainty_score":0.5670499},"labels":[],"label_agreement":null},{"id":"W1976039492","doi":"10.1007/s12325-012-0064-2","title":"A Cross-sectional Survey of Hypertension Diagnosis and Treatment Practices Among Physicians in Yaroslavl Region, Russia","year":2012,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Healthcare Systems and Public Health","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dyslipidemia; Blood pressure; Cross-sectional study; Internal medicine; Diabetes mellitus; Obesity; Abdominal obesity; Family history; Left ventricular hypertrophy; Pediatrics; Metabolic syndrome","score_opus":0.15393799147255197,"score_gpt":0.4277835206994374,"score_spread":0.27384552922688543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976039492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97601956,0.022482144,0.000008356365,0.0004799873,0.00024827212,0.00050902885,0.000008994043,0.000012097307,0.0002315839],"genre_scores_gemma":[0.95179254,0.047503363,0.0000876514,0.0002768795,0.0001550169,0.00010753672,0.00001686956,0.000013420222,0.000046754423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986393,0.00030598434,0.0004012121,0.000205464,0.00016476591,0.00028328894],"domain_scores_gemma":[0.9987815,0.00049722736,0.00034006833,0.00017944502,0.000093542265,0.00010822718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008949719,0.00011829691,0.00036131305,0.00012177208,0.00004266195,0.0000088532,0.000034118395,0.00009314373,0.000012176626],"category_scores_gemma":[0.0002471655,0.00008625361,0.000029001305,0.00030244625,0.000087793596,0.00054754416,0.000006421489,0.00011510804,0.0000010938933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022109,0.00046952482,0.8929799,0.00005387637,0.00001108585,0.000006103551,0.0007277036,0.000003061403,0.00003115498,0.000057397756,0.000008999572,0.1054301],"study_design_scores_gemma":[0.0015465774,0.000483897,0.9851149,0.00012872029,0.000001489091,0.000025343335,0.000114072485,0.000021553999,0.00011678299,0.000021842685,0.012353549,0.000071308736],"about_ca_topic_score_codex":0.02749578,"about_ca_topic_score_gemma":0.0076832813,"teacher_disagreement_score":0.10535879,"about_ca_system_score_codex":0.0001315824,"about_ca_system_score_gemma":0.000144044,"threshold_uncertainty_score":0.9789802},"labels":[],"label_agreement":null},{"id":"W1976067058","doi":"10.1007/s12325-014-0146-4","title":"Lixisenatide Treatment for Older Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetics: Meta-Analysis of Five Randomized Controlled Trials","year":2014,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Lixisenatide; Medicine; Hypoglycemia; Placebo; Glycated hemoglobin; Internal medicine; Type 2 Diabetes Mellitus; Type 2 diabetes; Postprandial; Diabetes mellitus; Clinical endpoint; Randomized controlled trial; Endocrinology; Exenatide","score_opus":0.05755748832539071,"score_gpt":0.37941524918592817,"score_spread":0.32185776086053747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976067058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025502747,0.97305214,0.000095909825,0.000038288224,0.00022360361,0.025766198,0.00016352361,0.000030822463,0.00037448437],"genre_scores_gemma":[0.00063930696,0.9860941,0.0013462332,0.00016930365,0.000062244464,0.009522734,0.0012091716,0.00008805145,0.00086880877],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9934668,0.0020133762,0.0027724574,0.00074210553,0.00053154095,0.00047370768],"domain_scores_gemma":[0.9826694,0.013256974,0.0028675913,0.000760382,0.00034363873,0.0001020254],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0032086843,0.0010544477,0.046678398,0.0012568602,0.00004141187,0.000031064537,0.00019453287,0.0001951091,0.00024771754],"category_scores_gemma":[0.00093397946,0.00044261897,0.011173444,0.00077801076,0.00013896367,0.00008851309,0.000014568255,0.00011029654,0.000004617895],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06368486,0.001395668,0.0000372763,0.0010940391,0.5430041,0.0000012838942,0.000038893122,0.00054821116,3.2942545e-8,0.0001047635,0.00001636231,0.39007452],"study_design_scores_gemma":[0.3639641,0.002388952,0.0000022710128,0.0006270842,0.49963143,1.13529435e-8,0.000004406037,0.00018284004,0.0000050912527,0.00005955809,0.13287866,0.00025560614],"about_ca_topic_score_codex":0.000008120689,"about_ca_topic_score_gemma":0.000016055801,"teacher_disagreement_score":0.38981894,"about_ca_system_score_codex":0.00019058223,"about_ca_system_score_gemma":0.000106246975,"threshold_uncertainty_score":0.99980253},"labels":[],"label_agreement":null},{"id":"W1986615261","doi":"10.1007/bf02850309","title":"A giant congenital nevus spilus in an 8-year-old girl","year":2006,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Genetic and rare skin diseases.","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Girl; Lesion; Dermatology; Lumbosacral joint; Anatomy; Surgery","score_opus":0.0048184559617286795,"score_gpt":0.2561688543908048,"score_spread":0.2513503984290761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986615261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718571,0.025072675,0.00011831603,0.000042589785,0.00014988182,0.00017261687,0.000013065637,0.000009208592,0.002564604],"genre_scores_gemma":[0.995189,0.0032473896,0.00067418173,0.00021441487,0.0002061765,0.00003273109,0.00007558198,0.00001850096,0.00034202854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991517,0.00004396712,0.00017465153,0.00030121024,0.00008565887,0.0002428175],"domain_scores_gemma":[0.9996267,0.0000058954192,0.000037726833,0.00025933507,0.000024328154,0.00004600568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000063023566,0.00013219024,0.00011494933,0.0000463123,0.000022455679,0.000013999278,0.00017154968,0.00008691587,0.000044678258],"category_scores_gemma":[0.0000074662125,0.00011980041,0.000045482426,0.00010209078,0.000079099,0.000010139875,0.00002515337,0.00006139697,0.000007510644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010503388,0.0011098215,0.48326355,0.000019461459,0.000028221344,0.00012213743,0.00014042367,0.0031969005,0.38048628,0.0009818334,0.00056249404,0.12903854],"study_design_scores_gemma":[0.007893955,0.0014516311,0.68611056,0.00003490245,0.00000865656,0.000029903671,0.00038539016,0.00017852242,0.13045545,0.0067357817,0.16570728,0.001007955],"about_ca_topic_score_codex":0.000088916364,"about_ca_topic_score_gemma":0.0010259867,"teacher_disagreement_score":0.25003085,"about_ca_system_score_codex":0.000011941832,"about_ca_system_score_gemma":0.00003562448,"threshold_uncertainty_score":0.4885319},"labels":[],"label_agreement":null},{"id":"W1986770646","doi":"10.1007/s12325-011-0015-3","title":"Surgical treatment of morbid obesity among patients with bipolar disorder: a research agenda","year":2011,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism","keywords":"Medicine; Morbid obesity; Bipolar disorder; Rheumatology; Obesity; Internal medicine; Psychiatry; Physical therapy; Family medicine; Intensive care medicine; Weight loss; Lithium (medication)","score_opus":0.0777282307428856,"score_gpt":0.3996709975142271,"score_spread":0.3219427667713415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986770646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006521678,0.9898055,0.000003118007,0.0000036642193,0.00006916718,0.0025216758,0.000073273965,0.000024692536,0.0009772053],"genre_scores_gemma":[0.0013788142,0.99744505,0.0001488366,0.0000019335762,0.000041704483,0.0004257745,0.0002643962,0.00007314403,0.00022037551],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976566,0.00034616032,0.0005308598,0.0005591729,0.00044659825,0.00046060342],"domain_scores_gemma":[0.9986747,0.0001835526,0.00021761034,0.00068009953,0.00012471413,0.00011933678],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019101879,0.00047718614,0.0018282069,0.00037645068,0.000071858936,0.0000072336884,0.00018115163,0.00022753992,0.00016326577],"category_scores_gemma":[0.000007966821,0.00026905793,0.00035897517,0.0006383669,0.00034008856,0.00012203388,0.000030394323,0.0003240843,0.000020067308],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021747552,0.0036413602,0.2884826,0.0011062461,0.00026966864,0.000026930638,0.00019023205,9.131056e-8,6.0885594e-9,0.000042395222,0.0000013543076,0.7060216],"study_design_scores_gemma":[0.0044809836,0.0041473005,0.022186333,0.0026420925,0.00021468822,0.000010471267,0.000016007822,2.0963031e-7,0.0000027840638,0.000054589877,0.96602315,0.00022140374],"about_ca_topic_score_codex":0.00061740004,"about_ca_topic_score_gemma":0.0007570015,"teacher_disagreement_score":0.9660218,"about_ca_system_score_codex":0.00025563024,"about_ca_system_score_gemma":0.0002099322,"threshold_uncertainty_score":0.99997616},"labels":[],"label_agreement":null},{"id":"W1986954788","doi":"10.1007/s12325-015-0182-8","title":"Ivabradine in Combination with Beta-Blockers in Patients with Chronic Stable Angina After Percutaneous Coronary Intervention","year":2015,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Heart rate and cardiovascular health","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Servier","keywords":"Medicine; Ivabradine; Percutaneous coronary intervention; Cardiology; Internal medicine; BETA (programming language); Angina; Stable angina; Rheumatology; Coronary heart disease; Heart rate; Myocardial infarction; Blood pressure","score_opus":0.00832923111248719,"score_gpt":0.26286330621842985,"score_spread":0.25453407510594267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986954788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865413,0.012179856,0.00008481753,0.00025145555,0.00006538474,0.00073176937,0.0000023306948,0.000017279926,0.00012583],"genre_scores_gemma":[0.997908,0.0012457718,0.00046227258,0.00015834799,0.000022333345,0.000066684115,0.00005706401,0.000023059429,0.00005646676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988719,0.000106900894,0.00021901383,0.00022988794,0.00030756998,0.00026471156],"domain_scores_gemma":[0.9995919,0.000014877777,0.000043973178,0.0002035331,0.000071718205,0.00007400289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003150013,0.00013310176,0.00030029748,0.00018008574,0.000012573887,0.000006830722,0.000044292134,0.000052119944,0.0000291064],"category_scores_gemma":[0.0000053510994,0.00009856081,0.000037041715,0.0003602819,0.000046467183,0.00033449937,0.000007918147,0.00018876766,0.000005764737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038326436,0.0006210558,0.9130858,0.00007381012,0.000031007705,0.0002727163,0.00069746224,0.00040243517,0.000009136193,0.000011222206,0.000014592822,0.08094811],"study_design_scores_gemma":[0.023095934,0.00701277,0.9564768,0.00064642826,0.000015054978,0.00010273304,0.00036067876,0.0002431579,0.00010772109,0.000115122675,0.011603897,0.00021969665],"about_ca_topic_score_codex":0.0002131307,"about_ca_topic_score_gemma":0.0016355322,"teacher_disagreement_score":0.08072841,"about_ca_system_score_codex":0.00055376143,"about_ca_system_score_gemma":0.00013245142,"threshold_uncertainty_score":0.4019193},"labels":[],"label_agreement":null},{"id":"W1988415653","doi":"10.1007/s12325-010-0025-6","title":"Serum vitamin D concentration and short-term mortality among geriatric inpatients in acute care settings","year":2010,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Creatinine; Internal medicine; Vitamin D and neurology; Body mass index; Acute care; Odds ratio; Mortality rate; Confounding; Blood pressure; Proportional hazards model; Pediatrics; Health care","score_opus":0.009918325388342076,"score_gpt":0.33360327759883873,"score_spread":0.32368495221049665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988415653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99466187,0.0037871297,0.0000053593735,0.0001265943,0.00022896234,0.00074179843,0.00001552835,0.000025074667,0.0004076636],"genre_scores_gemma":[0.9883297,0.011116293,0.00023428955,0.000094199255,0.00006817061,0.00009009705,0.000025367608,0.000014531164,0.00002735844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881566,0.000050081926,0.00025493518,0.00030357786,0.00027030133,0.0003054749],"domain_scores_gemma":[0.9995164,0.000063334846,0.00005439205,0.0002138952,0.00007947158,0.00007249491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019542592,0.00014829262,0.00026509515,0.00008321084,0.000056689278,0.000017226657,0.00008538888,0.00008279254,0.000016819944],"category_scores_gemma":[0.00006870088,0.00012138354,0.000027954937,0.00027420121,0.0002157687,0.00038672186,0.000046265563,0.00036402702,0.0000011110733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056182726,0.00006288561,0.92410314,0.00006518181,0.000023628667,0.00004503729,0.0026670876,0.0000019324973,0.008377418,0.000009953757,0.000007611481,0.06457992],"study_design_scores_gemma":[0.0018677011,0.00021804459,0.99058056,0.00006647037,0.000009204348,0.0000040287237,0.0006417088,0.000050386097,0.0060260827,0.00007684814,0.0003422942,0.000116698066],"about_ca_topic_score_codex":0.000034887533,"about_ca_topic_score_gemma":0.00081433717,"teacher_disagreement_score":0.066477366,"about_ca_system_score_codex":0.00006525305,"about_ca_system_score_gemma":0.000034068653,"threshold_uncertainty_score":0.49498773},"labels":[],"label_agreement":null},{"id":"W1989894661","doi":"10.1007/s12325-011-0053-x","title":"Blood pressure control rates with an antihypertensive regimen including trandolapril in a canadian usual-care setting","year":2011,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Abbott (Canada); Hamilton Health Sciences","funders":"","keywords":"Medicine; Trandolapril; Blood pressure; Tolerability; Internal medicine; Regimen; Population; Physical therapy; Adverse effect; ACE inhibitor; Angiotensin-converting enzyme","score_opus":0.030645875290255628,"score_gpt":0.29488349914857104,"score_spread":0.2642376238583154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989894661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7125886,0.28066677,0.0000070280976,0.00068703253,0.00010220252,0.0009327048,0.000018262703,0.00005775144,0.0049396185],"genre_scores_gemma":[0.9897607,0.0053459127,0.0008620654,0.0037943826,0.00008829531,0.00006577703,0.00000828987,0.000034633627,0.00003995651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859434,0.00010490372,0.00025689285,0.00038555844,0.0001695502,0.0004887692],"domain_scores_gemma":[0.99916947,0.0000937373,0.00007936064,0.00028104495,0.00020587131,0.00017049832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021029843,0.00023133292,0.00063790317,0.00023090535,0.000121280784,0.000011561052,0.00011323219,0.00009997009,0.000034677512],"category_scores_gemma":[0.000032823256,0.00016473293,0.000042285454,0.00023763276,0.00009836092,0.00036830935,0.000011381982,0.00026795405,0.0000016920949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004169932,0.00034972047,0.92939657,0.00013184846,0.0009605963,0.0012910746,0.034993585,0.000041661104,0.0027150614,0.00014468508,0.00006873361,0.025736555],"study_design_scores_gemma":[0.12606756,0.009394125,0.5571265,0.0031610832,0.0038073158,0.0009544724,0.052214738,0.00065967103,0.047364693,0.0012032462,0.19557294,0.0024736437],"about_ca_topic_score_codex":0.028933132,"about_ca_topic_score_gemma":0.15074866,"teacher_disagreement_score":0.37227005,"about_ca_system_score_codex":0.000012136653,"about_ca_system_score_gemma":0.0001563414,"threshold_uncertainty_score":0.9775333},"labels":[],"label_agreement":null},{"id":"W1992925095","doi":"10.1007/bf02850083","title":"Penile dog bite in an adolescent","year":2005,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Rabies epidemiology and control","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Penis; Saline; Dog bite; Surgery; Syringe; External genitalia; Anesthesia; Anatomy; Pathology","score_opus":0.013125697588765457,"score_gpt":0.3090259655514643,"score_spread":0.2959002679626988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992925095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8952957,0.10157633,0.00008077221,0.001000079,0.00041683632,0.00021534055,0.000003929261,0.00003561469,0.0013754081],"genre_scores_gemma":[0.9893092,0.0075111315,0.00013593993,0.0025491107,0.00006315408,0.000051890755,0.000015107483,0.000009388928,0.00035508216],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987516,0.00033740985,0.00028843086,0.0002651078,0.000014248686,0.0003432066],"domain_scores_gemma":[0.9995319,0.00013673176,0.00006663327,0.00023793151,0.000013695088,0.000013107413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033583934,0.00013109959,0.00026630415,0.00009908005,0.00004751339,0.0000031929605,0.00022674832,0.00017804958,0.000369256],"category_scores_gemma":[0.000028105593,0.000109271146,0.0000410134,0.00010459195,0.00014979146,0.0002493282,0.000014852423,0.0003279478,0.00020749679],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009317556,0.0005821,0.3919643,0.0000057200846,0.00001821173,0.0000088463785,0.00071930495,0.0014898882,0.06408469,0.003289619,0.00033120572,0.53657436],"study_design_scores_gemma":[0.0057331175,0.00035448896,0.15833217,0.000030005438,0.000002823239,0.0000184662,0.0001897451,0.00007811949,0.010493781,0.0030905392,0.8213743,0.00030244477],"about_ca_topic_score_codex":0.000020605974,"about_ca_topic_score_gemma":0.000693599,"teacher_disagreement_score":0.8210431,"about_ca_system_score_codex":0.00003783041,"about_ca_system_score_gemma":0.000016467435,"threshold_uncertainty_score":0.4455948},"labels":[],"label_agreement":null},{"id":"W1995320490","doi":"10.1007/bf02877702","title":"A large hypopigmented skin lesion following extravasation of intravenous fluid","year":2007,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Extravasation; Lesion; Intravenous fluid; Complication; Anesthesia; Surgery; Radiology; Pathology","score_opus":0.01399578055989709,"score_gpt":0.31930434474719765,"score_spread":0.30530856418730057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995320490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96840847,0.014229204,0.014765622,0.00009200443,0.00022907485,0.00047469808,0.0000023823457,0.000055475408,0.0017431],"genre_scores_gemma":[0.99013865,0.006510673,0.0027867605,0.000343667,0.000079955586,0.0000072716994,0.000016981216,0.000032149623,0.00008386468],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860805,0.000039926013,0.00046171647,0.00024886304,0.00031497778,0.0003264892],"domain_scores_gemma":[0.9993534,0.00013041585,0.00013549779,0.0002764467,0.000043774202,0.00006045832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006860203,0.00016054236,0.00033146265,0.0002041259,0.000039507664,0.0000039455117,0.00009622451,0.00013434658,0.00009434099],"category_scores_gemma":[0.00004818205,0.00014405175,0.000121190744,0.00042506625,0.000044154564,0.00018411769,0.000011250166,0.00019972723,0.000005409133],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016170666,0.0009933035,0.021056417,0.000047463185,0.0000854914,0.00007839375,0.003905684,0.000046263147,0.57169855,0.0003845485,0.000021533786,0.40006527],"study_design_scores_gemma":[0.01119159,0.00085169205,0.051459678,0.0003970337,0.000021001113,0.000031686173,0.000747949,0.0001998839,0.9157404,0.0020737317,0.017017653,0.00026771484],"about_ca_topic_score_codex":0.0000234299,"about_ca_topic_score_gemma":0.00007327587,"teacher_disagreement_score":0.39979756,"about_ca_system_score_codex":0.00013464855,"about_ca_system_score_gemma":0.000034825134,"threshold_uncertainty_score":0.587426},"labels":[],"label_agreement":null},{"id":"W1996943621","doi":"10.1007/s12325-009-0039-0","title":"Long-acting risperidone: a review of its role in the treatment of bipolar disorder","year":2009,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Center for Research Resources","keywords":"Risperidone; Tolerability; Bipolar disorder; Medicine; Mania; Psychiatry; Treatment of bipolar disorder; Mood; Schizophrenia (object-oriented programming); Internal medicine; Adverse effect","score_opus":0.030544713264928573,"score_gpt":0.3798057100356378,"score_spread":0.3492609967707092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996943621","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005252994,0.99651235,0.000004155039,0.00007551718,0.000052034025,0.0025870015,0.000023873068,0.000009188063,0.00068337005],"genre_scores_gemma":[0.00010190819,0.9992246,0.00009448553,0.000076290824,0.00004310335,0.00030982323,0.000080915626,0.000033680786,0.000035183668],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980347,0.00026679528,0.00087208085,0.00031696472,0.0002666242,0.00024281131],"domain_scores_gemma":[0.99869585,0.00020414467,0.00046678586,0.0005619773,0.000039733324,0.00003151254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024969506,0.00041059867,0.0022200982,0.00017745768,0.000021001446,0.0000033637157,0.00020124191,0.00012606104,0.00006795868],"category_scores_gemma":[0.00002525927,0.00021797178,0.00052823283,0.0006778436,0.000053150634,0.00008321354,0.00000760559,0.00019930041,0.000005445624],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036885198,0.0017801959,0.0019248158,0.023894113,0.00012878075,0.000009677697,0.00035229186,4.9790185e-7,3.2633974e-7,0.000024693161,0.0000012810204,0.97184646],"study_design_scores_gemma":[0.0013263708,0.0012447545,0.0004149275,0.061925538,0.0003353583,0.000026872513,0.000044953103,6.1786153e-7,0.000009626796,0.000029129737,0.93449545,0.00014639176],"about_ca_topic_score_codex":0.000059942427,"about_ca_topic_score_gemma":0.00020639472,"teacher_disagreement_score":0.9717001,"about_ca_system_score_codex":0.00011933113,"about_ca_system_score_gemma":0.00012265009,"threshold_uncertainty_score":0.88886315},"labels":[],"label_agreement":null},{"id":"W1998390661","doi":"10.1007/s12325-013-0014-7","title":"Ocular Surface Tolerability of Prostaglandin Analogs and Prostamides in Patients with Glaucoma or Ocular Hypertension","year":2013,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Allergan","keywords":"Bimatoprost; Latanoprost; Travoprost; Medicine; Tolerability; Ophthalmology; Glaucoma; Ocular hypertension; Prostaglandin analogue; Intraocular pressure; Internal medicine; Adverse effect","score_opus":0.006345377738646314,"score_gpt":0.23164891159234205,"score_spread":0.22530353385369573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998390661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938316,0.0044840993,0.000010763674,0.00020502548,0.000026510179,0.0013674321,0.0000024039828,0.000012609792,0.000059603077],"genre_scores_gemma":[0.99714655,0.001706874,0.00091717095,0.00014150667,0.000004246128,0.000025601885,0.000013582529,0.000014474488,0.000030021642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900174,0.000061383675,0.00026808714,0.00026011694,0.0002065398,0.00020212759],"domain_scores_gemma":[0.9994909,0.000055332916,0.00007894573,0.00021154541,0.00011079107,0.000052449006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001234133,0.00014880163,0.0003745715,0.00006987588,0.000022171598,0.000006848603,0.000052660427,0.000060291935,0.000035181034],"category_scores_gemma":[0.00004050743,0.00008422501,0.000026032434,0.00026390766,0.00017574438,0.00022439967,0.000015463356,0.000118923104,0.0000013408388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018343454,0.0004842782,0.9856734,0.000114345334,0.000012544699,0.000011581826,0.00024351286,0.0000061530604,0.001391038,0.000012463324,0.0000042127303,0.010212076],"study_design_scores_gemma":[0.005518687,0.0016446093,0.99027276,0.00021915503,0.000006300814,0.0000049535547,0.00020393264,0.00017071272,0.001120916,0.00036943165,0.0003503159,0.00011820171],"about_ca_topic_score_codex":0.000241739,"about_ca_topic_score_gemma":0.00008568554,"teacher_disagreement_score":0.010093873,"about_ca_system_score_codex":0.000025558444,"about_ca_system_score_gemma":0.000028329503,"threshold_uncertainty_score":0.3434596},"labels":[],"label_agreement":null},{"id":"W2000423618","doi":"10.1007/bf02849889","title":"Eczema exacerbation and food atopy beyond infancy: How should we advise Chinese parents about dietary history, eczema severity, and skin prick testing?","year":2007,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Food Allergy and Anaphylaxis Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Atopy; Exacerbation; Atopic dermatitis; Food allergy; Allergy; Elimination diet; Food allergens; Egg white; Pediatrics; Dermatology; Immunology; Food science","score_opus":0.03479998323195881,"score_gpt":0.325063328086119,"score_spread":0.29026334485416017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000423618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88017446,0.116295576,0.00006966167,0.00081458787,0.0001911365,0.00043592395,0.000005397803,0.00005358208,0.0019596948],"genre_scores_gemma":[0.95877403,0.03860739,0.0014515659,0.0005120829,0.00019989243,0.00002944966,0.000020028378,0.000035003868,0.00037057148],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998374,0.00006322183,0.00027706038,0.00045211831,0.00041044512,0.00042317735],"domain_scores_gemma":[0.9990592,0.00026641335,0.00011204388,0.00027389493,0.00009242062,0.00019602869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042959448,0.00027553082,0.0003684891,0.00024566712,0.00009834883,0.000023647177,0.000121968485,0.00014309876,0.000036284855],"category_scores_gemma":[0.00016162342,0.00022151467,0.000050189385,0.00034781662,0.00024765637,0.0004986869,0.000066911714,0.00037839328,0.0000020255309],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008326962,0.00028420312,0.41672453,0.00023503703,0.000064069405,0.000046674715,0.0017273573,0.0000074954874,0.0010787835,0.0000990663,0.00015648578,0.5787436],"study_design_scores_gemma":[0.0036508245,0.0018954164,0.8850132,0.00025543105,0.0000043748582,0.000048014925,0.00023578806,0.0003118574,0.00060690497,0.0029847745,0.10464967,0.00034372977],"about_ca_topic_score_codex":0.000038662918,"about_ca_topic_score_gemma":0.000462968,"teacher_disagreement_score":0.57839984,"about_ca_system_score_codex":0.00010004364,"about_ca_system_score_gemma":0.00006600107,"threshold_uncertainty_score":0.9033106},"labels":[],"label_agreement":null},{"id":"W2001296167","doi":"10.1007/bf02849985","title":"Necrotizing fasciitis and gangrene associated with topical herbs in an infant","year":2007,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Streptococcal Infections and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Children's Hospital","funders":"","keywords":"Medicine; Fasciitis; Gangrene; Dermatology; Rheumatology; Fournier gangrene; Surgery; Internal medicine; Necrotising fasciitis","score_opus":0.016373178314668425,"score_gpt":0.3343752169303377,"score_spread":0.3180020386156693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001296167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996198,0.0021122163,0.00013770748,0.00006048224,0.000042218166,0.00026107338,9.1968235e-7,0.000023545193,0.0011638475],"genre_scores_gemma":[0.9981918,0.0009988826,0.0005300349,0.0001774415,0.000027393753,0.000021180947,0.000007047233,0.000008466047,0.000037760594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994599,0.000018196608,0.00012754294,0.00015417094,0.000072419854,0.00016772741],"domain_scores_gemma":[0.9997373,0.00007009302,0.000028681678,0.000092182956,0.000017505647,0.000054206914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009839094,0.000081648366,0.00015714935,0.000083827406,0.000026473508,0.0000082922425,0.000016083597,0.00004561652,0.000032358865],"category_scores_gemma":[0.000016098602,0.000058554207,0.0000132251225,0.00018985447,0.000049059046,0.00015993617,0.0000049414393,0.00009945106,8.102439e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001487452,0.00020870968,0.84222984,0.0000021941316,0.000012366421,0.0001331028,0.00017438778,0.000007297021,0.00027754946,0.00007887752,3.993131e-7,0.15672655],"study_design_scores_gemma":[0.0037699074,0.0009452104,0.9921467,0.00010004,0.0000040136456,0.000027548462,0.00011303906,0.000032159987,0.0014638447,0.00032421143,0.0010006555,0.000072717296],"about_ca_topic_score_codex":0.00013603776,"about_ca_topic_score_gemma":0.0035447867,"teacher_disagreement_score":0.15665384,"about_ca_system_score_codex":0.000060624014,"about_ca_system_score_gemma":0.000011583292,"threshold_uncertainty_score":0.23877713},"labels":[],"label_agreement":null},{"id":"W2001359221","doi":"10.1007/s12325-008-0044-8","title":"Unusual loss of body hair in childhood: Trichotillomania or alopecia","year":2008,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Hair loss; Medicine; Scalp; Alopecia universalis; Dermatology; Psychosocial; Eyebrow; Alopecia areata; Body hair; Hair disease; Cabello; Pediatrics; Surgery; Psychiatry","score_opus":0.012844124039914353,"score_gpt":0.2946241467758194,"score_spread":0.281780022735905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001359221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97766674,0.012949289,0.000051797462,0.00017648224,0.00012176234,0.00035641337,0.0000033283015,0.00002920262,0.0086449925],"genre_scores_gemma":[0.97358555,0.024953118,0.00041011797,0.0006470748,0.00006436691,0.000022146189,0.000007917543,0.000019152227,0.00029055512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989489,0.00003667885,0.00033647247,0.00021578495,0.0002028436,0.00025935838],"domain_scores_gemma":[0.999548,0.00008018246,0.0000669619,0.00020745888,0.000029849583,0.00006751198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000099798286,0.00014122433,0.00036007285,0.00023030676,0.000024938989,0.0000016958281,0.00011485223,0.00006954402,0.00014854602],"category_scores_gemma":[0.00007452544,0.00010480648,0.00005681872,0.00063401664,0.00013291428,0.00019235762,0.000010534777,0.00015638223,0.000012100108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003144868,0.0014423658,0.8973609,0.000046779343,0.000027111178,0.00043739402,0.0032988966,0.00009141994,0.00044223445,0.0004243093,0.0001794424,0.093104236],"study_design_scores_gemma":[0.01561088,0.0012259445,0.91529775,0.00012370515,0.000004900101,0.00010632948,0.0005224387,0.00003874209,0.0033942165,0.001029366,0.06240548,0.00024025656],"about_ca_topic_score_codex":0.00005630483,"about_ca_topic_score_gemma":0.00028940936,"teacher_disagreement_score":0.092863984,"about_ca_system_score_codex":0.000031616015,"about_ca_system_score_gemma":0.00012434181,"threshold_uncertainty_score":0.4273884},"labels":[],"label_agreement":null},{"id":"W2005097633","doi":"10.1007/s12325-012-0010-3","title":"Advances in Hemophilia Care: Report of Two Symposia at the Hemophilia 2010 World Congress","year":2012,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Queen's University","funders":"","keywords":"Medicine; Population; Health care; Factor VIIa; Family medicine; Gerontology; Pediatrics; Internal medicine","score_opus":0.022120555082914023,"score_gpt":0.36518792943755923,"score_spread":0.3430673743546452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005097633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7551186,0.22871771,0.000002349917,0.0014584274,0.0010111616,0.0009558868,0.000008406942,0.000029210903,0.012698205],"genre_scores_gemma":[0.93220276,0.058620576,0.00027953825,0.00019032207,0.0003055643,0.00014732475,0.00004341235,0.000039088278,0.008171445],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975944,0.00013591207,0.0006172416,0.00038498998,0.00059394125,0.0006735266],"domain_scores_gemma":[0.9984538,0.0003096176,0.00020448682,0.0007562,0.00012163851,0.00015426551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006038797,0.00028774797,0.00057081156,0.00028044172,0.00009299557,0.000009282616,0.00026175604,0.00008658899,0.00030647413],"category_scores_gemma":[0.00006697679,0.00017585163,0.00014035632,0.00078275334,0.00047877224,0.0005850777,0.00008208429,0.0003820045,0.00004161541],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009781123,0.0004907509,0.9087293,0.0001461858,0.000039732775,0.00032802112,0.0009734729,0.00007459186,0.004588089,0.0012263409,0.00018044023,0.08224494],"study_design_scores_gemma":[0.011117596,0.0005174625,0.07592292,0.0006431487,0.00004584246,0.0004914439,0.000590246,0.00003372968,0.122173406,0.0021733274,0.7857259,0.0005649745],"about_ca_topic_score_codex":0.00005641381,"about_ca_topic_score_gemma":0.00074345694,"teacher_disagreement_score":0.8328064,"about_ca_system_score_codex":0.0002654425,"about_ca_system_score_gemma":0.000090222304,"threshold_uncertainty_score":0.7171021},"labels":[],"label_agreement":null},{"id":"W2006060882","doi":"10.1007/s12325-009-0011-z","title":"Teratogenesis associated with antibipolar agents","year":2009,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University Health Network","funders":"","keywords":"Medicine; Rheumatology; Internal medicine; Intensive care medicine","score_opus":0.07467462525885635,"score_gpt":0.42572389444615055,"score_spread":0.3510492691872942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006060882","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004055228,0.9969308,0.0000055405835,0.000036810405,0.00009971168,0.0010437034,0.000015941938,0.000062839026,0.0013991522],"genre_scores_gemma":[0.0002743937,0.99838746,0.00009758475,0.00085211854,0.00010254941,0.000064286025,0.000045774297,0.00003321122,0.00014261059],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861157,0.00014117389,0.00033044786,0.0003719502,0.000224264,0.00032056755],"domain_scores_gemma":[0.9992617,0.00023604739,0.00021259325,0.00017967536,0.000036982216,0.00007305112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018635883,0.00039116238,0.0018489943,0.00013136014,0.000060436218,0.000011848004,0.00013381617,0.00017764587,0.00005697984],"category_scores_gemma":[0.000065193744,0.00021353217,0.00022078435,0.0004904654,0.00007919322,0.00009123655,0.000018165669,0.00035091685,0.000012565503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054204473,0.0003366057,0.00023686934,0.0008038445,0.00030120183,0.00019254023,0.000014799278,8.958879e-7,0.0000022046327,0.000006992556,0.000076387114,0.99797344],"study_design_scores_gemma":[0.0012675008,0.0008716542,0.00043405357,0.008525914,0.00026111206,0.000017187793,0.0000022713336,0.0000018278995,0.000015403339,0.000036277834,0.98831236,0.00025445817],"about_ca_topic_score_codex":0.0000026129458,"about_ca_topic_score_gemma":0.000009461608,"teacher_disagreement_score":0.997719,"about_ca_system_score_codex":0.00012644097,"about_ca_system_score_gemma":0.00006360113,"threshold_uncertainty_score":0.8707589},"labels":[],"label_agreement":null},{"id":"W2012548303","doi":"10.1007/bf02850087","title":"The role of nebulized inhaled corticosteroid therapy in adult patients with asthma and chronic obstructive pulmonary disease","year":2005,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"New York Institute of Technology","funders":"AstraZeneca","keywords":"Medicine; Asthma; Corticosteroid; Pulmonary disease; Inhalation; Intensive care medicine; Anesthesia; Internal medicine","score_opus":0.008815677961129417,"score_gpt":0.28584112533893147,"score_spread":0.27702544737780205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012548303","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03984078,0.95795053,9.622603e-7,0.000017883087,0.00009076938,0.001807422,0.000019760984,0.000013637388,0.00025826838],"genre_scores_gemma":[0.015758201,0.9836502,0.00003180266,0.00010787824,0.00010317025,0.00020455172,0.00005110679,0.000048471462,0.000044588156],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982145,0.00022008781,0.0006435463,0.0003637159,0.00030105538,0.0002571213],"domain_scores_gemma":[0.9987713,0.00018978029,0.00044248774,0.00036397701,0.00013952391,0.000092901035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107024534,0.00035588682,0.000961823,0.00018731013,0.000058651145,0.000012266647,0.0001490962,0.00012503208,0.000026270765],"category_scores_gemma":[0.000026926768,0.00019101333,0.00012924797,0.00032674414,0.00026003047,0.00019252149,0.000022921018,0.00036377134,0.0000028706354],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012816832,0.00023260243,0.005035749,0.00048266098,0.00004960844,0.000024889358,0.000095969284,0.000007025844,0.0000019972308,0.000028722456,5.0096924e-7,0.9927586],"study_design_scores_gemma":[0.005460882,0.0005508913,0.008500896,0.0050362246,0.000046032375,0.000017331917,0.000077865734,0.000043768312,0.000012339279,0.00006587121,0.9798726,0.00031531663],"about_ca_topic_score_codex":0.00000390442,"about_ca_topic_score_gemma":0.0000323561,"teacher_disagreement_score":0.99244326,"about_ca_system_score_codex":0.00018146419,"about_ca_system_score_gemma":0.0002744615,"threshold_uncertainty_score":0.7789297},"labels":[],"label_agreement":null},{"id":"W2012910796","doi":"10.1007/s12325-010-0095-5","title":"Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding","year":2010,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Gastrointestinal Bleeding Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Esomeprazole; Tolerability; Internal medicine; Rheumatology; Peptic ulcer; Peptic; Gastroenterology; Adverse effect","score_opus":0.013608774039409877,"score_gpt":0.30872021979472913,"score_spread":0.2951114457553193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012910796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973453,0.0012681425,0.00034478714,0.00022298624,0.000119312084,0.0005494444,0.000007794263,0.000008931781,0.00013325922],"genre_scores_gemma":[0.9831662,0.0019592296,0.014741865,0.000017960301,0.00004077496,0.00003739045,0.0000072881644,0.000009276585,0.000020007777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993011,0.000011448264,0.00030707312,0.00016767462,0.000092768685,0.00011996932],"domain_scores_gemma":[0.9993912,0.00020270691,0.00014124965,0.00014201387,0.00008637607,0.00003642598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023938272,0.00008896585,0.00031362267,0.00005542161,0.000021036512,0.0000025922618,0.00003817838,0.000034526623,0.000029536632],"category_scores_gemma":[0.00010378053,0.000070081696,0.000050830087,0.00007958967,0.000095117575,0.00009418262,0.000009825907,0.00009007539,2.3806625e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028666893,0.0017833981,0.50746083,0.00035057825,0.000068371264,0.0000029552382,0.00061106024,0.0001026191,0.080939524,0.0039146803,0.000005695099,0.4018936],"study_design_scores_gemma":[0.0092227785,0.005719771,0.88811207,0.0005190027,0.00006868985,0.000039827668,0.00019206015,0.000201442,0.08036179,0.014310671,0.0011220672,0.00012986164],"about_ca_topic_score_codex":0.00003836838,"about_ca_topic_score_gemma":0.000039502727,"teacher_disagreement_score":0.40176374,"about_ca_system_score_codex":0.000021188234,"about_ca_system_score_gemma":0.000018903424,"threshold_uncertainty_score":0.28578487},"labels":[],"label_agreement":null},{"id":"W2015342809","doi":"10.1007/bf02850032","title":"Group A β-hemolytic streptococcal pharyngitis in children","year":2004,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Streptococcal Infections and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"University of Calgary; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Pharyngitis; Throat culture; Penicillin; Cephalosporin; Antibiotics; Intensive care medicine; Acute Pharyngitis; Group A; Internal medicine; Streptococcus; Throat; Streptococcus pyogenes; Antibiotic therapy; Tonsillitis; Pediatrics; Surgery; Staphylococcus aureus; Microbiology","score_opus":0.025628955530901564,"score_gpt":0.37949815440554363,"score_spread":0.3538691988746421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015342809","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012651302,0.99402016,0.000012719807,0.000008053493,0.00017144646,0.003379152,0.000031772837,0.000062497114,0.0010490376],"genre_scores_gemma":[0.00081184186,0.9969746,0.00024692804,0.000044437475,0.00014716608,0.0013303803,0.00027307714,0.00007041099,0.00010118826],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981404,0.00007167855,0.00063457945,0.0005895561,0.00016830521,0.00039546823],"domain_scores_gemma":[0.99918514,0.00009169522,0.00017611898,0.0004320774,0.000016268856,0.000098673954],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008356287,0.00049027434,0.0015837416,0.00045358756,0.00003324047,0.00001735054,0.00013935677,0.00025782516,0.00030577445],"category_scores_gemma":[0.000016770575,0.00036798386,0.00041699174,0.0007779127,0.00008608509,0.00019118575,0.000026603368,0.0005209489,0.00009013931],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024507954,0.0007942581,0.02955523,0.0010032404,0.00015676582,0.000098509714,0.000014814869,0.0000024555811,1.6509192e-7,0.00014832967,0.0000034450654,0.9681983],"study_design_scores_gemma":[0.008284581,0.0008947171,0.0087926,0.030376967,0.00023382384,0.00061441405,0.0000065364798,0.0000012280649,0.000004661651,0.0012845017,0.94892514,0.00058085134],"about_ca_topic_score_codex":0.00013715307,"about_ca_topic_score_gemma":0.00005095974,"teacher_disagreement_score":0.96761745,"about_ca_system_score_codex":0.00058157597,"about_ca_system_score_gemma":0.00017672796,"threshold_uncertainty_score":0.9998772},"labels":[],"label_agreement":null},{"id":"W2015769584","doi":"10.1007/bf02850204","title":"The dilution of benzalkonium chloride (BAK) in the tear Film","year":2006,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Ocular Infections and Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Allergan","keywords":"Gatifloxacin; Benzalkonium chloride; Medicine; Eye drop; Dilution; Chromatography; Ophthalmology; Antibiotics; Chemistry; Ciprofloxacin","score_opus":0.005948167077176857,"score_gpt":0.2835199093547235,"score_spread":0.2775717422775466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015769584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769099,0.013092939,0.000046153702,0.0006182978,0.00014349942,0.0003085838,0.0000022721113,0.000009648342,0.008868709],"genre_scores_gemma":[0.9916109,0.007953159,0.00006798831,0.000093969,0.00006773946,0.000044116285,0.0000063184552,0.0000057842944,0.00015005318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994864,0.000038777802,0.00015317876,0.00008586746,0.00011878285,0.000117017276],"domain_scores_gemma":[0.99962604,0.000101977574,0.000046890418,0.00019915742,0.000018765712,0.0000071554855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017557693,0.000064091386,0.00009528148,0.000042190328,0.000060020542,0.0000061483192,0.00006306616,0.0000259324,0.000011303345],"category_scores_gemma":[0.000011970595,0.000031454565,0.00004304944,0.00022538811,0.000064424385,0.00008023672,0.0000046542054,0.00008808063,0.0000042165684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007704108,0.001390357,0.80658484,0.000022579641,0.00005678556,0.00003700002,0.0006027861,0.0013323302,0.0012124598,0.019872429,0.00020449431,0.16791353],"study_design_scores_gemma":[0.0044559985,0.0005839489,0.70205617,0.00008472595,0.000017259525,0.000029008539,0.0005080631,0.00014419288,0.017728608,0.01567215,0.25860703,0.00011281307],"about_ca_topic_score_codex":0.0002881859,"about_ca_topic_score_gemma":0.0005166535,"teacher_disagreement_score":0.25840256,"about_ca_system_score_codex":0.000034583034,"about_ca_system_score_gemma":0.00001399579,"threshold_uncertainty_score":0.12826799},"labels":[],"label_agreement":null},{"id":"W2015855111","doi":"10.1007/bf02877781","title":"Rabies: Epidemiology, pathogenesis, and prophylaxis","year":2007,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Rabies epidemiology and control","field":"Immunology and Microbiology","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Merck Canada","keywords":"Rabies; Medicine; Vaccination; Rabies virus; Rabies vaccine; Post-exposure prophylaxis; Epidemiology; Herd immunity; Pre-exposure prophylaxis; Immunology; Virology; Pediatrics; Internal medicine; Syphilis","score_opus":0.07866749751149223,"score_gpt":0.40162682976966124,"score_spread":0.32295933225816903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015855111","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046704372,0.9968314,0.00022344339,0.00004720666,0.0011991222,0.001002748,0.000043499003,0.000074489384,0.0005313401],"genre_scores_gemma":[0.0000629976,0.99787533,0.00021863483,0.00055639667,0.00011292713,0.0003705277,0.00013982951,0.000050291535,0.000613058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943317,0.0025804506,0.0013517928,0.00088419754,0.000021911157,0.0008299404],"domain_scores_gemma":[0.99274737,0.005984453,0.0006294337,0.0005695624,0.0000328185,0.000036358324],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0029241217,0.0006528072,0.0034977894,0.00033381674,0.00015025666,0.0000038451526,0.00047478618,0.0017406566,0.0001612434],"category_scores_gemma":[0.00081295514,0.00045590723,0.00038487458,0.00027499456,0.0013107116,0.00014118142,0.0000797473,0.0011792284,0.00019839655],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097062744,0.000050377133,0.00070652243,0.00088929647,0.00017975354,0.000010914069,0.00003530166,9.090846e-7,0.000007654405,0.0020097517,0.000108245804,0.9959042],"study_design_scores_gemma":[0.0007729075,0.00032057022,0.00010203208,0.0012145019,0.00005838202,0.00016273273,0.00002384682,1.4655804e-7,0.000003762501,0.0027075782,0.99419516,0.00043837802],"about_ca_topic_score_codex":0.00001678242,"about_ca_topic_score_gemma":0.000026821399,"teacher_disagreement_score":0.9954658,"about_ca_system_score_codex":0.00006452999,"about_ca_system_score_gemma":0.000093295945,"threshold_uncertainty_score":0.99978924},"labels":[],"label_agreement":null},{"id":"W2025271862","doi":"10.1007/s12325-010-0065-y","title":"Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs","year":2010,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Circadian rhythm and melatonin","field":"Neuroscience","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; Centre for Addiction and Mental Health","funders":"","keywords":"Circadian rhythm; Medicine; Melatonin; Depression (economics); Internal medicine; Rhythm; Rheumatology; Sleep (system call); Lag; Endocrinology; Neuroscience; Psychology; Keynesian economics","score_opus":0.020232468540926883,"score_gpt":0.30113624049935034,"score_spread":0.2809037719584235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025271862","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004175438,0.99267894,0.0000031174263,0.000028089442,0.0004839147,0.000802575,0.00008069887,0.000026867763,0.0017203594],"genre_scores_gemma":[0.025870249,0.97350943,0.000029010256,0.000110435714,0.00019390977,0.00014274145,0.000005427001,0.000051481205,0.00008733046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977489,0.0002809517,0.00054481433,0.0007591186,0.00025721767,0.0004089587],"domain_scores_gemma":[0.9980598,0.0007940257,0.00045429516,0.00052872684,0.000024156518,0.0001390064],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002944232,0.0004587696,0.0011328988,0.00017760898,0.0001650888,0.00004862974,0.00042141118,0.00033856678,0.00003101942],"category_scores_gemma":[0.00017241795,0.00028365615,0.00015500799,0.00047410614,0.00041769308,0.00037469968,0.00009608489,0.0008585695,0.000007864145],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010667798,0.000024482837,0.0005771564,0.00041176664,0.000008329829,0.0000199132,0.00027149593,8.546807e-7,0.000110515284,0.009976424,0.0000025965178,0.98858577],"study_design_scores_gemma":[0.00034013623,0.000038659695,0.00019699888,0.0012906593,0.000033078897,0.00029221285,0.000026516487,0.000024799483,0.0037093286,0.0011330271,0.9925851,0.00032945018],"about_ca_topic_score_codex":0.000007631444,"about_ca_topic_score_gemma":0.000053452295,"teacher_disagreement_score":0.99258256,"about_ca_system_score_codex":0.000023244316,"about_ca_system_score_gemma":0.00007625054,"threshold_uncertainty_score":0.99996156},"labels":[],"label_agreement":null},{"id":"W2029482308","doi":"10.1007/bf02849951","title":"Hepatitis A: A preventable threat","year":2005,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Hepatitis Viruses Studies and Epidemiology","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Centers for Disease Control and Prevention; Merck Canada","keywords":"Medicine; Hepatitis A; Subclinical infection; Fulminant hepatitis; Hepatitis; Transmission (telecommunications); Immunology; Population; Vaccination; Public health; Pediatrics; Hepatitis A vaccine; Disease; Internal medicine; Environmental health; Pathology","score_opus":0.0993260033890419,"score_gpt":0.4554084732739031,"score_spread":0.3560824698848612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029482308","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001688544,0.99005073,0.000035193523,0.00008319879,0.00040465497,0.0010039179,0.00002558906,0.000050348615,0.008329461],"genre_scores_gemma":[0.0000012200113,0.99576527,0.001143075,0.00081041513,0.00062170485,0.00046638958,0.000065056636,0.0000626577,0.0010642098],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998037,0.00017236966,0.0007389696,0.00045867558,0.00013050629,0.00046249555],"domain_scores_gemma":[0.9989227,0.0003132188,0.00023498133,0.0004231299,0.000026654641,0.00007930295],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002539314,0.00039840295,0.0026631614,0.00014244702,0.000051920408,0.000005246315,0.00015713244,0.00026336583,0.0004476851],"category_scores_gemma":[0.00008335836,0.00027929113,0.0004021792,0.00028311618,0.00009550666,0.00013251968,0.000047989266,0.0004248925,0.00016303902],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017129443,0.00008790741,0.0055622575,0.0016984296,0.000105989595,0.000040604442,0.00002727983,0.0000013114959,2.0152102e-8,0.00015900352,0.00082363066,0.9914764],"study_design_scores_gemma":[0.00053420285,0.00026261614,0.00011178145,0.0064280145,0.00009896608,0.00008254174,0.000003509398,0.00000274217,1.4195176e-7,0.0002618988,0.9919763,0.00023724171],"about_ca_topic_score_codex":0.0007017195,"about_ca_topic_score_gemma":0.0022311257,"teacher_disagreement_score":0.9912392,"about_ca_system_score_codex":0.00027686273,"about_ca_system_score_gemma":0.000121745965,"threshold_uncertainty_score":0.9999659},"labels":[],"label_agreement":null},{"id":"W2030454755","doi":"10.1007/s12325-014-0105-0","title":"A Vision for Drug Discovery and Development: Novel Targets and Multilateral Partnerships","year":2014,"lang":"en","type":"letter","venue":"Advances in Therapy","topic":"Treatment of Major Depression","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psychiatry; Antidepressant; Anxiety; Psychotropic Agent; Tolerability; Psychotropic drug; Tetrabenazine; Mood; Drug; Pharmacology; Adverse effect","score_opus":0.03910138715306772,"score_gpt":0.3250471489770344,"score_spread":0.2859457618239667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030454755","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28018704,0.21392082,0.0064941756,0.48937193,0.0017435305,0.007366978,0.00011770164,0.00029660334,0.00050122396],"genre_scores_gemma":[0.22037935,0.044826046,0.10452428,0.61115557,0.0040595117,0.0014236306,0.0023420095,0.00046798395,0.010821625],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986011,0.000039111896,0.00027980332,0.0005474892,0.00021750949,0.00031499105],"domain_scores_gemma":[0.9992392,0.00032013137,0.00014011693,0.00022396375,0.000025407484,0.00005120383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016284421,0.00034210453,0.00049996993,0.00013940045,0.00006977891,0.000043132135,0.000075935575,0.00026054142,0.000005218725],"category_scores_gemma":[0.00002372049,0.00024236883,0.0000447907,0.00003644842,0.00009304778,0.00037451787,0.000035753077,0.00039622307,0.0000018175504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005863771,0.00086840213,0.05891949,0.0030117496,0.00043743785,0.0003390087,0.00392375,0.000009720326,0.0053028273,0.0000556204,0.16619118,0.75507706],"study_design_scores_gemma":[0.0071925707,0.00025309954,0.004461393,0.0007057941,0.0000185145,0.00003072616,0.0000127345875,0.000048856135,0.0014863173,0.0002309194,0.9852793,0.00027978123],"about_ca_topic_score_codex":0.0000038497383,"about_ca_topic_score_gemma":0.000014328172,"teacher_disagreement_score":0.8190881,"about_ca_system_score_codex":0.000054226955,"about_ca_system_score_gemma":0.000033292246,"threshold_uncertainty_score":0.98835135},"labels":[],"label_agreement":null},{"id":"W2031131661","doi":"10.1007/s12325-013-0060-1","title":"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis","year":2013,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":520,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Sanofi; Genentech; AstraZeneca; Amgen; Pfizer; Allergan; Bristol-Myers Squibb; Genomic Health; GlaxoSmithKline","keywords":"Exemestane; Everolimus; Medicine; Hazard ratio; Internal medicine; Aromatase inhibitor; Breast cancer; Oncology; Clinical endpoint; Placebo; Population; Adverse effect; Progression-free survival; Confidence interval; Cancer; Clinical trial; Aromatase; Chemotherapy; Pathology","score_opus":0.004021741589793851,"score_gpt":0.25670740316139484,"score_spread":0.252685661571601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031131661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849027,0.014117971,0.00003588784,0.00011922634,0.00010789063,0.0004636488,0.000030060552,0.000011868672,0.00021073723],"genre_scores_gemma":[0.9913831,0.0077166082,0.00034230755,0.000114788396,0.000055618613,0.00017058487,0.00013129789,0.0000244017,0.0000613203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987189,0.000094420066,0.00021582407,0.00038748083,0.0002302955,0.00035307137],"domain_scores_gemma":[0.9993565,0.000017982158,0.000104635496,0.00036055245,0.00008496077,0.00007535975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092801696,0.00021754466,0.0002670918,0.000115244045,0.00004355888,0.000019477786,0.00026658317,0.00013834285,0.000048384554],"category_scores_gemma":[0.000007997705,0.00015348877,0.0000541005,0.00045741213,0.00008983387,0.000028779288,0.00005657515,0.00015943061,0.0000040579343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021945569,0.00044592738,0.89803344,0.000012390377,0.00031301554,0.000016864675,0.000086788656,0.0026993628,0.010012187,0.00001727493,0.00005743412,0.08611077],"study_design_scores_gemma":[0.009300088,0.001864647,0.98042065,0.000080734,0.000059552487,0.0000072652088,0.00006333051,0.00029189012,0.0058258018,0.00016908019,0.0013760641,0.00054091896],"about_ca_topic_score_codex":0.0002028602,"about_ca_topic_score_gemma":0.00030671328,"teacher_disagreement_score":0.08556985,"about_ca_system_score_codex":0.00004645712,"about_ca_system_score_gemma":0.00006618691,"threshold_uncertainty_score":0.62590903},"labels":[],"label_agreement":null},{"id":"W2031765694","doi":"10.1007/bf02850014","title":"Twice-daily and once-daily nedocromil sodium 2% ophthalmic solution for the treatment of seasonal allergic conjunctivitis","year":2002,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Ocular Surface and Contact Lens","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Niagara","funders":"","keywords":"Medicine; Nedocromil Sodium; Regimen; Itching; Allergic conjunctivitis; Allergy; Erythema; Anesthesia; Nedocromil; Activities of daily living; Photophobia; Surgery; Dermatology; Internal medicine; Physical therapy; Placebo","score_opus":0.0250427320413113,"score_gpt":0.2884445988140779,"score_spread":0.2634018667727666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031765694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84545344,0.15106294,0.00035826644,0.0016175564,0.00018810415,0.00067342387,0.000014074606,0.000017721924,0.00061445386],"genre_scores_gemma":[0.875424,0.12292196,0.0004740257,0.00028570023,0.00010065029,0.00010236836,0.000006157146,0.00001718667,0.0006679197],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999195,0.000034868473,0.00018325211,0.00021913658,0.00014385888,0.00022388675],"domain_scores_gemma":[0.99937344,0.00023433748,0.00008138604,0.00022086338,0.00004431923,0.00004567182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007675237,0.00015678222,0.00029009362,0.000037842143,0.00007336291,0.000009171494,0.00006045802,0.000055412267,0.00010418431],"category_scores_gemma":[0.000009534908,0.00010244223,0.00010802888,0.00009380293,0.00011847093,0.00015346312,0.000005843696,0.00006129052,0.000005028869],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023596098,0.0010241065,0.059483513,0.00005357738,0.00028065447,0.000033605527,0.002373622,0.000059951195,0.012699753,0.000405515,0.000091896254,0.9211342],"study_design_scores_gemma":[0.038800653,0.017111056,0.10349693,0.00027727042,0.00022560064,0.00010051978,0.001323438,0.019036379,0.023056895,0.0016680525,0.7942492,0.0006540264],"about_ca_topic_score_codex":0.00005657915,"about_ca_topic_score_gemma":0.00007459166,"teacher_disagreement_score":0.9204802,"about_ca_system_score_codex":0.000064391206,"about_ca_system_score_gemma":0.000022835993,"threshold_uncertainty_score":0.41774732},"labels":[],"label_agreement":null},{"id":"W2034737107","doi":"10.1007/bf02850362","title":"Spermicidal activity of a new contraceptive sponge","year":2002,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hemostasis and retained surgical items","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Collège Shawinigan","funders":"","keywords":"Medicine; Sponge; Colposcopy; Cervix; Irritation; Gynecology; Internal medicine; Biology; Immunology","score_opus":0.04216022221333456,"score_gpt":0.32608020600497994,"score_spread":0.2839199837916454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034737107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597477,0.024415119,0.00014024976,0.00092947367,0.00009089182,0.00025045735,0.0000035642809,0.000017781242,0.014404771],"genre_scores_gemma":[0.97866184,0.018994424,0.00029042302,0.00025916562,0.00010230601,0.0000036634906,9.658839e-7,0.000009823321,0.0016773918],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993483,0.000032779524,0.0001617302,0.00014679818,0.00014375939,0.00016663673],"domain_scores_gemma":[0.9995912,0.00009535481,0.000058754435,0.00014702517,0.000027521222,0.00008019432],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009036462,0.000094513984,0.0003135643,0.000050279887,0.000012666071,0.000002610034,0.00004956685,0.000058678743,0.0010165033],"category_scores_gemma":[0.000032168624,0.00006531424,0.000078891426,0.00017989993,0.00008091046,0.00012822742,0.000006192432,0.0001410122,0.000015423935],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062582776,0.00036758243,0.0105132805,0.000012494817,0.000024072264,0.000050501214,0.0007182381,0.00001618483,0.017363755,0.0002503857,0.000114299626,0.9699434],"study_design_scores_gemma":[0.014463097,0.001844703,0.05040815,0.00024664422,0.000019720099,0.00007722424,0.00034985653,0.0018542451,0.13653935,0.0013922836,0.79240125,0.000403472],"about_ca_topic_score_codex":0.000038616774,"about_ca_topic_score_gemma":0.000013829515,"teacher_disagreement_score":0.9695399,"about_ca_system_score_codex":0.000024993273,"about_ca_system_score_gemma":0.0000147513265,"threshold_uncertainty_score":0.9998967},"labels":[],"label_agreement":null},{"id":"W2037948983","doi":"10.1007/bf02849883","title":"Do angiotensin II antagonists provide benefits beyond blood pressure reduction?","year":2005,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Losartan; Irbesartan; Diabetes mellitus; Blood pressure; Internal medicine; Nephropathy; Angiotensin II; Diabetic nephropathy; Angiotensin II receptor type 1; Endocrinology; Pathophysiology of hypertension; Cardiology; Pharmacology","score_opus":0.04083159708548231,"score_gpt":0.3511079407050125,"score_spread":0.31027634361953016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037948983","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011679127,0.9946041,5.304474e-7,0.0007866927,0.00070832175,0.0016586201,0.000059850176,0.00012041637,0.0020497523],"genre_scores_gemma":[0.000054327415,0.9927573,0.0015467318,0.00072068174,0.0017571436,0.00020360888,0.000075074204,0.00011091927,0.0027741985],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972667,0.000120135526,0.00081281987,0.0008789553,0.00042871985,0.000492675],"domain_scores_gemma":[0.998367,0.00011773092,0.0003849425,0.0008140567,0.0001949439,0.00012129025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024098628,0.0006751968,0.0029725994,0.0003138138,0.00022594444,0.000031572985,0.00024786216,0.00044755184,0.00009587699],"category_scores_gemma":[0.000034547473,0.00048073375,0.0005007115,0.00050319155,0.00016994307,0.0002805241,0.000114392475,0.00073062134,0.00002460113],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008189042,0.00045360558,0.000015097988,0.0018611802,0.0015601087,0.00006730467,0.00020311863,0.000003928282,0.000006228114,0.00011888166,0.0055657257,0.99006295],"study_design_scores_gemma":[0.001449412,0.00038780546,0.000010276661,0.0070522195,0.0054336856,0.00090551074,0.000024385372,6.291778e-7,0.000030621504,0.00010500692,0.9841325,0.00046793494],"about_ca_topic_score_codex":0.00001141098,"about_ca_topic_score_gemma":0.0000144041205,"teacher_disagreement_score":0.989595,"about_ca_system_score_codex":0.000015244579,"about_ca_system_score_gemma":0.00019015594,"threshold_uncertainty_score":0.99976444},"labels":[],"label_agreement":null},{"id":"W2039599497","doi":"10.1007/bf02849796","title":"Attention deficit hyperactivity disorder: An update","year":2003,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"University of Calgary","keywords":"Attention deficit hyperactivity disorder; Stimulant; Medicine; Attention deficit disorder; Psychiatry; Attention deficit; Pediatrics","score_opus":0.05501411464251477,"score_gpt":0.4041931295709455,"score_spread":0.34917901492843073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039599497","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01047516,0.98549914,0.00040288572,0.000050841532,0.0005037574,0.0016439065,0.000029228264,0.00012581074,0.0012692707],"genre_scores_gemma":[0.0005498605,0.9971868,0.00057907676,0.00013216022,0.000113189904,0.0003197612,0.0004575861,0.00017346386,0.00048814135],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99673516,0.0005609361,0.00079042825,0.00094404124,0.00044719232,0.0005222548],"domain_scores_gemma":[0.99810797,0.00018433326,0.0005167038,0.00095852464,0.00009117611,0.00014131797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040250944,0.0007076853,0.0022150846,0.00044129914,0.000112956644,0.000046201763,0.00023954267,0.00042877562,0.00048669006],"category_scores_gemma":[0.00006996545,0.0005940311,0.0005995809,0.00078463904,0.00010628258,0.0011491157,0.000031830365,0.0009766705,0.00031106535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051448587,0.0010753903,0.0058434606,0.0018391685,0.000085603424,0.00003401591,0.00000716434,0.000008900405,0.000002730469,0.00020206225,0.0000041188246,0.9908459],"study_design_scores_gemma":[0.0014408606,0.00022715658,0.00045174544,0.0022410783,0.00023251053,0.00021688061,0.0001060564,0.000011515193,1.2628075e-7,0.0000953884,0.99439746,0.0005792252],"about_ca_topic_score_codex":0.000017996641,"about_ca_topic_score_gemma":0.000081070975,"teacher_disagreement_score":0.99439335,"about_ca_system_score_codex":0.0002173082,"about_ca_system_score_gemma":0.00020680788,"threshold_uncertainty_score":0.99965113},"labels":[],"label_agreement":null},{"id":"W2041092876","doi":"10.1007/bf02849904","title":"Pertussis in Adolescents","year":2007,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Bacterial Infections and Vaccines","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Sanofi Pasteur; Sanofi","keywords":"Medicine; Vaccination; Pediatrics; Diphtheria; Immunization; Immunology; Booster dose; Tetanus; Pertussis vaccine; Immunity; Pneumonia; Internal medicine; Immune system","score_opus":0.04383583736231224,"score_gpt":0.3751473641219168,"score_spread":0.33131152675960457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041092876","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029425722,0.99695134,0.0000054116,0.000004072927,0.0018867173,0.0003549379,0.0000091449265,0.000026157493,0.00046795906],"genre_scores_gemma":[0.00039485298,0.99909335,0.000009887929,0.000032855,0.00007421568,0.00006670551,0.000050407238,0.00002546876,0.0002522566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987706,0.00017879548,0.0004593389,0.00028439699,0.000008701013,0.0002981688],"domain_scores_gemma":[0.9995472,0.00006754508,0.00013983884,0.00022406393,0.000013011989,0.000008372388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018565869,0.00026151893,0.00089225476,0.0003555904,0.000034954897,0.000007349174,0.00020057832,0.00043526458,0.00027121656],"category_scores_gemma":[0.000013810246,0.00019076465,0.00016131547,0.00036572362,0.00004764194,0.00012188535,0.000026009684,0.00044739808,0.00020360909],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029501147,0.00013274557,0.00057212234,0.00054236816,0.000021052083,0.0000019072503,0.00002272801,1.7528382e-7,0.000022997443,0.000045727782,0.000021754393,0.9985869],"study_design_scores_gemma":[0.000608848,0.00005115504,0.00019849371,0.0052751424,0.000009637917,0.000024612971,0.0000074146637,1.385765e-8,0.000015124628,0.000045420944,0.9935626,0.0002015337],"about_ca_topic_score_codex":0.0000611898,"about_ca_topic_score_gemma":0.0002642697,"teacher_disagreement_score":0.99838537,"about_ca_system_score_codex":0.00007294954,"about_ca_system_score_gemma":0.000039565522,"threshold_uncertainty_score":0.77791566},"labels":[],"label_agreement":null},{"id":"W2042419273","doi":"10.1007/bf02852391","title":"Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa","year":2001,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Sinusitis and nasal conditions","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Clarithromycin; Gastroenterology; Edema; Internal medicine; Sinusitis; Inflammation; Maxillary sinus; Sinus (botany); CD68; Pathology; Surgery; Immunohistochemistry","score_opus":0.008429592275651009,"score_gpt":0.28125749022338076,"score_spread":0.27282789794772977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042419273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408233,0.0037134376,0.00010341099,0.00022145995,0.000057815254,0.000416459,0.000005572956,0.000030035015,0.0013694507],"genre_scores_gemma":[0.9926251,0.0065539377,0.00046641805,0.00020605132,0.0000597703,0.00003434049,0.000010012929,0.000018466724,0.000025900905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998998,0.000055114313,0.0002749468,0.00023379854,0.00020443602,0.00023370596],"domain_scores_gemma":[0.9993902,0.00010443416,0.00011532717,0.0002684392,0.00006525037,0.000056381337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014601905,0.00014092457,0.00037623988,0.00016689532,0.000024089664,0.00000418475,0.00008439034,0.00009201582,0.00011634109],"category_scores_gemma":[0.000025447418,0.000111988214,0.00004555722,0.00042440166,0.00016955339,0.00031138756,0.000011946388,0.00026748952,0.0000037462275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004492127,0.0009022548,0.8501683,0.00010036504,0.000042449512,0.00080006954,0.000521033,0.00032064208,0.02548193,0.00038686808,0.000016742706,0.11676724],"study_design_scores_gemma":[0.0079286685,0.00080714654,0.97930974,0.0006339111,0.0000057460434,0.00009977603,0.000096411866,0.00007860482,0.008878953,0.00015509831,0.0018568175,0.00014910444],"about_ca_topic_score_codex":0.00009311781,"about_ca_topic_score_gemma":0.0016220863,"teacher_disagreement_score":0.12914148,"about_ca_system_score_codex":0.00008867422,"about_ca_system_score_gemma":0.00013450874,"threshold_uncertainty_score":0.4566747},"labels":[],"label_agreement":null},{"id":"W2042533101","doi":"10.1007/s12325-012-0040-x","title":"Impact of Daily Dosing Frequency on Adherence to Chronic Medications Among Nonvalvular Atrial Fibrillation Patients","year":2012,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Atrial fibrillation; Internal medicine; Dosing; Confounding; Odds ratio; Regimen; Logistic regression; Diabetes mellitus; Cardiology; Endocrinology","score_opus":0.03148974737146387,"score_gpt":0.37759576891472324,"score_spread":0.34610602154325937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042533101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895403,0.006723131,0.00089248165,0.00007918104,0.00031624208,0.00063140795,0.0000065687377,0.000023354993,0.0017873804],"genre_scores_gemma":[0.9956101,0.0027775036,0.0009221653,0.00010573922,0.0004371668,0.0000262145,0.000034445635,0.000012989457,0.00007368335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998743,0.000051480252,0.00036007664,0.00019033016,0.00040045357,0.00025463276],"domain_scores_gemma":[0.99907285,0.000093592564,0.00020375177,0.00035730918,0.000104999664,0.00016750964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021243455,0.00012918819,0.0002415003,0.00013248953,0.00004011597,0.000004928214,0.00013397692,0.00006132992,0.00059279485],"category_scores_gemma":[0.00014231518,0.00010215136,0.00010809807,0.00043111498,0.00007511253,0.0003663972,0.000011210581,0.00012040262,0.0001375031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014822607,0.00007929142,0.8708799,0.000014691309,0.000025396783,2.250869e-7,0.00037611433,0.00030024134,0.00084856874,0.00014901916,0.00007653883,0.12710178],"study_design_scores_gemma":[0.0021271524,0.0017906238,0.9928535,0.00034919192,0.000011601119,8.9578015e-7,0.000029814137,0.0001582442,0.00059670216,0.00026915153,0.0016927489,0.00012035653],"about_ca_topic_score_codex":0.0000814155,"about_ca_topic_score_gemma":0.000008744082,"teacher_disagreement_score":0.12698142,"about_ca_system_score_codex":0.00020772507,"about_ca_system_score_gemma":0.00014865362,"threshold_uncertainty_score":0.6490688},"labels":[],"label_agreement":null},{"id":"W2042751221","doi":"10.1007/s12325-015-0195-3","title":"Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial","year":2015,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Metformin; Linagliptin; Medicine; Type 2 diabetes; Internal medicine; Nausea; Gastroenterology; Vildagliptin; Clinical endpoint; Diabetes mellitus; Vomiting; Dipeptidyl peptidase-4 inhibitor; Randomized controlled trial; Endocrinology; Insulin","score_opus":0.0350316925553353,"score_gpt":0.32522749050495703,"score_spread":0.29019579794962175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042751221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862337,0.0051636,0.00001048517,0.00005192726,0.0002766395,0.006577009,0.000016419544,0.000038649134,0.0016315372],"genre_scores_gemma":[0.9913602,0.0044395016,0.0028543444,0.00007248383,0.00006727915,0.00058138993,0.00028888162,0.000056724497,0.00027920387],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976281,0.00016681956,0.0007132149,0.0005412802,0.00047848513,0.00047210863],"domain_scores_gemma":[0.9981003,0.000653903,0.00042568828,0.0004868991,0.00014426016,0.000188962],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006210065,0.00047682415,0.0014893132,0.0003339126,0.000040440616,0.000029978313,0.00015650288,0.00009778321,0.000023568935],"category_scores_gemma":[0.00008800327,0.0002927414,0.00008365641,0.0005866386,0.00029458973,0.00056347315,0.000036070305,0.00013959369,0.000005732458],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9055531,0.002535234,0.006476252,0.00005102634,0.00067630806,0.000035738078,0.001328246,0.00006168463,0.000017820128,0.000113098344,0.000005281727,0.08314624],"study_design_scores_gemma":[0.9662702,0.02628315,0.0012482399,0.0003181527,0.00037374048,6.580191e-7,0.00035114278,0.00004440994,0.0012865338,0.000059489397,0.003453435,0.00031082742],"about_ca_topic_score_codex":0.0000836109,"about_ca_topic_score_gemma":0.00016519168,"teacher_disagreement_score":0.082835406,"about_ca_system_score_codex":0.00027024784,"about_ca_system_score_gemma":0.00017232604,"threshold_uncertainty_score":0.9999525},"labels":[],"label_agreement":null},{"id":"W2046049334","doi":"10.1007/s12325-013-0042-3","title":"The Effect of Personality Dimensions on Functional Outcomes in Mood Disorders","year":2013,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Personality Disorders and Psychopathology","field":"Psychology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Extraversion and introversion; Neuroticism; Agreeableness; Conscientiousness; Openness to experience; Big Five personality traits; Clinical psychology; Major depressive disorder; Personality; Psychology; Personality disorders; Mood; Medicine; Psychiatry","score_opus":0.012852323324248505,"score_gpt":0.33146203620695885,"score_spread":0.31860971288271034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046049334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756259,0.005736355,0.000020865638,0.0021017408,0.00085322716,0.00046024425,0.000007925122,0.000015124086,0.015178635],"genre_scores_gemma":[0.9974624,0.0014094111,0.000012555388,0.00037155332,0.000022688848,0.00033253257,0.000004879736,0.000012425051,0.00037157643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853134,0.00047111555,0.00026923342,0.0002791823,0.00015600365,0.0002931168],"domain_scores_gemma":[0.998226,0.0013261869,0.00008852352,0.00031533948,0.00001506158,0.000028905375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041998833,0.0001622897,0.00027028265,0.00007999695,0.00007644228,0.0000072952425,0.00018415645,0.00008277133,0.00065368495],"category_scores_gemma":[0.000045917404,0.00009849775,0.00011003478,0.00019876487,0.00023686112,0.00010147295,0.000011745019,0.00023106829,0.00007458352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000613187,0.00027963435,0.92497647,0.0000042608317,0.00002699434,6.8188785e-7,0.0009824364,0.00007173919,0.00006745855,0.0046497136,0.00022643784,0.06810102],"study_design_scores_gemma":[0.0029845922,0.0006804652,0.97633266,0.000010309169,0.0000020189643,0.0000014873692,0.0006667114,0.00001692289,0.000019862859,0.011605088,0.0075572254,0.0001226336],"about_ca_topic_score_codex":0.0004232647,"about_ca_topic_score_gemma":0.0017535852,"teacher_disagreement_score":0.06797838,"about_ca_system_score_codex":0.000020942936,"about_ca_system_score_gemma":0.000007397073,"threshold_uncertainty_score":0.7157392},"labels":[],"label_agreement":null},{"id":"W2048070250","doi":"10.1007/bf02853165","title":"Nedocromil sodium in golfers with seasonal allergic conjunctivitis","year":2001,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Ocular Surface and Contact Lens","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Niagara College; Regional Municipality of Niagara","funders":"Allergan","keywords":"Medicine; Nedocromil Sodium; Ragweed; Erythema; Nedocromil; Allergy; Allergic conjunctivitis; Dermatology; Anesthesia; Photophobia; Eye drop; Itching; Internal medicine; Ophthalmology; Placebo","score_opus":0.00952622852601325,"score_gpt":0.2660237597901255,"score_spread":0.25649753126411223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048070250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743439,0.015838342,0.00009881266,0.0011612532,0.00009957244,0.00025719282,0.0000013631069,0.000032332682,0.008167226],"genre_scores_gemma":[0.97362083,0.023676123,0.000398406,0.001517582,0.000059059388,0.0000303532,0.0000074606237,0.000021859134,0.0006683254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990977,0.000036907462,0.00014321569,0.00024047874,0.00019149929,0.00029018923],"domain_scores_gemma":[0.9996268,0.00004656181,0.000037276575,0.00020068292,0.000026053036,0.00006261693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009480658,0.00014630158,0.00026315512,0.00007926589,0.000021525864,0.000008767145,0.00007060196,0.00005078523,0.00021415812],"category_scores_gemma":[0.000007105275,0.00011244362,0.000042684886,0.00027883085,0.00006515322,0.00025501996,0.0000078392595,0.00019390834,0.00002329243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024624013,0.00023350159,0.8945687,0.000011196383,0.00003446931,0.0007093199,0.00032619206,0.00016235042,0.0010851875,0.0002786009,0.000017839347,0.10011023],"study_design_scores_gemma":[0.019709,0.0019352544,0.5181343,0.00036224644,0.000014600847,0.00011837212,0.00096263416,0.0003552013,0.0029855843,0.0010900053,0.4538225,0.0005103457],"about_ca_topic_score_codex":0.00008065177,"about_ca_topic_score_gemma":0.001050066,"teacher_disagreement_score":0.45380464,"about_ca_system_score_codex":0.000066867615,"about_ca_system_score_gemma":0.00007318628,"threshold_uncertainty_score":0.45853177},"labels":[],"label_agreement":null},{"id":"W2048501761","doi":"10.1007/bf02849928","title":"Genital infection with human papillomavirus in adolescents","year":2005,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Colposcopy; Genital warts; HPV infection; Sex organ; Dysplasia; Cervical cancer; Chlamydia; Cryotherapy; Gynecology; Subclinical infection; Cervical intraepithelial neoplasia; Dermatology; Internal medicine; Cancer; Immunology; Surgery","score_opus":0.07235310809388833,"score_gpt":0.46633267731604733,"score_spread":0.393979569222159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048501761","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022755357,0.991857,0.0000050264603,0.000011236968,0.00007429645,0.0008365623,0.0000051567026,0.000027619895,0.006955545],"genre_scores_gemma":[0.0020169448,0.9969557,0.000035171095,0.00010533702,0.00037027433,0.00018676963,0.000043681015,0.000054011976,0.00023210605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984187,0.00011978545,0.00039381185,0.00039356027,0.00033452563,0.0003396575],"domain_scores_gemma":[0.9994431,0.000027058906,0.0000900415,0.00029724787,0.00005627598,0.00008625853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001602343,0.0002794624,0.0010340497,0.0003031167,0.000032018263,0.000014480049,0.00010526338,0.00018160358,0.0005232559],"category_scores_gemma":[0.000011193576,0.00019394302,0.00014927941,0.0006331703,0.00007826963,0.00014992728,0.000025797717,0.00078971003,0.000051768035],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017391439,0.0002690696,0.005370165,0.0040912754,0.000021731432,0.00008768356,0.000022216396,0.0000016225648,5.777554e-7,0.000025303923,0.0000043274163,0.9899321],"study_design_scores_gemma":[0.0023465352,0.00038498337,0.007355105,0.005674177,0.000031030813,0.000050541552,0.0000033826923,5.638675e-7,0.0000036561903,0.00009651045,0.98384,0.0002135432],"about_ca_topic_score_codex":0.000087677814,"about_ca_topic_score_gemma":0.0024746389,"teacher_disagreement_score":0.98971856,"about_ca_system_score_codex":0.00040299149,"about_ca_system_score_gemma":0.00020509964,"threshold_uncertainty_score":0.7908767},"labels":[],"label_agreement":null},{"id":"W2049211995","doi":"10.1007/bf02854842","title":"Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis","year":2000,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Ocular Surface and Contact Lens","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AGE-WELL","keywords":"Ketorolac Tromethamine; Medicine; Tolerability; Ketorolac; Anesthesia; Eye drop; Placebo; Pharmacology; Adverse effect","score_opus":0.0068114426366543785,"score_gpt":0.25747307312865775,"score_spread":0.25066163049200335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049211995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899269,0.009216775,0.00002176158,0.000103525716,0.000022907174,0.00044147734,0.000008757848,0.000009112324,0.00024881255],"genre_scores_gemma":[0.99353874,0.005550668,0.00063918345,0.00015905451,0.000012531459,0.000008327084,0.000016903237,0.000014290367,0.00006031241],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916196,0.00005345085,0.0002279955,0.00021888204,0.00016924918,0.00016848774],"domain_scores_gemma":[0.99961823,0.00011015398,0.000059538612,0.00012566529,0.000030393148,0.0000559886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009184979,0.00014063591,0.0003902802,0.000063780906,0.000016576943,0.0000042550264,0.00003309848,0.000040401002,0.00013326795],"category_scores_gemma":[0.000011861032,0.00010598224,0.000018693054,0.00013369022,0.00009653657,0.00016176447,0.000008739801,0.00013440229,0.0000010223731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010360989,0.000506584,0.7672146,0.000023666842,0.000031653886,0.0000070949463,0.00041108954,0.000053454125,0.00014761659,0.0000059978247,9.165587e-7,0.22123636],"study_design_scores_gemma":[0.028052216,0.0016934958,0.96391135,0.00021979034,0.000011012267,0.0000014209726,0.000064845735,0.00032227297,0.00022417521,0.0000067622905,0.0053842636,0.000108414984],"about_ca_topic_score_codex":0.000033655546,"about_ca_topic_score_gemma":0.00012489906,"teacher_disagreement_score":0.22112796,"about_ca_system_score_codex":0.00002188558,"about_ca_system_score_gemma":0.000014648614,"threshold_uncertainty_score":0.43218303},"labels":[],"label_agreement":null},{"id":"W2052480782","doi":"10.1007/bf02850250","title":"Herbal medicine in pregnancy and childbirth","year":2001,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"Medicine; Miscarriage; Alternative medicine; Childbirth; Pregnancy; Traditional medicine; Medicinal herbs; Biomedicine; Intervention (counseling); Reproductive medicine; Family medicine; Nursing; Bioinformatics","score_opus":0.07442254208158312,"score_gpt":0.43475722358077035,"score_spread":0.36033468149918724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052480782","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016218609,0.99074364,0.0000090533495,0.00017892888,0.0003122754,0.0011882952,0.000006660288,0.000020733773,0.0073782164],"genre_scores_gemma":[0.00008876125,0.99859285,0.00008448293,0.0001517333,0.0005132504,0.00016339814,0.00004760867,0.00003187962,0.00032603272],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827486,0.000103457234,0.0006585104,0.00044943177,0.00021539677,0.00029831307],"domain_scores_gemma":[0.999226,0.00026479003,0.00018471801,0.00024062312,0.00001861146,0.00006531008],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017190001,0.00040368168,0.001975491,0.00033196434,0.000033202934,0.0000027026922,0.000126706,0.000034932735,0.00024062177],"category_scores_gemma":[0.00005485576,0.00025214194,0.00008830143,0.00052216055,0.0002461529,0.00010399468,0.000047822974,0.00044007014,0.0000034957918],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037620735,0.000087006134,0.00714642,0.0029101695,0.00006614153,0.0002169502,0.00027551633,1.2257473e-7,7.039624e-8,0.00014970962,0.000018614592,0.98909163],"study_design_scores_gemma":[0.003004568,0.00079140405,0.00100034,0.080094896,0.00006299237,0.00011059144,0.00013440748,6.420715e-7,1.8053866e-7,0.0005007723,0.9141105,0.00018872028],"about_ca_topic_score_codex":0.000049717604,"about_ca_topic_score_gemma":0.00016491015,"teacher_disagreement_score":0.9889029,"about_ca_system_score_codex":0.00008215492,"about_ca_system_score_gemma":0.000038651247,"threshold_uncertainty_score":0.9999931},"labels":[],"label_agreement":null},{"id":"W2058135699","doi":"10.1007/bf02849948","title":"Successful alpha-1 receptor blockade therapy in a toddler with infrequent and difficult voiding","year":2005,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Discontinuation; Blockade; Toddler; Glans penis; Penis; Urology; Internal medicine; Surgery; Anesthesia; Receptor","score_opus":0.016447433172502468,"score_gpt":0.31616925180182165,"score_spread":0.2997218186293192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058135699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9469436,0.048525244,0.000023785497,0.0023670837,0.000031086518,0.00062678545,0.0000034256589,0.000033055232,0.0014459803],"genre_scores_gemma":[0.84805703,0.14990814,0.001055903,0.00042414578,0.00013108812,0.00009740387,0.000009276702,0.000025993117,0.00029102637],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986538,0.00008190239,0.0002461627,0.00033475753,0.0002833735,0.00039994772],"domain_scores_gemma":[0.9994631,0.000120009565,0.000045401113,0.0002089127,0.000056685254,0.000105882486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026100985,0.0001915374,0.00028827562,0.00019551172,0.00005082333,0.000025759246,0.000104879364,0.00006565588,0.000226572],"category_scores_gemma":[0.000015780057,0.0001286006,0.000024833313,0.00044122088,0.00012512926,0.00040448463,0.000019498859,0.00033842854,0.000009416462],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036340377,0.0006088997,0.3658662,0.000041304742,0.00004431888,0.00007241938,0.0035402097,0.00015909936,0.01535842,0.00006442756,0.00006311088,0.61054754],"study_design_scores_gemma":[0.03811845,0.009122415,0.19366123,0.0008147939,0.000010938891,0.00026665672,0.002613472,0.00058132136,0.095984384,0.00087200885,0.6569195,0.0010348194],"about_ca_topic_score_codex":0.00007303822,"about_ca_topic_score_gemma":0.00022767176,"teacher_disagreement_score":0.6568564,"about_ca_system_score_codex":0.00008764552,"about_ca_system_score_gemma":0.00006563228,"threshold_uncertainty_score":0.524418},"labels":[],"label_agreement":null},{"id":"W2058586677","doi":"10.1007/s12325-010-0072-z","title":"The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder","year":2010,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto","funders":"Core Research for Evolutional Science and Technology; University Health Network","keywords":"Medicine; Metabolic syndrome; Internal medicine; Blood pressure; Hypertriglyceridemia; Bipolar disorder; Abdominal obesity; Asymptomatic; National Cholesterol Education Program; Waist; Endocrinology; Diabetes mellitus; Obesity; Physical therapy; Cardiology; Triglyceride; Cholesterol; Lithium (medication)","score_opus":0.005858365976466883,"score_gpt":0.2597760844916533,"score_spread":0.2539177185151864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058586677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82349575,0.17437674,0.0000027389437,0.0009800021,0.00009521222,0.0003964906,0.000014134489,0.000007617347,0.00063133845],"genre_scores_gemma":[0.96983993,0.029549817,0.00020991903,0.00015425286,0.000011617026,0.0000714619,0.000010550514,0.000019201307,0.00013326442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914855,0.000050132527,0.00020356759,0.00017841857,0.00011642943,0.00030292012],"domain_scores_gemma":[0.99943036,0.000071904826,0.00006125504,0.00032272853,0.000026751735,0.00008697475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026321458,0.00014383606,0.00026984664,0.00018671971,0.000092240894,0.0000079499805,0.00014142644,0.000060742695,0.000059263875],"category_scores_gemma":[0.00001651463,0.00008210382,0.000036086174,0.00041699177,0.00015103752,0.00012900813,0.000010876428,0.00027537197,0.0000056643544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006721699,0.00015420458,0.9010159,0.0000057803763,0.000061996296,0.000009870616,0.000545079,0.000010650425,0.00021644811,0.0027463904,0.000001286231,0.09516521],"study_design_scores_gemma":[0.0021639008,0.0002474357,0.6830229,0.000022628681,0.000012903711,0.000029404575,0.00010572735,0.000004432641,0.0005733927,0.0011162901,0.31261984,0.00008115286],"about_ca_topic_score_codex":0.024186486,"about_ca_topic_score_gemma":0.6513253,"teacher_disagreement_score":0.6271388,"about_ca_system_score_codex":0.00001598188,"about_ca_system_score_gemma":0.00017104387,"threshold_uncertainty_score":0.98231155},"labels":[],"label_agreement":null},{"id":"W2060221163","doi":"10.1007/s12325-012-0037-5","title":"Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World Settings","year":2012,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thomson Reuters (Canada)","funders":"Pfizer; Amgen","keywords":"Etanercept; Medicine; Adalimumab; Infliximab; Golimumab; Psoriatic arthritis; Rheumatoid arthritis; Internal medicine; Abatacept; Ankylosing spondylitis; Psoriasis; Ustekinumab; Tumor necrosis factor alpha; Rituximab; Dermatology; Lymphoma","score_opus":0.020276430449864838,"score_gpt":0.3219488934943859,"score_spread":0.30167246304452106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060221163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98750126,0.009549421,0.0000019882107,0.0016431954,0.00007407434,0.00055136427,0.000016112768,0.00001992735,0.00064266677],"genre_scores_gemma":[0.92202246,0.076592855,0.00022063738,0.00067136233,0.00007931339,0.0003560231,0.000007981746,0.000022050279,0.000027292377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986722,0.000102699625,0.00028580983,0.00018823329,0.00023302913,0.00051805936],"domain_scores_gemma":[0.9993983,0.00023273012,0.00005773037,0.00023098162,0.000014543996,0.00006574135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023027301,0.00017029396,0.0002653942,0.0002117025,0.00004400556,0.000026799918,0.00011180011,0.000029368395,0.00023167832],"category_scores_gemma":[0.000029295063,0.00010957952,0.000059100832,0.00031603972,0.000064719665,0.00035375074,0.000015562877,0.00020672918,0.000017680744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034162975,0.00029546238,0.9522063,0.000013702901,0.000013861495,0.000051421972,0.010502642,0.0000016245361,0.00006656018,0.000050445124,0.000013184037,0.036443178],"study_design_scores_gemma":[0.0046047154,0.00040048093,0.933554,0.00040428928,8.87338e-7,0.000012321374,0.0023504796,0.000020704567,0.001232454,0.0002066279,0.057046525,0.0001665076],"about_ca_topic_score_codex":0.000874584,"about_ca_topic_score_gemma":0.0074385335,"teacher_disagreement_score":0.06704343,"about_ca_system_score_codex":0.000159023,"about_ca_system_score_gemma":0.000027431666,"threshold_uncertainty_score":0.44685233},"labels":[],"label_agreement":null},{"id":"W2060833967","doi":"10.1007/s12325-009-0042-5","title":"Aqueous prostaglandin E2 of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing","year":2009,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"Ketorolac; Medicine; Dosing; Cataract surgery; Anesthesia; Latanoprost; Analgesic; Ophthalmology; Pharmacology; Intraocular pressure","score_opus":0.010197662211326224,"score_gpt":0.29404091042541247,"score_spread":0.28384324821408624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060833967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9637735,0.035201527,0.0000060389057,0.00006671658,0.000058536007,0.0003886947,0.000045117813,0.0000107988,0.00044909527],"genre_scores_gemma":[0.9908756,0.008453767,0.00019676442,0.00024917294,0.000027718052,0.000017046556,0.00003806929,0.000010601607,0.0001312702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99926007,0.000023777951,0.00018859695,0.00019675934,0.00015932099,0.00017149656],"domain_scores_gemma":[0.99964345,0.00002901848,0.000078527235,0.0001531849,0.000028673156,0.000067180925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000032589254,0.00013041966,0.00023139239,0.000045745513,0.00002759814,0.0000075490216,0.00003371937,0.000035964757,0.00003207963],"category_scores_gemma":[0.000010499142,0.0000934426,0.00004242598,0.00007366114,0.000045259665,0.00018527193,0.000009605597,0.000051575877,0.000002474923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037250633,0.00056855386,0.8180354,0.000031006144,0.000023771896,0.000055336383,0.00044649915,0.00000508584,0.0005260599,0.000016535902,0.000011048538,0.17655563],"study_design_scores_gemma":[0.0044322237,0.0015890171,0.9871675,0.00014054844,0.000020441907,0.00000867966,0.000016137095,0.00001668768,0.0012982573,0.0006055571,0.004603889,0.00010109915],"about_ca_topic_score_codex":0.000026982727,"about_ca_topic_score_gemma":0.000006424697,"teacher_disagreement_score":0.17645454,"about_ca_system_score_codex":0.00006467723,"about_ca_system_score_gemma":0.000013536514,"threshold_uncertainty_score":0.38104784},"labels":[],"label_agreement":null},{"id":"W2061217629","doi":"10.1007/s12325-009-0084-8","title":"New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010","year":2009,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; McMaster University","funders":"","keywords":"Medicine; Antithrombotic; Atrial fibrillation; Stroke (engine); Internal medicine; Intensive care medicine; Heart failure; Diabetes mellitus; Cardiology; Pharmacotherapy","score_opus":0.10478713936967743,"score_gpt":0.4629706243164416,"score_spread":0.35818348494676416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061217629","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013213327,0.9923955,0.0015688073,0.0004222689,0.0012565299,0.003992285,0.00001385158,0.000055432447,0.0002820658],"genre_scores_gemma":[0.0000025019078,0.9833319,0.004879689,0.00010715598,0.0055660354,0.000013496938,0.000268725,0.00005453762,0.0057759676],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99799305,0.000115660296,0.0009133906,0.00043921042,0.00024128021,0.00029738102],"domain_scores_gemma":[0.9989401,0.00023556643,0.00045038792,0.00027471196,0.000030516547,0.00006869555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036616036,0.00038497255,0.001540666,0.0004827867,0.000033813852,0.000028637409,0.00014390281,0.00022762586,0.00030970568],"category_scores_gemma":[0.000030825227,0.0003159388,0.00092452334,0.0004675769,0.000017438113,0.00035908425,0.000012293982,0.00020169387,0.000024933355],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066781644,0.0000043737186,0.0003799638,0.0007512179,0.000099918085,0.0000026678829,0.000017738876,0.000100774254,0.0000010076645,0.00028365155,0.00039684706,0.997294],"study_design_scores_gemma":[0.0069125937,0.00028154824,0.000054778524,0.0019255292,0.00016297642,0.0000035003552,0.000003378083,0.000026748268,0.0000043646496,0.0018435459,0.9885006,0.0002804651],"about_ca_topic_score_codex":0.0000055850674,"about_ca_topic_score_gemma":0.000020621734,"teacher_disagreement_score":0.99701357,"about_ca_system_score_codex":0.00014636708,"about_ca_system_score_gemma":0.00020348286,"threshold_uncertainty_score":0.99992925},"labels":[],"label_agreement":null},{"id":"W2063592677","doi":"10.1007/bf02850036","title":"Surgical outcome following treatment of isolated subaortic obstruction","year":2004,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Cardiovascular Syncope and Autonomic Disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Asymptomatic; Ventricular outflow tract; Surgery; Stenosis; Regurgitation (circulation); Internal medicine; Aortic valve replacement; Cardiology","score_opus":0.01501869987417275,"score_gpt":0.31362138837833886,"score_spread":0.2986026885041661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063592677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97209007,0.02594788,0.00022600472,0.000110365756,0.00025877982,0.0002123628,6.3550885e-7,0.000025232914,0.0011286528],"genre_scores_gemma":[0.9898575,0.009690221,0.00030504097,0.000027509897,0.00003260214,0.00001405587,0.0000062183444,0.000011428949,0.000055457156],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993697,0.000014575465,0.00024485047,0.00014508553,0.00009949577,0.00012633912],"domain_scores_gemma":[0.9997268,0.000017365253,0.000041458454,0.0001758017,0.000010154874,0.000028449134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000056527788,0.000093537725,0.00033429396,0.0000653382,0.000015087177,0.0000029060486,0.000028991244,0.0000383803,0.00002261921],"category_scores_gemma":[0.0000038851895,0.00007224386,0.00029861703,0.00014704329,0.000030143736,0.00010733181,0.000002984861,0.00003548376,0.000006094757],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068258675,0.00060180645,0.16222054,0.000022616416,0.00036231912,0.0002579358,0.00066530315,0.003190735,0.0015978959,0.00050137186,4.2240197e-7,0.82989645],"study_design_scores_gemma":[0.21685125,0.01085221,0.34538856,0.0006698047,0.00066549866,0.00097161805,0.003744898,0.00045286427,0.06704505,0.015039731,0.33660272,0.001715773],"about_ca_topic_score_codex":0.0000687569,"about_ca_topic_score_gemma":0.000018859995,"teacher_disagreement_score":0.8281807,"about_ca_system_score_codex":0.0001257806,"about_ca_system_score_gemma":0.00003127887,"threshold_uncertainty_score":0.29460195},"labels":[],"label_agreement":null},{"id":"W2073818920","doi":"10.1007/s12325-009-0021-x","title":"Psychotropic drugs and renal failure: Translating the evidence for clinical practice","year":2009,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Nephrotoxicity and Medicinal Plants","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Ottawa; University Health Network","funders":"","keywords":"Medicine; Pharmacokinetics; Dosing; Intensive care medicine; Renal function; Psychotropic drug; Pharmacology; Drug; Adverse effect; Psychotropic Agent; Internal medicine; Psychiatry","score_opus":0.20780326168326121,"score_gpt":0.5466009045532716,"score_spread":0.33879764287001035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073818920","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002155567,0.99304336,0.00039841066,0.003112655,0.00022853535,0.0028418216,0.0000062909576,0.000022198747,0.00032518813],"genre_scores_gemma":[0.000019693745,0.98786455,0.0077148373,0.0031565859,0.0009102255,0.00021207088,0.000011929425,0.000026548323,0.00008357328],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997765,0.00034258753,0.0008491113,0.00046516318,0.00029267048,0.00028546367],"domain_scores_gemma":[0.99418616,0.004887817,0.0004207461,0.00035411076,0.000055465465,0.00009570494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017104411,0.0003000127,0.0013377616,0.00008124156,0.00008262346,0.000019598294,0.00020658682,0.00023808856,0.000007786961],"category_scores_gemma":[0.0009551712,0.00016590573,0.00027930966,0.00024360558,0.00014833093,0.00033463663,0.000007518288,0.0008894994,0.0000035908574],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055396353,0.00008152861,0.000008055533,0.0020249325,0.00007451725,0.000019239818,0.00020381216,1.18792414e-7,0.0000018270067,0.00009245595,0.00036801962,0.99657154],"study_design_scores_gemma":[0.0014881577,0.0009549069,0.000015350128,0.026972238,0.00038668205,0.00023843482,0.00010756572,0.0000029800804,0.0000014538152,0.00047142123,0.96920115,0.00015968154],"about_ca_topic_score_codex":0.0000035647306,"about_ca_topic_score_gemma":0.000014505588,"teacher_disagreement_score":0.99641186,"about_ca_system_score_codex":0.00003250743,"about_ca_system_score_gemma":0.0002023871,"threshold_uncertainty_score":0.67654395},"labels":[],"label_agreement":null},{"id":"W2075706156","doi":"10.1007/s12325-010-0074-x","title":"Food effects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules","year":2010,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celerion (Canada)","funders":"","keywords":"Naltrexone; Bioavailability; Morphine; Pharmacokinetics; Pharmacology; Naloxone Hydrochloride; Medicine; Area under the curve; Opioid; (+)-Naloxone; Anesthesia; Internal medicine","score_opus":0.009219676054082446,"score_gpt":0.2752405418032308,"score_spread":0.26602086574914835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075706156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908764,0.00610161,0.000034586283,0.001477949,0.00022407457,0.0004880402,0.0000026962991,0.000024940622,0.0007697242],"genre_scores_gemma":[0.9772792,0.020973852,0.00038119592,0.001042813,0.00015486554,0.000034595574,0.000004060838,0.000016983393,0.00011245963],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992582,0.000039874514,0.00017338665,0.00018072645,0.00017976746,0.00016801365],"domain_scores_gemma":[0.9992136,0.00034619225,0.000083129555,0.0002792412,0.000026123247,0.000051758143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002500455,0.00013861524,0.00020931242,0.00008958722,0.000035733632,0.0000061755322,0.00011057886,0.000034557783,0.00003645268],"category_scores_gemma":[0.00011651281,0.00008649041,0.000038295097,0.00016661684,0.00011499603,0.00007365327,0.000020539102,0.00025125078,0.0000031629318],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039763716,0.00071249757,0.04519214,0.00041721578,0.00020856953,0.00009683377,0.00074558216,0.00008262012,0.5769632,0.010541102,0.00039602845,0.36066782],"study_design_scores_gemma":[0.010625876,0.0026247117,0.1459288,0.0002941588,0.0000722148,0.0000063297452,0.000102705315,0.001735743,0.77477807,0.015622552,0.04787983,0.00032902282],"about_ca_topic_score_codex":0.0000056929316,"about_ca_topic_score_gemma":0.00001948967,"teacher_disagreement_score":0.3603388,"about_ca_system_score_codex":0.0000068022255,"about_ca_system_score_gemma":0.000008950898,"threshold_uncertainty_score":0.35269764},"labels":[],"label_agreement":null},{"id":"W2076727357","doi":"10.1007/s12325-010-0011-z","title":"Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: Points of pathophysiological commonality with mood disorders?","year":2010,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Management and Education","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Neurocognitive; Mood disorders; Medicine; Major depressive disorder; Neuroimaging; Brain size; Mood; Neuroscience; Depression (economics); Brain morphometry; Psychiatry; Psychology; Magnetic resonance imaging; Cognition; Anxiety","score_opus":0.019410776111079563,"score_gpt":0.31175643743194625,"score_spread":0.2923456613208667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076727357","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.092589654,0.9051583,0.0000032932505,0.00014870531,0.00009968447,0.0010431478,0.000021884323,0.000015983615,0.0009193601],"genre_scores_gemma":[0.019632239,0.97947484,0.00019913472,0.00018879755,0.00004811597,0.00021639503,0.00015104133,0.00002749392,0.0000619378],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850327,0.00023440713,0.0004569275,0.00036436715,0.00016129673,0.00027972652],"domain_scores_gemma":[0.998938,0.00046133334,0.00027911688,0.00023436265,0.000041091,0.00004607276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035282839,0.00030907878,0.0012338657,0.00019720453,0.000022628128,0.000012779816,0.0001292762,0.00014933405,0.000028949904],"category_scores_gemma":[0.00009758552,0.00021151804,0.00009763316,0.0003243716,0.00027972055,0.00022355912,0.00003855953,0.0004378231,0.00000265786],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006973476,0.00033627023,0.027080866,0.004243076,0.0000337627,0.0000014352868,0.00020617212,3.9626812e-7,0.0000014935217,0.00020771983,0.000005711557,0.9678134],"study_design_scores_gemma":[0.002497638,0.0017977614,0.07846184,0.012749264,0.00018493677,0.000002636302,0.00045110815,0.000015005769,0.000010437735,0.009178302,0.8940087,0.00064236036],"about_ca_topic_score_codex":0.000013622338,"about_ca_topic_score_gemma":0.00011756852,"teacher_disagreement_score":0.967171,"about_ca_system_score_codex":0.000022789694,"about_ca_system_score_gemma":0.000048073387,"threshold_uncertainty_score":0.86254555},"labels":[],"label_agreement":null},{"id":"W2080506224","doi":"10.1007/s12325-013-0027-2","title":"Efficacy and Safety of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder and Recent Methylphenidate Use","year":2013,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Interior Health","funders":"","keywords":"Methylphenidate; Attention deficit hyperactivity disorder; Medicine; Stimulant; Tolerability; Rating scale; Post-hoc analysis; Placebo; Population; Atomoxetine; Randomized controlled trial; Psychiatry; Adverse effect; Physical therapy; Pediatrics; Psychology; Internal medicine","score_opus":0.01579585432148466,"score_gpt":0.2965676978646019,"score_spread":0.28077184354311724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080506224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894465,0.008294342,0.00021094916,0.00059499434,0.000029256327,0.0013047511,0.00000775196,0.00002495006,0.00008646898],"genre_scores_gemma":[0.95027703,0.048334032,0.0011014595,0.00007141907,0.000011991773,0.00005727852,0.000027957296,0.000033479133,0.000085337895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986101,0.0001249578,0.00036635756,0.00042283107,0.00021872645,0.00025705594],"domain_scores_gemma":[0.99909693,0.0002677902,0.0001712245,0.00029634213,0.000094312396,0.000073410745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018656772,0.000238556,0.00050706073,0.00019539199,0.000043266828,0.000024219198,0.000058109115,0.00007765778,0.000111978276],"category_scores_gemma":[0.00010284699,0.0001823652,0.000031267882,0.00040537017,0.00019479744,0.0011256725,0.000040019288,0.00027533877,0.0000044880426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070678827,0.0005776572,0.85173696,0.00001791259,0.000067156165,0.0000019104286,0.00007294183,0.00010894281,0.003042539,0.000037594193,4.4325546e-7,0.14362912],"study_design_scores_gemma":[0.009730677,0.0003309309,0.9884197,0.00010840178,0.000025422973,0.000037433583,0.0002472276,0.00012548425,0.00006652499,0.000047376263,0.0006611707,0.00019966654],"about_ca_topic_score_codex":0.00036893008,"about_ca_topic_score_gemma":0.00018959142,"teacher_disagreement_score":0.14342946,"about_ca_system_score_codex":0.00002993801,"about_ca_system_score_gemma":0.000023315459,"threshold_uncertainty_score":0.7436637},"labels":[],"label_agreement":null},{"id":"W2085150507","doi":"10.1007/bf02877706","title":"Urinary bladder calculi in a sliding vesical-inguinal-scrotal hernia diagnosed preoperatively by plain abdominal radiography","year":2007,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Urological Disorders and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Groin; Inguinal hernia; Hernia; Abdomen; Surgery; Urinary bladder; Radiography; Radiology; Urology; General surgery","score_opus":0.010834104121687015,"score_gpt":0.3038250883144985,"score_spread":0.2929909841928115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085150507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95531577,0.040506974,0.00048216776,0.00032639547,0.00008064122,0.00066200236,0.000008747788,0.00004033378,0.0025769593],"genre_scores_gemma":[0.98964506,0.0072235293,0.0015197454,0.0013376278,0.00006058416,0.00009960711,0.000021809645,0.000024401988,0.00006760123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984207,0.00008332098,0.0003670626,0.0004211482,0.00022721874,0.00048054336],"domain_scores_gemma":[0.99936014,0.00025370982,0.000072762065,0.00016840514,0.000023065908,0.000121916775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002720037,0.00025437135,0.00040943688,0.00020675763,0.00006910077,0.00001373961,0.0001087027,0.00010314406,0.00010492579],"category_scores_gemma":[0.000047205227,0.00019166998,0.00011867897,0.0004995848,0.00012366206,0.00018843167,0.00001873748,0.00029151049,0.000010207938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042900993,0.004305443,0.87225485,0.000020549476,0.00013121047,0.002197888,0.0014020748,0.000017163737,0.0046450845,0.00021710552,0.00017614067,0.11034236],"study_design_scores_gemma":[0.026052859,0.007853715,0.91512436,0.00017120564,0.000036271154,0.00008515211,0.0007851284,0.00018607531,0.0031236166,0.0021994791,0.04379253,0.00058959646],"about_ca_topic_score_codex":0.000074882606,"about_ca_topic_score_gemma":0.000077354816,"teacher_disagreement_score":0.10975277,"about_ca_system_score_codex":0.000070694055,"about_ca_system_score_gemma":0.000020692694,"threshold_uncertainty_score":0.7816075},"labels":[],"label_agreement":null},{"id":"W2087672673","doi":"10.1007/bf02849989","title":"Assessing itch in children with atopic dermatitis treated with tacrolimus: Objective versus subjective assessment","year":2007,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Atopic dermatitis; SCORAD; Tacrolimus; Interquartile range; Internal medicine; Sleep disorder; Scratching; Anesthesia; Dermatology; Dermatology Life Quality Index; Insomnia; Pharmacology; Transplantation","score_opus":0.01014758653676302,"score_gpt":0.33327214353218987,"score_spread":0.32312455699542686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087672673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857922,0.0041691912,0.00063028286,0.000085025466,0.000053176052,0.000597771,0.0000030177066,0.000055043412,0.008614292],"genre_scores_gemma":[0.9971231,0.0010794026,0.0012923788,0.00034131043,0.000036984362,0.000059118956,0.00002855199,0.000023681756,0.000015462825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881583,0.00008476653,0.00022240203,0.00031346068,0.00020895762,0.00035457604],"domain_scores_gemma":[0.99934155,0.00021614559,0.000100527344,0.00020358145,0.00006554164,0.00007262787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013818317,0.00020852807,0.00035675734,0.00020994493,0.00006641827,0.000021235091,0.00007957113,0.00008412291,0.000030157064],"category_scores_gemma":[0.000015939904,0.00014810135,0.000032123364,0.00051320315,0.00017581969,0.0006059984,0.000009399846,0.000272857,0.000002496737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012047467,0.00032729987,0.9737889,0.000010590836,0.00013705064,0.00034122137,0.0003723031,0.00006455947,0.000022142349,0.00007391174,0.000004769474,0.023652477],"study_design_scores_gemma":[0.011920545,0.00041626047,0.9835927,0.00017745157,0.000028719684,0.00020846057,0.0010768139,0.000020898839,0.0020368586,0.0001832484,0.00015323759,0.00018479118],"about_ca_topic_score_codex":0.0000993798,"about_ca_topic_score_gemma":0.0007754221,"teacher_disagreement_score":0.023467686,"about_ca_system_score_codex":0.00020017751,"about_ca_system_score_gemma":0.00014643118,"threshold_uncertainty_score":0.6039398},"labels":[],"label_agreement":null},{"id":"W2095488032","doi":"10.1007/bf02850199","title":"Managing childhood atopic dermatitis","year":2003,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Novartis Pharmaceuticals Canada; University of Calgary","keywords":"Medicine; Pimecrolimus; Atopic dermatitis; Tacrolimus; Adverse effect; Dermatology; Calcineurin; Quality of life (healthcare); Allergy; Safety profile; Rheumatology; Intensive care medicine; Immunology; Internal medicine","score_opus":0.019004405860379953,"score_gpt":0.3447816084987121,"score_spread":0.32577720263833215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095488032","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000082975075,0.9820075,0.000023807761,0.0000747902,0.00036753365,0.0006076783,0.0000061251994,0.000049483082,0.016854774],"genre_scores_gemma":[0.00004530143,0.99783486,0.00021515983,0.0012763273,0.000075829645,0.00013931464,0.000060240178,0.000039274993,0.00031370152],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99879026,0.00013587883,0.0004025988,0.0002906935,0.000121019715,0.00025951624],"domain_scores_gemma":[0.99930114,0.00010784945,0.0001426252,0.00036569868,0.000013779348,0.00006893325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000062839565,0.00029043877,0.0012365684,0.00019095672,0.0000427135,0.000009233159,0.00014772212,0.00017827272,0.00024418643],"category_scores_gemma":[0.000020569489,0.00022392065,0.00027307903,0.00025838093,0.00007540566,0.00013391355,0.000013894575,0.00032242315,0.000100959645],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000018943066,0.00010441579,0.0005456858,0.0036207547,0.00007238401,0.00023732518,0.00003233789,2.8657348e-7,2.0505688e-9,0.0001979138,0.00059736177,0.9945896],"study_design_scores_gemma":[0.0006352196,0.000020001658,0.00033299252,0.0071474165,0.00010698289,0.0005964958,0.000009249097,3.198829e-7,5.515816e-7,0.0023270263,0.988625,0.00019872955],"about_ca_topic_score_codex":8.435365e-7,"about_ca_topic_score_gemma":0.0000021038572,"teacher_disagreement_score":0.9943909,"about_ca_system_score_codex":0.000044699038,"about_ca_system_score_gemma":0.000117980104,"threshold_uncertainty_score":0.9131219},"labels":[],"label_agreement":null},{"id":"W2118917324","doi":"10.1007/s12325-009-0041-6","title":"Ramelteon: a review of its therapeutic potential in sleep disorders","year":2009,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Sleep and Wakefulness Research","field":"Neuroscience","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Sleep Institute","funders":"","keywords":"Medicine; Rheumatology; Sleep (system call); Internal medicine","score_opus":0.06156079004945493,"score_gpt":0.41364070236413764,"score_spread":0.3520799123146827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118917324","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007754193,0.996069,0.00004241245,0.000109855275,0.00027391105,0.0019400351,0.000014038314,0.000025467352,0.0015174873],"genre_scores_gemma":[0.00030536644,0.9985656,0.000014315402,0.0006027717,0.000060282495,0.00034314848,0.0000071647046,0.000051319297,0.00004999253],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99608135,0.0010200961,0.0009671489,0.0007377522,0.00063165225,0.0005619984],"domain_scores_gemma":[0.99840087,0.00051718357,0.00039670977,0.0005921655,0.000032225216,0.000060840972],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005481179,0.00045693948,0.0018392707,0.00046480045,0.000040834035,0.000021059126,0.0011206775,0.00019888143,0.00019529798],"category_scores_gemma":[0.00018454825,0.00034308966,0.00042496147,0.001858833,0.00016999456,0.0003490062,0.000059127204,0.00073361036,0.000039204107],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028593346,0.00016716857,0.0000030458352,0.018647494,0.000007630608,0.000023112238,0.000023253255,0.000010267128,0.000010306599,0.00047263986,0.000004632176,0.98060185],"study_design_scores_gemma":[0.00054033357,0.00016344404,0.0000035194735,0.048564103,0.00002120426,0.000010498579,0.0000040778077,0.000014289348,0.00014422183,0.0011212905,0.94907296,0.00034004182],"about_ca_topic_score_codex":0.0000059608897,"about_ca_topic_score_gemma":0.000017770508,"teacher_disagreement_score":0.9802618,"about_ca_system_score_codex":0.00008699362,"about_ca_system_score_gemma":0.00013523281,"threshold_uncertainty_score":0.9999021},"labels":[],"label_agreement":null},{"id":"W2124283923","doi":"10.1007/s12325-010-0081-y","title":"Lasofoxifene in osteoporosis and its place in therapy","year":2010,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Raloxifene; Osteoporosis; Selective estrogen receptor modulator; Endometrial cancer; Antiestrogen; Internal medicine; Breast cancer; Endometrial hyperplasia; Oncology; Tamoxifen; Gynecology; Cancer; Hyperplasia","score_opus":0.05658703699730556,"score_gpt":0.4284445847616713,"score_spread":0.37185754776436575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124283923","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01191827,0.9837359,2.1409198e-7,0.000315523,0.00026894693,0.0028793537,0.000019118612,0.000028815695,0.00083383586],"genre_scores_gemma":[0.00040575257,0.99749064,0.00019577106,0.0005036353,0.00015872298,0.00072208646,0.00005563031,0.000094548486,0.00037322083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966085,0.0003553415,0.0010248073,0.0007527225,0.00043601386,0.0008226166],"domain_scores_gemma":[0.99827176,0.00067282486,0.00024182255,0.0005070658,0.00005842125,0.00024810518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011648039,0.000525219,0.0022572572,0.0008560099,0.000043488042,0.000024030442,0.0002823715,0.0006920613,0.00015380567],"category_scores_gemma":[0.00016251567,0.00039393854,0.00015184682,0.001126815,0.00011764946,0.00026100132,0.00005302992,0.0021151581,0.000030704785],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035412709,0.00024796935,0.0018119459,0.0037562586,0.000009427942,0.00007160626,0.0002810757,5.210468e-7,0.00001532005,0.00003199679,0.000018671193,0.99340105],"study_design_scores_gemma":[0.0043897773,0.00052760326,0.0010057077,0.007460891,0.0000074423288,0.00005712971,0.00005642719,0.00000764562,0.00003324215,0.000089282476,0.98603195,0.0003329285],"about_ca_topic_score_codex":0.00013071856,"about_ca_topic_score_gemma":0.0018878283,"teacher_disagreement_score":0.99306816,"about_ca_system_score_codex":0.00021459203,"about_ca_system_score_gemma":0.0006344872,"threshold_uncertainty_score":0.9998512},"labels":[],"label_agreement":null},{"id":"W2162865421","doi":"10.1007/s12325-015-0239-8","title":"Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease","year":2015,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Tiotropium bromide; COPD; Inhaler; Bronchodilator; Placebo; Anesthesia; Indacaterol; Lama; Crossover study; Fixed-dose combination; Internal medicine; Lung; Lung function; Asthma","score_opus":0.04984266687401399,"score_gpt":0.35668945740424357,"score_spread":0.30684679053022956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162865421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977392,0.004518713,0.00019499668,0.0009504586,0.0002766648,0.016226318,0.00005703566,0.0000457134,0.00033806456],"genre_scores_gemma":[0.99378693,0.00012747712,0.0004218491,0.0002545693,0.0002542643,0.004672948,0.000128038,0.00008976388,0.0002641505],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963793,0.0004693271,0.00066062185,0.0008607918,0.00087671407,0.00075322686],"domain_scores_gemma":[0.9977297,0.0003748288,0.00020972571,0.00088421407,0.0003313716,0.00047012576],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081822,0.0004382232,0.00086278486,0.00042904387,0.00012310637,0.00005202825,0.00047920342,0.00007837418,0.00007747639],"category_scores_gemma":[0.00016065808,0.000280334,0.00014216446,0.0005946444,0.00035178324,0.0006297232,0.00014927976,0.000389854,0.000018325461],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7333431,0.001456189,0.2369362,0.000106520594,0.00012983692,0.00010379492,0.0015541083,0.00028023263,0.00001585542,0.000059027017,0.000021343007,0.025993787],"study_design_scores_gemma":[0.61410606,0.0017866285,0.3778459,0.00023597566,0.000080022866,0.000005969063,0.00090915925,0.00044002422,0.0000646786,0.0021072167,0.002018985,0.00039936692],"about_ca_topic_score_codex":0.000085557025,"about_ca_topic_score_gemma":0.00024606066,"teacher_disagreement_score":0.14090972,"about_ca_system_score_codex":0.0011109404,"about_ca_system_score_gemma":0.0005277395,"threshold_uncertainty_score":0.9999649},"labels":[],"label_agreement":null},{"id":"W2170947953","doi":"10.1007/s12325-010-0059-9","title":"Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease","year":2010,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Dialysis and Renal Disease Management","field":"Medicine","cited_by":232,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; The Scarborough Hospital","funders":"","keywords":"Medicine; Kidney disease; Creatinine; Uric acid; Internal medicine; Renal function; Blood urea nitrogen; Probiotic; Adverse effect; Placebo; Gastroenterology; Statistical significance; Physiology; Biology; Pathology","score_opus":0.012994408743484414,"score_gpt":0.29893293728402465,"score_spread":0.28593852854054025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170947953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948886,0.0002824342,0.000072165516,0.00039248378,0.00024076547,0.004047838,0.000025175561,0.000013370076,0.0000371863],"genre_scores_gemma":[0.99822575,0.00013139994,0.00023219008,0.0005810034,0.00006540914,0.00036935587,0.00036062353,0.000017565255,0.000016692282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989986,0.0000430666,0.00030683068,0.00025301674,0.00021944263,0.00017905932],"domain_scores_gemma":[0.9994299,0.000021969528,0.00013872415,0.0001883574,0.00006140148,0.00015964698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018915768,0.000117420765,0.00020751827,0.0001528979,0.000035210698,0.000007021948,0.00005459303,0.000009565548,0.00005040425],"category_scores_gemma":[0.000044543955,0.0000827616,0.000028089542,0.00022606287,0.000027934178,0.00018520659,0.000011404079,0.000089804234,6.61375e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014653994,0.010753057,0.9287943,0.0006831819,0.00008045318,0.0000019364793,0.00042916596,0.00016101758,0.00057415984,0.00003953266,0.00010068096,0.043728508],"study_design_scores_gemma":[0.024119236,0.026118478,0.9468532,0.00026110696,0.000091312904,3.8121843e-8,0.00012675597,0.00032120466,0.00008415191,0.00016504822,0.0017384142,0.00012102731],"about_ca_topic_score_codex":0.000049201422,"about_ca_topic_score_gemma":0.00047177612,"teacher_disagreement_score":0.04360748,"about_ca_system_score_codex":0.000062588755,"about_ca_system_score_gemma":0.00012497601,"threshold_uncertainty_score":0.33749202},"labels":[],"label_agreement":null},{"id":"W2171321375","doi":"10.1007/s12325-013-0054-z","title":"OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology","year":2013,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Anticholinergic; Concomitant; Urinary incontinence; Urinary system; Etiology; Placebo; Adverse effect; Urology; Spinal cord injury; Internal medicine; Overactive bladder; Anticholinergic agents; Anesthesia; Spinal cord","score_opus":0.015837238646286878,"score_gpt":0.3063505204633182,"score_spread":0.2905132818170313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171321375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963292,0.0006365244,0.00003673197,0.0005240783,0.000068582085,0.0022960072,0.000014567085,0.000019548064,0.000074781325],"genre_scores_gemma":[0.99665797,0.0017786203,0.00038817857,0.00081783195,0.000020018892,0.00024408706,0.0000062970967,0.000026687449,0.00006029838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981832,0.00036811008,0.00029815573,0.00047259356,0.00025153317,0.0004264369],"domain_scores_gemma":[0.99855304,0.00065801246,0.00011095761,0.00037616244,0.00018547759,0.00011637952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020430173,0.00022469804,0.00056106644,0.00026158046,0.000030486044,0.000010698543,0.00018523111,0.00009239996,0.00008483718],"category_scores_gemma":[0.00016053015,0.00014615142,0.000046282097,0.000650168,0.00018718024,0.0004572833,0.000077414974,0.00041140427,0.000010625839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020898268,0.0013441679,0.9280051,0.0000679098,0.000030853193,0.00033596402,0.00041692978,0.0000892099,0.0027725878,0.0000072237694,0.00001120476,0.04602061],"study_design_scores_gemma":[0.0066049607,0.015177619,0.97230756,0.000064436266,0.000006417429,0.00005603232,0.000024579454,0.00012716933,0.00488186,0.0001285027,0.00046245154,0.00015842046],"about_ca_topic_score_codex":0.00016147178,"about_ca_topic_score_gemma":0.000060716164,"teacher_disagreement_score":0.045862187,"about_ca_system_score_codex":0.000048348356,"about_ca_system_score_gemma":0.00007543511,"threshold_uncertainty_score":0.5959882},"labels":[],"label_agreement":null},{"id":"W2178569306","doi":"10.1007/s12325-015-0261-x","title":"Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease","year":2015,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Metformin; Liraglutide; Kidney disease; Intensive care medicine; Glycemic; Diabetes mellitus; Guideline; Alogliptin; Type 2 Diabetes Mellitus; Type 2 diabetes; Saxagliptin; Internal medicine; Pharmacology; Sitagliptin; Endocrinology; Pathology","score_opus":0.1538682301300158,"score_gpt":0.41104867924444327,"score_spread":0.2571804491144275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2178569306","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003213781,0.99813986,0.0000017654587,0.000113230184,0.000121163954,0.0010330018,0.0001386513,0.0000075838566,0.0001233943],"genre_scores_gemma":[0.00042395177,0.99826777,0.000172425,0.000112383386,0.000046870795,0.00006499967,0.00082022813,0.000024083489,0.00006728647],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867046,0.00012914558,0.0005027639,0.00030622323,0.00021429769,0.0001771321],"domain_scores_gemma":[0.99832404,0.00029911287,0.00033189383,0.0009028754,0.000043779783,0.000098326076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003483098,0.00021410949,0.0010789551,0.00014204672,0.000013829257,0.000006824667,0.00032754874,0.000056441102,0.000038360246],"category_scores_gemma":[0.0001246748,0.00012739243,0.00006318002,0.00041736077,0.00022055846,0.00027672015,0.00014465018,0.00014137432,0.0000026244372],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030579056,0.00011261556,0.0017989507,0.0071819252,0.00020844664,0.0000034041998,0.00004323611,0.0000019207384,6.120425e-7,0.00022702124,0.00016768597,0.9902236],"study_design_scores_gemma":[0.0009679142,0.00015076027,0.00019913002,0.015432301,0.0005466361,3.3693755e-7,0.000009381396,0.000045131615,9.909238e-7,0.00011739532,0.98242754,0.00010248026],"about_ca_topic_score_codex":0.000016298403,"about_ca_topic_score_gemma":0.00001692597,"teacher_disagreement_score":0.9901211,"about_ca_system_score_codex":0.000089897134,"about_ca_system_score_gemma":0.00046005068,"threshold_uncertainty_score":0.5194912},"labels":[],"label_agreement":null},{"id":"W2185217562","doi":"10.1007/bf02850040","title":"Travelers’ diarrhea","year":2006,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Travel-related health issues","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Sanofi Pasteur","keywords":"Medicine; Diarrhea; Rheumatology; Internal medicine; Traveler's diarrhea; Intensive care medicine","score_opus":0.06446604584214048,"score_gpt":0.4379302285489221,"score_spread":0.3734641827067816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185217562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010421244,0.9889249,0.000027897904,0.00009164348,0.0005734909,0.001583443,0.000018142053,0.00011626354,0.008653769],"genre_scores_gemma":[0.000009995013,0.9964512,0.0009131361,0.00025749826,0.00047527568,0.00021533444,0.00014417282,0.00012464514,0.0014087466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758536,0.00014093111,0.00092697196,0.0005251884,0.00028790734,0.0005336269],"domain_scores_gemma":[0.9987602,0.00024260141,0.00030213388,0.0005300719,0.000034819186,0.0001301314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024846708,0.0004976203,0.0022398953,0.0003562982,0.000041665775,0.000009606978,0.00021682923,0.0005252626,0.00016294485],"category_scores_gemma":[0.000025603273,0.0003719995,0.00032564512,0.0005840283,0.00010512103,0.00011968245,0.000012124087,0.0009793213,0.00017615779],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028379109,0.000106482934,0.000047439986,0.007064654,0.000040382893,0.000083170526,0.00008419133,0.0000011834838,1.1772737e-7,0.0001906828,0.00023119638,0.9921221],"study_design_scores_gemma":[0.0010011222,0.00020484152,0.0000883868,0.014196838,0.000088591834,0.00007237786,0.0000066752054,9.2517774e-7,0.000002249245,0.00031493744,0.9837163,0.0003067304],"about_ca_topic_score_codex":0.000053159016,"about_ca_topic_score_gemma":0.000040857776,"teacher_disagreement_score":0.9918154,"about_ca_system_score_codex":0.0002518457,"about_ca_system_score_gemma":0.00032419982,"threshold_uncertainty_score":0.9998732},"labels":[],"label_agreement":null},{"id":"W2292982366","doi":"10.1007/s12325-016-0310-0","title":"Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology; Allergan; Novartis Pharma; National Institute for Health and Care Research","keywords":"Medicine; Diabetic macular edema; Visual impairment; Rheumatology; Ophthalmology; Diabetic retinopathy; Internal medicine; Clinical trial; Optometry; Diabetes mellitus","score_opus":0.08482711340155047,"score_gpt":0.4125311927779988,"score_spread":0.32770407937644835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292982366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954466,0.0024550878,0.0007118402,0.00007342266,0.000096993186,0.0010310116,0.00013651338,0.000009934575,0.00003857267],"genre_scores_gemma":[0.9909035,0.0005712776,0.008267676,0.00009527041,0.000030880663,0.000050829647,0.000049310558,0.000021155249,0.000010123671],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985581,0.00006681075,0.00039183162,0.00034460874,0.0003560757,0.00028259252],"domain_scores_gemma":[0.9992033,0.00009382613,0.00014264137,0.0003688738,0.00008480285,0.000106541236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016258912,0.00016992699,0.00037841493,0.00013400745,0.000028818225,0.000013727196,0.00016813922,0.000037690857,0.000034516128],"category_scores_gemma":[0.00007060094,0.00010024177,0.00002436526,0.00037442707,0.00008322571,0.00024380493,0.0000902311,0.000050334897,0.000004233045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009480524,0.001294254,0.96477056,0.00002160973,0.00009580299,0.000037435468,0.00031286705,0.00018189884,0.0006038354,0.000022846018,0.000013406355,0.023164967],"study_design_scores_gemma":[0.080901384,0.0066176374,0.902345,0.0012909331,0.00006544209,0.000012040303,0.00032921936,0.000234155,0.003799789,0.00014429001,0.0039104787,0.00034963875],"about_ca_topic_score_codex":0.00006323527,"about_ca_topic_score_gemma":0.00002866737,"teacher_disagreement_score":0.071420856,"about_ca_system_score_codex":0.000103656115,"about_ca_system_score_gemma":0.00015085643,"threshold_uncertainty_score":0.40877408},"labels":[],"label_agreement":null},{"id":"W2307057396","doi":"10.1007/s12325-016-0285-x","title":"Differential Protein Expression Profiles in Glaucomatous Trabecular Meshwork: An Evaluation Study on a Small Primary Open Angle Glaucoma Population","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Fondazione Roma; Ministero della Salute","keywords":"Trabecular meshwork; Medicine; Population; Glaucoma; Vascular endothelial growth factor; Myocilin; Ophthalmology; Pathology; Internal medicine","score_opus":0.03003669115185202,"score_gpt":0.3344425589051861,"score_spread":0.30440586775333406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307057396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99175227,0.0012071606,0.00014624577,0.00022656051,0.00012202927,0.0061556036,0.0000028211762,0.00004542931,0.00034189576],"genre_scores_gemma":[0.9978906,0.0002453649,0.00054453575,0.00009690823,0.000056997575,0.0010012068,0.00006365853,0.000037288017,0.000063472085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977542,0.0005381058,0.0004185063,0.0005111523,0.00048604302,0.0002919474],"domain_scores_gemma":[0.999246,0.000048758655,0.00014945799,0.00042542184,0.00005769226,0.000072638846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004739556,0.00023889159,0.00039499192,0.00020503813,0.00007047269,0.000030167927,0.00026581742,0.000101745594,0.000110051114],"category_scores_gemma":[0.000050166742,0.00014591403,0.00005420354,0.00024052097,0.000039963594,0.00046977738,0.000049240763,0.00014734578,0.0000055865503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002455093,0.0026423726,0.711738,0.000025028115,0.000011634613,0.000024214873,0.0006312581,0.0000014615227,0.08996249,0.00006482775,0.0000029308933,0.19244072],"study_design_scores_gemma":[0.011404913,0.0025618265,0.9684486,0.0007593306,0.000013306717,0.0000043428095,0.00046029768,0.00011192834,0.0132624125,0.002609367,0.00014503693,0.00021863409],"about_ca_topic_score_codex":0.00012838321,"about_ca_topic_score_gemma":0.00041209068,"teacher_disagreement_score":0.25671062,"about_ca_system_score_codex":0.00017729348,"about_ca_system_score_gemma":0.000055044704,"threshold_uncertainty_score":0.5950201},"labels":[],"label_agreement":null},{"id":"W2339565695","doi":"10.1007/s12325-016-0327-4","title":"nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Hôpital du Sacré-Cœur de Montréal; Royal Victoria Regional Health Centre; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Celgene","keywords":"Medicine; Gemcitabine; Hazard ratio; Clinical endpoint; Internal medicine; Subgroup analysis; Population; Deoxycytidine; Gastroenterology; Pancreatic cancer; Oncology; Cancer; Randomized controlled trial; Confidence interval","score_opus":0.02993689696633579,"score_gpt":0.3525140922893385,"score_spread":0.3225771953230027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339565695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933949,0.0032905205,0.00006981965,0.00056231127,0.00015552902,0.0016722807,0.00009901767,0.000010115296,0.00074547605],"genre_scores_gemma":[0.99793124,0.0011848147,0.00031982703,0.00011722722,0.000041309017,0.00014678173,0.000038601924,0.00002524403,0.00019494197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975473,0.0003116949,0.00060088234,0.0003789299,0.00055327936,0.0006079076],"domain_scores_gemma":[0.99789745,0.0008472937,0.0002150155,0.00065588526,0.00015442203,0.00022992761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060658145,0.00025425,0.0011767107,0.0008269506,0.000062818304,0.000007463289,0.0002806998,0.000082591374,0.00039274534],"category_scores_gemma":[0.00047212318,0.00012637422,0.00016709993,0.0019141731,0.00037846164,0.00023737167,0.000024004388,0.00021642593,0.0000056427198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086501695,0.0006793765,0.90330863,0.000024896046,0.0010045718,0.000029822131,0.0003872255,0.000026969348,0.00004425674,0.0001395279,0.000013924813,0.007839102],"study_design_scores_gemma":[0.2399552,0.004541863,0.75354457,0.00012286266,0.00076084875,0.0000011590232,0.00015663785,0.0002099478,0.000048342215,0.00012699072,0.00037656605,0.00015501384],"about_ca_topic_score_codex":0.012563945,"about_ca_topic_score_gemma":0.07837426,"teacher_disagreement_score":0.15345351,"about_ca_system_score_codex":0.0007688772,"about_ca_system_score_gemma":0.00089633226,"threshold_uncertainty_score":0.99401146},"labels":[],"label_agreement":null},{"id":"W2343491610","doi":"10.1007/s12325-016-0333-6","title":"Quality of Life in Glaucoma: A Review of the Literature","year":2016,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Fondazione Roma; Ministero della Salute","keywords":"Medicine; Blinding; Quality of life (healthcare); Glaucoma; Intensive care medicine; Anxiety; Disease; Affect (linguistics); Disease management; Physical therapy; Open angle glaucoma; Internal medicine; Ophthalmology; Psychiatry; Randomized controlled trial; Nursing","score_opus":0.026842871584040952,"score_gpt":0.38615842102961173,"score_spread":0.35931554944557076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343491610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035204703,0.9965036,0.0000013305423,0.0003214777,0.00018931805,0.0013239031,0.000028541162,0.0000054892516,0.0012742894],"genre_scores_gemma":[0.00006312016,0.99911624,0.000048899983,0.00048891496,0.000043876156,0.000073070456,0.000014527668,0.000023405324,0.00012795314],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975406,0.0005322873,0.0012149255,0.00024737336,0.00028950584,0.00017534173],"domain_scores_gemma":[0.9981816,0.00030212314,0.00077477767,0.0006229128,0.00008058271,0.00003802922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063105597,0.00026798423,0.0024279484,0.00012220113,0.000009178836,0.000001687468,0.00033327672,0.00019013045,0.00006268806],"category_scores_gemma":[0.0003963747,0.00011646159,0.0006154434,0.00081756787,0.00016239133,0.00006413393,0.000036053603,0.00039323905,0.000002912249],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060686572,0.00012652506,0.005347047,0.19979496,0.00003299896,0.0000027795058,0.00006229173,2.06599e-9,0.0000017151191,0.0003132962,0.0000620859,0.7941956],"study_design_scores_gemma":[0.0005323956,0.0000531396,0.0018298953,0.3717606,0.000020996331,0.0000057002167,0.0000064624946,1.2865674e-8,0.0000010519444,0.00028054786,0.6254264,0.00008279462],"about_ca_topic_score_codex":0.000011669758,"about_ca_topic_score_gemma":0.000018194656,"teacher_disagreement_score":0.7941128,"about_ca_system_score_codex":0.00003982233,"about_ca_system_score_gemma":0.00023998029,"threshold_uncertainty_score":0.47491658},"labels":[],"label_agreement":null},{"id":"W2346712961","doi":"10.1007/s12325-016-0331-8","title":"Cost-Effectiveness of Different Forms of Intra-Articular Injections for the Treatment of Osteoarthritis of the Knee","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ferring Pharmaceuticals","keywords":"Medicine; Osteoarthritis; Viscosupplementation; Cost effectiveness; Physical therapy; Quality-adjusted life year; Quality of life (healthcare); Randomized controlled trial; Surgery; Intra articular; Alternative medicine","score_opus":0.022036727815490015,"score_gpt":0.30876176629746077,"score_spread":0.28672503848197073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346712961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98346263,0.012379369,0.00096068415,0.0000869625,0.0002350976,0.0027291565,0.00007314624,0.000005476378,0.000067446184],"genre_scores_gemma":[0.9892447,0.009936594,0.000107656364,0.0000073667934,0.000018530602,0.00062922935,0.0000036137515,0.000012553483,0.000039740495],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99922454,0.000064875865,0.00031123398,0.00012179212,0.00014414944,0.00013340604],"domain_scores_gemma":[0.99875444,0.0006129784,0.00018784552,0.00032609852,0.00009808526,0.000020536676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010830428,0.00012269289,0.00040629797,0.000051693,0.000028768729,9.3994225e-7,0.000072658135,0.000043278138,0.000017157628],"category_scores_gemma":[0.000028684244,0.00004847492,0.00021612064,0.00012965014,0.00020336393,0.00007063604,0.000008353673,0.000022969083,1.80645e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017501818,0.0008523381,0.015744723,0.000074154676,0.00009224614,5.206805e-7,0.00048746052,0.000010622335,0.26042014,0.002858943,3.7932458e-7,0.7177083],"study_design_scores_gemma":[0.013955873,0.014095999,0.01082616,0.0005638109,0.00007200069,0.0000043637297,0.00022476615,0.0000029152038,0.95424485,0.0048283455,0.0011293818,0.000051527237],"about_ca_topic_score_codex":0.00001041725,"about_ca_topic_score_gemma":0.00011156659,"teacher_disagreement_score":0.71765673,"about_ca_system_score_codex":0.00005374478,"about_ca_system_score_gemma":0.000029342378,"threshold_uncertainty_score":0.19767499},"labels":[],"label_agreement":null},{"id":"W2360207919","doi":"10.1007/s12325-016-0342-5","title":"Erratum to: Quality of Life in Glaucoma: A Review of the Literature","year":2016,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Glaucoma; Rheumatology; Quality of life (healthcare); Ophthalmology; Optometry; Internal medicine; Nursing","score_opus":0.026939274480881646,"score_gpt":0.386671971147752,"score_spread":0.35973269666687036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2360207919","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004024481,0.995177,0.0000018825787,0.00066524744,0.0003366869,0.0017520823,0.000033134977,0.0000065628715,0.0016249558],"genre_scores_gemma":[0.00007274451,0.99833953,0.00007515363,0.0010416261,0.00005306874,0.00010921297,0.000014019077,0.000027859454,0.00026675873],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737257,0.0005209461,0.0012662498,0.00030136935,0.00032424822,0.00021460505],"domain_scores_gemma":[0.9982249,0.00025284177,0.0006441547,0.0007134426,0.000101054284,0.000063618216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065819983,0.00030567197,0.0025195759,0.00015831852,0.000011146582,0.0000025271224,0.00039884463,0.00020132017,0.0000478021],"category_scores_gemma":[0.0005313339,0.00013826475,0.00057606015,0.0011475666,0.0001197858,0.00006458706,0.00004993896,0.00043589246,0.0000048612824],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010319232,0.0001654515,0.0037227606,0.18625481,0.000041428753,0.000003854428,0.00013791032,6.561095e-9,0.0000047828457,0.00029165274,0.00044317238,0.808831],"study_design_scores_gemma":[0.0004323548,0.0000852813,0.0018038467,0.36725286,0.000022676386,0.0000049147297,0.000009045403,1.1096344e-8,0.0000015030349,0.00026268073,0.6300241,0.00010076287],"about_ca_topic_score_codex":0.000014592325,"about_ca_topic_score_gemma":0.00003241328,"teacher_disagreement_score":0.8087302,"about_ca_system_score_codex":0.00004893117,"about_ca_system_score_gemma":0.00027545946,"threshold_uncertainty_score":0.5638273},"labels":[],"label_agreement":null},{"id":"W2423086444","doi":"10.1007/s12325-016-0363-0","title":"Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel®","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals; University of Washington","keywords":"Medicine; Medical prescription; Internal medicine; Mallinckrodt; Confidence interval; Retrospective cohort study; Multiple sclerosis; Prescription costs; Logistic regression; Prescription drug; Immunology","score_opus":0.050959097623084565,"score_gpt":0.31567756864026963,"score_spread":0.26471847101718504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2423086444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927308,0.0051480364,0.000033925167,0.000851406,0.000011365129,0.0010224103,0.000025006415,0.00004297427,0.00013406613],"genre_scores_gemma":[0.9692379,0.029930877,0.00040503687,0.00018223735,0.000017235585,0.000122139,0.000022483477,0.00003194957,0.000050125243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985761,0.000117995834,0.00021493968,0.00038148242,0.00036633026,0.00034312322],"domain_scores_gemma":[0.9991361,0.0002890731,0.00008335596,0.00024980362,0.00013966765,0.00010201557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014047229,0.00018641434,0.0003146834,0.00018640305,0.00007037807,0.000010614957,0.00006985097,0.00005620414,0.000013865715],"category_scores_gemma":[0.00016301354,0.0000977035,0.000014591128,0.000409447,0.00021734418,0.00033024562,0.00002594297,0.0001253749,0.0000019053967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004022557,0.00016525855,0.730772,0.000026264313,0.000017346354,0.0000027753151,0.00025827865,0.0000045032784,0.00043423419,0.000004988655,0.000014227686,0.26427758],"study_design_scores_gemma":[0.016047232,0.0015908408,0.97487473,0.00130089,0.0000033750205,7.6499714e-7,0.00018610709,0.000020943045,0.0020815793,0.0000068385716,0.0037495948,0.00013712642],"about_ca_topic_score_codex":0.00018216971,"about_ca_topic_score_gemma":0.0015671165,"teacher_disagreement_score":0.26414043,"about_ca_system_score_codex":0.00021213575,"about_ca_system_score_gemma":0.000030818785,"threshold_uncertainty_score":0.3984233},"labels":[],"label_agreement":null},{"id":"W2467376457","doi":"10.1007/s12325-016-0364-z","title":"Promoting Patient and Family Partnerships in Ambulatory Care Improvement: A Narrative Review and Focus Group Findings","year":2016,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Mental Health and Patient Involvement","field":"Health Professions","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre","funders":"Gordon and Betty Moore Foundation","keywords":"General partnership; Medicine; Focus group; Ambulatory care; Nursing; Quality management; Family medicine; Ambulatory; Empowerment; Patient satisfaction; Health care; Management; Internal medicine","score_opus":0.16735982206120661,"score_gpt":0.459091784820796,"score_spread":0.29173196275958935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2467376457","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00229606,0.9881875,0.0000013282552,0.00006512005,0.00036840202,0.008569887,0.000077977515,0.00002414455,0.0004095662],"genre_scores_gemma":[0.00049990095,0.993577,0.00007852551,0.0019073517,0.00006803292,0.0036622062,0.00012414744,0.000049681963,0.00003316595],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958692,0.00093284086,0.0015112554,0.000701856,0.00025089388,0.0007339466],"domain_scores_gemma":[0.9982068,0.000506298,0.00074776774,0.00029684647,0.000052550397,0.00018976218],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00088399515,0.00050431315,0.001571228,0.00017215022,0.000330339,0.0000068286545,0.00015794495,0.00026523776,0.00003824371],"category_scores_gemma":[0.000024917486,0.000335697,0.00009911932,0.0002709536,0.00008876736,0.00026995002,0.00012844408,0.00078484014,0.000010701683],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021487871,0.000040157724,0.0007882591,0.12416759,0.000013583178,0.0000030698013,0.016399547,3.1128031e-9,4.1041233e-7,0.000105439496,0.000032057214,0.8584284],"study_design_scores_gemma":[0.00088188564,0.0006408672,0.000016117787,0.22726199,0.00002386874,6.317242e-7,0.002701804,2.7978692e-7,5.5883714e-7,0.00028006255,0.7679016,0.00029035416],"about_ca_topic_score_codex":0.000046158533,"about_ca_topic_score_gemma":0.00034633718,"teacher_disagreement_score":0.858138,"about_ca_system_score_codex":0.0005664844,"about_ca_system_score_gemma":0.00020803163,"threshold_uncertainty_score":0.9999095},"labels":[],"label_agreement":null},{"id":"W2470584189","doi":"10.1007/s12325-016-0368-8","title":"Comparative Analysis of Length of Stay and Inpatient Costs for Orthopedic Surgery Patients Treated with IV Acetaminophen and IV Opioids vs. IV Opioids Alone for Post-Operative Pain","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Acetaminophen; Orthopedic surgery; Rheumatology; Anesthesia; Pain management; Opioid; Surgery; Internal medicine","score_opus":0.013558695467122945,"score_gpt":0.2987284612931916,"score_spread":0.2851697658260686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470584189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902026,0.005503607,0.0008896538,0.00017074187,0.00003537265,0.002510213,0.0006470841,0.0000150818005,0.000025627776],"genre_scores_gemma":[0.98883355,0.008302665,0.0017116392,0.00013376893,0.000012090273,0.0005091566,0.00041561783,0.0000267776,0.000054730877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827874,0.00017682028,0.0005606495,0.0004518611,0.00025092103,0.00028098992],"domain_scores_gemma":[0.99730057,0.001472332,0.00034268099,0.00026988445,0.00051700824,0.000097511496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032992783,0.00031278215,0.0012886877,0.00040151732,0.000055419256,0.0000070567567,0.00006246639,0.00007378748,0.000015316895],"category_scores_gemma":[0.000113417715,0.00018378517,0.00012000628,0.0004664497,0.00028524903,0.00027685158,0.00001944515,0.000051173585,1.5454735e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007800018,0.0010331599,0.885116,0.00012271118,0.0016539437,0.0000014473336,0.004029497,0.000019396619,0.00048758832,0.00004682583,0.000020736343,0.099668674],"study_design_scores_gemma":[0.030224971,0.019597147,0.9278062,0.00075212895,0.0011909434,9.0619835e-7,0.00280674,0.00092559756,0.014551059,0.00012248449,0.0014854581,0.00053638633],"about_ca_topic_score_codex":0.000109303204,"about_ca_topic_score_gemma":0.00030101376,"teacher_disagreement_score":0.09913229,"about_ca_system_score_codex":0.00010842265,"about_ca_system_score_gemma":0.00009291886,"threshold_uncertainty_score":0.7494542},"labels":[],"label_agreement":null},{"id":"W2472041818","doi":"10.1007/s12325-016-0361-2","title":"Healthcare Costs and Resource Utilization in Patients with Infantile Spasms Treated with H.P. Acthar Gel®","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals; University of Washington","keywords":"Medicine; Medical prescription; Mallinckrodt; Medicaid; Health care; Emergency medicine; Family medicine; Emergency department; Pharmacy; Pediatrics; Psychiatry; Nursing","score_opus":0.011470060869914842,"score_gpt":0.26962164256589277,"score_spread":0.2581515816959779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2472041818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994886,0.0026739328,0.000025731477,0.001348627,0.000012720047,0.0004914605,0.000004525755,0.000036431262,0.000520618],"genre_scores_gemma":[0.9868058,0.011955501,0.000068582616,0.0010542813,0.000006469634,0.00001749266,0.00001458009,0.000017675362,0.000059594164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921364,0.000060281716,0.00014346979,0.00025178812,0.000137706,0.00019311144],"domain_scores_gemma":[0.9996488,0.000065433334,0.000056641784,0.0001342951,0.000031789983,0.000063049745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045186374,0.0001250653,0.00019175651,0.00008332204,0.000024889212,0.0000041706608,0.000039981205,0.00009097282,0.00002454443],"category_scores_gemma":[0.000014397761,0.000058532238,0.000010260824,0.00028043252,0.00011995279,0.00014101215,0.0000072996395,0.00013351979,0.0000019622648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039541093,0.00016105329,0.83343816,0.000010304606,0.0000069931266,0.000014347836,0.00008505919,0.000010477092,0.00006824203,0.000032043343,0.000006238057,0.16221298],"study_design_scores_gemma":[0.01281685,0.0032330884,0.97243226,0.00034394785,0.0000048246625,0.0000049560945,0.000044878732,0.000018548035,0.0005128106,0.00011336637,0.010343335,0.00013111296],"about_ca_topic_score_codex":0.000020575279,"about_ca_topic_score_gemma":0.00011197892,"teacher_disagreement_score":0.16208187,"about_ca_system_score_codex":0.00003134068,"about_ca_system_score_gemma":0.000013802786,"threshold_uncertainty_score":0.23868753},"labels":[],"label_agreement":null},{"id":"W2505145747","doi":"10.1007/s12325-016-0377-7","title":"Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Heart rate and cardiovascular health","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Servier Deutschland","keywords":"Ivabradine; Medicine; Tolerability; Internal medicine; Angina; Concomitant; Cardiology; Canadian Cardiovascular Society; Myocardial infarction; Beta blocker; Aspirin; Heart rate; Heart failure; Adverse effect; Blood pressure","score_opus":0.016993157748444145,"score_gpt":0.34925465251682297,"score_spread":0.33226149476837885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2505145747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891997,0.0084434375,0.00025951792,0.0003459112,0.000048823476,0.0016043308,0.000005411614,0.000013198046,0.00007965206],"genre_scores_gemma":[0.98439753,0.014272427,0.0009888946,0.00018501733,0.000038943337,0.000076676195,0.0000032319813,0.000027247961,0.000010033123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976539,0.0007075983,0.0005389175,0.00043762953,0.00032521778,0.000336753],"domain_scores_gemma":[0.9983732,0.00079855823,0.00015750372,0.00042128572,0.00015778128,0.00009165113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022401984,0.0002044575,0.0009831743,0.000098940654,0.000020791209,0.000004971066,0.000066289154,0.00009256013,0.000021666228],"category_scores_gemma":[0.000120898076,0.0000987277,0.00004928385,0.00040292335,0.00023067079,0.0004443082,0.000013221277,0.0002451164,8.333185e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019789787,0.00074181776,0.8313328,0.000101095226,0.00008209071,0.000020526653,0.00017016947,0.000009832579,0.000090926194,0.0000168548,7.9228704e-7,0.14764333],"study_design_scores_gemma":[0.038676586,0.008249617,0.946404,0.0007700031,0.000015466014,0.000012510948,0.000055882025,0.000014659902,0.0011377749,0.000031157928,0.0044773887,0.00015499667],"about_ca_topic_score_codex":0.00021492806,"about_ca_topic_score_gemma":0.00054679293,"teacher_disagreement_score":0.14748834,"about_ca_system_score_codex":0.0002109573,"about_ca_system_score_gemma":0.00037030966,"threshold_uncertainty_score":0.4025999},"labels":[],"label_agreement":null},{"id":"W2539484952","doi":"10.1007/s12325-016-0426-2","title":"Self-Administration of Medicines and Dietary Supplements Among Female Amateur Runners: A Cross-Sectional Analysis","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Muscle metabolism and nutrition","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency","keywords":"Medicine; Context (archaeology); Self-administration; Dietary supplement; Amateur; Athletes; Interquartile range; Family medicine; Confounding; Self-medication; Physical therapy; Environmental health; Internal medicine; Food science","score_opus":0.01027175277952836,"score_gpt":0.31093646866712515,"score_spread":0.3006647158875968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539484952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932199,0.0060843737,0.0004118412,0.000030140895,0.00007210726,0.000089592366,0.000033405882,0.0000048067877,0.000053829073],"genre_scores_gemma":[0.97453004,0.02462791,0.00057254796,0.000034965473,0.00009727497,0.000019133799,0.00008820406,0.0000048796937,0.000025017067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994037,0.00003432721,0.00018703422,0.0001926032,0.00009163036,0.00009071617],"domain_scores_gemma":[0.9997208,0.000013700828,0.00008207271,0.00011971794,0.00003937417,0.000024308767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014582058,0.00007285567,0.00011456366,0.00006660765,0.000024111163,0.000006334688,0.000057548732,0.00004984313,0.000029562214],"category_scores_gemma":[0.000011637464,0.000050867726,0.000043996784,0.000110099245,0.00008716175,0.000020877918,0.00001272319,0.000017230082,2.4546966e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025577864,0.00006674298,0.90640795,0.00001534227,0.00007283292,6.775677e-7,0.000026902006,0.0000052802957,0.08498228,0.000020111158,0.0000064754104,0.008139609],"study_design_scores_gemma":[0.0012373949,0.00026679167,0.9086227,0.0000076252704,0.000015309379,0.0000011895365,0.000021943188,0.000011126242,0.0835896,0.00022541155,0.0059271273,0.00007379109],"about_ca_topic_score_codex":0.000008120676,"about_ca_topic_score_gemma":0.000116201525,"teacher_disagreement_score":0.018689835,"about_ca_system_score_codex":0.0000036216195,"about_ca_system_score_gemma":0.00000932977,"threshold_uncertainty_score":0.20743255},"labels":[],"label_agreement":null},{"id":"W2544647701","doi":"10.1007/s12325-016-0430-6","title":"Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; COPD; Clinical endpoint; Internal medicine; Hazard ratio; Confidence interval; Population; Exacerbation; Post-hoc analysis; Tiotropium bromide; Randomized controlled trial; Lung function; Lung","score_opus":0.033483033267643056,"score_gpt":0.35798235088669333,"score_spread":0.32449931761905026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544647701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990147,0.003807574,0.0041410774,0.00014898833,0.000066852896,0.0015267615,0.00002649169,0.000015601943,0.00011963211],"genre_scores_gemma":[0.9938995,0.0051358044,0.00067983917,0.000038494523,0.000031164847,0.0001478324,0.000029929644,0.000023568913,0.000013849665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973676,0.00063170766,0.0008456031,0.00042860498,0.0004143633,0.00031209947],"domain_scores_gemma":[0.9978172,0.0012551616,0.00033950695,0.00030968533,0.00019636277,0.000082041006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001465151,0.00021321543,0.0015893057,0.0006028141,0.00003334082,0.00003184601,0.000105789026,0.000071893424,0.00011566111],"category_scores_gemma":[0.00062106,0.00012037317,0.00017479494,0.0006788428,0.00028662945,0.00073559646,0.000031429394,0.00012441764,5.996169e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04704573,0.00016513791,0.72381216,0.000058225043,0.00048085029,0.000016032636,0.00014541465,0.0000141502705,0.0052663377,0.000019002191,7.6510355e-7,0.22297622],"study_design_scores_gemma":[0.101242885,0.00016968772,0.89550805,0.0007733434,0.000359291,0.0000019357874,0.00008341836,0.0008128288,0.00050730724,0.0003853075,0.000011621736,0.00014432604],"about_ca_topic_score_codex":0.000040298804,"about_ca_topic_score_gemma":0.00044158203,"teacher_disagreement_score":0.22283189,"about_ca_system_score_codex":0.00025319398,"about_ca_system_score_gemma":0.00009729124,"threshold_uncertainty_score":0.49086756},"labels":[],"label_agreement":null},{"id":"W2549779468","doi":"10.1007/s12325-016-0438-y","title":"Estimating the Effect of Intravenous Acetaminophen for Postoperative Pain Management on Length of Stay and Inpatient Hospital Costs","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Acetaminophen; Perioperative; Emergency medicine; Opioid; Complication; Orthopedic surgery; Adverse effect; Health care; Anesthesia; Surgery; Internal medicine","score_opus":0.004345064428919162,"score_gpt":0.27259209289911807,"score_spread":0.2682470284701989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549779468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928808,0.0031064407,0.0011351083,0.0005037839,0.000088501445,0.0020608283,0.000015850093,0.000007685444,0.00020097698],"genre_scores_gemma":[0.99511236,0.0016183781,0.0028807984,0.00008358471,0.000011938623,0.00025250833,0.000004650351,0.000013539888,0.000022215814],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99928576,0.00010316027,0.0001918973,0.00016267381,0.00013090133,0.00012563923],"domain_scores_gemma":[0.9990196,0.0006433567,0.00010386618,0.00018360234,0.00003030658,0.000019226789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030764993,0.00012333438,0.0002456127,0.00004680444,0.00002621037,0.0000023185762,0.000059077298,0.000021131935,0.0000047367294],"category_scores_gemma":[0.00006948373,0.000056956447,0.00003513023,0.00005821946,0.00009081464,0.000055900247,0.000014523423,0.000034550827,4.1093244e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010946196,0.00028502345,0.026438765,0.00011428413,0.00012783782,0.0000026546122,0.0029785049,0.00005733016,0.00055129663,0.00044483686,0.0000061357878,0.9678987],"study_design_scores_gemma":[0.08672264,0.2578855,0.24125104,0.00644914,0.0003552584,0.000007655336,0.0062132906,0.0025371504,0.38838366,0.005291524,0.0038954802,0.0010076966],"about_ca_topic_score_codex":0.000008277712,"about_ca_topic_score_gemma":0.000003615815,"teacher_disagreement_score":0.966891,"about_ca_system_score_codex":0.00007161199,"about_ca_system_score_gemma":0.000007992994,"threshold_uncertainty_score":0.23226164},"labels":[],"label_agreement":null},{"id":"W2557456288","doi":"10.1007/s12325-016-0455-x","title":"Sirukumab: A Potential Treatment for Mood Disorders?","year":2016,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; University Health Network","funders":"Pfizer; H. Lundbeck A/S; Purdue University; AstraZeneca; Allergan; Eli Lilly and Company","keywords":"Medicine; Mood; Anxiety; Mood disorders; Cognition; Anhedonia; Disease; Major depressive disorder; Research Domain Criteria; Bioinformatics; Psychiatry; Clinical psychology; Immunology; Internal medicine","score_opus":0.04639387100269654,"score_gpt":0.3714001226772261,"score_spread":0.32500625167452957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557456288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008951454,0.9944083,0.00062355003,0.00007498603,0.00073061057,0.0020382053,0.0001444684,0.00008238422,0.0018885349],"genre_scores_gemma":[0.00013234072,0.9973539,0.00013267109,0.00009340927,0.00019772151,0.001213107,0.000013304003,0.00008441418,0.00077911234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798405,0.00016118767,0.00041966746,0.0007792288,0.00016796749,0.00048789996],"domain_scores_gemma":[0.99867445,0.0005942245,0.00024419726,0.00042040722,0.000008619356,0.000058114256],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006620263,0.00049816346,0.0009791711,0.00018281832,0.00009907478,0.00003680004,0.0004951681,0.00017241502,0.000102184415],"category_scores_gemma":[0.000072336756,0.00030218167,0.0005794079,0.000261298,0.00014441178,0.0002651842,0.000026079933,0.00010474676,0.00006963353],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057691785,0.00020930766,4.205684e-7,0.00043797895,0.000013050555,0.0000021431158,0.000041501185,0.0000020399762,0.000022539904,0.0010798974,0.000017827195,0.9981156],"study_design_scores_gemma":[0.0020103746,0.00041110037,4.5855705e-7,0.0011378527,0.000012438075,0.0000059470444,0.000009399224,0.0000026858143,0.00013923345,0.007905048,0.98798245,0.0003830255],"about_ca_topic_score_codex":0.000002609446,"about_ca_topic_score_gemma":0.0000411525,"teacher_disagreement_score":0.9977326,"about_ca_system_score_codex":0.0001276002,"about_ca_system_score_gemma":0.00010510716,"threshold_uncertainty_score":0.999943},"labels":[],"label_agreement":null},{"id":"W2560603998","doi":"10.1007/s12325-016-0449-8","title":"Hospitalization Costs for Patients Undergoing Orthopedic Surgery Treated With Intravenous Acetaminophen (IV-APAP) Plus Other IV Analgesics or IV Opioid Monotherapy for Postoperative Pain","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Anesthesia and Pain Management","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Acetaminophen; Orthopedic surgery; Anesthesia; Opioid; Postoperative pain; Rheumatology; Pain management; Surgery; Internal medicine","score_opus":0.014268676420290291,"score_gpt":0.26463255496456717,"score_spread":0.2503638785442769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560603998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8489933,0.0022396105,0.14235882,0.001256682,0.000093824776,0.004819907,0.000018106935,0.00010187056,0.0001178885],"genre_scores_gemma":[0.96425134,0.019512648,0.004692202,0.007388274,0.00019751569,0.0012939334,0.00018798852,0.00017647851,0.0022996087],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983558,0.0001863662,0.0003892058,0.00043455284,0.00023185655,0.00040219547],"domain_scores_gemma":[0.99791926,0.0013046474,0.00022232499,0.00027516505,0.00019711164,0.000081512604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005927992,0.00031521896,0.0005201289,0.00014586493,0.00011898563,0.000024350475,0.00010782172,0.00009924537,0.000053342847],"category_scores_gemma":[0.0001308679,0.00017961214,0.00009769021,0.00028207578,0.0000978427,0.00033464926,0.0000055760966,0.000053118336,0.0000025861364],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011248928,0.00044976757,0.5578823,0.00013295321,0.00021016436,0.000015201646,0.0010512337,0.00010473574,0.00008027288,0.00052134506,0.00045076388,0.4278523],"study_design_scores_gemma":[0.111604154,0.056664936,0.23948494,0.005768741,0.0003971568,0.000023476694,0.0028145947,0.0057958923,0.0030585027,0.0048859143,0.5659676,0.0035340667],"about_ca_topic_score_codex":0.000020880518,"about_ca_topic_score_gemma":0.00014064676,"teacher_disagreement_score":0.5655169,"about_ca_system_score_codex":0.00029028807,"about_ca_system_score_gemma":0.00015249352,"threshold_uncertainty_score":0.732437},"labels":[],"label_agreement":null},{"id":"W2562907299","doi":"10.1007/s12325-016-0468-5","title":"Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Obsessive-Compulsive Spectrum Disorders","field":"Psychology","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Placebo; Medicine; Internal medicine; Randomized controlled trial; Adverse effect; Interim analysis","score_opus":0.012365340215467053,"score_gpt":0.3564717850763892,"score_spread":0.3441064448609222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562907299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97898114,0.0024105427,0.00026311434,0.00024663136,0.0008952676,0.014386664,0.000025419971,0.000029822373,0.0027613747],"genre_scores_gemma":[0.9954346,0.00009754177,0.0002917984,0.000111275614,0.00006599784,0.0037976275,0.00001194548,0.000047997844,0.00014122759],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961657,0.0011185566,0.0010720792,0.0007465937,0.00039538703,0.0005016694],"domain_scores_gemma":[0.9975498,0.0005137211,0.0009604436,0.00075098,0.00014796758,0.00007708809],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009967976,0.000380139,0.0012607506,0.00041532054,0.00017136073,0.00005573878,0.0005748098,0.00009911506,0.00014969199],"category_scores_gemma":[0.00044956556,0.00032120856,0.00016624335,0.00033206513,0.00025622136,0.0005650767,0.000053994732,0.00029455853,0.00001209814],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7877178,0.006589195,0.056828834,0.0000139630365,0.00030689526,0.000045442262,0.04409216,0.00059925066,0.00025099632,0.00037967277,0.000058763417,0.103117],"study_design_scores_gemma":[0.9556684,0.00372154,0.024742357,0.00014540523,0.000032690878,6.9275956e-7,0.0068916273,0.00007208161,0.0054593664,0.0025494387,0.0002659997,0.00045041554],"about_ca_topic_score_codex":0.00063976453,"about_ca_topic_score_gemma":0.0017639351,"teacher_disagreement_score":0.16795056,"about_ca_system_score_codex":0.0002151324,"about_ca_system_score_gemma":0.000058129674,"threshold_uncertainty_score":0.999924},"labels":[],"label_agreement":null},{"id":"W2569887051","doi":"10.1007/s12325-016-0467-6","title":"Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Cilag; Takeda Oncology; Pfizer; Takeda Pharmaceuticals International; Biogen; Bristol-Myers Squibb","keywords":"Vedolizumab; Medicine; Ulcerative colitis; Internal medicine; Placebo; Adverse effect; Incidence (geometry); Clinical trial; Gastroenterology; Disease; Pathology","score_opus":0.006579731256089791,"score_gpt":0.2727616399943329,"score_spread":0.2661819087382431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569887051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971768,0.0018457603,0.000009539743,0.00001775414,0.000042004896,0.0003460758,0.00010455579,0.0000020588325,0.00045544625],"genre_scores_gemma":[0.99376,0.0059906337,0.000046021916,0.000054829205,0.000017310593,0.000025739364,0.0000570708,0.000009335574,0.000039097977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999359,0.00006326459,0.00016207984,0.0002249926,0.00006387624,0.00012680054],"domain_scores_gemma":[0.9995396,0.000013260239,0.00009923169,0.00025676526,0.000023262162,0.00006784605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006510615,0.000105658015,0.0001158456,0.000019325258,0.000067302266,0.000021997605,0.00011137858,0.000045097382,0.0000052152864],"category_scores_gemma":[0.00006574291,0.00010147641,0.000016132779,0.000012818272,0.00023114141,0.0000222558,0.000043076012,0.000043615153,1.9302031e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022932189,0.0005041955,0.8409366,0.00009469841,0.000039797582,0.00018470958,0.0005986296,0.00005244924,0.007086648,0.00061064895,0.00009218637,0.12686722],"study_design_scores_gemma":[0.004905027,0.00009176002,0.99124265,0.000030061241,0.0000020915415,1.7204795e-7,0.000020926705,0.000008936042,0.0014679903,0.00042157894,0.0016946883,0.000114141774],"about_ca_topic_score_codex":0.000014647372,"about_ca_topic_score_gemma":0.0003068262,"teacher_disagreement_score":0.150306,"about_ca_system_score_codex":0.000009229232,"about_ca_system_score_gemma":0.00002903169,"threshold_uncertainty_score":0.4138088},"labels":[],"label_agreement":null},{"id":"W2587678696","doi":"10.1007/s12325-017-0480-4","title":"When People with Opioid-Induced Constipation Speak: A Patient Survey","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AstraZeneca; Pfizer","keywords":"Medicine; Constipation; Opioid; Rheumatology; Opioid epidemic; Internal medicine; Physical therapy; Family medicine; Intensive care medicine; Receptor","score_opus":0.028674183054209615,"score_gpt":0.30907903382730484,"score_spread":0.28040485077309524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587678696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950427,0.00060327427,0.00054464134,0.00046269753,0.0001080792,0.00037957937,0.0000048026845,0.000023785267,0.002830469],"genre_scores_gemma":[0.9975818,0.00035284148,0.0017090087,0.00025354952,0.000020226515,0.000023625924,0.000018573171,0.000010402254,0.000029966044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999278,0.000047629506,0.00014536765,0.00020136617,0.00015855387,0.00016908819],"domain_scores_gemma":[0.9992607,0.00008504413,0.00012362874,0.00038645684,0.00008625363,0.000057916663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015516597,0.000108695865,0.0001915526,0.000041646468,0.000103327584,0.00002615234,0.00010152457,0.00002710098,0.00005843401],"category_scores_gemma":[0.00027164503,0.00008184377,0.00002357967,0.000047183566,0.00009084468,0.0002761511,0.000014782037,0.000113634276,0.00000937865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011318586,0.00017171234,0.9154057,0.000014068535,0.0000072254693,0.000009518655,0.0006699773,0.000019435349,0.00022341192,0.000062301355,0.00001740049,0.0822674],"study_design_scores_gemma":[0.0025431172,0.0012679728,0.9924976,0.00012132667,0.000003802309,0.00001852384,0.00017741827,0.00007518197,0.0005908574,0.00095420226,0.0016609209,0.000089038076],"about_ca_topic_score_codex":0.0011286373,"about_ca_topic_score_gemma":0.008592393,"teacher_disagreement_score":0.08217837,"about_ca_system_score_codex":0.000027324397,"about_ca_system_score_gemma":0.0000625167,"threshold_uncertainty_score":0.4794757},"labels":[],"label_agreement":null},{"id":"W2606607892","doi":"10.1007/s12325-017-0529-4","title":"Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada?","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Heart rate and cardiovascular health","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Health Sciences Centre; The Scarborough Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Health Canada; Servier","keywords":"Ivabradine; Medicine; Ejection fraction; Heart failure; Internal medicine; Sinus rhythm; Guideline; Cardiology; Adverse effect; Heart rate; Atrial fibrillation; Blood pressure","score_opus":0.027726990296504602,"score_gpt":0.33454451083910275,"score_spread":0.30681752054259814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606607892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743484,0.019125205,0.0000046107284,0.004862846,0.00002867239,0.001507115,0.0000197914,0.0000030953188,0.000100235695],"genre_scores_gemma":[0.99193716,0.006189027,0.0002568228,0.0014443112,0.000022056396,0.00011270272,0.000016976785,0.000015922027,0.000004996992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861914,0.00031316315,0.0003738159,0.00018597266,0.0002438236,0.0002641119],"domain_scores_gemma":[0.99906015,0.00015062178,0.00010591899,0.0006108322,0.000025797233,0.000046660425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011052833,0.00014137644,0.00047987714,0.000070063485,0.000095319454,0.000008039697,0.00021561515,0.000081665974,0.0000041114376],"category_scores_gemma":[0.000017595956,0.00009582234,0.00004601803,0.0001382705,0.00008829882,0.00020946281,0.000032511736,0.0007442553,2.1847006e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004000893,0.00012572018,0.98604953,0.0002484966,0.000029707015,0.0000071214436,0.00097148493,0.000026300018,0.00001201194,0.00002252387,0.00015689233,0.0119501045],"study_design_scores_gemma":[0.007859119,0.00051292527,0.89289194,0.00060731615,0.000005515318,0.0000025552404,0.0031420186,0.000053467604,0.00007913703,0.0002435212,0.09450337,0.000099109595],"about_ca_topic_score_codex":0.11388616,"about_ca_topic_score_gemma":0.66952354,"teacher_disagreement_score":0.55563736,"about_ca_system_score_codex":0.00016343736,"about_ca_system_score_gemma":0.0004537457,"threshold_uncertainty_score":0.89201456},"labels":[],"label_agreement":null},{"id":"W2607307651","doi":"10.1007/s12325-017-0523-x","title":"Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Merck Canada Inc. (Canada); Université de Montréal","funders":"Merck","keywords":"Medicine; Rheumatoid arthritis; Crossover study; Randomized controlled trial; Crossover; Preference; Rheumatology; Health professionals; Health care; Internal medicine; Physical therapy; Alternative medicine; Statistics","score_opus":0.03973123510095347,"score_gpt":0.3763175813045308,"score_spread":0.3365863462035773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607307651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9155506,0.0739714,0.0009644715,0.0013622488,0.0011725246,0.006642239,0.00026235436,0.00005173441,0.000022460716],"genre_scores_gemma":[0.9814083,0.014815519,0.0021049897,0.00071002427,0.000017544224,0.00067396427,0.000015511338,0.000019638119,0.00023452449],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99824655,0.0003944862,0.0004926289,0.00044885094,0.000044546006,0.00037295168],"domain_scores_gemma":[0.9973216,0.0017954214,0.0003256167,0.00038207322,0.00014323015,0.00003207441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073787733,0.00022370163,0.00077614037,0.000053121654,0.00052102504,0.0000730912,0.00021065064,0.00021801353,0.000035097273],"category_scores_gemma":[0.0008163923,0.00015132425,0.00012769425,0.00003346009,0.00038758418,0.00032352554,0.00006889816,0.00018966415,0.0000012708623],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35492188,0.0021390715,0.024099056,0.00014550945,0.000583344,0.000004054116,0.0035009373,0.00001632753,0.0027666595,0.0042832275,0.00051490247,0.607025],"study_design_scores_gemma":[0.7597728,0.009130701,0.02136829,0.0012664875,0.000056337565,0.000019030567,0.0012269982,0.00052976096,0.02159519,0.039848838,0.14384277,0.0013428233],"about_ca_topic_score_codex":0.00007820901,"about_ca_topic_score_gemma":0.00015565573,"teacher_disagreement_score":0.6056822,"about_ca_system_score_codex":0.000019067795,"about_ca_system_score_gemma":0.000050348368,"threshold_uncertainty_score":0.61708236},"labels":[],"label_agreement":null},{"id":"W2730094282","doi":"10.1007/s12325-017-0569-9","title":"Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications","year":2017,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Rheumatoid arthritis; Dermatomyositis; Internal medicine; Intensive care medicine; Immunology","score_opus":0.15013388212145573,"score_gpt":0.5094959900189787,"score_spread":0.359362107897523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2730094282","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009822147,0.99506027,0.000008400745,0.00013317185,0.00007906553,0.0036133765,0.000055401906,0.0000057949555,0.00006233762],"genre_scores_gemma":[0.0008792967,0.99802226,0.00018719856,0.00002103584,0.0000773711,0.0005341914,0.00023366473,0.000017837361,0.000027165106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796605,0.0006066303,0.00087010476,0.00030629596,0.00014787703,0.000103020924],"domain_scores_gemma":[0.9981788,0.00032069368,0.00086719706,0.0003521168,0.0002176773,0.000063530766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000598409,0.00017324473,0.0012539397,0.00014345287,0.00009584706,0.0000141859155,0.00006824861,0.00013856763,0.0000052354144],"category_scores_gemma":[0.00027759507,0.00012683037,0.00014142368,0.000082506,0.00025304512,0.00013107173,0.00001228062,0.00014289026,1.4837092e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001503014,0.00008245621,0.0003768624,0.013697214,0.00013603386,5.933358e-7,0.0010283074,5.3440357e-7,2.8111393e-7,0.00012446525,0.000016183441,0.98438674],"study_design_scores_gemma":[0.0028743441,0.0025008565,0.00047046697,0.15028715,0.0000700027,0.000075686716,0.00008682863,0.000026599075,0.0000031510372,0.00022174045,0.84328425,0.000098902674],"about_ca_topic_score_codex":0.000012365524,"about_ca_topic_score_gemma":0.000036051966,"teacher_disagreement_score":0.98428786,"about_ca_system_score_codex":0.00012664522,"about_ca_system_score_gemma":0.0006414581,"threshold_uncertainty_score":0.5171993},"labels":[],"label_agreement":null},{"id":"W2752535758","doi":"10.1007/s12325-017-0604-x","title":"Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University; AstraZeneca","keywords":"Medicine; Fluticasone propionate; Formoterol; Budesonide; Formoterol Fumarate; Inhaler; COPD; Budesonide/formoterol; Dry-powder inhaler; Physical therapy; Internal medicine; Asthma","score_opus":0.05241790545422739,"score_gpt":0.3686619351293873,"score_spread":0.31624402967515985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752535758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96686083,0.027605904,0.000016086926,0.0017005348,0.00020686562,0.0028191297,0.00044774555,0.000031247902,0.00031166413],"genre_scores_gemma":[0.9781459,0.019635763,0.0001422393,0.00058435,0.00013952368,0.000115407514,0.0011208764,0.000047421578,0.000068505906],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974828,0.00037614963,0.000371996,0.0006885719,0.00065766694,0.00042280927],"domain_scores_gemma":[0.99744004,0.00037948275,0.00032639096,0.0015707646,0.00015479853,0.00012851559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049290713,0.00024703812,0.00045061216,0.00008202267,0.00030630067,0.00007471671,0.0007103839,0.00011022965,0.00005550771],"category_scores_gemma":[0.00048173234,0.00016585329,0.000032546523,0.00025334253,0.0003549783,0.00077882904,0.0001469948,0.00041058206,0.0000023188998],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050402507,0.00038932043,0.47306302,0.000010374051,0.00003094806,0.000010686093,0.0002979637,0.000004957161,0.000010971798,0.000014971492,0.00007207364,0.4756922],"study_design_scores_gemma":[0.11619803,0.0010596891,0.8582609,0.00026744712,0.000007655414,4.4470784e-7,0.000400089,0.00043093463,0.000035163084,0.00032557597,0.022835659,0.00017840588],"about_ca_topic_score_codex":0.0006226811,"about_ca_topic_score_gemma":0.0020851926,"teacher_disagreement_score":0.4755138,"about_ca_system_score_codex":0.00039655482,"about_ca_system_score_gemma":0.0002560346,"threshold_uncertainty_score":0.6763301},"labels":[],"label_agreement":null},{"id":"W2766244499","doi":"10.1007/s12325-017-0627-3","title":"Prevalence of Co-existing Autoimmune Disease in Rheumatoid Arthritis: A Cross-Sectional Study","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University","funders":"Genentech; Bristol-Myers Squibb","keywords":"Medicine; Rheumatoid arthritis; Psoriatic arthritis; Ankylosing spondylitis; Rheumatology; Internal medicine; Autoimmune disease; Psoriasis; Odds ratio; Cross-sectional study; Arthritis; Population; Immunology; Disease; Pathology","score_opus":0.03297485079590612,"score_gpt":0.38565105918668574,"score_spread":0.3526762083907796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766244499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8868268,0.11147843,0.000012148788,0.00004638915,0.00013077343,0.0006950845,0.00001944978,0.000026520982,0.00076436275],"genre_scores_gemma":[0.72163343,0.27803466,0.00009288997,0.000012853685,0.000020490412,0.00011242585,0.0000037412021,0.000015007154,0.000074467105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819577,0.00010227143,0.0005532394,0.00034144107,0.00047223043,0.00033502758],"domain_scores_gemma":[0.9988257,0.00012848162,0.00021877328,0.0006271532,0.00009642462,0.00010342672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006962361,0.0001578949,0.0003538009,0.0001671319,0.00021951023,0.000077099074,0.00033437044,0.00003943744,0.00019427165],"category_scores_gemma":[0.0004847305,0.00014412828,0.000073347066,0.00009290255,0.00047298035,0.0006947015,0.000051305055,0.00025760796,0.000010404541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015331212,0.0008476381,0.9446792,0.000064454965,0.000023079234,0.0001070419,0.0005671476,0.000053310006,0.0006396917,0.00022092873,0.0000013454027,0.051263012],"study_design_scores_gemma":[0.007760438,0.00049786613,0.9877334,0.0007513974,2.0869638e-7,0.000012859325,0.00011385856,0.00011457589,0.0003601124,0.0014817503,0.0010472446,0.00012627177],"about_ca_topic_score_codex":0.00023252222,"about_ca_topic_score_gemma":0.00014564992,"teacher_disagreement_score":0.16655624,"about_ca_system_score_codex":0.0000478832,"about_ca_system_score_gemma":0.00012598197,"threshold_uncertainty_score":0.5877381},"labels":[],"label_agreement":null},{"id":"W2789321069","doi":"10.1007/s12325-018-0689-x","title":"Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Breast cancer; Internal medicine; Metastatic breast cancer; Oncology; Rheumatology; Cancer; Gynecology","score_opus":0.009575853979504405,"score_gpt":0.3136427364288696,"score_spread":0.3040668824493652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789321069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98913455,0.0076597566,0.00022144371,0.00047971046,0.00043281686,0.0005843742,0.00008388464,0.00006573368,0.0013377554],"genre_scores_gemma":[0.9896583,0.006946116,0.0016869424,0.00037752566,0.00061767676,0.00031329837,0.0000061606806,0.000066314984,0.00032767528],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99826133,0.0000611878,0.00049866166,0.00042867564,0.00023592608,0.00051423983],"domain_scores_gemma":[0.9988773,0.000071280825,0.00028107953,0.00045852826,0.00018276031,0.00012907882],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018688911,0.00028333944,0.0006071555,0.00016814188,0.000047177567,0.000009784717,0.00023760785,0.000056477656,0.0017098881],"category_scores_gemma":[0.000013125659,0.00024085103,0.00006104541,0.0002381165,0.0006209588,0.000572067,0.000032345706,0.00016966289,0.000028901031],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008065622,0.00037225705,0.1449889,0.00024339947,0.0006077224,0.000024311717,0.013891216,0.0018778536,0.023289166,0.0007715704,0.000042971904,0.805825],"study_design_scores_gemma":[0.056149796,0.0099353995,0.578052,0.003294029,0.00024426624,0.00047384138,0.012667853,0.002724492,0.12937197,0.028958727,0.17504069,0.0030869462],"about_ca_topic_score_codex":0.00068430725,"about_ca_topic_score_gemma":0.0005523176,"teacher_disagreement_score":0.8027381,"about_ca_system_score_codex":0.00052362337,"about_ca_system_score_gemma":0.0001719507,"threshold_uncertainty_score":0.99920267},"labels":[],"label_agreement":null},{"id":"W2789545915","doi":"10.1007/s12325-018-0688-y","title":"A Comparison Between Rheological Properties of Intra-articular Hyaluronic Acid Preparations and Reported Human Synovial Fluid","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Proteoglycans and glycosaminoglycans research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Ferring Pharmaceuticals","keywords":"Synovial fluid; Rheology; Hyaluronic acid; Medicine; Crossover study; Shear rate; Viscosity; Osteoarthritis; Materials science; Pathology; Composite material; Anatomy","score_opus":0.049905807584411814,"score_gpt":0.3757283335257441,"score_spread":0.32582252594133226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789545915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98672587,0.011553111,0.0010062034,0.00007513086,0.000032772983,0.00033163317,0.0000052334262,0.0000090736885,0.00026095082],"genre_scores_gemma":[0.9982457,0.0009928507,0.00041858084,0.000031450058,0.0001398053,0.000065580214,0.000024698425,0.000009873921,0.00007143796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889284,0.000101135745,0.0003359671,0.00030628557,0.00013694022,0.00022685068],"domain_scores_gemma":[0.9994662,0.000008098919,0.000090167276,0.0002906501,0.00009592122,0.000048978978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023702256,0.00011856926,0.00021772092,0.00004841959,0.00009150196,0.000013799613,0.00015687033,0.00010302155,0.000020300788],"category_scores_gemma":[0.0000710121,0.000091759925,0.000036469413,0.00011248027,0.000559946,0.000014081613,0.00006885768,0.000091524016,0.0000013181506],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025052053,0.00009334022,0.046588328,0.000013099858,0.000039233037,0.0000018351041,0.00015356312,0.000011849531,0.9426028,0.00012952898,0.000028414426,0.010087466],"study_design_scores_gemma":[0.00075021136,0.0020443352,0.009982077,0.000022585025,0.0000056790036,0.000006974223,0.000053263608,0.00011697216,0.9763362,0.00035149168,0.010197101,0.00013314173],"about_ca_topic_score_codex":0.000028280792,"about_ca_topic_score_gemma":0.00014764824,"teacher_disagreement_score":0.036606252,"about_ca_system_score_codex":0.000010621495,"about_ca_system_score_gemma":0.000051044834,"threshold_uncertainty_score":0.3741861},"labels":[],"label_agreement":null},{"id":"W2790461977","doi":"10.1007/s12325-018-0681-5","title":"Efficacy of Ivabradine in Combination with Beta-Blockers Versus Uptitration of Beta-Blockers in Patients with Stable Angina (CONTROL-2 Study)","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Heart rate and cardiovascular health","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Servier","keywords":"Ivabradine; Medicine; BETA (programming language); Bisoprolol; Internal medicine; Cardiology; Angina; Carvedilol; Beta blocker; Stable angina; Adrenergic beta-Antagonists; Heart failure; Heart rate; Coronary artery disease; Blood pressure; Myocardial infarction","score_opus":0.01224413159374573,"score_gpt":0.2892618491991901,"score_spread":0.2770177176054444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790461977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99702,0.000954205,0.000100387006,0.00020545085,0.00007518344,0.0015038396,0.000004315639,0.000010587798,0.00012600837],"genre_scores_gemma":[0.9986933,0.00033103337,0.00082179136,0.000046929992,0.000025441115,0.000035129346,0.000020121568,0.000019805244,0.000006471547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985089,0.00015081713,0.0004048205,0.0002525758,0.00043765968,0.00024523327],"domain_scores_gemma":[0.9992366,0.00008005412,0.00014725479,0.0003064354,0.00018176089,0.00004791473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005177607,0.00015196163,0.00055462605,0.00028353263,0.000023451526,0.0000037029624,0.000070274364,0.000053940053,0.000015137429],"category_scores_gemma":[0.000018653549,0.00011363625,0.000046315876,0.000756823,0.00011836027,0.00027539552,0.000005516303,0.00014392092,0.000001121889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014624028,0.0019622897,0.9587578,0.000052478474,0.00016852554,0.000006198756,0.0016786896,0.00033529405,0.00011541147,0.000047592715,0.000008596045,0.022243105],"study_design_scores_gemma":[0.067273855,0.011389301,0.91758454,0.00016927006,0.00004647053,5.076863e-7,0.000493871,0.00009552634,0.0020143986,0.0000143559855,0.00079231244,0.00012559537],"about_ca_topic_score_codex":0.0003231657,"about_ca_topic_score_gemma":0.0013053584,"teacher_disagreement_score":0.05264983,"about_ca_system_score_codex":0.00011926041,"about_ca_system_score_gemma":0.00012698385,"threshold_uncertainty_score":0.46339518},"labels":[],"label_agreement":null},{"id":"W2790923252","doi":"10.1007/s12325-018-0676-2","title":"Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Regimen; Fulvestrant; Internal medicine; Metastatic breast cancer; Discontinuation; Oncology; Aromatase inhibitor; Breast cancer; Cancer; Tamoxifen","score_opus":0.138153164960228,"score_gpt":0.4640211901505986,"score_spread":0.3258680251903706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790923252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944996,0.0029646535,0.00008810465,0.00031223273,0.00024691687,0.00167049,0.000097785174,0.000058744445,0.0000614564],"genre_scores_gemma":[0.99340826,0.0033877133,0.0007375742,0.0004428974,0.00023398954,0.0016702559,0.00004120013,0.000057807094,0.00002031143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973209,0.00077528943,0.0004756796,0.00046212994,0.0003749043,0.00059109094],"domain_scores_gemma":[0.9981653,0.0002982569,0.00053413154,0.0006087972,0.00021839835,0.00017512035],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005564214,0.00038341052,0.0006700498,0.00020161907,0.00014914747,0.000022935086,0.00025377463,0.000049191825,0.00039040417],"category_scores_gemma":[0.000022594571,0.00027675438,0.00002466845,0.00048699797,0.00033445132,0.0012195886,0.00003433356,0.0004911606,0.000004327729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006943347,0.0062993183,0.6720209,0.000023310758,0.00017649675,0.00004982068,0.016407961,0.00025743095,0.00017256368,0.000010378328,2.4011436e-7,0.2976382],"study_design_scores_gemma":[0.012300286,0.019155232,0.9513284,0.00017775231,0.000044132874,0.00007294109,0.011714633,0.0000790237,0.00011512689,0.00032769146,0.004404585,0.00028022102],"about_ca_topic_score_codex":0.0058408617,"about_ca_topic_score_gemma":0.07452022,"teacher_disagreement_score":0.297358,"about_ca_system_score_codex":0.0021534378,"about_ca_system_score_gemma":0.00048414068,"threshold_uncertainty_score":0.99996847},"labels":[],"label_agreement":null},{"id":"W2790983276","doi":"10.1007/s12325-018-0678-0","title":"Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"AbbVie","keywords":"Adalimumab; Medicine; Placebo; Internal medicine; Arthritis; Crohn's disease; Rheumatology; Gastroenterology; Surgery; Disease; Pathology","score_opus":0.017511156106649904,"score_gpt":0.3510851749995052,"score_spread":0.3335740188928553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790983276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99736637,0.0021567591,0.0000719734,0.000022864937,0.0000638588,0.00021060476,0.000040399074,0.0000055710066,0.00006160547],"genre_scores_gemma":[0.99806595,0.0009971302,0.00063426734,0.00010270746,0.000053690223,0.000039905583,0.00006978054,0.000011321241,0.00002527554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892056,0.00013089523,0.0003588851,0.00029658197,0.00013338293,0.00015969978],"domain_scores_gemma":[0.9992764,0.000042017866,0.00015295383,0.00026082984,0.00021210464,0.000055673558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018349652,0.00012254521,0.00018973343,0.00012937821,0.00003183022,0.000005042076,0.00014370796,0.000034168665,0.000019058667],"category_scores_gemma":[0.00016267801,0.00009939109,0.00007780885,0.00025430816,0.00037623907,0.000015271838,0.000027364578,0.000044731958,9.642622e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024259645,0.00033693484,0.9908991,0.000009708909,0.00026159539,0.000040779985,0.00014722416,0.00033973032,0.00013587144,0.000049735605,0.000012796348,0.0053406022],"study_design_scores_gemma":[0.0016766316,0.00027854872,0.9970244,0.000035612982,0.000106704974,1.6177054e-7,0.00015860343,0.000058141268,0.00017775375,0.00014625372,0.00021174118,0.00012544316],"about_ca_topic_score_codex":0.0000047369253,"about_ca_topic_score_gemma":0.00083020754,"teacher_disagreement_score":0.0061253468,"about_ca_system_score_codex":0.000015535828,"about_ca_system_score_gemma":0.00007731726,"threshold_uncertainty_score":0.4053051},"labels":[],"label_agreement":null},{"id":"W2792899705","doi":"10.1007/s12325-018-0666-4","title":"Prospective Evaluation of Two iStent® Trabecular Stents, One iStent Supra® Suprachoroidal Stent, and Postoperative Prostaglandin in Refractory Glaucoma: 4-year Outcomes","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Glaucoma; Ophthalmology; Intraocular pressure; Glaucoma surgery; Cataract surgery; Prospective cohort study; Glaucoma medication; Visual acuity; Surgery","score_opus":0.0229214098921999,"score_gpt":0.33895937717182156,"score_spread":0.31603796727962163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792899705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98638284,0.009384136,0.00001923143,0.00052656897,0.00013594356,0.002069735,0.0000129290465,0.000018120394,0.0014505076],"genre_scores_gemma":[0.9966826,0.0023006212,0.00047152775,0.00018086795,0.000040754054,0.0001176449,0.000027200671,0.000027098293,0.00015169277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978737,0.00027832267,0.0004761569,0.00043703654,0.0006371063,0.0002976838],"domain_scores_gemma":[0.9990405,0.00007527912,0.0001739311,0.00027095448,0.00036612054,0.000073210664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074377644,0.00023798567,0.00051871035,0.00021590237,0.000055927496,0.000013841279,0.00009689405,0.00008669079,0.000086076325],"category_scores_gemma":[0.00012223102,0.00018176337,0.000081504375,0.00029239236,0.00035108536,0.00034124157,0.000028423596,0.00024558615,0.000005400982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016110166,0.0009495959,0.9730083,0.000045045064,0.00008214284,0.000009764085,0.0031518005,0.0000022941983,0.009445151,0.00060091313,0.0000049417795,0.011089082],"study_design_scores_gemma":[0.016651262,0.0027311584,0.97046584,0.00024017984,0.000055258755,0.000011751418,0.0027153066,0.0002276011,0.004883024,0.001287318,0.00052478706,0.00020653398],"about_ca_topic_score_codex":0.00017806425,"about_ca_topic_score_gemma":0.0007871809,"teacher_disagreement_score":0.015040245,"about_ca_system_score_codex":0.00020962702,"about_ca_system_score_gemma":0.000102786,"threshold_uncertainty_score":0.74120957},"labels":[],"label_agreement":null},{"id":"W2806677947","doi":"10.1007/s12325-018-0701-5","title":"Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Palbociclib; Medicine; Dosing; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Cancer; Medical prescription; Pharmacology","score_opus":0.012626847874048403,"score_gpt":0.326261645675861,"score_spread":0.31363479780181264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806677947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808433,0.017135147,0.00021195762,0.00084081705,0.00023741715,0.00040258834,0.000081869584,0.000027681375,0.00021919873],"genre_scores_gemma":[0.9829231,0.014971898,0.0013042939,0.00031983867,0.0002692041,0.00006859788,0.0000051522998,0.000047056215,0.00009089116],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986202,0.00006600119,0.0004382982,0.00038245379,0.00014397364,0.0003490567],"domain_scores_gemma":[0.99928576,0.00010731335,0.00019274493,0.00029478187,0.0000459542,0.00007346001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020704619,0.0002329119,0.0005301544,0.00019991596,0.000033003274,0.000010937969,0.00013342148,0.000038494796,0.0004054399],"category_scores_gemma":[0.0000063018533,0.00020222987,0.0000497283,0.00017845599,0.000313176,0.00047737447,0.000033938464,0.00016971095,0.000004636841],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020022772,0.0001260128,0.3597183,0.00018502086,0.000099973506,0.000025617637,0.0068022623,0.00067053223,0.0066823587,0.00021343683,0.000005612558,0.62346864],"study_design_scores_gemma":[0.042440135,0.0013808224,0.808657,0.0045704218,0.00011720416,0.0004303828,0.01169066,0.003211909,0.06691362,0.0126644615,0.046148222,0.0017751664],"about_ca_topic_score_codex":0.0024299326,"about_ca_topic_score_gemma":0.003251343,"teacher_disagreement_score":0.62169343,"about_ca_system_score_codex":0.00021078963,"about_ca_system_score_gemma":0.00008293381,"threshold_uncertainty_score":0.8246695},"labels":[],"label_agreement":null},{"id":"W2810702595","doi":"10.1007/s12325-018-0740-y","title":"Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2− Metastatic Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Breast cancer; Rheumatology; Metastatic breast cancer; Oncology; Cancer; Cardiac function curve; Hematology; Heart failure","score_opus":0.010532308368372332,"score_gpt":0.3003753413487511,"score_spread":0.2898430329803788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810702595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96987593,0.028937865,0.00019184836,0.00017438714,0.00023597437,0.00044010163,0.000016544589,0.000033439344,0.000093903574],"genre_scores_gemma":[0.98903054,0.00829147,0.0020696553,0.00013835057,0.0001387368,0.00026994766,0.0000018424608,0.000034838515,0.000024608713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987227,0.000067650915,0.00030329326,0.00032138888,0.000230355,0.00035461056],"domain_scores_gemma":[0.9993064,0.0000896223,0.00015473246,0.0002316264,0.0001457894,0.00007184925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018473386,0.00021818154,0.0005703177,0.00017156918,0.000035366393,0.0000070119154,0.000072377064,0.00004202541,0.00008483167],"category_scores_gemma":[0.000011116575,0.00016079843,0.000015101789,0.0004013248,0.00030070535,0.00041088052,0.000017265154,0.00015238888,0.0000017096107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077732624,0.00016709478,0.5747075,0.00015509289,0.00018487936,0.000018353972,0.002562458,0.000081821614,0.034986887,0.000057046065,3.8126362e-7,0.37930524],"study_design_scores_gemma":[0.0058397506,0.0042458554,0.96668196,0.00077660364,0.000047910074,0.000117292504,0.0035253812,0.000027149268,0.015538285,0.0018043949,0.0010696719,0.00032572675],"about_ca_topic_score_codex":0.00022956695,"about_ca_topic_score_gemma":0.00014367429,"teacher_disagreement_score":0.3919745,"about_ca_system_score_codex":0.0002308274,"about_ca_system_score_gemma":0.00008356076,"threshold_uncertainty_score":0.65571696},"labels":[],"label_agreement":null},{"id":"W2887418167","doi":"10.1007/s12325-018-0764-3","title":"Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2− Advanced Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Chemotherapy; Breast cancer; Cancer; Oncology","score_opus":0.010342238505599505,"score_gpt":0.30675490596671456,"score_spread":0.29641266746111505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887418167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98804027,0.010096108,0.00023176482,0.00023040774,0.00027351675,0.00069071027,0.000033228756,0.00011566725,0.00028832673],"genre_scores_gemma":[0.97843075,0.018336248,0.0013805168,0.00011350868,0.0006455783,0.0007704451,0.0000032029313,0.00007880127,0.00024095569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982836,0.00003754068,0.00026211143,0.0005649099,0.00023905995,0.0006127285],"domain_scores_gemma":[0.9991217,0.000046884285,0.00013931867,0.0003857046,0.00011837007,0.00018797569],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000685967,0.0003800976,0.00047451118,0.00012052905,0.00010897556,0.000023330442,0.000110047906,0.00006582771,0.00017591445],"category_scores_gemma":[0.0000032722337,0.00027096467,0.00002347792,0.00026296003,0.0003632782,0.00070172345,0.000023380706,0.00014913554,0.0000035624273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037058415,0.000120380806,0.5219996,0.000023448998,0.0000866458,0.00001963271,0.0018570848,0.00005038866,0.003997079,0.000009477653,1.451993e-7,0.4681303],"study_design_scores_gemma":[0.010533057,0.00442122,0.95668447,0.0005381519,0.000022093365,0.00015211248,0.001581198,0.000023179013,0.016547905,0.00022803867,0.008846211,0.00042236233],"about_ca_topic_score_codex":0.00022230687,"about_ca_topic_score_gemma":0.00033736034,"teacher_disagreement_score":0.46770793,"about_ca_system_score_codex":0.0007535913,"about_ca_system_score_gemma":0.00008104995,"threshold_uncertainty_score":0.99997425},"labels":[],"label_agreement":null},{"id":"W2888099086","doi":"10.1007/s12325-018-0757-2","title":"Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute for Health and Care Research; Pfizer","keywords":"Medicine; Adalimumab; Etanercept; Certolizumab pegol; Tofacitinib; Abatacept; Tocilizumab; Internal medicine; Rheumatoid arthritis; Combination therapy; Randomized controlled trial; Rheumatism; Rheumatology; Golimumab; Physical therapy; Rituximab","score_opus":0.033422360059289696,"score_gpt":0.3604072040944361,"score_spread":0.3269848440351464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888099086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025364003,0.9891703,0.000046369005,0.000052040465,0.0000643113,0.010335244,0.000045382047,0.00001661515,0.000016111417],"genre_scores_gemma":[0.00007623948,0.99707985,0.00038838765,0.000044953664,0.000041180643,0.0022745272,0.000028856932,0.000053636493,0.000012389133],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771136,0.00024849208,0.0011571656,0.00035130524,0.00024930816,0.0002823697],"domain_scores_gemma":[0.996823,0.0015668562,0.00078673294,0.00061717664,0.00014310556,0.000063091866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005104871,0.00042804808,0.0036875894,0.00015731348,0.000058665228,0.000011255345,0.00019749843,0.00011863063,0.000013998815],"category_scores_gemma":[0.00012475051,0.0001876218,0.00042274242,0.0003324174,0.0005770946,0.00007841661,0.000010078375,0.00010871701,0.0000014594441],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038388354,0.00032259114,0.000018926641,0.18505709,0.0006379398,0.0000027926833,0.00023003413,1.3060577e-7,0.0000010709439,0.0000974427,0.00001407113,0.81323403],"study_design_scores_gemma":[0.0031060223,0.0042674546,0.0000014177471,0.47780293,0.00003259583,0.0000674801,0.000044445886,0.0000012693268,0.000026757667,0.00006712074,0.514453,0.00012954562],"about_ca_topic_score_codex":0.000012387196,"about_ca_topic_score_gemma":0.000025277566,"teacher_disagreement_score":0.8131045,"about_ca_system_score_codex":0.00005066738,"about_ca_system_score_gemma":0.00016029134,"threshold_uncertainty_score":0.76509947},"labels":[],"label_agreement":null},{"id":"W2888908066","doi":"10.1007/s12325-018-0772-3","title":"Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Nilotinib; Dasatinib; Medicine; Myeloid leukemia; Internal medicine; Cohort; Retrospective cohort study; Oncology; Imatinib","score_opus":0.023342761391455184,"score_gpt":0.34780418259492707,"score_spread":0.3244614212034719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888908066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949258,0.0006154714,0.0000067499936,0.00021652093,0.00026442893,0.0027653421,0.000020735988,0.00007273891,0.0011122319],"genre_scores_gemma":[0.99008846,0.008670428,0.00011533318,0.0001855525,0.0002738163,0.0003340575,0.00009571587,0.000055138928,0.00018148459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971637,0.00046866134,0.0007817282,0.0005454564,0.00052866933,0.0005117912],"domain_scores_gemma":[0.99797595,0.0005098546,0.00039823403,0.0007402174,0.00029578037,0.00007998912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005876816,0.0003331781,0.00061268674,0.0005802528,0.00016177435,0.000018525345,0.00028885968,0.00009432067,0.00012389233],"category_scores_gemma":[0.00016525039,0.00022087575,0.00007234103,0.002538955,0.00035416058,0.00030974872,0.00005561101,0.00055733026,0.000008417314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008619446,0.0008198004,0.96035385,0.000057722005,0.000094621566,0.000020670295,0.020371992,0.00031849745,0.000030664796,0.000047212696,0.000035255136,0.01698774],"study_design_scores_gemma":[0.012115049,0.008882513,0.97050637,0.0005412444,0.000028570108,0.000004160051,0.0047079013,0.00044589204,0.00021293142,0.00046451215,0.0018816136,0.00020926933],"about_ca_topic_score_codex":0.020460216,"about_ca_topic_score_gemma":0.11157649,"teacher_disagreement_score":0.09111627,"about_ca_system_score_codex":0.004620247,"about_ca_system_score_gemma":0.0006619082,"threshold_uncertainty_score":0.9992008},"labels":[],"label_agreement":null},{"id":"W2894087307","doi":"10.1007/s12325-018-0796-8","title":"The Association Between Overactive Bladder and Falls and Fractures: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Broadcom (Canada); Vancouver Coastal Health","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Medicine; Overactive bladder; Rheumatology; Systematic review; Internal medicine; MEDLINE; Urology; Physical therapy; Alternative medicine; Pathology","score_opus":0.034209186532766216,"score_gpt":0.43118571396180544,"score_spread":0.3969765274290392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894087307","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011490622,0.9950342,0.000003357363,0.00019189474,0.000057039724,0.0039341906,0.00002479755,0.000013594429,0.000729424],"genre_scores_gemma":[0.000014661918,0.9984407,0.000025596373,0.00027810578,0.00018884976,0.00039645453,0.0000359098,0.000034453013,0.0005852724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99769807,0.00067332404,0.00059595075,0.00033842013,0.00040029592,0.00029391146],"domain_scores_gemma":[0.9957641,0.0032231468,0.0004820448,0.00034802424,0.00010146711,0.000081221115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015254616,0.00029549183,0.0019013556,0.000087805514,0.0001287323,0.00005557829,0.00013533668,0.00018157573,0.00001749033],"category_scores_gemma":[0.000559632,0.00015023343,0.00013793574,0.00024282797,0.00009836426,0.00018839474,0.00004696311,0.0005650791,0.000015528722],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002283384,0.000021873253,0.00016254997,0.4926737,0.00064870785,0.000008635779,0.00017221217,2.770321e-9,4.0238554e-8,0.000013590086,0.0001555752,0.50612026],"study_design_scores_gemma":[0.00028306196,0.0002479999,0.00005429345,0.2574885,0.00062610477,0.000030779254,0.000026537116,2.047203e-7,3.5730613e-7,0.00023874038,0.74087644,0.00012699376],"about_ca_topic_score_codex":0.000005595164,"about_ca_topic_score_gemma":0.000007282595,"teacher_disagreement_score":0.74072087,"about_ca_system_score_codex":0.00015779592,"about_ca_system_score_gemma":0.00012940484,"threshold_uncertainty_score":0.6126341},"labels":[],"label_agreement":null},{"id":"W2898518424","doi":"10.1007/s12325-018-0805-y","title":"Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician","year":2018,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Chronic Disease Management Strategies","field":"Medicine","cited_by":720,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Family Medicine; Western University","funders":"National Institute for Health and Care Research; Novo Nordisk; Intarcia Therapeutics; Sanofi; Janssen Pharmaceuticals; NIHR Leicester Biomedical Research Centre; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Interpretation (philosophy); Rheumatology; Medical physics; Internal medicine; Physical therapy; Intensive care medicine; Computer science","score_opus":0.28715436918372156,"score_gpt":0.6055987002079172,"score_spread":0.3184443310241956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898518424","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025960058,0.9950667,0.000333846,0.00006285579,0.00038318615,0.002053927,0.00008262131,0.000016332944,0.0019745592],"genre_scores_gemma":[0.00029818714,0.99811786,0.00051987526,0.00007406104,0.00049207587,0.00007814654,0.0002829866,0.000035550576,0.00010123908],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99812526,0.00017383051,0.00095364754,0.0004423921,0.00013590163,0.00016896988],"domain_scores_gemma":[0.9945632,0.0034056013,0.00083135435,0.0011064503,0.00005241089,0.00004094055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015700004,0.0002257192,0.001161814,0.00013577164,0.000031332547,0.000023860724,0.00038761037,0.000080205224,0.000037234102],"category_scores_gemma":[0.000554613,0.00012399213,0.00029371076,0.00022867433,0.00027437694,0.00035054408,0.000118595315,0.00023949932,0.0000022304118],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038334023,0.00009080331,0.00042559614,0.0037992299,0.00047092265,0.0000019325355,0.00003223389,0.0000015849296,1.016446e-8,0.00016019247,0.00069498084,0.99393916],"study_design_scores_gemma":[0.001067671,0.0006725753,0.00068770646,0.008714944,0.00084088155,0.0000027658675,0.00007304685,0.0005365265,3.182609e-8,0.00046453215,0.98682016,0.0001191728],"about_ca_topic_score_codex":0.00006757639,"about_ca_topic_score_gemma":0.00025422717,"teacher_disagreement_score":0.99382,"about_ca_system_score_codex":0.00008054333,"about_ca_system_score_gemma":0.0003921271,"threshold_uncertainty_score":0.5056252},"labels":[],"label_agreement":null},{"id":"W2902165389","doi":"10.1007/s12325-018-0847-1","title":"The Impact of Excluding Patients with End-Stage Knee Disease in Intra-Articular Hyaluronic Acid Trials: A Systematic Review and Meta-Analysis","year":2018,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Ferring Pharmaceuticals","keywords":"Medicine; Osteoarthritis; Subgroup analysis; Adverse effect; Internal medicine; Meta-analysis; Randomized controlled trial; Hyaluronic acid; Relative risk; Stage (stratigraphy); Rheumatology; Knee pain; Saline; Surgery; Confidence interval; Pathology","score_opus":0.08384372937227681,"score_gpt":0.4099463210476332,"score_spread":0.3261025916753564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902165389","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003498047,0.9923076,0.000011792719,0.0000121004105,0.000025719477,0.0071591185,0.00011131896,0.000009858555,0.000012671677],"genre_scores_gemma":[0.002307902,0.9958156,0.00007470897,0.000032635162,0.0000140928705,0.001553624,0.00009952343,0.000038601564,0.00006330815],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99612504,0.0012729468,0.0015364734,0.00041923273,0.00034903473,0.0002972621],"domain_scores_gemma":[0.9971468,0.0006523222,0.0012294011,0.0007694308,0.000085283864,0.00011679069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018591562,0.00050466956,0.008646549,0.00027729693,0.000045034692,0.000023038165,0.0001542278,0.00007551605,0.00013719272],"category_scores_gemma":[0.0004224223,0.00020240941,0.0019740516,0.0008313375,0.00010593806,0.00016126901,0.000024943625,0.00016981665,0.0000030970302],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006239761,0.00069475395,0.00048822636,0.6284944,0.14813805,0.00009621511,0.00019175613,0.000006421995,5.608376e-7,0.00010383409,0.000003491438,0.22115833],"study_design_scores_gemma":[0.0041618315,0.003767279,0.000025889582,0.10839304,0.8752079,0.0000055917053,0.000025033165,0.0000043593336,0.0000043088535,0.00012238075,0.007832472,0.000449926],"about_ca_topic_score_codex":0.00000984492,"about_ca_topic_score_gemma":0.00005057568,"teacher_disagreement_score":0.72706985,"about_ca_system_score_codex":0.0001481129,"about_ca_system_score_gemma":0.00015503903,"threshold_uncertainty_score":0.82540166},"labels":[],"label_agreement":null},{"id":"W2903222903","doi":"10.1007/s12325-018-0845-3","title":"Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Spirometry; Interstitial lung disease; Vital capacity; Physical therapy; Clinical endpoint; Disease; Radiological weapon; Internal medicine; Lung; Surgery; Diffusing capacity; Clinical trial; Lung function; Asthma","score_opus":0.008695563804266344,"score_gpt":0.2921466742122927,"score_spread":0.28345111040802634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903222903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99308443,0.0031232215,0.00022038975,0.00013718699,0.00021470162,0.0031590215,0.000022756647,0.000020464457,0.000017853641],"genre_scores_gemma":[0.9991444,0.00015218102,0.0000335386,0.00010430558,0.00018310608,0.00031394602,0.0000084470375,0.00003651173,0.000023607412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980628,0.0003635613,0.00039891826,0.00037679577,0.0004991435,0.00029877143],"domain_scores_gemma":[0.9988532,0.00018635299,0.0001412501,0.0005222685,0.00015509209,0.00014182672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029518068,0.0002452911,0.0003086375,0.00010928463,0.00019352834,0.00005092243,0.00027601642,0.000021843143,0.00009316918],"category_scores_gemma":[0.00014979095,0.00012975372,0.00006756223,0.00030390668,0.0003195283,0.00038215294,0.00007015023,0.00022594276,0.0000016694995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025262171,0.0045086667,0.9650621,0.0000448568,0.00005555205,0.0001875725,0.0034638308,0.00038744483,0.000018693425,0.000003565427,0.000003729087,0.0010018116],"study_design_scores_gemma":[0.005322618,0.005992248,0.981888,0.00046823703,0.00015405034,0.0000012178278,0.005394317,0.0005726364,0.000005613371,0.000016910393,0.000018777448,0.00016539464],"about_ca_topic_score_codex":0.00008173449,"about_ca_topic_score_gemma":0.00007508787,"teacher_disagreement_score":0.019939555,"about_ca_system_score_codex":0.00014856434,"about_ca_system_score_gemma":0.0001751881,"threshold_uncertainty_score":0.5291203},"labels":[],"label_agreement":null},{"id":"W2913175198","doi":"10.1007/s12325-019-0880-8","title":"Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review","year":2019,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Broadcom (Canada); Vancouver Coastal Health","funders":"U.S. Food and Drug Administration; Astellas Pharma Global Development; Astellas Pharma","keywords":"Medicine; Overactive bladder; Quality of life (healthcare); Patient-reported outcome; Rheumatology; Health related quality of life; Intensive care medicine; Disease; Systematic review; Internal medicine; Urology; MEDLINE; Physical therapy; Alternative medicine; Pathology; Nursing","score_opus":0.23859904890892009,"score_gpt":0.4527896577481489,"score_spread":0.2141906088392288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913175198","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003646919,0.9897068,0.000008313647,0.0002252519,0.00028019652,0.009151343,0.00016424316,0.000019906302,0.00007926107],"genre_scores_gemma":[0.0009358038,0.9981038,0.000045419732,0.00024608694,0.000069365815,0.00024565947,0.0002150482,0.00008065086,0.00005816627],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99060994,0.002928611,0.0042958385,0.00058724504,0.0011363797,0.0004419904],"domain_scores_gemma":[0.99250525,0.0012403189,0.004200562,0.0013971978,0.00045588796,0.00020079191],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002777984,0.0005699637,0.0058436785,0.0003209075,0.00007104946,0.000023152825,0.00036359005,0.00019629009,0.000063462474],"category_scores_gemma":[0.00074174034,0.0003189822,0.00091222435,0.001260275,0.0001503897,0.00031175945,0.00007282106,0.001047649,0.0000057707525],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000543564,0.0002149454,0.0001570856,0.81538564,0.0009018102,0.000044346125,0.001520904,0.0000028337251,0.000010808494,0.000024365125,0.000011567844,0.18118213],"study_design_scores_gemma":[0.0010212063,0.00043606877,0.00010413423,0.8187991,0.00049476593,0.00010170538,0.00021902789,0.0000076141364,0.0000015442006,0.000034221914,0.17843558,0.0003450599],"about_ca_topic_score_codex":0.000041514086,"about_ca_topic_score_gemma":0.0000010947878,"teacher_disagreement_score":0.18083708,"about_ca_system_score_codex":0.00024344985,"about_ca_system_score_gemma":0.00097145303,"threshold_uncertainty_score":0.9999262},"labels":[],"label_agreement":null},{"id":"W2920055646","doi":"10.1007/s12325-019-00911-y","title":"Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Université Laval; University of Toronto; Women's College Hospital; Institut Universitaire de Cardiologie et de Pneumologie de Québec","funders":"Grifols; GlaxoSmithKline; Boehringer Ingelheim; AstraZeneca; Pfizer","keywords":"Medicine; Tiotropium bromide; COPD; Fixed-dose combination; Bronchodilator; Anesthesia; Clinical endpoint; Internal medicine; Randomized controlled trial; Asthma; Lung; Lung function","score_opus":0.010788667445627217,"score_gpt":0.331679366715968,"score_spread":0.32089069927034075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920055646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9644622,0.001620136,0.00045453358,0.00039972004,0.0008603152,0.031877667,0.00006759148,0.00003546085,0.00022237955],"genre_scores_gemma":[0.98980254,0.0004190471,0.0008604613,0.00012376346,0.00016678053,0.007569493,0.00040651494,0.000052072002,0.0005993483],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975863,0.00027680723,0.00067582366,0.0005160694,0.00049735047,0.00044765073],"domain_scores_gemma":[0.9974853,0.001355906,0.00031744342,0.00035430957,0.00038576697,0.00010129925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006277049,0.00029610647,0.0013195452,0.0003427781,0.000092314076,0.000026833723,0.00017433567,0.00009289957,0.00012906914],"category_scores_gemma":[0.00036749072,0.00021803191,0.00027542756,0.00025793104,0.00016528467,0.0005136819,0.000027435473,0.00018072136,0.000005599175],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9600193,0.0031661468,0.0019779338,0.00015936725,0.0001332788,0.000004287918,0.00025900928,0.000044520802,0.00007460886,0.00038243402,0.000029241977,0.0337499],"study_design_scores_gemma":[0.97859126,0.0077079106,0.0018824873,0.000118978896,0.00007624643,5.711623e-7,0.000072462135,0.008442566,0.00016805227,0.0009178838,0.0017994336,0.00022214686],"about_ca_topic_score_codex":0.000010032105,"about_ca_topic_score_gemma":0.000026174244,"teacher_disagreement_score":0.033527754,"about_ca_system_score_codex":0.00045456676,"about_ca_system_score_gemma":0.00022883566,"threshold_uncertainty_score":0.88910836},"labels":[],"label_agreement":null},{"id":"W2931180315","doi":"10.1007/s12325-019-00904-x","title":"Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph's Hospital; Western University","funders":"Feinberg School of Medicine; Northwestern University","keywords":"Tacrolimus; Medicine; Transplantation; Kidney transplantation; Intensive care medicine; Health care; Rheumatology; Immediate release; Internal medicine; Pharmacology","score_opus":0.04955026989090665,"score_gpt":0.40331114580104915,"score_spread":0.3537608759101425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2931180315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941006,0.0020772251,0.000016123471,0.0005481572,0.0004748726,0.0017252043,0.0000763215,0.00004888721,0.000932609],"genre_scores_gemma":[0.9486152,0.04993707,0.00020903302,0.00064892287,0.000058130787,0.00007823469,0.00019441951,0.000043975455,0.00021504071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969638,0.00036450045,0.0011564068,0.0006294444,0.0004971382,0.00038870078],"domain_scores_gemma":[0.9980975,0.0007435382,0.0003313072,0.00044647505,0.00008742135,0.00029375416],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037620385,0.00035025907,0.0009127316,0.00038001643,0.00005541765,0.000016071011,0.00015005402,0.0001370525,0.000065242304],"category_scores_gemma":[0.000052723844,0.00028464923,0.00013761516,0.0006086433,0.00010885452,0.00033685047,0.000014281306,0.00035527992,0.0000121963185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01753605,0.0015897679,0.9342594,0.00041069617,0.00014597448,0.00024325552,0.002684585,0.00021077693,0.000032328957,0.0001582327,0.0000039727206,0.042724926],"study_design_scores_gemma":[0.060334716,0.003733952,0.9318892,0.00056767435,0.00010135267,0.0000132619325,0.0015851646,0.00018825002,0.00013981193,0.00009636652,0.0010898904,0.0002603796],"about_ca_topic_score_codex":0.0013380611,"about_ca_topic_score_gemma":0.003432567,"teacher_disagreement_score":0.047859844,"about_ca_system_score_codex":0.00010155687,"about_ca_system_score_gemma":0.00014549289,"threshold_uncertainty_score":0.99996054},"labels":[],"label_agreement":null},{"id":"W2933517521","doi":"10.1007/s12325-019-00925-6","title":"Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different","year":2019,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Management and Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"HLS Therapeutics; Novo Nordisk; Intarcia Therapeutics; Sanofi; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Insulin; Insulin glargine; Insulin degludec; Insulin detemir; Basal (medicine); Glycemic; Hypoglycemia; Internal medicine; Diabetes mellitus; Endocrinology; Basal insulin; Type 2 diabetes; Intensive care medicine","score_opus":0.17621454717089274,"score_gpt":0.39889117346332426,"score_spread":0.2226766262924315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2933517521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027905137,0.992698,0.0006033719,0.00029168258,0.0006746122,0.0027854843,0.000015861824,0.00008507172,0.002566842],"genre_scores_gemma":[0.0051549324,0.99172384,0.00011094399,0.00013961365,0.00034223942,0.00041427003,0.00019580233,0.00010921408,0.0018091692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971167,0.0003856781,0.0005608514,0.0006850538,0.0006242056,0.000627546],"domain_scores_gemma":[0.9979461,0.0006797265,0.00048835675,0.0007359635,0.000044139135,0.0001057527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039090306,0.00059451745,0.00185293,0.0005393501,0.00013931435,0.0001689494,0.00044405504,0.00025274433,0.00010950467],"category_scores_gemma":[0.000106735686,0.00037622175,0.0004526519,0.00041763316,0.00007055968,0.0003278129,0.00014767505,0.0007836721,0.000037880058],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011589188,0.00037679553,0.0032002737,0.009958157,0.00044217362,0.000018040739,0.00043622934,0.000017069182,7.5738564e-7,0.0009528424,0.0003734362,0.9841083],"study_design_scores_gemma":[0.0020625498,0.00035035098,0.00027829577,0.036992002,0.00026196946,0.0000011799442,0.00067678286,0.000070353584,0.0000018025199,0.0034816149,0.95517975,0.000643324],"about_ca_topic_score_codex":0.0000021140472,"about_ca_topic_score_gemma":0.000074999516,"teacher_disagreement_score":0.983465,"about_ca_system_score_codex":0.00049641443,"about_ca_system_score_gemma":0.000074833646,"threshold_uncertainty_score":0.999869},"labels":[],"label_agreement":null},{"id":"W2939873404","doi":"10.1007/s12325-019-00944-3","title":"Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Leeds Biomedical Research Centre; National Institute for Health and Care Research; U.S. Department of Defense","keywords":"Medicine; Triamcinolone acetonide; Post-hoc analysis; Osteoarthritis; Rheumatology; Post hoc; Physical therapy; Internal medicine; Surgery; Alternative medicine; Pathology","score_opus":0.01081824141690586,"score_gpt":0.2841077123767207,"score_spread":0.2732894709598149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939873404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843076,0.013980454,0.0000073633046,0.00009609468,0.00009519274,0.0010520209,0.0000135603395,0.00003352166,0.00041423144],"genre_scores_gemma":[0.99626213,0.002413474,0.00067532517,0.00014792592,0.000024603798,0.00008427002,0.000055482422,0.000027585678,0.00030918737],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99837565,0.00008433852,0.00043645114,0.00038856358,0.00026328265,0.00045169322],"domain_scores_gemma":[0.9991439,0.00010363576,0.00014861043,0.00043683976,0.00006379494,0.00010322675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015747006,0.00023116753,0.00077546854,0.00045488574,0.000018136621,0.000009166148,0.00009097019,0.00008566424,0.00019183755],"category_scores_gemma":[0.00002020241,0.00017834849,0.00013769926,0.0009308519,0.000077769655,0.00028519888,0.000016739423,0.00016097598,0.000023448847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031187698,0.0014937771,0.33226052,0.000048695532,0.00032243328,0.00043417167,0.0015406974,0.00050393667,0.027744578,0.000383919,5.4302853e-7,0.60407907],"study_design_scores_gemma":[0.24014778,0.0898485,0.5838359,0.0018504543,0.00084055855,0.00008898931,0.0020065447,0.00022698479,0.07706102,0.0007672296,0.002240848,0.0010851957],"about_ca_topic_score_codex":0.000045273384,"about_ca_topic_score_gemma":0.00092634273,"teacher_disagreement_score":0.60299385,"about_ca_system_score_codex":0.000060869308,"about_ca_system_score_gemma":0.00007655839,"threshold_uncertainty_score":0.727284},"labels":[],"label_agreement":null},{"id":"W2944942906","doi":"10.1007/s12325-019-00964-z","title":"Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Merck Sharp and Dohme; Celgene; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AbbVie","keywords":"Medicine; Psoriatic arthritis; Hazard ratio; Ankylosing spondylitis; Internal medicine; Cohort; Retrospective cohort study; Psoriasis; Cohort study; Rheumatoid arthritis; Confidence interval; Immunology","score_opus":0.007925741234522941,"score_gpt":0.2905770794905939,"score_spread":0.28265133825607097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944942906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99152136,0.005218333,0.000016274384,0.000037430254,0.00014352605,0.001257175,0.00022786457,0.000024060699,0.001553984],"genre_scores_gemma":[0.98414785,0.013948982,0.0012528356,0.00004894534,0.000020712985,0.00025190072,0.00020649878,0.0000140707,0.00010821077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909735,0.000043992877,0.0002743706,0.00021589086,0.00022934805,0.00013907623],"domain_scores_gemma":[0.99936175,0.0001758547,0.00015224716,0.00017425648,0.00011702387,0.000018841029],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012401269,0.00011526677,0.00034520132,0.00008465167,0.000043642118,0.0000031271352,0.000046362635,0.000028046443,0.0009957419],"category_scores_gemma":[0.000072893075,0.00009530965,0.000047699952,0.00024811187,0.000042674546,0.00012567143,0.000015010013,0.00009820582,0.00004637018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031919603,0.00042916724,0.9955715,0.000007868537,0.00028521175,0.00003322954,0.0006133297,0.000006286146,0.00007447336,0.00013034319,0.000016208822,0.0025132129],"study_design_scores_gemma":[0.005762141,0.0008034436,0.9897142,0.00010247772,0.000020274185,0.00001006134,0.0015265592,0.000006919953,0.00012898393,0.001019834,0.0008185869,0.00008651214],"about_ca_topic_score_codex":0.00007975636,"about_ca_topic_score_gemma":0.00011058966,"teacher_disagreement_score":0.008730649,"about_ca_system_score_codex":0.00012400861,"about_ca_system_score_gemma":0.00004343384,"threshold_uncertainty_score":0.9999175},"labels":[],"label_agreement":null},{"id":"W2947268672","doi":"10.1007/s12325-019-00986-7","title":"Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto; Pfizer","keywords":"Medicine; Biosimilar; Rheumatoid arthritis; Methotrexate; Rheumatology; Internal medicine; Antirheumatic Agents; Arthritis; Intensive care medicine; Oncology; Pharmacology","score_opus":0.01538381736389248,"score_gpt":0.2861293139357488,"score_spread":0.2707454965718563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947268672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904567,0.0077326237,0.00012380208,0.000048023936,0.00015307832,0.0012981334,0.00009828744,0.000020905249,0.00006846313],"genre_scores_gemma":[0.98696285,0.010367367,0.002300513,0.0000938278,0.0000028567538,0.00019069882,0.000025040266,0.000021937012,0.000034924175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981781,0.00065981905,0.00029294664,0.00044311688,0.00004934229,0.00037666628],"domain_scores_gemma":[0.9988557,0.0005662025,0.00014913795,0.00031864483,0.000086946224,0.000023337345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003594614,0.00031151596,0.0006956474,0.00015554974,0.000024946927,0.000011405045,0.00017510152,0.00022580112,0.00025972378],"category_scores_gemma":[0.000016191474,0.00015029556,0.000059521448,0.00046352262,0.0002984789,0.00025694867,0.00002211755,0.00020113193,0.000006439521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01901097,0.0006057091,0.88531923,0.000023291974,0.00015912131,0.000007980833,0.00018998227,0.0000141412675,0.002567004,0.00007621506,0.0000017327042,0.09202463],"study_design_scores_gemma":[0.031717107,0.020748088,0.7621906,0.0010296799,0.000016073007,0.000010819326,0.00028195314,0.0000030895324,0.13365704,0.000671946,0.048912667,0.00076097425],"about_ca_topic_score_codex":0.0000322281,"about_ca_topic_score_gemma":0.00025710132,"teacher_disagreement_score":0.13109004,"about_ca_system_score_codex":0.00007879198,"about_ca_system_score_gemma":0.00005488522,"threshold_uncertainty_score":0.6128875},"labels":[],"label_agreement":null},{"id":"W2949352054","doi":"10.1007/s12325-019-00994-7","title":"Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Mirabegron; Medicine; Overactive bladder; Quality of life (healthcare); Internal medicine; Adverse effect; Prospective cohort study; Discontinuation; Intensive care medicine; Urology; Alternative medicine","score_opus":0.041444666041875966,"score_gpt":0.36510910909168837,"score_spread":0.3236644430498124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949352054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956776,0.0010194503,3.810508e-7,0.00003251967,0.00006953553,0.0026920612,0.00001526376,0.000024018558,0.0004691672],"genre_scores_gemma":[0.9979724,0.0011321848,0.00001090518,0.0000118379,0.000003951865,0.000105332336,0.00001759118,0.00003318332,0.00071261043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981666,0.00012220582,0.0004248639,0.0004619533,0.00046176362,0.00036258486],"domain_scores_gemma":[0.9989376,0.00021907652,0.00025843174,0.0004087807,0.000114125156,0.00006196269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108591645,0.0002708381,0.00068793463,0.00026097076,0.000031442498,0.0000094879415,0.000083612635,0.00006459395,0.00015109725],"category_scores_gemma":[0.000051645133,0.00016041292,0.00007374943,0.0004967404,0.00005910885,0.00032171575,0.000023980028,0.00019070931,0.0000013926843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044187605,0.0064287204,0.97675586,0.000025715426,0.00088526105,0.00060082873,0.007175798,0.000032390897,0.0013193223,0.0000011192296,2.7854617e-7,0.0023559632],"study_design_scores_gemma":[0.018305913,0.017522398,0.9468507,0.00012505219,0.000029461407,0.000013032404,0.013069551,0.000007539631,0.0038578424,0.000027554835,0.000021651633,0.00016927045],"about_ca_topic_score_codex":0.00064281165,"about_ca_topic_score_gemma":0.00045536493,"teacher_disagreement_score":0.02990511,"about_ca_system_score_codex":0.00061292615,"about_ca_system_score_gemma":0.00015047376,"threshold_uncertainty_score":0.6541449},"labels":[],"label_agreement":null},{"id":"W2955635155","doi":"10.1007/s12325-019-01015-3","title":"A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"AstraZeneca","keywords":"Dry-powder inhaler; Medicine; Glycopyrrolate; Inhaler; Formoterol Fumarate; Metered-dose inhaler; COPD; Anesthesia; Crossover study; Double blind; Formoterol; Internal medicine; Asthma; Atropine","score_opus":0.039033257202496,"score_gpt":0.35943753139944573,"score_spread":0.3204042741969497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955635155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740323,0.006683243,0.00004417868,0.00029847876,0.00038414073,0.012807117,0.000021842887,0.000055694076,0.005672996],"genre_scores_gemma":[0.9950505,0.0016799958,0.00022037822,0.00039136517,0.000094612195,0.0012121238,0.000037340935,0.00010560706,0.0012080655],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99494815,0.0006086638,0.0014333917,0.0010975833,0.0010200209,0.0008922139],"domain_scores_gemma":[0.9973743,0.0005434728,0.00040243243,0.0010800725,0.00029303378,0.0003067183],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012361683,0.00061890174,0.001981054,0.0010945165,0.000058475496,0.00003908113,0.0005224157,0.00023639464,0.00092007435],"category_scores_gemma":[0.00005192225,0.0004919555,0.00029946296,0.0013205215,0.00025576897,0.0011647806,0.0002184727,0.00087883684,0.00020421669],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90329486,0.002649608,0.07558379,0.00026757727,0.0005209765,0.0002630045,0.0067515164,0.0005930955,0.0024457003,0.00019776454,0.000023336022,0.007408786],"study_design_scores_gemma":[0.96281564,0.0021692717,0.025324365,0.00067402795,0.000078410594,0.00003092911,0.0025295343,0.00072946475,0.0032590928,0.0007984223,0.0009955707,0.0005952927],"about_ca_topic_score_codex":0.00051216746,"about_ca_topic_score_gemma":0.0005065778,"teacher_disagreement_score":0.059520777,"about_ca_system_score_codex":0.0004770472,"about_ca_system_score_gemma":0.00021682403,"threshold_uncertainty_score":0.9999932},"labels":[],"label_agreement":null},{"id":"W2966608893","doi":"10.1007/s12325-019-01035-z","title":"An Evaluation of Longitudinal Measures of Anticholinergic Exposure for Application in Retrospective Administrative Data Analyses","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pesticide Exposure and Toxicity","field":"Agricultural and Biological Sciences","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Vancouver Coastal Health","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Anticholinergic; Medicine; Interquartile range; Adverse effect; Retrospective cohort study; Gold standard (test); Internal medicine; Potency","score_opus":0.20861809529254643,"score_gpt":0.4335322824545844,"score_spread":0.22491418716203798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966608893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662876,0.0024024409,0.00014857053,0.000030434769,0.000029852274,0.00051459257,0.00008754762,0.000004996633,0.00015282824],"genre_scores_gemma":[0.99905705,0.00041914705,0.0002929574,0.00000954171,0.000041429535,0.000033632998,0.00014411302,6.5003843e-7,0.000001499505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989912,0.0001196935,0.00026136675,0.0002748862,0.00025774707,0.0000951051],"domain_scores_gemma":[0.9992953,0.00015587077,0.00019190305,0.00014185043,0.00019958688,0.000015472324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008676825,0.00007656164,0.0002103989,0.000021766275,0.000015096958,0.0000051675347,0.00027535245,0.000045031993,0.00002512148],"category_scores_gemma":[0.00008332015,0.000033956818,0.000026846918,0.00032566095,0.000042487696,0.00039254598,0.000011868874,0.00004641416,3.4478555e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019215669,0.0002052558,0.63374496,0.0000043074856,0.0000086404625,7.660263e-8,0.00007388186,0.00076221395,0.27739966,0.00023271117,7.5086217e-7,0.08737536],"study_design_scores_gemma":[0.00055693666,0.000962836,0.9444106,0.000017716206,0.0000091782185,2.9079146e-7,0.00021879004,0.0031889437,0.04488203,0.005595778,0.00007974881,0.00007712987],"about_ca_topic_score_codex":0.0001527532,"about_ca_topic_score_gemma":0.0038530848,"teacher_disagreement_score":0.31066564,"about_ca_system_score_codex":0.000019766589,"about_ca_system_score_gemma":0.000017663362,"threshold_uncertainty_score":0.21501116},"labels":[],"label_agreement":null},{"id":"W2972252679","doi":"10.1007/s12325-019-01071-9","title":"Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Merck KGaA","keywords":"Medicine; Health professionals; Health care; Patient care; Medical emergency; Nursing","score_opus":0.0456769955406498,"score_gpt":0.38274375470398936,"score_spread":0.33706675916333956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972252679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752484,0.021088045,0.000013760102,0.001994238,0.00006318149,0.0013867945,0.000021390142,0.000004037205,0.00018017013],"genre_scores_gemma":[0.9872655,0.007693983,0.0047015646,0.00018335106,0.000005302201,0.00012533137,0.000006882374,0.00000602817,0.000012038037],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990996,0.0000749392,0.00028112493,0.00011450644,0.0003150842,0.000114710405],"domain_scores_gemma":[0.9992045,0.00013772731,0.00009820085,0.0002769609,0.00024997443,0.00003262088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002072653,0.00006696225,0.00022744492,0.000045495126,0.00004781169,0.0000026268444,0.00008144228,0.000021664453,0.000014268023],"category_scores_gemma":[0.00007485801,0.000038510614,0.00001863984,0.00009612468,0.000072126495,0.00006466156,0.00010086156,0.00010882758,7.1293914e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093108986,0.000056077137,0.039307725,0.00024447363,0.000021875776,1.02423684e-7,0.032434303,0.000013505869,0.029720776,0.00014048733,0.000015500647,0.8971141],"study_design_scores_gemma":[0.0035776633,0.002571241,0.6388417,0.0016277407,0.000002740729,5.620676e-7,0.033048417,0.000017545388,0.26999286,0.00019804346,0.049981095,0.00014040008],"about_ca_topic_score_codex":0.000024745024,"about_ca_topic_score_gemma":0.00014585612,"teacher_disagreement_score":0.89697367,"about_ca_system_score_codex":0.00008224961,"about_ca_system_score_gemma":0.00012225611,"threshold_uncertainty_score":0.15704173},"labels":[],"label_agreement":null},{"id":"W2972614719","doi":"10.1007/s12325-019-01074-6","title":"Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Medicine; Placebo; Pharmacokinetics; Cannabidiol; Bioavailability; Dosing; Area under the curve; Dose; Pharmacology; Anesthesia; Internal medicine; Pathology","score_opus":0.037461864111367565,"score_gpt":0.37129879425205675,"score_spread":0.33383693014068916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972614719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652485,0.014845539,0.0005664046,0.0005423437,0.00017605936,0.01771624,0.0000047926715,0.000018558065,0.00088155334],"genre_scores_gemma":[0.9898263,0.0050134375,0.0006648083,0.00023309875,0.000107942804,0.0022044762,0.00001885315,0.00003595847,0.0018951172],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976251,0.00034336798,0.0007315551,0.0004142192,0.00047519867,0.00041055487],"domain_scores_gemma":[0.9990176,0.00014419583,0.00021266367,0.00029313474,0.00022031335,0.0001121052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024906218,0.00022190396,0.0012876574,0.0004974301,0.000024002335,0.000015018054,0.00017525407,0.000089632624,0.000057631165],"category_scores_gemma":[0.00009807848,0.0001685418,0.0001908543,0.0005582091,0.000078109646,0.00018924389,0.000023904178,0.00027423375,0.0000014436844],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9248457,0.0015362067,0.0060667237,0.00021429051,0.000116114614,0.000005350318,0.0023809448,0.0015589679,0.00068332965,0.000078616096,0.00018480461,0.062328983],"study_design_scores_gemma":[0.9817491,0.0029742653,0.0022326407,0.00005058154,0.000041142936,0.000004846517,0.001830338,0.007178259,0.0010087689,0.00009124728,0.0026611504,0.00017761801],"about_ca_topic_score_codex":0.00068058056,"about_ca_topic_score_gemma":0.00028624767,"teacher_disagreement_score":0.062151365,"about_ca_system_score_codex":0.00017283607,"about_ca_system_score_gemma":0.000414111,"threshold_uncertainty_score":0.68729347},"labels":[],"label_agreement":null},{"id":"W2972756983","doi":"10.1007/s12325-019-01086-2","title":"The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Genentech; Gilead Sciences","keywords":"Medicine; Pirfenidone; Rheumatoid arthritis; Interstitial lung disease; Rheumatology; Internal medicine; Randomized controlled trial; Clinical trial; Physical therapy; Lung; Intensive care medicine; Idiopathic pulmonary fibrosis","score_opus":0.03812078492113691,"score_gpt":0.36960967182665533,"score_spread":0.3314888869055184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972756983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.970058,0.021205015,0.0002396156,0.0005350275,0.0010475725,0.006770776,0.000025303108,0.000009427072,0.00010921092],"genre_scores_gemma":[0.95539457,0.044001747,0.000046853253,0.00009478638,0.00010464103,0.0002777828,0.000016842023,0.000015952586,0.00004682989],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99716,0.00089680025,0.001174426,0.00025235754,0.0003236626,0.00019273757],"domain_scores_gemma":[0.9973036,0.0017739915,0.0004595645,0.0002942363,0.0000890792,0.00007950008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022188197,0.00016369301,0.00085751794,0.000076651195,0.000051960065,0.000015363006,0.00017915774,0.000088060115,0.000056799763],"category_scores_gemma":[0.00053141196,0.00009537691,0.0003770055,0.0002078306,0.0005019783,0.00017191519,0.000031737083,0.00023753369,8.5336154e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98509187,0.0015779388,0.0005280493,0.000028678876,0.000096550946,0.0000054636866,0.00023740112,0.000057303492,0.00015754541,0.0008554831,0.000021750193,0.011341975],"study_design_scores_gemma":[0.9898966,0.004103776,0.00018219488,0.000787053,0.0000378793,0.0000018260417,0.00010340315,0.0026837343,0.000114223876,0.0016794278,0.00030810188,0.000101775615],"about_ca_topic_score_codex":0.000028127142,"about_ca_topic_score_gemma":0.00002839301,"teacher_disagreement_score":0.022796733,"about_ca_system_score_codex":0.000042446576,"about_ca_system_score_gemma":0.00026918692,"threshold_uncertainty_score":0.38893577},"labels":[],"label_agreement":null},{"id":"W2981743123","doi":"10.1007/s12325-019-01126-x","title":"Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine","year":2019,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Sanofi","keywords":"Lixisenatide; Medicine; Insulin glargine; Type 2 diabetes; Population; Insulin; Diabetes mellitus; Basal insulin; Glucagon-like peptide 1 receptor; Intensive care medicine; Internal medicine; Endocrinology; Receptor","score_opus":0.016104954431143098,"score_gpt":0.2998611474260131,"score_spread":0.28375619299487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981743123","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022156043,0.97396606,8.515589e-7,0.00010508504,0.00023065423,0.0023619854,0.0000135426135,0.000036230434,0.0011295638],"genre_scores_gemma":[0.0045195846,0.9938711,0.00049881754,0.0002909933,0.00007359827,0.00024970027,0.00017950404,0.000084852,0.0002318641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981788,0.00010234749,0.0004556525,0.00064823986,0.0002297671,0.0003852044],"domain_scores_gemma":[0.99900323,0.00027303305,0.00023538372,0.0003582781,0.000035946003,0.00009409905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020266564,0.0005275751,0.00161239,0.0003862716,0.00002865998,0.00003207253,0.0001150513,0.00017083419,0.00003457944],"category_scores_gemma":[0.000034204964,0.00035871848,0.00006445202,0.0004627812,0.000094268886,0.00017798622,0.000053469183,0.00037767805,0.000023651955],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046895456,0.00037958237,0.001951185,0.0044874204,0.00016617964,0.00003169608,0.00026074934,0.0000012823486,4.322244e-7,0.00008225882,0.000038875252,0.9921314],"study_design_scores_gemma":[0.013480519,0.0034546598,0.0012009755,0.04686084,0.00017905093,0.0000025317552,0.000076715594,0.000021988082,0.000018901334,0.000117050324,0.9340319,0.0005548786],"about_ca_topic_score_codex":0.000011596663,"about_ca_topic_score_gemma":0.000043219166,"teacher_disagreement_score":0.9915765,"about_ca_system_score_codex":0.0001297683,"about_ca_system_score_gemma":0.000069438494,"threshold_uncertainty_score":0.99988645},"labels":[],"label_agreement":null},{"id":"W2982028489","doi":"10.1007/s12325-019-01123-0","title":"Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Liver Centre","funders":"AbbVie","keywords":"Medicine; Internal medicine; Regimen; Gastroenterology; Cirrhosis; Adverse effect; Hepatitis C virus; Hepatitis C; Viral load; Immunology; Virus","score_opus":0.03369446746467003,"score_gpt":0.36134465885659334,"score_spread":0.3276501913919233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982028489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922712,0.0016442734,0.0000030822193,0.000032829903,0.00003603976,0.0048652375,0.000019945259,0.000008056833,0.0011193438],"genre_scores_gemma":[0.9955091,0.0038276513,0.00043175093,0.000037429803,0.0000055471646,0.00009163818,0.000024637955,0.000029734812,0.00004253184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814814,0.00028171693,0.0005609287,0.00038586892,0.00033011258,0.00029320188],"domain_scores_gemma":[0.99900794,0.00028192447,0.00015863187,0.0004006766,0.00008699193,0.00006385622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023855481,0.00020707793,0.0006949859,0.00031343426,0.000012963351,0.000010581413,0.0001873386,0.00005751879,0.00010134693],"category_scores_gemma":[0.00006922258,0.00015049145,0.000017369119,0.00058910024,0.00010531139,0.00037989448,0.000081559905,0.00017712735,0.0000047360522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007947969,0.016232494,0.77261865,0.000050672865,0.000057113626,0.000010409204,0.0015747605,0.000021808877,0.0013050912,0.0000034888908,6.353241e-7,0.20017688],"study_design_scores_gemma":[0.102053486,0.01734815,0.87708926,0.0005428041,0.000010669893,2.5571856e-7,0.00018535578,0.00008487929,0.0014324263,0.0000080590435,0.0011088392,0.00013583266],"about_ca_topic_score_codex":0.0006967031,"about_ca_topic_score_gemma":0.0019429869,"teacher_disagreement_score":0.20004104,"about_ca_system_score_codex":0.00018841898,"about_ca_system_score_gemma":0.000062642,"threshold_uncertainty_score":0.6136863},"labels":[],"label_agreement":null},{"id":"W2983410614","doi":"10.1007/s12325-019-01128-9","title":"Dyspnea in COPD: New Mechanistic Insights and Management Implications","year":2019,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; University of British Columbia; Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; COPD; Deconditioning; Intensive care medicine; Psychological intervention; Physical therapy; Physical medicine and rehabilitation; Internal medicine; Psychiatry","score_opus":0.05063204960442954,"score_gpt":0.3964695328104613,"score_spread":0.3458374832060318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983410614","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003603142,0.9903898,0.00009857072,0.00010994066,0.00015784874,0.0034617404,0.000024927118,0.000027269618,0.005693827],"genre_scores_gemma":[0.00006760868,0.9967837,0.00058151863,0.0001072455,0.00010574239,0.00047341757,0.000132293,0.00006450007,0.0016839817],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980539,0.00011375613,0.0004941331,0.00068934506,0.0002754391,0.00037340398],"domain_scores_gemma":[0.9987665,0.00018320265,0.00014493457,0.0007059226,0.00003207956,0.00016735344],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000117719996,0.00036523413,0.0011759258,0.000528503,0.000035511926,0.000020661098,0.00027247646,0.00014830922,0.00014536205],"category_scores_gemma":[0.000016591086,0.00029501852,0.0001298379,0.00068093004,0.000090097514,0.00016272417,0.00011204097,0.00041381104,0.00008557349],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044071305,0.00012237047,0.00011520729,0.012593103,0.000077177945,0.00007667435,0.000038520735,0.0000017183356,7.793878e-7,0.009014347,0.000064957254,0.9778511],"study_design_scores_gemma":[0.0015299524,0.00007606344,0.0012857675,0.0060957656,0.000108775064,0.00003321875,0.000029905765,0.0000132388395,5.245645e-7,0.0074404157,0.9831299,0.00025643012],"about_ca_topic_score_codex":0.00002548034,"about_ca_topic_score_gemma":0.000066210196,"teacher_disagreement_score":0.983065,"about_ca_system_score_codex":0.0005992969,"about_ca_system_score_gemma":0.00034379406,"threshold_uncertainty_score":0.9999502},"labels":[],"label_agreement":null},{"id":"W2990283038","doi":"10.1007/s12325-019-01145-8","title":"Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"AbbVie; Celgene; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Adalimumab; Clinical trial; Rheumatology; Internal medicine; Term (time); Intensive care medicine; Safety profile; Adverse effect; Medical physics; Rheumatoid arthritis","score_opus":0.04198891975818134,"score_gpt":0.44708754123904815,"score_spread":0.40509862148086684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990283038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99650615,0.0011106862,0.00012986909,0.00011587898,0.00020583239,0.001022915,0.00077879167,0.000022278347,0.000107576],"genre_scores_gemma":[0.99275726,0.003278556,0.000708535,0.00007699825,0.000042455868,0.000038436083,0.0030635027,0.000013791871,0.00002046999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688876,0.0006879102,0.0013918214,0.00046269485,0.00031356042,0.0002552488],"domain_scores_gemma":[0.9982425,0.00047391243,0.0005069241,0.0005354894,0.00013376714,0.00010742711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022368054,0.00019919123,0.0011282866,0.00012482061,0.00003106881,0.000011536264,0.00018807233,0.00016839807,0.0003849814],"category_scores_gemma":[0.0003018862,0.00015395136,0.0002363691,0.000897383,0.00010599999,0.00044279627,0.000024861154,0.00016802723,0.000030400122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003189655,0.0019836864,0.904833,0.0000053559047,0.00053459604,0.00003416277,0.00054441637,0.00001633037,0.00003740304,0.000015459425,0.0000018180698,0.088804096],"study_design_scores_gemma":[0.025667118,0.0006616728,0.9724441,0.00007230217,0.00012107083,0.0000024249464,0.00018738501,0.00014088908,0.00028640812,0.0001799596,0.000104448685,0.0001321846],"about_ca_topic_score_codex":0.00040271773,"about_ca_topic_score_gemma":0.0034176896,"teacher_disagreement_score":0.08867191,"about_ca_system_score_codex":0.000131291,"about_ca_system_score_gemma":0.00006474359,"threshold_uncertainty_score":0.6277954},"labels":[],"label_agreement":null},{"id":"W2995427723","doi":"10.1007/s12325-019-01169-0","title":"Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia","year":2019,"lang":"en","type":"letter","venue":"Advances in Therapy","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada); TransCanada (Canada)","funders":"Pfizer","keywords":"Blinatumomab; Medicine; Refractory (planetary science); Lymphoblastic Leukemia; Internal medicine; Oncology; Salvage therapy; Pediatrics; Leukemia; Chemotherapy","score_opus":0.03605871875456865,"score_gpt":0.36249777461210675,"score_spread":0.3264390558575381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995427723","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2640016,0.007917684,0.002392059,0.6648955,0.035576478,0.022796633,0.0012547915,0.00035099973,0.00081428926],"genre_scores_gemma":[0.11090823,0.006451072,0.010488609,0.7548218,0.070062794,0.0063696858,0.0012563685,0.0013604187,0.03828102],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99420315,0.0006485308,0.0011874626,0.0012867525,0.0014359273,0.0012381863],"domain_scores_gemma":[0.9863237,0.01065313,0.000554012,0.0019039845,0.00038143614,0.0001837112],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008964951,0.0009320582,0.0021193812,0.0011300072,0.0001398483,0.000051732695,0.0010758914,0.0010761847,0.00007065453],"category_scores_gemma":[0.0016047447,0.00057111174,0.00042669981,0.0010329841,0.00022288773,0.00021521492,0.0001709787,0.0014676532,0.00015839798],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18742442,0.00019325124,0.00008638884,0.00016554992,0.00064395095,0.0003055437,0.001511477,0.00042801953,0.0024013175,0.0000013776815,0.791771,0.01506769],"study_design_scores_gemma":[0.029778628,0.020847641,0.000093985676,0.0007290203,0.00023968163,0.000030870448,0.00014146155,0.0003489323,0.00907885,0.000009525362,0.93813586,0.00056554214],"about_ca_topic_score_codex":0.00007407931,"about_ca_topic_score_gemma":0.00009215335,"teacher_disagreement_score":0.15764579,"about_ca_system_score_codex":0.012548247,"about_ca_system_score_gemma":0.0034836007,"threshold_uncertainty_score":0.999674},"labels":[],"label_agreement":null},{"id":"W2996864695","doi":"10.1007/s12325-019-01185-0","title":"Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine","year":2019,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lixisenatide; Medicine; Basal insulin; Insulin glargine; Internal medicine; Glucagon-like peptide 1 receptor; Endocrinology; Type 2 diabetes; Insulin; Diabetes mellitus; Basal (medicine); Receptor; Agonist","score_opus":0.004104802182319163,"score_gpt":0.2401947953812758,"score_spread":0.23608999319895665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996864695","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4174831,0.5726301,0.000008379855,0.00004095703,0.008194913,0.00054925896,0.000033141918,0.0000111526915,0.0010490001],"genre_scores_gemma":[0.16466023,0.8298666,0.00023124096,0.0012375927,0.00084996846,0.00014850247,0.00046514746,0.000096624164,0.0024441078],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982645,0.0001132501,0.00030154045,0.0007589759,0.00018804416,0.00037367677],"domain_scores_gemma":[0.99924964,0.00005428042,0.00017595949,0.00033830895,0.00008941999,0.00009238805],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018930862,0.00040070995,0.0005170696,0.00016961522,0.000042270574,0.000038308473,0.00016726014,0.00034342738,0.000024253131],"category_scores_gemma":[0.00009315694,0.00034592088,0.000033483142,0.0002581889,0.00008601066,0.000019716186,0.000055731583,0.00049587514,0.000005800568],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00285116,0.00022828188,0.0042731883,0.00017860282,0.0000750108,0.000004130144,0.0006759946,0.00011558593,0.0014477045,0.000011079059,0.03872777,0.9514115],"study_design_scores_gemma":[0.005663357,0.0024701222,0.005217988,0.0015631721,0.000010107832,0.0000014233782,0.00015486598,0.00011808047,0.012048241,0.00008555535,0.9719451,0.0007220016],"about_ca_topic_score_codex":0.00004330946,"about_ca_topic_score_gemma":0.00065649993,"teacher_disagreement_score":0.9506895,"about_ca_system_score_codex":0.000041905532,"about_ca_system_score_gemma":0.00012333316,"threshold_uncertainty_score":0.99989927},"labels":[],"label_agreement":null},{"id":"W2997991791","doi":"10.1007/s12325-019-01205-z","title":"New Technologies and Applications in Sacral Neuromodulation: An Update","year":2019,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Institute for Health and Care Research; Medtronic","keywords":"Medicine; Neuromodulation; Sacral nerve stimulation; Groundwater recharge; Magnetic resonance imaging; Perspective (graphical); Health professionals; Medical physics; Health care; Radiology; Surgery; Internal medicine; Computer science; Engineering; Artificial intelligence","score_opus":0.0701502830510855,"score_gpt":0.43091270964932504,"score_spread":0.36076242659823954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997991791","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000065606124,0.9974554,0.00011072062,0.00012526526,0.00003867305,0.0016724543,0.000009601031,0.00006679945,0.00045549087],"genre_scores_gemma":[0.00009202426,0.99849707,0.00076627726,0.000023431616,0.00006195254,0.00019599481,0.0001300781,0.000030262241,0.00020292877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989028,0.00006893838,0.00028762466,0.0003881204,0.00013378028,0.00021874557],"domain_scores_gemma":[0.9993177,0.00009812588,0.00007163088,0.000450363,0.00001622947,0.00004595276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012429881,0.00020594688,0.0007315515,0.00033996126,0.0000234642,0.00001811938,0.00017887345,0.00016244818,0.000033686316],"category_scores_gemma":[0.000009134161,0.0001514578,0.000054086813,0.00053801853,0.000064327854,0.00024886162,0.000045203986,0.00045709248,0.000016064563],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002519361,0.000048372684,0.00070167135,0.0015038104,0.000009616622,0.000011638434,0.000029755854,0.0000019151473,5.4427846e-7,0.00028254077,0.000009197707,0.9973757],"study_design_scores_gemma":[0.0005132251,0.00029502992,0.00019523656,0.00092873373,0.000016071834,0.000042345284,0.000044834116,0.0000069069697,0.0000023218183,0.0025668251,0.99524873,0.0001397521],"about_ca_topic_score_codex":0.000013429174,"about_ca_topic_score_gemma":0.00002377475,"teacher_disagreement_score":0.997236,"about_ca_system_score_codex":0.000041124567,"about_ca_system_score_gemma":0.00015846301,"threshold_uncertainty_score":0.617627},"labels":[],"label_agreement":null},{"id":"W3009978386","doi":"10.1007/s12325-020-01262-9","title":"Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ortho Dermatologics; LEO Pharma; Dermira; Valeant Pharmaceuticals International; Regeneron Pharmaceuticals; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Apremilast; Psoriatic arthritis; Propensity score matching; Internal medicine; Wilcoxon signed-rank test; Rheumatology; Physical therapy; Arthritis; Mann–Whitney U test","score_opus":0.015003431222160853,"score_gpt":0.28428561481140935,"score_spread":0.2692821835892485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009978386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9522304,0.045013912,0.000005333589,0.0017102773,0.00006538446,0.00081675505,0.00004547993,0.000021225727,0.000091238275],"genre_scores_gemma":[0.86601174,0.13279213,0.00016322553,0.00081047666,0.00003500572,0.00012668922,0.00004477578,0.000012739766,0.0000032174557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991206,0.000037535643,0.00018909283,0.00031239502,0.00010779837,0.00023259137],"domain_scores_gemma":[0.9996722,0.00004668473,0.00005621559,0.000104586004,0.000030257781,0.00009005563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000017949662,0.00017801591,0.00037527387,0.000043737502,0.00003955911,0.000006110539,0.000029378209,0.00004003433,0.000019982504],"category_scores_gemma":[0.000011374072,0.0001170035,0.000023829289,0.00015370357,0.000041367228,0.00009080399,0.000012508374,0.00007510391,0.0000037464451],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067323964,0.00019524034,0.62309176,0.000010719186,0.000024152429,0.000093584116,0.0006967435,0.0000010432838,0.0000023292603,0.000022396849,9.661611e-7,0.3751878],"study_design_scores_gemma":[0.025689993,0.009804987,0.9601485,0.00028080234,0.0000072832463,0.000008032747,0.0006665107,0.000008121778,0.000099320445,0.00010765491,0.003028236,0.0001505161],"about_ca_topic_score_codex":0.00034365067,"about_ca_topic_score_gemma":0.0018090751,"teacher_disagreement_score":0.3750373,"about_ca_system_score_codex":0.0001356286,"about_ca_system_score_gemma":0.000018450697,"threshold_uncertainty_score":0.47712645},"labels":[],"label_agreement":null},{"id":"W3015761876","doi":"10.1007/s12325-020-01324-y","title":"A Map of Racial and Ethnic Disparities in Influenza Vaccine Uptake in the Medicare Fee-for-Service Program","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Sanofi Pasteur; Sanofi","keywords":"Medicine; Vaccination; Ethnic group; Zip code; Public health; Influenza vaccine; Environmental health; Health equity; Fee-for-service; Demography; Gerontology; Health care; Immunology; Geography; Nursing; Economic growth","score_opus":0.12331492227544757,"score_gpt":0.4532602491306299,"score_spread":0.3299453268551823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015761876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8521319,0.13356465,0.0000071038735,0.011987389,0.000044058277,0.0019696099,0.000016988944,0.000025789186,0.00025249657],"genre_scores_gemma":[0.9594565,0.024370724,0.0010013686,0.013977707,0.0001652663,0.0009861741,0.000010304089,0.000024518069,0.0000074227883],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985598,0.000106928084,0.00042726373,0.00023777298,0.00033564868,0.00033263583],"domain_scores_gemma":[0.99920297,0.00039356775,0.00007586122,0.0001759273,0.000097958386,0.000053747022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000552413,0.00015421526,0.0004273323,0.00011808144,0.0000328307,0.00000901579,0.00020849863,0.00007271966,0.000015629388],"category_scores_gemma":[0.0003697816,0.00010161841,0.00003840937,0.00047505187,0.00012725277,0.00018133277,0.000056531684,0.00036476547,0.0000017071686],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074119316,0.00045725075,0.33660394,0.0016003378,0.00007470415,0.000049116785,0.048481192,0.00010297656,0.0009971278,0.0010317905,0.00016294008,0.6030267],"study_design_scores_gemma":[0.016881108,0.0021222453,0.6911999,0.0004989817,0.000015178547,0.000003757017,0.0071916296,0.0005064013,0.00056057743,0.003041553,0.2777266,0.0002520721],"about_ca_topic_score_codex":0.00017975328,"about_ca_topic_score_gemma":0.0022237694,"teacher_disagreement_score":0.6027746,"about_ca_system_score_codex":0.000034860863,"about_ca_system_score_gemma":0.0000624358,"threshold_uncertainty_score":0.41438785},"labels":[],"label_agreement":null},{"id":"W3016333849","doi":"10.1007/s12325-020-01303-3","title":"Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Gilead Sciences; AbbVie; Sanofi; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Tofacitinib; Rheumatoid arthritis; Internal medicine; Rheumatology; Janus kinase inhibitor; Randomized controlled trial; Gastroenterology","score_opus":0.07489998418923918,"score_gpt":0.3565567765297657,"score_spread":0.28165679234052654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016333849","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3712167,0.61369455,0.0084147025,0.0031699778,0.00009035339,0.002627375,0.000114493654,0.000085098865,0.00058672036],"genre_scores_gemma":[0.8376055,0.15618765,0.004922079,0.0008356513,0.00006590407,0.00030168597,0.00004145664,0.000023853598,0.000016255586],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979706,0.00014424499,0.0006292933,0.00044031462,0.00037916956,0.0004364245],"domain_scores_gemma":[0.9986537,0.0004607906,0.00015623933,0.00028438854,0.00019052076,0.00025434213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030025115,0.0002536999,0.0019033606,0.00017947436,0.00008534993,0.000026979378,0.00017930695,0.00006016798,0.00027976133],"category_scores_gemma":[0.00010421328,0.00019965389,0.000770416,0.0012056057,0.0001317689,0.00025255303,0.000031348343,0.00018409018,0.000016940496],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06345202,0.0026293306,0.016197221,0.00024244517,0.23377302,0.000093389186,0.033752978,0.39178994,0.00659984,0.0073266244,0.0094405515,0.23470265],"study_design_scores_gemma":[0.07873256,0.016174212,0.0056578387,0.00080191443,0.003198797,0.000056861594,0.0043668454,0.02649549,0.06358565,0.017152214,0.7808007,0.0029769351],"about_ca_topic_score_codex":0.000021955737,"about_ca_topic_score_gemma":0.00013939326,"teacher_disagreement_score":0.77136016,"about_ca_system_score_codex":0.00002049409,"about_ca_system_score_gemma":0.00007314538,"threshold_uncertainty_score":0.81416494},"labels":[],"label_agreement":null},{"id":"W3016888407","doi":"10.1007/s12325-020-01318-w","title":"Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Medicine; Overactive bladder; Public health; Cohort; Health care; Retrospective cohort study; Diagnosis code; Family medicine; Medical record; Population; Observational study; Cohort study; Emergency medicine; Internal medicine; Environmental health; Alternative medicine; Nursing","score_opus":0.18177862390595162,"score_gpt":0.41671995338618817,"score_spread":0.23494132948023655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016888407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99232024,0.0023544668,0.00019673372,0.0024893617,0.000038009228,0.0020928292,0.0002219226,0.000014641428,0.0002717701],"genre_scores_gemma":[0.9974815,0.00091275084,0.000756833,0.0005399099,0.00004086518,0.000033358585,0.00021161485,0.000018037206,0.0000050962117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822956,0.00023769359,0.0003055016,0.00040410514,0.00059004215,0.00023311334],"domain_scores_gemma":[0.9990916,0.00013458333,0.00014229053,0.00045666914,0.00010277344,0.00007208346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039357287,0.00012425511,0.00029846237,0.000054997807,0.00006034705,0.000017822798,0.0002986536,0.00001907828,0.000047419155],"category_scores_gemma":[0.00002147244,0.00008014693,0.000016513535,0.00066393334,0.00006271254,0.00059036264,0.0001265211,0.0002381759,0.0000015524585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018176021,0.00086242554,0.98317236,0.000059870756,0.00021744313,0.00003171794,0.004458451,0.00005475534,0.0000044100643,0.00007913773,0.00002614597,0.009215702],"study_design_scores_gemma":[0.005349358,0.0013451127,0.98289156,0.0001411966,0.000008050829,5.195918e-7,0.008021033,0.0009471251,0.0000063477837,0.00006193899,0.0011525385,0.00007522016],"about_ca_topic_score_codex":0.00038103273,"about_ca_topic_score_gemma":0.00022207986,"teacher_disagreement_score":0.009140482,"about_ca_system_score_codex":0.00021484838,"about_ca_system_score_gemma":0.00016060963,"threshold_uncertainty_score":0.32682967},"labels":[],"label_agreement":null},{"id":"W3017316429","doi":"10.1007/s12325-020-01327-9","title":"Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hepatitis Viruses Studies and Epidemiology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"Grifols","keywords":"Medicine; Cmax; Adverse effect; Tolerability; Pharmacokinetics; Internal medicine; Titer; Antibody; Antibody titer; Hepatitis A; Gastroenterology; Hepatitis; Immunology","score_opus":0.10374191705892144,"score_gpt":0.45089586179378316,"score_spread":0.3471539447348617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017316429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615076,0.03195801,0.0002010855,0.0024759923,0.00023787848,0.0029399944,0.000046423123,0.000054673925,0.00057833927],"genre_scores_gemma":[0.8308363,0.1645206,0.0011795475,0.0031358826,0.00013072834,0.00012684579,0.000015174565,0.00004273721,0.000012173179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968031,0.00051246485,0.0009793554,0.00084276806,0.00024761388,0.0006146655],"domain_scores_gemma":[0.99887687,0.00025294244,0.0003088943,0.0002775559,0.00010178591,0.00018193464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068172626,0.00039247627,0.0013492453,0.00012562059,0.00026966032,0.000047588182,0.00027021943,0.000093890245,0.000046198424],"category_scores_gemma":[0.00022334952,0.00034665543,0.000043494245,0.00057021255,0.00024947754,0.00046214633,0.0002817072,0.0005616885,0.000004811367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015340112,0.002010891,0.9598702,0.00009778053,0.00011399369,0.00020872986,0.0046972837,0.000023302811,0.009913717,0.00014040769,0.000019095767,0.021370556],"study_design_scores_gemma":[0.024557438,0.0047128657,0.9652436,0.00022914397,0.000027452785,0.000013000961,0.0011394253,0.00053454237,0.00082220515,0.00022839401,0.0021438906,0.0003480917],"about_ca_topic_score_codex":0.013162637,"about_ca_topic_score_gemma":0.01217564,"teacher_disagreement_score":0.1325626,"about_ca_system_score_codex":0.0002550308,"about_ca_system_score_gemma":0.000111392925,"threshold_uncertainty_score":0.99989855},"labels":[],"label_agreement":null},{"id":"W3018014849","doi":"10.1007/s12325-020-01348-4","title":"Developing Classifications of Laryngeal Dysplasia: The Historical Basis","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Oral Health Pathology and Treatment","field":"Dentistry","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dysplasia; Grading (engineering); Larynx; Cervical intraepithelial neoplasia; Dermatology; Intraepithelial neoplasia; Pathology; Terminology; Cancer; Radiology; Internal medicine; Surgery; Cervical cancer; Prostate cancer","score_opus":0.13085465112690103,"score_gpt":0.42986762151626207,"score_spread":0.29901297038936103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018014849","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008941677,0.9969285,0.00027061094,0.00051391457,0.00093446486,0.000575021,0.00003716888,0.000028587563,0.0007027615],"genre_scores_gemma":[0.000067919784,0.9976037,0.0014859241,0.00011023598,0.00011899236,0.00032636142,0.00003617232,0.000026985723,0.00022369865],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825823,0.00038821565,0.00066811027,0.00032941048,0.00014696758,0.00020906975],"domain_scores_gemma":[0.9985768,0.0005688943,0.0004193941,0.0003677806,0.000028521777,0.00003857088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018170674,0.00024570173,0.0010203583,0.000079028,0.00010644829,0.0000050856834,0.00038115948,0.00024056283,0.00004623717],"category_scores_gemma":[0.000038470036,0.00015167917,0.0002106192,0.00045240804,0.000086602086,0.000083172774,0.00003576492,0.0004649798,0.00011502331],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012569866,0.00006170487,0.00023264375,0.0013298456,0.000045971432,0.00007422394,0.00006153946,2.388939e-7,3.539348e-8,0.005822526,0.00012446487,0.99223423],"study_design_scores_gemma":[0.00021004802,0.000065363296,0.00017576032,0.0009095747,0.00006287909,0.00005521411,0.000012202521,5.254842e-7,0.0000016177405,0.0008625973,0.9975242,0.00012001552],"about_ca_topic_score_codex":0.000013745057,"about_ca_topic_score_gemma":0.000099474564,"teacher_disagreement_score":0.99739975,"about_ca_system_score_codex":0.00066156144,"about_ca_system_score_gemma":0.0003055515,"threshold_uncertainty_score":0.6185297},"labels":[],"label_agreement":null},{"id":"W3020183939","doi":"10.1007/s12325-020-01314-0","title":"The Myeloproliferative Neoplasm Landscape: A Patient’s Eye View","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Foundation for Healthcare Improvement","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Polycythaemia; Quality of life (healthcare); Myelofibrosis; Myeloproliferative neoplasm; Psychosocial; Anxiety; Palliative care; Depression (economics); Physical therapy; Disease; Intensive care medicine; Internal medicine; Psychiatry; Nursing","score_opus":0.026338501614843735,"score_gpt":0.3577173501751318,"score_spread":0.33137884856028804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020183939","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027854896,0.9907696,0.0000061473734,0.0010652402,0.00049166183,0.0035240483,0.0000557967,0.00007070058,0.0039889216],"genre_scores_gemma":[0.00005515531,0.995001,0.00028061375,0.00089130644,0.000342764,0.00291703,0.00013541848,0.0001047715,0.0002719087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967874,0.0003891007,0.0010062942,0.0008029475,0.00047391417,0.00054032006],"domain_scores_gemma":[0.99771744,0.00088453904,0.00048082415,0.0006037528,0.00010676687,0.0002066945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018856546,0.00083170814,0.0026168413,0.00013240929,0.00024376792,0.00008263943,0.00029416115,0.0002488765,0.0001427787],"category_scores_gemma":[0.00012470986,0.00042911363,0.00057937985,0.0006904043,0.0001419344,0.0001681244,0.00007287098,0.00077427976,0.00023470323],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013110161,0.00022379494,0.00039653547,0.0013292287,0.00040202148,0.0002040841,0.00039304534,0.0000010539529,7.398034e-8,0.00056359696,0.00044081386,0.99591464],"study_design_scores_gemma":[0.0013975337,0.0008886759,0.000040891988,0.006323505,0.00020732683,0.000077381104,0.00007121319,0.0000060312013,0.000011694489,0.00022320433,0.9903644,0.00038815817],"about_ca_topic_score_codex":0.0000039576694,"about_ca_topic_score_gemma":0.000051476447,"teacher_disagreement_score":0.9955265,"about_ca_system_score_codex":0.00021983826,"about_ca_system_score_gemma":0.0004995546,"threshold_uncertainty_score":0.99981606},"labels":[],"label_agreement":null},{"id":"W3022780576","doi":"10.1007/s12325-020-01275-4","title":"Qualitative Interviews to Better Understand the Patient Experience and Evaluate Patient-Reported Outcomes (PRO) in RLBP1 Retinitis Pigmentosa (RLBP1 RP)","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Retinal Development and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Retinitis pigmentosa; Qualitative research; Rheumatology; Family medicine; Physical therapy; Internal medicine; Ophthalmology","score_opus":0.054409213103887,"score_gpt":0.3765654363577753,"score_spread":0.32215622325388826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022780576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99048924,0.004080158,0.0003404899,0.003493333,0.00009322911,0.00054620934,0.0000041942635,0.00000620579,0.0009469581],"genre_scores_gemma":[0.9882011,0.004150002,0.0005483291,0.0069032367,0.000011948282,0.00013843378,0.000017508086,0.000013279991,0.000016176573],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861884,0.00022523102,0.00038384864,0.00038106903,0.00017796968,0.00021304692],"domain_scores_gemma":[0.9995739,0.00004396949,0.00011842344,0.00016944103,0.000033983808,0.000060294482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001959766,0.00017790266,0.00018595411,0.00003478747,0.000045429435,0.00002401649,0.00014501122,0.000044818502,0.00003182198],"category_scores_gemma":[0.00012167468,0.00012282627,0.000041102765,0.00016063108,0.00010420912,0.000018984429,0.00009114342,0.00008117386,0.0000024414608],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016685413,0.00017739114,0.22218393,0.00003712215,0.00009625439,0.000028297767,0.34251097,0.000097557844,0.025276516,0.00014099735,0.00050898973,0.4072734],"study_design_scores_gemma":[0.010905659,0.006663997,0.09550934,0.00028702916,0.000023571285,0.000015439908,0.32935587,0.000153484,0.12888665,0.008042364,0.4177994,0.002357192],"about_ca_topic_score_codex":0.00001820398,"about_ca_topic_score_gemma":0.00007732059,"teacher_disagreement_score":0.41729042,"about_ca_system_score_codex":0.000018141782,"about_ca_system_score_gemma":0.00002181074,"threshold_uncertainty_score":0.500871},"labels":[],"label_agreement":null},{"id":"W3024587646","doi":"10.1007/s12325-020-01364-4","title":"Identification of Patient Needs and Preferences in Pigmented Villonodular Synovitis (PVNS) Using a Qualitative Online Bulletin Board Study","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis","keywords":"Pigmented villonodular synovitis; Medicine; Tendon sheath; Rheumatology; Referral; Internal medicine; Family medicine; Physical therapy; Surgery; Synovitis; Tendon; Rheumatoid arthritis","score_opus":0.029991610497227365,"score_gpt":0.34877265339725144,"score_spread":0.31878104290002407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024587646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422216,0.004334523,0.00005585531,0.00044627322,0.00004385597,0.0008237802,0.000025195517,0.000011846164,0.000036488098],"genre_scores_gemma":[0.99718297,0.002150622,0.0003975691,0.00017358828,0.000017947554,0.000038305505,0.000020435664,0.000010889797,0.000007692731],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9987932,0.00016894941,0.0004847549,0.00021607794,0.00020337613,0.00013366975],"domain_scores_gemma":[0.9995509,0.000068903035,0.00017224299,0.00010897062,0.000046608562,0.000052391682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012791555,0.00013286363,0.00033378846,0.00011001917,0.00002291676,0.0000074272184,0.000049919454,0.000030172374,0.00004409935],"category_scores_gemma":[0.00004423015,0.000107269385,0.00003467944,0.00031854966,0.00006794958,0.00011930727,0.00002565132,0.000084691994,0.0000010642534],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003118352,0.0053617954,0.65423644,0.00044263754,0.00034022995,0.00006895984,0.1617327,0.0004182222,0.0142111955,0.00035695016,0.0000063579364,0.15970618],"study_design_scores_gemma":[0.033054627,0.022623228,0.43827486,0.0012027815,0.00019145386,0.00001536319,0.47359008,0.0021469381,0.018311337,0.002718588,0.006823545,0.0010472141],"about_ca_topic_score_codex":0.0007117586,"about_ca_topic_score_gemma":0.0001462552,"teacher_disagreement_score":0.31185737,"about_ca_system_score_codex":0.00004301571,"about_ca_system_score_gemma":0.000016668304,"threshold_uncertainty_score":0.43743184},"labels":[],"label_agreement":null},{"id":"W3024736928","doi":"10.1007/s12325-020-01371-5","title":"Preoperative Versus Extended Postoperative Antimicrobial Prophylaxis of Surgical Site Infection During Spinal Surgery: A Comprehensive Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Surgical site infection prevention","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Spinal surgery; Meta-analysis; Antimicrobial; Surgical site infection; Surgery; Antibiotic prophylaxis; Orthopedic surgery; Rheumatology; Surgical Infections; Internal medicine; Antibiotics","score_opus":0.07163690651770108,"score_gpt":0.39063357979123453,"score_spread":0.3189966732735334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024736928","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011887448,0.9934712,0.000027216938,0.00008267299,0.00008973582,0.0050018844,0.00005721291,0.00004509036,0.000036238245],"genre_scores_gemma":[0.0026915276,0.99629015,0.000074030104,0.000073648225,0.000035614397,0.0006226085,0.00012910232,0.00003964582,0.000043647753],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9950824,0.0018552368,0.0017264802,0.000739645,0.00035727065,0.00023900972],"domain_scores_gemma":[0.9972732,0.00077982945,0.001121839,0.00037968263,0.00032967541,0.00011579376],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047424878,0.00061943935,0.010648338,0.00055679725,0.00007230295,0.000026429867,0.00008074556,0.00022833205,0.00047894637],"category_scores_gemma":[0.00016299756,0.00040331864,0.0029423772,0.0022500858,0.00015299757,0.00031915357,0.00005748483,0.0005509676,0.000013345969],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010555404,0.00035105145,0.000068376285,0.86789817,0.09940874,0.00021669985,0.000115526076,0.000009557357,0.000010200432,0.000024025507,0.0000022019224,0.030839913],"study_design_scores_gemma":[0.0031857174,0.002275662,0.00017504599,0.105017714,0.80700845,0.00084854243,0.000018603689,0.0000058125606,0.00011483192,0.000007910859,0.080277406,0.0010643287],"about_ca_topic_score_codex":0.000032856777,"about_ca_topic_score_gemma":0.000020667803,"teacher_disagreement_score":0.76288044,"about_ca_system_score_codex":0.00018580157,"about_ca_system_score_gemma":0.000118473945,"threshold_uncertainty_score":0.99984187},"labels":[],"label_agreement":null},{"id":"W3025066905","doi":"10.1007/s12325-020-01359-1","title":"Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Parathyroid Disorders and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AbbVie","keywords":"Medicine; Middle East; Rheumatology; East Asia; Internal medicine; China; Geography; Archaeology","score_opus":0.026024623134855776,"score_gpt":0.25363635452912137,"score_spread":0.2276117313942656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025066905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.877648,0.121413186,0.0000218522,0.00021508057,0.000012232393,0.00026285034,0.00004052569,0.0000028915774,0.00038337876],"genre_scores_gemma":[0.88471794,0.11463078,0.00022550688,0.00039150717,0.0000031723785,0.000014138834,0.0000044708954,0.0000074181307,0.0000050524454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939007,0.000040097977,0.00022812608,0.00014479282,0.0001064944,0.00009044699],"domain_scores_gemma":[0.9996597,0.000039903458,0.00011904765,0.0001225692,0.000029368375,0.000029387083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000041185678,0.00009661533,0.00027774545,0.00003470684,0.00001073093,0.0000023000064,0.0000569402,0.00001536049,0.0000036962435],"category_scores_gemma":[0.000004555013,0.00006659574,0.000016802882,0.0002689055,0.00022624992,0.000083600265,0.000022231477,0.000061415696,6.7523166e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013275255,0.00047972111,0.8790996,0.0003239338,0.00023803559,0.00007397327,0.01399518,0.00014325746,0.0010107574,0.00012674634,0.0001286843,0.1030526],"study_design_scores_gemma":[0.020939507,0.0034362348,0.91131055,0.00024845402,0.00010600169,0.000006997521,0.016522385,0.00029231785,0.005337966,0.0001813952,0.04127037,0.00034783644],"about_ca_topic_score_codex":0.000028633154,"about_ca_topic_score_gemma":0.00003708916,"teacher_disagreement_score":0.10270476,"about_ca_system_score_codex":0.000004354641,"about_ca_system_score_gemma":0.000019195924,"threshold_uncertainty_score":0.27156955},"labels":[],"label_agreement":null},{"id":"W3045848823","doi":"10.1007/s12325-020-01445-4","title":"The Burden of Pain Associated with Osteoarthritis in the Hip or Knee from the Patient’s Perspective: A Multinational Cross-Sectional Study","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Teva Pharmaceutical Industries","keywords":"Medicine; Cross-sectional study; Osteoarthritis; Rheumatology; Physical therapy; Perspective (graphical); Multinational corporation; Knee pain; Internal medicine; Alternative medicine; Pathology","score_opus":0.020184110138256273,"score_gpt":0.30509680475788925,"score_spread":0.284912694619633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045848823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98944104,0.0063143945,0.000010841812,0.0023037111,0.00008871125,0.0015554909,0.000048233716,0.000018592884,0.00021897652],"genre_scores_gemma":[0.9984274,0.00032279122,0.00006998906,0.0006544166,0.00014436385,0.00028835688,0.000031022893,0.000015251558,0.000046405476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983644,0.00044705,0.00028125476,0.00024250544,0.00048911973,0.00017567757],"domain_scores_gemma":[0.9978496,0.0016682007,0.00013738303,0.00017819509,0.00013981179,0.000026817805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005246782,0.00014225548,0.00019306416,0.000025015588,0.00016297252,0.000035992405,0.0001691222,0.000043183092,0.00006517735],"category_scores_gemma":[0.00047318975,0.00006162885,0.00005276601,0.00034219096,0.00015316282,0.00013107507,0.000018391058,0.00022539249,0.000002201414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006302448,0.0009838266,0.74558616,0.000003236632,0.00013264263,0.00012588817,0.053847834,0.00020310756,0.0005388681,0.00058563554,0.000027816992,0.19166255],"study_design_scores_gemma":[0.043837503,0.036762826,0.78601664,0.00022654932,0.0000395663,0.000017615144,0.1219479,0.000299745,0.0008000437,0.0033886128,0.0063470076,0.00031597062],"about_ca_topic_score_codex":0.00022025769,"about_ca_topic_score_gemma":0.0015814753,"teacher_disagreement_score":0.19134659,"about_ca_system_score_codex":0.00008169973,"about_ca_system_score_gemma":0.0000762307,"threshold_uncertainty_score":0.25131518},"labels":[],"label_agreement":null},{"id":"W3082719138","doi":"10.1007/s12325-020-01466-z","title":"Terlipressin May Decrease In-Hospital Mortality of Cirrhotic Patients with Acute Gastrointestinal Bleeding and Renal Dysfunction: A Retrospective Multicenter Observational Study","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Terlipressin; Observational study; Gastrointestinal bleeding; Internal medicine; Retrospective cohort study; Multicenter study; Acute kidney injury; Hepatology; Intensive care medicine; Cirrhosis; Randomized controlled trial; Hepatorenal syndrome","score_opus":0.023841223111348835,"score_gpt":0.2943993613864541,"score_spread":0.2705581382751053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082719138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988089,0.00017307134,0.00021137099,0.000105038096,0.000027480512,0.00060001557,0.000024124396,0.000011632428,0.000038364866],"genre_scores_gemma":[0.9989424,0.000079915764,0.0007355912,0.00012511668,0.000031870768,0.000027519327,0.00004743609,0.000008568905,0.0000016345491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992001,0.000031276344,0.00020185566,0.00022900103,0.00023373587,0.000104054634],"domain_scores_gemma":[0.99963754,0.000035132194,0.000085442865,0.00006859603,0.00008928604,0.00008398646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049979757,0.00010465999,0.00017986028,0.000044416458,0.000019819445,0.0000069422927,0.00003411857,0.000012553552,0.000026233018],"category_scores_gemma":[0.000013307989,0.00008174507,0.000019330724,0.00016005023,0.00005514168,0.00038369905,0.000006813782,0.00009971604,3.7386442e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004106292,0.00091285084,0.9924792,0.00003280653,0.000113294336,0.00008986663,0.0016564202,0.00003586493,0.0002257241,0.000015605074,6.7167304e-7,0.00033138448],"study_design_scores_gemma":[0.010182921,0.0027728463,0.98586917,0.00017121834,0.00012104543,0.0000029811606,0.00032808149,0.0002603602,0.00015895488,0.000056878445,0.0000016559043,0.000073867595],"about_ca_topic_score_codex":0.0000340314,"about_ca_topic_score_gemma":0.00003154555,"teacher_disagreement_score":0.00661003,"about_ca_system_score_codex":0.00003289556,"about_ca_system_score_gemma":0.000037690832,"threshold_uncertainty_score":0.33334672},"labels":[],"label_agreement":null},{"id":"W3083451975","doi":"10.1007/s12325-020-01483-y","title":"Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Medicine; Internal medicine; Coronary artery disease; Lipoprotein(a); Population; Platelet; P2Y12; Gastroenterology; Univariate analysis; Endocrinology; Lipoprotein; Cardiology; Cholesterol; Multivariate analysis; Platelet aggregation","score_opus":0.014335108524475558,"score_gpt":0.2750602372448577,"score_spread":0.2607251287203821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083451975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915599,0.0044206795,0.00084102945,0.0018603186,0.000022732702,0.0011935043,0.000012601917,0.000016439819,0.000072794704],"genre_scores_gemma":[0.9947115,0.0025681928,0.0017888662,0.00074967736,0.000054617223,0.000090778536,0.00001891497,0.0000125483175,0.0000049057085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914175,0.00007260313,0.00019419215,0.00022674317,0.00023478108,0.0001299498],"domain_scores_gemma":[0.99956024,0.000026330557,0.000062834086,0.00018003315,0.000025881509,0.00014469866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017856952,0.00009645869,0.0002890646,0.000054272703,0.000020535423,0.0000048351803,0.000034146484,0.00003535517,0.000009523381],"category_scores_gemma":[0.000036931076,0.000076546,0.00002482209,0.00024317908,0.000050615745,0.00023919159,0.000010144334,0.00013536448,9.5003895e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019058689,0.00013700161,0.79370785,0.00008795492,0.000044616823,0.000038080456,0.0011713923,0.0005156487,0.0011486186,0.00036216847,0.0000034372692,0.20087738],"study_design_scores_gemma":[0.00398483,0.0006756067,0.98975885,0.00018408251,0.0000109631865,0.00001262288,0.00010404432,0.00007525792,0.0019978504,0.00041232945,0.002684707,0.000098842866],"about_ca_topic_score_codex":0.00011170431,"about_ca_topic_score_gemma":0.00010199973,"teacher_disagreement_score":0.20077854,"about_ca_system_score_codex":0.000030879608,"about_ca_system_score_gemma":0.00008841064,"threshold_uncertainty_score":0.31214553},"labels":[],"label_agreement":null},{"id":"W3085906625","doi":"10.1007/s12325-020-01472-1","title":"The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Robarts Clinical Trials; Western University","funders":"AbbVie","keywords":"Biosimilar; Medicine; Narrative review; Interchangeability; Clinical Practice; Randomized controlled trial; Intensive care medicine; Risk analysis (engineering); Family medicine; Surgery; Internal medicine","score_opus":0.1170445249525093,"score_gpt":0.437350677947818,"score_spread":0.32030615299530873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085906625","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012724806,0.9981267,0.000019429,0.0005263074,0.0003810955,0.00085843244,0.000021984026,0.0000117690715,0.00004157258],"genre_scores_gemma":[0.000492355,0.99899423,0.00024160038,0.000103042614,0.000028533144,0.00010945691,0.0000063898487,0.000022041038,0.0000023343594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960387,0.0020011538,0.0011188011,0.00046125753,0.00008220836,0.00029788495],"domain_scores_gemma":[0.99574465,0.0028855181,0.0007976776,0.00044717817,0.00010454059,0.000020435069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015108075,0.00038725638,0.0020457604,0.00012457184,0.00006614382,0.000008157488,0.0007503437,0.00024865853,0.00004520476],"category_scores_gemma":[0.000699149,0.0002116058,0.0003375255,0.00047573898,0.00026951582,0.00023604196,0.00008516755,0.0007679643,0.0000015330569],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006277016,0.00009694236,0.00011214898,0.016003896,0.00010308366,0.000001334883,0.0010629522,1.3222996e-7,0.00006555543,0.00022728243,0.00003068154,0.9822332],"study_design_scores_gemma":[0.00032176657,0.00032972652,0.000041784457,0.15336937,0.00006297748,0.00000457794,0.0005465762,0.0000033113902,0.00008877321,0.0003466414,0.8446436,0.00024089811],"about_ca_topic_score_codex":0.000002969861,"about_ca_topic_score_gemma":0.000098566816,"teacher_disagreement_score":0.9819923,"about_ca_system_score_codex":0.000035992267,"about_ca_system_score_gemma":0.00012980957,"threshold_uncertainty_score":0.8629034},"labels":[],"label_agreement":null},{"id":"W3088534458","doi":"10.1007/s12325-020-01497-6","title":"PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Manchester Biomedical Research Centre; LEO Pharma; Regeneron Pharmaceuticals; Sun Pharma; Dermira; National Institute for Health and Care Research; Celgene; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Calcipotriol; Betamethasone dipropionate; Psoriasis; Discontinuation; Adverse effect; Randomized controlled trial; Maintenance therapy; Clinical trial; Internal medicine; Dermatology; Surgery; Chemotherapy","score_opus":0.07843577025216758,"score_gpt":0.32965928514946174,"score_spread":0.25122351489729416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088534458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840848,0.00743173,0.0056993663,0.00029478475,0.0005376243,0.0014575383,0.000030041172,0.000026721627,0.00043742763],"genre_scores_gemma":[0.98969114,0.006655772,0.0031391187,0.00013791012,0.00007886595,0.00016491652,0.000014932626,0.000020050573,0.00009732095],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980986,0.00043228897,0.0006916559,0.0004194487,0.00006523268,0.00029277412],"domain_scores_gemma":[0.9986513,0.0006784508,0.0003333226,0.00025064216,0.00005700395,0.000029235562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034628218,0.00022242284,0.00072780024,0.00007259533,0.000027870105,0.0000032445146,0.00027315217,0.00023176728,0.00005226018],"category_scores_gemma":[0.00016487241,0.00015945152,0.00012093045,0.0002831985,0.00031915176,0.00016643078,0.00002674402,0.00023412984,0.000003892066],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44869843,0.005166474,0.06514077,0.00004371663,0.0008257539,0.000042428364,0.0039021138,0.00042939206,0.026218299,0.0006631735,0.00008363868,0.4487858],"study_design_scores_gemma":[0.5786313,0.06823794,0.0886328,0.00045238913,0.00027515987,0.00003094524,0.0029168387,0.00013528472,0.23775744,0.0010252136,0.020626403,0.0012783087],"about_ca_topic_score_codex":0.000054877855,"about_ca_topic_score_gemma":0.00014909945,"teacher_disagreement_score":0.4475075,"about_ca_system_score_codex":0.00003528841,"about_ca_system_score_gemma":0.00011603744,"threshold_uncertainty_score":0.65022445},"labels":[],"label_agreement":null},{"id":"W3091817477","doi":"10.1007/s12325-020-01520-w","title":"Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Vetenskapsrådet; Cancerfonden","keywords":"Mesothelin; Ovarian cancer; Medicine; Oncology; Serous fluid; Immunohistochemistry; Cancer research; Internal medicine; Cancer; Pathology","score_opus":0.016252761461244766,"score_gpt":0.30337798459558013,"score_spread":0.28712522313433536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091817477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704736,0.0013922638,0.00007020643,0.00066450756,0.00013452108,0.0005408217,0.00008984165,0.00003480233,0.000025695403],"genre_scores_gemma":[0.9944412,0.0017696688,0.001266785,0.0021323387,0.00010428821,0.00013211888,0.000075560005,0.000034891404,0.00004316633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983116,0.00010084436,0.00049595,0.00045088553,0.00040234445,0.0002383977],"domain_scores_gemma":[0.99936396,0.00013205114,0.00015673209,0.00018354935,0.000015473457,0.00014821313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008398603,0.00022707989,0.000420531,0.000069239606,0.000031044387,0.000008045178,0.000121902835,0.00007199432,0.00014351677],"category_scores_gemma":[0.000029412618,0.00012369339,0.000039907132,0.0001743132,0.00012079057,0.00031413086,0.000034774566,0.00027856586,0.00000492334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013829627,0.00089662895,0.9781807,0.000039454353,0.000012572999,0.000053860047,0.00019448581,0.0010403986,0.0009273609,0.0000055915248,0.0000135374175,0.0048057544],"study_design_scores_gemma":[0.011773089,0.001149326,0.98089844,0.0006234626,0.000012115713,7.2661294e-7,0.00011040568,0.00015790931,0.004466594,0.000086185406,0.00052918406,0.0001925504],"about_ca_topic_score_codex":0.00011337993,"about_ca_topic_score_gemma":0.00014068121,"teacher_disagreement_score":0.004613204,"about_ca_system_score_codex":0.00008683972,"about_ca_system_score_gemma":0.00004083498,"threshold_uncertainty_score":0.504407},"labels":[],"label_agreement":null},{"id":"W3097915981","doi":"10.1007/s12325-020-01525-5","title":"Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Dorzolamide; Tolerability; Medicine; Pharmacology; Intraocular pressure; Timolol; Ophthalmology","score_opus":0.018950805254272715,"score_gpt":0.311059292853311,"score_spread":0.2921084875990383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097915981","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033505107,0.99090093,0.000031509215,0.0067387884,0.0004339742,0.000925638,0.000003665118,0.000039586528,0.0005908353],"genre_scores_gemma":[0.0012390509,0.9967999,0.00005906716,0.00086567085,0.00075350644,0.000089066474,0.00007635606,0.00004223926,0.000075160315],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985402,0.0003277752,0.00034733443,0.00034542268,0.00023721372,0.00020201341],"domain_scores_gemma":[0.9987877,0.000644617,0.00023908907,0.00025193446,0.000031321615,0.000045344772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018925691,0.00032286567,0.00087335357,0.000039556333,0.00015505729,0.000043375232,0.00028351837,0.00016862132,0.000056835182],"category_scores_gemma":[0.000053474465,0.00014614861,0.0002055859,0.00031950927,0.00017641328,0.00008165977,0.00005592929,0.0010860683,0.000013417474],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045733508,0.000022567627,0.0045680213,0.0007092582,0.00008748336,0.000029043755,0.0011636602,6.676241e-7,3.8568535e-7,0.00020697364,0.00010138792,0.9930648],"study_design_scores_gemma":[0.00072430726,0.00017241144,0.0021726722,0.0029268821,0.00014253703,0.000039510633,0.001312696,0.00001305678,3.2083187e-7,0.0005529166,0.99177325,0.0001694375],"about_ca_topic_score_codex":0.000015819407,"about_ca_topic_score_gemma":0.00001328974,"teacher_disagreement_score":0.99289536,"about_ca_system_score_codex":0.000036842277,"about_ca_system_score_gemma":0.0000659546,"threshold_uncertainty_score":0.59597677},"labels":[],"label_agreement":null},{"id":"W3109214388","doi":"10.1007/s12325-020-01577-7","title":"A Patient Charter for Chronic Obstructive Pulmonary Disease","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; COPD; Quality of life (healthcare); Guideline; Intensive care medicine; Disease; Health care; Socioeconomic status; Population; Internal medicine; Nursing; Environmental health; Pathology","score_opus":0.018755212966720843,"score_gpt":0.3109301882022402,"score_spread":0.2921749752355194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109214388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84164363,0.14081572,0.0007250352,0.008269027,0.00043188827,0.004844788,0.00031716554,0.00016707415,0.002785662],"genre_scores_gemma":[0.99241316,0.0040504714,0.00043969322,0.0015519137,0.00055666926,0.0007262446,0.000095874406,0.000060135902,0.00010580485],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982024,0.000053489384,0.00028858712,0.000596383,0.00036155505,0.00049760944],"domain_scores_gemma":[0.9989246,0.000102620514,0.000075798,0.0003303174,0.000107984575,0.00045866307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000536075,0.00024046331,0.00033180197,0.00009086458,0.00006995573,0.000013127116,0.00015384446,0.00005130908,0.00035647993],"category_scores_gemma":[0.00007558051,0.00021061636,0.00017720871,0.00031128016,0.00018598253,0.00036001616,0.000052062336,0.00022960943,0.000035012865],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008031689,0.000535059,0.045388155,0.0008067684,0.00007248141,0.0004295991,0.0008817095,0.00021505743,0.0032577622,0.00081168563,0.00015858382,0.93941146],"study_design_scores_gemma":[0.009840731,0.0018768833,0.48567346,0.0003056011,0.00006188722,0.000035121775,0.0009824696,0.01573571,0.0033606314,0.011403315,0.46986404,0.00086016906],"about_ca_topic_score_codex":0.0000039749502,"about_ca_topic_score_gemma":0.0000025675374,"teacher_disagreement_score":0.9385513,"about_ca_system_score_codex":0.0004043912,"about_ca_system_score_gemma":0.00030356564,"threshold_uncertainty_score":0.8588686},"labels":[],"label_agreement":null},{"id":"W3111560043","doi":"10.1007/s12325-020-01591-9","title":"Naltrexone’s Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Mount Sinai Hospital; Western University","funders":"","keywords":"Medicine; Naltrexone; Cancer; Oncology; Clinical trial; Internal medicine; Animal studies; Bioinformatics; Opioid","score_opus":0.08723121654515832,"score_gpt":0.48236513564791916,"score_spread":0.39513391910276086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111560043","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013286517,0.995191,2.943718e-7,0.000054184195,0.000056942994,0.0032837524,0.000023423445,0.000015196206,0.000046581194],"genre_scores_gemma":[0.0007009646,0.99816567,0.000028028286,0.00015852228,0.00009330254,0.00076802034,0.000013386163,0.00004271361,0.000029371355],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9975672,0.000420911,0.0010005168,0.00046039806,0.0003218113,0.00022915842],"domain_scores_gemma":[0.9986239,0.00024407185,0.00067118526,0.0003282844,0.00006181322,0.00007070875],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042674632,0.0005066289,0.004360995,0.00017364188,0.00003161997,0.000010825742,0.00012589914,0.00012823398,0.0000064657597],"category_scores_gemma":[0.0000772082,0.00028154804,0.00026607406,0.0003284222,0.00019203113,0.00015086008,0.000032898897,0.0003493753,4.6327898e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039188244,0.000108271626,0.000109178385,0.84454864,0.00021767094,0.00005799607,0.0006263416,0.0000016636891,0.0000024056094,0.000011880051,0.000030781597,0.15389329],"study_design_scores_gemma":[0.0008455269,0.0009184488,0.00005629734,0.95002383,0.00067148596,0.000046218134,0.00019020363,0.000009385018,0.000007843659,0.000040064988,0.046924315,0.0002663914],"about_ca_topic_score_codex":0.000054055803,"about_ca_topic_score_gemma":0.000036961443,"teacher_disagreement_score":0.15362689,"about_ca_system_score_codex":0.00018495703,"about_ca_system_score_gemma":0.00021359809,"threshold_uncertainty_score":0.99996364},"labels":[],"label_agreement":null},{"id":"W3112399669","doi":"10.1007/s12325-020-01557-x","title":"Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-/Pooled Analyses","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; COPD; Placebo; Lama; Bronchodilator; Physical therapy; Quality of life (healthcare); Pulmonary rehabilitation; Anesthesia; Internal medicine; Asthma","score_opus":0.02741308040920549,"score_gpt":0.3744169351233517,"score_spread":0.34700385471414624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112399669","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1074351,0.88685596,0.0000053152703,0.000059372633,0.000029200837,0.005469154,0.00007661573,0.000025411367,0.00004384361],"genre_scores_gemma":[0.08517879,0.91352457,0.000036970134,0.000034283083,0.000025733716,0.0010291792,0.00006891379,0.000082753744,0.000018792158],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99646604,0.00082950335,0.00044156457,0.001054863,0.0007866226,0.0004214196],"domain_scores_gemma":[0.9978442,0.0005947571,0.0006505869,0.0005789298,0.00015194983,0.00017953313],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013252322,0.00084068027,0.005384073,0.00028499245,0.00004888754,0.0000126529885,0.00025215745,0.00015776882,0.000031588504],"category_scores_gemma":[0.000066101136,0.00048727085,0.00036308714,0.0013099295,0.00044858604,0.00047075798,0.00006431426,0.0010017572,0.0000044895983],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039116023,0.001987669,0.0009623145,0.070407495,0.0020260403,0.00019858759,0.00024505614,0.000008473609,0.000014975879,0.0000059878657,0.0000033962556,0.9202284],"study_design_scores_gemma":[0.051654473,0.011602371,0.20409961,0.62449557,0.038096778,0.00005844943,0.00016718204,0.000158701,0.0020890916,0.00019380805,0.063182436,0.004201512],"about_ca_topic_score_codex":0.000034667963,"about_ca_topic_score_gemma":0.0000136963545,"teacher_disagreement_score":0.9160269,"about_ca_system_score_codex":0.00035281823,"about_ca_system_score_gemma":0.00035407356,"threshold_uncertainty_score":0.9997579},"labels":[],"label_agreement":null},{"id":"W3122551350","doi":"10.1007/s12325-020-01598-2","title":"The Myth of Mild: Severe Exacerbations in Mild Asthma: An Underappreciated, but Preventable Problem","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"AstraZeneca","keywords":"Medicine; Asthma; Exacerbation; Formoterol; Intensive care medicine; Asthma exacerbations; Salmeterol; Allergy; Budesonide; Pediatrics; Internal medicine; Immunology","score_opus":0.017427622104883734,"score_gpt":0.3125373688970818,"score_spread":0.29510974679219804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122551350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8396516,0.15434663,0.00014771216,0.001109385,0.00016002808,0.00068843394,0.000022117432,0.000033818502,0.00384031],"genre_scores_gemma":[0.9447042,0.04821109,0.0022901942,0.0017084702,0.00013189352,0.00016543338,0.000052937175,0.000042524985,0.002693269],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988808,0.0001560724,0.00031442792,0.0002318015,0.00019381166,0.00022306571],"domain_scores_gemma":[0.999337,0.000118449716,0.000085948304,0.00031386825,0.000080240214,0.00006449003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016495967,0.00012245472,0.00022907321,0.00006417935,0.000081104154,0.000011946666,0.000110657464,0.000058618218,0.00007764381],"category_scores_gemma":[0.000026390473,0.000084817126,0.0000619417,0.00041908034,0.00009550482,0.00025165672,0.00001909864,0.0001516168,0.0000028846237],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022355965,0.0045174835,0.20483437,0.0003404459,0.00016317364,0.00014436798,0.0028776443,0.008497266,0.009278274,0.0031768584,0.0018942707,0.76204026],"study_design_scores_gemma":[0.012612578,0.0014809098,0.12896125,0.0010714681,0.000029631561,0.000058506244,0.010028521,0.00042615435,0.024059368,0.015367243,0.8053075,0.00059686654],"about_ca_topic_score_codex":0.000027311773,"about_ca_topic_score_gemma":0.0003562037,"teacher_disagreement_score":0.8034132,"about_ca_system_score_codex":0.000053102365,"about_ca_system_score_gemma":0.0002408385,"threshold_uncertainty_score":0.34587422},"labels":[],"label_agreement":null},{"id":"W3128620818","doi":"10.1007/s12325-020-01583-9","title":"Efficacy of Agomelatine 25–50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies","year":2021,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","field":"Psychology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Servier","keywords":"Agomelatine; Placebo; Medicine; Internal medicine; Anxiety; Randomized controlled trial; Generalized anxiety disorder; Meta-analysis; Placebo-controlled study; Psychiatry; Antidepressant; Double blind","score_opus":0.13215638460390228,"score_gpt":0.439351069680078,"score_spread":0.3071946850761757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128620818","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032909345,0.989914,0.001118396,0.00003672304,0.00035540204,0.004853096,0.00037229952,0.000012421778,0.000046733727],"genre_scores_gemma":[0.004893865,0.9871589,0.0004747529,0.000018078068,0.00006514785,0.006996616,0.00018174203,0.000053977863,0.0001569104],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99588567,0.0006833208,0.001810867,0.00090042094,0.00037054537,0.00034915982],"domain_scores_gemma":[0.9904463,0.0066016875,0.0018599703,0.00071378774,0.0003350942,0.000043102384],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00073453115,0.00073795556,0.0073536932,0.0011460328,0.00007036806,0.000010186926,0.00026385224,0.00022028353,0.0003135305],"category_scores_gemma":[0.00019120134,0.00039285226,0.0028831363,0.0023295816,0.0003318626,0.00009235284,0.000044371038,0.0001425479,5.9442317e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033654952,0.0030102136,0.0058276476,0.00055994035,0.20930834,0.0000011981552,0.0010418006,0.00022034772,8.218075e-7,0.00018862807,0.000010494018,0.77646506],"study_design_scores_gemma":[0.06955009,0.0034002883,0.004108843,0.0006850137,0.24378313,0.000007511128,0.0011495204,0.000077317374,0.000010981405,0.0009791858,0.67545867,0.000789439],"about_ca_topic_score_codex":0.00010576308,"about_ca_topic_score_gemma":0.00048141886,"teacher_disagreement_score":0.77567565,"about_ca_system_score_codex":0.00013135803,"about_ca_system_score_gemma":0.00009152355,"threshold_uncertainty_score":0.99985236},"labels":[],"label_agreement":null},{"id":"W3128831572","doi":"10.1007/s12325-021-01627-8","title":"Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Natural Science Foundation of Hunan Province","keywords":"Cetuximab; Medicine; Internal medicine; Oncology; Colorectal cancer; Irinotecan; Cancer","score_opus":0.04293897035453263,"score_gpt":0.3990481494591079,"score_spread":0.35610917910457524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128831572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95342267,0.045158524,0.000010909608,0.00018962294,0.000070138725,0.00067486195,0.00004051269,0.000005223959,0.00042756659],"genre_scores_gemma":[0.9640182,0.035219196,0.000094566814,0.00014525511,0.000008687164,0.0004752598,0.000017011416,0.0000089047035,0.000012906916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986672,0.00032778672,0.0003116571,0.00030655105,0.00017547842,0.00021136097],"domain_scores_gemma":[0.99889755,0.0007688046,0.00009234695,0.00014039771,0.000075588374,0.00002533717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003772543,0.00016377748,0.000732887,0.00030085587,0.00002973404,0.0000091985385,0.00006784654,0.00003217181,0.0001072655],"category_scores_gemma":[0.00007579872,0.00010717528,0.000086961845,0.0024041515,0.0001358677,0.00010997271,0.000022872975,0.00014397367,3.8814312e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017696624,0.0006459842,0.86190134,0.000048057704,0.00067657983,0.00015920372,0.003523105,0.00095136836,0.0020427129,0.000057267334,8.920337e-7,0.12822382],"study_design_scores_gemma":[0.0059471563,0.0005368259,0.9821554,0.00011231457,0.00025496935,0.000009277381,0.0015081739,0.0004149738,0.0081387935,0.00028220649,0.0005236774,0.000116223324],"about_ca_topic_score_codex":0.0013724677,"about_ca_topic_score_gemma":0.046389405,"teacher_disagreement_score":0.12810759,"about_ca_system_score_codex":0.00014753564,"about_ca_system_score_gemma":0.00009910086,"threshold_uncertainty_score":0.9710115},"labels":[],"label_agreement":null},{"id":"W3130559363","doi":"10.1007/s12325-021-01621-0","title":"Global Quality Statements on Reliever Use in Asthma in Adults and Children Older than 5 Years of Age","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; College of Family Physicians of Canada; McMaster University; University of Toronto","funders":"Grifols; Novo Nordisk; University of New South Wales; Imperial College London; Imperial College Healthcare NHS Trust; Covis Pharma; Sanofi; Universidade do Minho; University of Toronto; GlaxoSmithKline; Purdue University; AstraZeneca; McMaster University; Pfizer","keywords":"Medicine; Asthma; Exacerbation; Health care; Quality (philosophy); Family medicine; Pandemic; Quality of life (healthcare); Quality management; Intensive care medicine; Disease; Nursing; Coronavirus disease 2019 (COVID-19); Internal medicine; Operations management; Infectious disease (medical specialty)","score_opus":0.01564464155227903,"score_gpt":0.35845565454646217,"score_spread":0.34281101299418315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130559363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926387,0.006881559,0.000003638139,0.000033266115,0.00004416551,0.00021507632,0.00003266907,0.00000630154,0.00014460251],"genre_scores_gemma":[0.9943293,0.0050268644,0.000118583615,0.00044197307,0.000015923697,0.000008224419,0.00002103538,0.000007258117,0.000030853113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991059,0.00010951122,0.00025700458,0.00022049507,0.00016901725,0.0001380763],"domain_scores_gemma":[0.9996631,0.000044743592,0.00005827783,0.00016995813,0.000019129531,0.00004475494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010637669,0.00008695687,0.00021989526,0.000054529806,0.0000065224885,0.0000047603503,0.00004007138,0.000041760202,0.000023493589],"category_scores_gemma":[0.00005039337,0.00007636062,0.000028752873,0.0002271442,0.000058319984,0.00017959514,0.000017511331,0.000075232514,0.0000011929606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009371033,0.0004438379,0.898035,0.000028920356,0.000007604158,0.00014984419,0.00031063778,0.00005088106,0.000057367946,0.00006097567,0.0000072518164,0.09991057],"study_design_scores_gemma":[0.004795603,0.00019290127,0.9928042,0.00046501387,0.0000010655066,0.0000020515874,0.00018876317,0.0000026260952,0.00022116827,0.00020976976,0.0010418056,0.00007502078],"about_ca_topic_score_codex":0.00023873325,"about_ca_topic_score_gemma":0.0014048913,"teacher_disagreement_score":0.09983555,"about_ca_system_score_codex":0.000042617674,"about_ca_system_score_gemma":0.00004192164,"threshold_uncertainty_score":0.3113896},"labels":[],"label_agreement":null},{"id":"W313488173","doi":"10.1007/s12325-015-0207-3","title":"Real-World Determinants of Adjunctive Antipsychotic Prescribing for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants: A Case Review Study","year":2015,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Treatment of Major Depression","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Irritability; Psychiatry; Adjunctive treatment; Antipsychotic; Major depressive disorder; Quetiapine; Mood; Psychomotor agitation; Bipolar disorder; Anxiety; Schizophrenia (object-oriented programming); Internal medicine","score_opus":0.04618772225519249,"score_gpt":0.4056765103500457,"score_spread":0.3594887880948532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W313488173","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11781541,0.86556983,0.000013633223,0.000011988779,0.00012356503,0.016212145,0.00019822737,0.000030721552,0.000024485926],"genre_scores_gemma":[0.009296227,0.9871365,0.0009683797,0.00004148608,0.000029330977,0.0022273485,0.000056916117,0.00014577394,0.00009806274],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9961631,0.0007254191,0.001114971,0.0010408565,0.0005158528,0.00043984797],"domain_scores_gemma":[0.9966038,0.0008964769,0.0009537615,0.0009716824,0.00035398695,0.00022029506],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074130273,0.00074658776,0.003362933,0.0005692042,0.00008157822,0.000016047456,0.00023438735,0.00012682978,0.0000071636837],"category_scores_gemma":[0.00040993854,0.00046803386,0.00017806441,0.00073142716,0.000108451604,0.00036343758,0.0001040648,0.0002710634,0.0000015540472],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010443765,0.0017351289,0.08432296,0.01568837,0.00026739138,0.00065428036,0.00025248682,0.000001092977,2.710824e-7,4.926873e-7,0.00003261424,0.88660115],"study_design_scores_gemma":[0.060222495,0.02219991,0.055534717,0.46318573,0.006142034,0.00060239754,0.00027262044,0.000008530402,0.000014708871,0.00007044058,0.38986513,0.001881273],"about_ca_topic_score_codex":0.000119860044,"about_ca_topic_score_gemma":0.00047450728,"teacher_disagreement_score":0.88471985,"about_ca_system_score_codex":0.00015662295,"about_ca_system_score_gemma":0.00019877334,"threshold_uncertainty_score":0.99977714},"labels":[],"label_agreement":null},{"id":"W3137313628","doi":"10.1007/s12325-021-01648-3","title":"Non-Inferiority of a Single Injection of Sodium Hyaluronate Plus Sorbitol to Hylan G-F20: A 6-Month Randomized Controlled Trial","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; WOMAC; Osteoarthritis; Randomized controlled trial; Viscosupplementation; Clinical endpoint; Clinical trial; Internal medicine; Physical therapy; Anesthesia; Surgery; Intra articular","score_opus":0.011345467674052341,"score_gpt":0.2894799067866917,"score_spread":0.27813443911263935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137313628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848051,0.00652327,0.0005072116,0.000114313705,0.0009401131,0.0042410158,0.000006214398,0.00002345852,0.0028393096],"genre_scores_gemma":[0.99615073,0.0011688592,0.0015400493,0.00011079617,0.00013754984,0.0004605084,0.000015923684,0.000018378267,0.00039718402],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985069,0.00016396672,0.00063793355,0.00024021014,0.0002600014,0.00019097891],"domain_scores_gemma":[0.9990351,0.00025408206,0.00024352112,0.0002385233,0.00016503007,0.00006369659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041679305,0.00017325701,0.0016897311,0.00014065449,0.000024074223,0.0000066420275,0.000055019722,0.00008077247,0.00007182402],"category_scores_gemma":[0.00021122678,0.00013239862,0.00032764714,0.00024099767,0.0000550362,0.00011054345,0.00001678916,0.0000920647,0.0000025566412],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8665142,0.000703331,0.0001202511,0.000029051329,0.00009278902,0.000029801051,0.00071392255,0.00003901114,0.10781025,0.00020520671,0.0000024302751,0.023739753],"study_design_scores_gemma":[0.8150398,0.006495149,0.000015489675,0.00015014362,0.000067163564,0.000011563503,0.00017111869,0.00008869133,0.17681275,0.000765788,0.0002897171,0.000092582246],"about_ca_topic_score_codex":0.000036503883,"about_ca_topic_score_gemma":0.0001823343,"teacher_disagreement_score":0.069002494,"about_ca_system_score_codex":0.00006808134,"about_ca_system_score_gemma":0.00016907303,"threshold_uncertainty_score":0.5399059},"labels":[],"label_agreement":null},{"id":"W3137461700","doi":"10.1007/s12325-021-01642-9","title":"Authors’ Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis","year":2021,"lang":"en","type":"letter","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Rheumatoid arthritis; Meta-analysis; Rheumatology; Internal medicine; Physical therapy","score_opus":0.05917231811826728,"score_gpt":0.3501777814734969,"score_spread":0.2910054633552296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137461700","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017588438,0.25148097,0.006301677,0.71375877,0.0031683813,0.006967784,0.0005286375,0.00009115865,0.000114164744],"genre_scores_gemma":[0.06839664,0.106840044,0.019555759,0.7650346,0.02783055,0.008407101,0.0007929041,0.0004056766,0.0027366912],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.993782,0.0014896012,0.0012508543,0.0011461172,0.0012252408,0.0011062109],"domain_scores_gemma":[0.99418586,0.0032601135,0.0003370534,0.0012949737,0.00062419934,0.0002977761],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00217541,0.0007172788,0.0035917687,0.0008582694,0.00028037577,0.00017005134,0.00063169445,0.00041606455,0.0002664111],"category_scores_gemma":[0.0006824654,0.00049619505,0.0017154311,0.002237173,0.00016138102,0.00024218879,0.00014944804,0.0014432463,0.000042568878],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012175662,0.000103775266,0.000041706095,0.00003493791,0.023202274,0.00009779892,0.003342766,0.017091332,0.00025546784,0.000014680835,0.93896544,0.0046741306],"study_design_scores_gemma":[0.0028075846,0.0009488478,0.000044134726,0.00056554005,0.00043213778,0.000015380658,0.00021885017,0.00007316424,0.000980555,0.00017554247,0.9932184,0.0005198476],"about_ca_topic_score_codex":0.00004847474,"about_ca_topic_score_gemma":0.00035885329,"teacher_disagreement_score":0.14464094,"about_ca_system_score_codex":0.00014300128,"about_ca_system_score_gemma":0.0002381979,"threshold_uncertainty_score":0.99974895},"labels":[],"label_agreement":null},{"id":"W3143513781","doi":"10.1007/s12325-021-01661-6","title":"Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Tolerability; Pharmacokinetics; Cmax; Confidence interval; Randomized controlled trial; Randomization; Adverse effect; Internal medicine; Pharmacology","score_opus":0.025623361726226656,"score_gpt":0.35381250518862584,"score_spread":0.3281891434623992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143513781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8907792,0.10549947,0.00014507862,0.0010607085,0.000632458,0.001271571,0.00006515047,0.000016567396,0.0005298201],"genre_scores_gemma":[0.96189725,0.036226414,0.0010203063,0.0004696277,0.000013107021,0.000067001754,0.0000178782,0.000010723213,0.0002776872],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99675673,0.0015710815,0.00092968997,0.00038140835,0.000044811397,0.0003162648],"domain_scores_gemma":[0.99822056,0.0013632607,0.0001572064,0.00019539525,0.000038189988,0.000025407811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001254631,0.00017968549,0.0013322775,0.000105393505,0.000025534693,0.0000065302524,0.00013444436,0.00017866211,0.0005231208],"category_scores_gemma":[0.00038351447,0.00013138218,0.00009457274,0.00030430083,0.00039053618,0.00007938167,0.000043972508,0.0003239114,9.497095e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96580976,0.0007922917,0.0023313474,0.000060573897,0.00006373927,0.0000071180407,0.00031050786,0.000018638668,0.008459738,0.00011883713,0.000034814395,0.021992652],"study_design_scores_gemma":[0.9514367,0.0012875665,0.00087742053,0.000102666876,0.000016281478,0.000009544309,0.00014026446,0.0002976203,0.018837374,0.0005441659,0.026237622,0.0002127794],"about_ca_topic_score_codex":0.0001274128,"about_ca_topic_score_gemma":0.0005771375,"teacher_disagreement_score":0.07111808,"about_ca_system_score_codex":0.000064588945,"about_ca_system_score_gemma":0.0001051481,"threshold_uncertainty_score":0.5727806},"labels":[],"label_agreement":null},{"id":"W3145132769","doi":"10.1007/s12325-021-01707-9","title":"Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Lubiprostone; Medicine; Placebo; Bioequivalence; Bioavailability; Internal medicine; Crossover study; Gastroenterology; Pharmacokinetics; Constipation; Pharmacology; Chronic constipation","score_opus":0.014422123039740801,"score_gpt":0.2503218450046884,"score_spread":0.2358997219649476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145132769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978863,0.00072123006,0.000670762,0.00029326507,0.000020583166,0.00017739773,0.000009215483,0.0000073326623,0.00021393479],"genre_scores_gemma":[0.99578434,0.0002140226,0.0037216435,0.00020861538,0.0000049228643,0.000009049664,0.00004460321,0.0000030818787,0.000009736237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995507,0.000016282582,0.00013996911,0.00012748511,0.0000885198,0.00007703979],"domain_scores_gemma":[0.9996973,0.000047911493,0.000054433738,0.00007283604,0.000106215135,0.00002124826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047908186,0.0000570193,0.00012763559,0.000042491905,0.000017392998,0.0000020525563,0.000013695933,0.00002435117,0.000042079864],"category_scores_gemma":[0.00010429324,0.00004370188,0.000012755601,0.00013643467,0.00008995519,0.000101151236,0.0000058652536,0.00006760966,4.2836018e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061873253,0.00034886893,0.9921617,0.000017267228,0.000003916401,0.000002712361,0.000048032125,0.00044469535,0.0007346444,0.00035780526,9.966371e-7,0.0052606366],"study_design_scores_gemma":[0.0033712706,0.00041102752,0.99416137,0.000079518155,0.0000025873574,0.000002738018,0.0001255933,0.00006936519,0.0007260517,0.0008941349,0.00011828798,0.000038033202],"about_ca_topic_score_codex":0.000008113123,"about_ca_topic_score_gemma":0.00014223266,"teacher_disagreement_score":0.005222603,"about_ca_system_score_codex":0.000014184404,"about_ca_system_score_gemma":0.000028906488,"threshold_uncertainty_score":0.1782111},"labels":[],"label_agreement":null},{"id":"W3149655449","doi":"10.1007/s12325-021-01718-6","title":"Sensitivity, Specificity and Accuracy of a Novel EEG-Based Objective Test, the Cognalyzer®, in Detecting Cannabis Psychoactive Effects","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Louisiana-Pacific (Canada)","funders":"Ontario Centre of Innovation","keywords":"McNemar's test; Medicine; Cannabis; Inhalation; Electroencephalography; Anesthesia; Internal medicine; Psychiatry","score_opus":0.01565861447248026,"score_gpt":0.3360289790813329,"score_spread":0.32037036460885265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149655449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827322,0.008330558,0.00086949713,0.0064869956,0.00009859379,0.00078906753,0.000017619803,0.000014402496,0.0006610709],"genre_scores_gemma":[0.9966976,0.0017945111,0.00029564384,0.0009374912,0.000044910903,0.000088344284,0.0000030227113,0.000021770149,0.00011668137],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984749,0.00021200109,0.0002618196,0.00039727418,0.00033627806,0.00031774023],"domain_scores_gemma":[0.9983352,0.0009243623,0.00012146421,0.0002934674,0.00025649156,0.00006904072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065892865,0.00017542823,0.00040226022,0.00016326217,0.00006728109,0.000020021096,0.000068150744,0.0000652635,0.000016003107],"category_scores_gemma":[0.0014965178,0.00012782415,0.000081998725,0.000880704,0.00024834927,0.0001455745,0.000040568924,0.00048640196,4.5496927e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022218316,0.0019338311,0.18173935,0.00029986262,0.00008114428,0.0003991469,0.0027686395,0.0004960857,0.49341884,0.00015090528,0.000272202,0.31621817],"study_design_scores_gemma":[0.008086939,0.00073710195,0.58505213,0.0004994864,0.000014687357,0.00010648832,0.0018239291,0.0029872912,0.3940197,0.00037398917,0.0060597546,0.00023849978],"about_ca_topic_score_codex":0.00054363225,"about_ca_topic_score_gemma":0.0028832648,"teacher_disagreement_score":0.4033128,"about_ca_system_score_codex":0.00013304208,"about_ca_system_score_gemma":0.00030081547,"threshold_uncertainty_score":0.5212518},"labels":[],"label_agreement":null},{"id":"W3154210799","doi":"10.1007/s12325-021-01731-9","title":"Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Université de Montréal","funders":"","keywords":"Medicine; Tolerability; Latanoprost; Ocular hypertension; Glaucoma; Post-hoc analysis; Ophthalmology; Internal medicine; Pooled analysis; Odds ratio; Randomized controlled trial; Intraocular pressure; Adverse effect; Confidence interval","score_opus":0.024013876953742578,"score_gpt":0.29905243355993355,"score_spread":0.275038556606191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154210799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8316852,0.16467343,0.00005323085,0.0027766603,0.000079347075,0.00057480263,0.000028804121,0.000009667352,0.0001188568],"genre_scores_gemma":[0.8791894,0.11805607,0.00177613,0.00027795215,0.000049514732,0.00015814655,0.000092908645,0.000020880972,0.00037904712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991502,0.00005473912,0.00020801254,0.00025267282,0.00016535983,0.00016898503],"domain_scores_gemma":[0.9986671,0.0004929323,0.000072902054,0.00052436447,0.00019997645,0.000042675456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007705122,0.00014158637,0.0004080378,0.00006746606,0.00006517876,0.000009484716,0.000110775414,0.00005005941,0.00003815862],"category_scores_gemma":[0.00011868627,0.000081237275,0.00019416331,0.0004735406,0.000118274664,0.00009334567,0.000024614628,0.000046288016,3.2118524e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03500797,0.0026944287,0.79748565,0.00020854216,0.0069051543,0.00020832516,0.0021240602,0.000047192083,0.023050461,0.0011614669,0.00012396011,0.13098279],"study_design_scores_gemma":[0.02841135,0.0058176517,0.86788136,0.00007109404,0.0015863925,0.000014245257,0.00207066,0.002285158,0.011605481,0.0012234896,0.07881887,0.00021424952],"about_ca_topic_score_codex":0.000087904955,"about_ca_topic_score_gemma":0.0006820035,"teacher_disagreement_score":0.13076854,"about_ca_system_score_codex":0.000022324639,"about_ca_system_score_gemma":0.000041295054,"threshold_uncertainty_score":0.331276},"labels":[],"label_agreement":null},{"id":"W3159176128","doi":"10.1007/s12325-021-01732-8","title":"Strategies to Prolong Ketamine’s Efficacy in Adults with Treatment-Resistant Depression","year":2021,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Treatment of Major Depression","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Auto Workers; University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"","keywords":"Medicine; Depression (economics); Ketamine; Rheumatology; Treatment-resistant depression; Internal medicine; Psychiatry; Intensive care medicine; Physical therapy; Major depressive disorder; Mood","score_opus":0.029440755236178173,"score_gpt":0.38051257478142037,"score_spread":0.3510718195452422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159176128","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005661314,0.9892748,0.000010133228,0.00004492051,0.00012396755,0.0036464464,0.000016759472,0.000075558266,0.001146105],"genre_scores_gemma":[0.0018334443,0.99469286,0.0014352244,0.000031260406,0.00010950834,0.0012704936,0.00023455414,0.00010672512,0.0002859209],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973606,0.00022307893,0.0006309071,0.00095210783,0.00037742849,0.00045591677],"domain_scores_gemma":[0.9984723,0.00030942835,0.00025054818,0.0007806902,0.000046154557,0.00014090557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009927078,0.00071270356,0.0022221885,0.0004287756,0.000039261828,0.00003884226,0.00019624303,0.00025193763,0.000053708252],"category_scores_gemma":[0.00003239209,0.00040504316,0.00022749737,0.0007141925,0.00005263174,0.00027494426,0.00003945177,0.00031482975,0.00001639416],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017037892,0.0013821786,0.0010859036,0.00237889,0.00012273643,0.0010957556,0.00035301552,0.000034083318,0.0000067958845,0.000018364564,0.000008875333,0.9918096],"study_design_scores_gemma":[0.009063967,0.0024816846,0.001691463,0.10194438,0.00019319348,0.00008285507,0.00019557853,0.0000014096487,0.000071862465,0.000010730001,0.8838151,0.00044776924],"about_ca_topic_score_codex":0.00006313861,"about_ca_topic_score_gemma":0.0006092129,"teacher_disagreement_score":0.99136186,"about_ca_system_score_codex":0.0004710155,"about_ca_system_score_gemma":0.00042914544,"threshold_uncertainty_score":0.99984014},"labels":[],"label_agreement":null},{"id":"W3160202558","doi":"10.1007/s12325-021-01753-3","title":"Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Gilead Sciences; AbbVie; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Rheumatology; Hepatitis C virus; Clinical trial; Hepatitis C; Virology; Virus","score_opus":0.05627558918075966,"score_gpt":0.41988705088490674,"score_spread":0.3636114617041471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160202558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892648,0.0068983235,0.00007904463,0.00010068846,0.00006216114,0.00096214714,0.00030518856,0.000026827864,0.0023008457],"genre_scores_gemma":[0.7849612,0.21242677,0.0017838409,0.00021456937,0.00006801924,0.000050597944,0.00032407013,0.000037118178,0.00013380041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670595,0.0010021287,0.000982815,0.0005022153,0.0005374188,0.00026944754],"domain_scores_gemma":[0.9974932,0.0013134693,0.0002984966,0.00047680546,0.00024740712,0.0001706272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008610852,0.00021503991,0.0012809688,0.00012402417,0.000040591087,0.00001608078,0.00009091464,0.00008812624,0.00054207083],"category_scores_gemma":[0.00036182682,0.00014255186,0.000077307894,0.000549391,0.00029547026,0.00025723228,0.00003451631,0.00027959244,0.000004257123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004602945,0.00040834566,0.7290033,0.000019707033,0.00019117023,0.000077764715,0.000068556845,0.000002921167,0.00018591875,0.00002176404,0.000030606076,0.26538697],"study_design_scores_gemma":[0.012527273,0.0014896002,0.9590234,0.00040183417,0.000058108133,0.0000012413227,0.000014098249,0.000023253218,0.005052754,0.00010519811,0.021138567,0.000164681],"about_ca_topic_score_codex":0.0037341833,"about_ca_topic_score_gemma":0.01835307,"teacher_disagreement_score":0.26522228,"about_ca_system_score_codex":0.00007414132,"about_ca_system_score_gemma":0.00018696232,"threshold_uncertainty_score":0.9995594},"labels":[],"label_agreement":null},{"id":"W3162743464","doi":"10.1007/s12325-021-01756-0","title":"Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"National Cancer Institute; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Odds ratio; Internal medicine; Hazard ratio; Confidence interval; Salvage therapy; Oncology; Refractory (planetary science); Chemotherapy","score_opus":0.025367968608400935,"score_gpt":0.35202477845148494,"score_spread":0.326656809843084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162743464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9219547,0.072464384,0.00004174261,0.00065604836,0.0001798375,0.0009034442,0.000032842272,0.000055963043,0.003711048],"genre_scores_gemma":[0.89742064,0.09894424,0.00080092397,0.0006119916,0.00010334009,0.00011466893,0.00006932973,0.000092136586,0.0018427145],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99684834,0.0003405278,0.0007643779,0.00067885855,0.00062484754,0.0007430692],"domain_scores_gemma":[0.99847144,0.0002941561,0.00016500933,0.00078898045,0.00011300304,0.000167387],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052899856,0.00042168723,0.0012586727,0.00039579315,0.00007254389,0.00003326583,0.00027404967,0.00022270602,0.0011205068],"category_scores_gemma":[0.000038784765,0.00036899562,0.00028799774,0.0010932891,0.0001471227,0.00030709212,0.000025142723,0.00044897545,0.000017175438],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008911409,0.041892458,0.22275153,0.00018779318,0.00017588015,0.00030364908,0.009410027,0.000024786494,0.18831383,0.000048588903,0.000067098306,0.527913],"study_design_scores_gemma":[0.09929012,0.002066628,0.035357874,0.00020540779,0.000019880901,0.00002051585,0.00089144055,0.00025282378,0.6199778,0.0001343236,0.24141988,0.00036333298],"about_ca_topic_score_codex":0.0001047788,"about_ca_topic_score_gemma":0.0007510213,"teacher_disagreement_score":0.5275496,"about_ca_system_score_codex":0.00052848546,"about_ca_system_score_gemma":0.0003060721,"threshold_uncertainty_score":0.9998762},"labels":[],"label_agreement":null},{"id":"W3164078411","doi":"10.1007/s12325-021-01746-2","title":"Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Pharmaceuticals; Janssen Scientific Affairs","keywords":"Rivaroxaban; Medicine; Polypharmacy; Warfarin; Atrial fibrillation; Internal medicine; Stroke (engine); Hazard ratio; Population; Confidence interval; Environmental health","score_opus":0.023315740702173942,"score_gpt":0.33370449795192714,"score_spread":0.3103887572497532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164078411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954224,0.003545915,0.000116839394,0.00010888218,0.00003514235,0.00071584136,0.0000054184115,0.00000674426,0.000042806045],"genre_scores_gemma":[0.9921986,0.0075031077,0.00013888741,0.000041925592,0.000045967823,0.0000012285974,0.000059242084,0.0000057055718,0.0000053350764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991629,0.00024906034,0.00018239915,0.00017072758,0.00014367668,0.00009125047],"domain_scores_gemma":[0.9992397,0.00049930526,0.00009144078,0.00008781561,0.00005849304,0.000023269064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024402121,0.000106773696,0.00029736094,0.000096936485,0.000048052654,0.000013271201,0.000023955712,0.000025493351,0.0000058955557],"category_scores_gemma":[0.000026641244,0.00006983891,0.000022688857,0.00033690676,0.00012573895,0.00022335626,0.00002399927,0.00006795604,1.0514593e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024654493,0.000010068778,0.9888902,0.000055293895,0.000049720737,0.0000032507644,0.0014392012,0.0014934149,0.000053255408,0.00013208609,3.7110794e-7,0.005407692],"study_design_scores_gemma":[0.008313725,0.0002113367,0.98798037,0.00008698727,0.00002609279,0.0000011674991,0.00036344252,0.00081357436,0.00044123415,0.0002803743,0.0014021004,0.00007959881],"about_ca_topic_score_codex":0.00013317952,"about_ca_topic_score_gemma":0.00007927477,"teacher_disagreement_score":0.005848276,"about_ca_system_score_codex":0.000016199916,"about_ca_system_score_gemma":0.000011402633,"threshold_uncertainty_score":0.28479484},"labels":[],"label_agreement":null},{"id":"W3171967615","doi":"10.1007/s12325-021-01790-y","title":"Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Windsor; Queen's University","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Spirometry; Interstitial lung disease; Idiopathic pulmonary fibrosis; Vital capacity; Quartile; Internal medicine; Physical therapy; Lung; Diffusing capacity; Asthma; Lung function; Confidence interval","score_opus":0.003816640828764195,"score_gpt":0.25071091482226937,"score_spread":0.24689427399350516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171967615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827429,0.0144564025,0.000010437894,0.0010031249,0.00028228923,0.0013273314,0.00007815644,0.00003247727,0.00006687455],"genre_scores_gemma":[0.9977772,0.0010991866,0.0000097705715,0.00036125924,0.00020141642,0.00026827186,0.00007627843,0.000038556507,0.00016803156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982668,0.00020551769,0.0003135038,0.00042702217,0.000443927,0.00034318407],"domain_scores_gemma":[0.99890196,0.00013168785,0.00007312613,0.00054944557,0.00014148086,0.00020229978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010126416,0.00024772648,0.00026505915,0.00007049251,0.00017463992,0.00005643484,0.00021279811,0.000026342208,0.0003327872],"category_scores_gemma":[0.00019071609,0.00013631138,0.00010539275,0.00035949083,0.00017166729,0.00025707897,0.00007596453,0.00032483545,0.000004060222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016463123,0.0020818433,0.9782191,0.000055946384,0.00004506845,0.0012753212,0.0008938502,0.0002213245,0.000013952808,0.000035037778,0.000015767086,0.0006796569],"study_design_scores_gemma":[0.004822901,0.00095655443,0.9910353,0.00038474353,0.00010218811,0.000004524811,0.0019330624,0.00014798355,0.0000072570588,0.00003489072,0.00037813204,0.00019248176],"about_ca_topic_score_codex":0.000055054592,"about_ca_topic_score_gemma":0.00026536148,"teacher_disagreement_score":0.015034323,"about_ca_system_score_codex":0.00021419997,"about_ca_system_score_gemma":0.00022603174,"threshold_uncertainty_score":0.5558617},"labels":[],"label_agreement":null},{"id":"W3173241664","doi":"10.1007/s12325-021-01818-3","title":"Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bell (Canada); Western University; Merck Canada Inc. (Canada); McGill University Health Centre; Montreal General Hospital; Dalhousie University","funders":"Janssen Canada","keywords":"Golimumab; Medicine; Adalimumab; Propensity score matching; Concomitant; Ulcerative colitis; Internal medicine; Infliximab; Retrospective cohort study; Vedolizumab; Tumor necrosis factor alpha","score_opus":0.02185147195618798,"score_gpt":0.3073743124811265,"score_spread":0.28552284052493854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173241664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882889,0.009521153,0.0007429472,0.00018446054,0.00009966369,0.00088592817,0.00018566502,0.000007262537,0.00008406262],"genre_scores_gemma":[0.97671497,0.022033006,0.00040903874,0.00028876748,0.000069892616,0.0001805528,0.00013573273,0.000016678287,0.00015134092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879354,0.00016579554,0.0002934194,0.00039256748,0.00011602738,0.00023863981],"domain_scores_gemma":[0.99904376,0.000038183945,0.00019261314,0.00047521605,0.00019404289,0.000056180186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013520764,0.00017098805,0.00038810665,0.000036975645,0.00011224558,0.000018256142,0.00013034783,0.00005970008,0.000020446287],"category_scores_gemma":[0.000023536557,0.00012441905,0.00022925122,0.00023056578,0.00012963271,0.0000088988145,0.000017807411,0.000037420014,7.063369e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010677202,0.0018504817,0.931004,0.00011813092,0.0027586243,0.00030260737,0.0022490483,0.0029850404,0.01626599,0.000800238,0.00008869515,0.030899942],"study_design_scores_gemma":[0.0029426867,0.0018771493,0.9221879,0.000022135267,0.00011075788,0.000018222721,0.0003582484,0.00016792353,0.05850927,0.00048215903,0.013058192,0.0002653288],"about_ca_topic_score_codex":0.00003284273,"about_ca_topic_score_gemma":0.0038093952,"teacher_disagreement_score":0.042243283,"about_ca_system_score_codex":0.000091657064,"about_ca_system_score_gemma":0.00026814666,"threshold_uncertainty_score":0.5073662},"labels":[],"label_agreement":null},{"id":"W3180183107","doi":"10.1007/s12325-021-01846-z","title":"Effectiveness of Radiofrequency Catheter Ablation Using Ablation Index Versus Second Generation Cryoballoon in the Treatment of Persistent Atrial Fibrillation: A Matching-Adjusted Indirect Comparison","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Biosense Webster","keywords":"Medicine; Atrial fibrillation; Ablation; Catheter ablation; Internal medicine; Radiofrequency ablation; Cardiology; Radiofrequency catheter ablation","score_opus":0.09545926004276585,"score_gpt":0.3690812414886553,"score_spread":0.27362198144588945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180183107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98286664,0.015005989,0.00062518066,0.00005807663,0.00042622696,0.0008176235,0.0000037550903,0.000009131909,0.00018734188],"genre_scores_gemma":[0.9962323,0.0027307395,0.00054487225,0.000006281705,0.0003468638,0.0000034855286,0.00011086205,0.000010732091,0.0000139144995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855095,0.00039798892,0.00047473455,0.0002034102,0.00026010198,0.00011284155],"domain_scores_gemma":[0.99909484,0.00034337235,0.00026925572,0.00019013156,0.00008732161,0.000015084241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036093273,0.00013634609,0.0004256702,0.00017734537,0.000041882795,0.000012495913,0.000040813793,0.00007473524,0.00004709647],"category_scores_gemma":[0.000031098665,0.0001046655,0.0002621041,0.00046091055,0.00003319863,0.00025040912,0.00000534099,0.000049758237,4.5034056e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036316616,0.00008333359,0.56543744,0.00014812314,0.00025376605,0.0000049293844,0.0048953705,0.363666,0.018116437,0.00024008115,5.299655e-7,0.043522317],"study_design_scores_gemma":[0.03619827,0.0037284298,0.817304,0.00038482394,0.00038692437,0.00001334078,0.0020554445,0.09655693,0.03846751,0.0006844074,0.0037956585,0.00042421548],"about_ca_topic_score_codex":0.00007730897,"about_ca_topic_score_gemma":0.00016932384,"teacher_disagreement_score":0.26710907,"about_ca_system_score_codex":0.0002461981,"about_ca_system_score_gemma":0.000059807455,"threshold_uncertainty_score":0.4268135},"labels":[],"label_agreement":null},{"id":"W3184516018","doi":"10.1007/s12325-021-01823-6","title":"Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Medicine; Prostate cancer; Internal medicine; Chemotherapy; Oncology; Cancer; Overall survival; Enzalutamide; Hormonal therapy","score_opus":0.02342395738069975,"score_gpt":0.34929700075028364,"score_spread":0.3258730433695839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184516018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455845,0.003213551,0.000001779004,0.0007267992,0.00005766577,0.0011465095,0.000119975666,0.000005101698,0.00017019441],"genre_scores_gemma":[0.97718793,0.021906862,0.00017820773,0.00009967201,0.000021162936,0.000301655,0.000053426986,0.000014450027,0.00023663245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988808,0.00010668744,0.00023725073,0.00024727941,0.0003058141,0.00022214235],"domain_scores_gemma":[0.9995036,0.0001019454,0.000065730186,0.00018242549,0.0000906963,0.000055610206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109170156,0.0001470672,0.00028385627,0.000099689234,0.000033957844,0.000016305208,0.00004450164,0.0000139892445,0.00003741638],"category_scores_gemma":[0.0000068798226,0.000078109755,0.000026553618,0.00033422254,0.000053946893,0.00012179463,0.000010673806,0.000075107026,3.4113668e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00291623,0.00054982794,0.94830275,0.00006686026,0.000072463394,0.00011014399,0.0030646895,0.0001525423,0.00053645443,0.000038492435,0.0000031520226,0.04418643],"study_design_scores_gemma":[0.008198571,0.0014392509,0.9808675,0.00023290368,0.0000226366,9.4591e-7,0.0005362435,0.0000069645093,0.0067826626,0.00007935793,0.0017355715,0.00009738666],"about_ca_topic_score_codex":0.0018898793,"about_ca_topic_score_gemma":0.0373998,"teacher_disagreement_score":0.04408904,"about_ca_system_score_codex":0.00019683327,"about_ca_system_score_gemma":0.00020383144,"threshold_uncertainty_score":0.9801651},"labels":[],"label_agreement":null},{"id":"W3184889104","doi":"10.1007/s12325-021-01825-4","title":"Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Apellis Pharmaceuticals","keywords":"Eculizumab; Medicine; Paroxysmal nocturnal hemoglobinuria; Discontinuation; Cohort; Population; Internal medicine; Pediatrics; Retrospective cohort study; Immunology","score_opus":0.015182163423706355,"score_gpt":0.2951789799775904,"score_spread":0.27999681655388403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184889104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838396,0.015323953,0.000016758624,0.00009132347,0.0001399014,0.00035447264,0.00003844245,0.000016471242,0.00017907667],"genre_scores_gemma":[0.9977189,0.0016077029,0.00012248543,0.00006661644,0.000010278851,0.000023311231,0.00040302085,0.000012628552,0.00003510118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870205,0.0003951187,0.0003773761,0.00026561043,0.00006133259,0.00019853885],"domain_scores_gemma":[0.9993956,0.000117924785,0.00020738902,0.00018542337,0.0000773435,0.000016335862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012409719,0.00012710842,0.0002555409,0.0001290915,0.000055800345,0.0000077932455,0.00007924499,0.00005801096,0.00008465293],"category_scores_gemma":[0.000034182278,0.00011361446,0.000021054282,0.0003269335,0.000071315684,0.00017552475,0.000029393459,0.00010749252,9.718535e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086395774,0.00012340763,0.9576825,0.000046844856,0.00001608302,0.0000028963113,0.00031641635,0.00015156541,0.00036028048,0.0004056455,0.000012840966,0.040017575],"study_design_scores_gemma":[0.0034212584,0.00016723826,0.99130946,0.00039154053,0.0000042899637,0.0000038115368,0.00028298833,0.000011138089,0.0013536338,0.0002399641,0.0026912286,0.00012346618],"about_ca_topic_score_codex":0.00085597136,"about_ca_topic_score_gemma":0.012941696,"teacher_disagreement_score":0.039894108,"about_ca_system_score_codex":0.00014541026,"about_ca_system_score_gemma":0.00004129153,"threshold_uncertainty_score":0.722177},"labels":[],"label_agreement":null},{"id":"W3187202922","doi":"10.1007/s12325-021-01855-y","title":"Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Lunds Universitet; GlaxoSmithKline","keywords":"Medicine; COPD; Internal medicine; Rheumatology; Family medicine; Intensive care medicine; Physical therapy","score_opus":0.024221451868375328,"score_gpt":0.34524699674950515,"score_spread":0.32102554488112983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187202922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538858,0.04468807,0.000023305081,0.00017491383,0.000060334176,0.00079708867,0.000032610762,0.0000033486613,0.00033455522],"genre_scores_gemma":[0.97509545,0.02470739,0.00006372106,0.000026827036,0.000024472303,0.000032387386,0.000011777335,0.000009894029,0.000028060556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987268,0.00014086583,0.0003463535,0.0002851525,0.00032095407,0.00017989993],"domain_scores_gemma":[0.99915147,0.0002758172,0.00012244754,0.00031659953,0.000077894154,0.00005580017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020649916,0.000121104524,0.0005118207,0.0001943829,0.000022228842,0.0000055296837,0.0000883057,0.000035841156,0.00007848102],"category_scores_gemma":[0.000068077235,0.000076466706,0.000078072546,0.00090717914,0.00028309145,0.00010789098,0.00005140085,0.00017838058,9.6689526e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13638817,0.0009914165,0.63080806,0.0003270683,0.0006945977,0.000032242624,0.001376995,0.0002574607,0.0015723447,0.00028449277,0.0000092442715,0.22725792],"study_design_scores_gemma":[0.06518767,0.00039866008,0.92790586,0.00033115206,0.00018282246,0.000007357032,0.00051455054,0.00045885562,0.0020313952,0.00017509013,0.0027021938,0.000104399514],"about_ca_topic_score_codex":0.000027494061,"about_ca_topic_score_gemma":0.00025807467,"teacher_disagreement_score":0.2970978,"about_ca_system_score_codex":0.00006819954,"about_ca_system_score_gemma":0.00014154124,"threshold_uncertainty_score":0.31182218},"labels":[],"label_agreement":null},{"id":"W3187334250","doi":"10.1007/s12325-021-01862-z","title":"Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug–Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Treatment of Major Depression","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Drug; Depression (economics); Adverse effect; Intensive care medicine; Rheumatology; Internal medicine; Psychiatry","score_opus":0.01014274449460175,"score_gpt":0.30348813988688,"score_spread":0.2933453953922783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187334250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593145,0.0022662967,0.0003039661,0.000059624395,0.00007851651,0.0011165203,0.00014485673,0.000034015065,0.00006477211],"genre_scores_gemma":[0.9942062,0.0020448572,0.0023710947,0.000017726063,0.0000152365365,0.00026681556,0.00032711044,0.00002744848,0.00072355015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886537,0.00010131407,0.00027256974,0.0003315917,0.00026148726,0.00016767102],"domain_scores_gemma":[0.9989843,0.0002557241,0.00031836034,0.00018883804,0.00020034428,0.00005245846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006359806,0.00018742018,0.00025719454,0.000089942674,0.00013259015,0.0000060855004,0.000040367315,0.000025911053,0.000035019588],"category_scores_gemma":[0.00004700852,0.00012425485,0.000050522274,0.0001388891,0.000094099276,0.0004912618,0.000012347273,0.00007168986,2.0513914e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004494865,0.0015026581,0.9770445,0.00009972835,0.0002655147,0.0000142026165,0.0012981223,0.00041937412,0.0046536857,0.0000083700525,0.000005234462,0.010193717],"study_design_scores_gemma":[0.014248698,0.0007982849,0.9664562,0.0017477574,0.00019597601,0.000004204061,0.00053281896,0.00014773333,0.015507487,0.00015902326,0.00007017979,0.00013166388],"about_ca_topic_score_codex":0.000034030607,"about_ca_topic_score_gemma":0.00028829149,"teacher_disagreement_score":0.010853801,"about_ca_system_score_codex":0.0001466755,"about_ca_system_score_gemma":0.0000537279,"threshold_uncertainty_score":0.5066965},"labels":[],"label_agreement":null},{"id":"W3192547636","doi":"10.1007/bf02849868","title":"Rotavirus gastroenteritis","year":2005,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Viral gastroenteritis research and epidemiology","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Merck Canada","keywords":"Medicine; Rotavirus; Vomiting; Diarrhea; Serotype; Rotavirus vaccine; Vaccination; Rotavirus gastroenteritis; Feces; Pediatrics; Virology; Internal medicine; Microbiology; Biology","score_opus":0.08661154738774483,"score_gpt":0.4706059393184704,"score_spread":0.38399439193072554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192547636","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017959419,0.9969313,0.0000507176,0.00013841214,0.00020514468,0.0008886584,0.000040458322,0.00004504381,0.0016822882],"genre_scores_gemma":[0.000016320198,0.99622005,0.001609888,0.00051873864,0.0006093446,0.0003451896,0.00013530064,0.00006413927,0.00048103146],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975496,0.00029660313,0.0007266252,0.00048057706,0.00020447765,0.0007421515],"domain_scores_gemma":[0.999149,0.000041502768,0.00016956616,0.00041689147,0.000029347533,0.00019364449],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027304777,0.00038053922,0.002177415,0.00027721803,0.000030397672,0.000012105946,0.00025892621,0.00018975796,0.0004456049],"category_scores_gemma":[0.00009053323,0.0002898894,0.00047179344,0.00021986463,0.00016703457,0.00017182587,0.000052962576,0.00072754634,0.00016117534],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014057942,0.00010617183,0.00032589975,0.001683358,0.00004339921,0.00020096061,0.0000039319066,5.362943e-7,6.4373495e-7,0.000013001691,0.00036039136,0.99712116],"study_design_scores_gemma":[0.0010328479,0.0008670592,0.0000555161,0.007839723,0.000023420382,0.00063610333,0.000003061743,0.0000015319397,1.763672e-7,0.00004589743,0.9893614,0.00013326439],"about_ca_topic_score_codex":0.00001162139,"about_ca_topic_score_gemma":0.000042280182,"teacher_disagreement_score":0.9969879,"about_ca_system_score_codex":0.00020638805,"about_ca_system_score_gemma":0.00009447645,"threshold_uncertainty_score":0.9999553},"labels":[],"label_agreement":null},{"id":"W3198178766","doi":"10.1007/s12325-021-01897-2","title":"Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Migraine; Quality of life (healthcare); Pediatrics; Internal medicine; Physical therapy","score_opus":0.0662035492485772,"score_gpt":0.3728287766856725,"score_spread":0.3066252274370953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198178766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9366462,0.05988471,0.00015019123,0.0017769382,0.000055110013,0.00033702338,0.000015163913,0.000016797341,0.0011178569],"genre_scores_gemma":[0.95729643,0.038567893,0.0018487889,0.0017780964,0.000036275873,0.000023145325,0.000015718257,0.000013923506,0.00041974385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982998,0.0001697785,0.00069436635,0.00027588615,0.0002477519,0.00031246126],"domain_scores_gemma":[0.9992043,0.00019377374,0.00013623046,0.00025912345,0.000118192926,0.00008838993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057311764,0.00013581145,0.0006091312,0.0001652344,0.000037522645,0.00000435401,0.00006385509,0.00002639047,0.00004358155],"category_scores_gemma":[0.0002594224,0.00012119776,0.00007311711,0.00049028016,0.000052083065,0.000096851276,0.000036260375,0.00015329996,0.000002584275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047599437,0.0004049642,0.8845056,0.00030927238,0.00003141136,0.00000423424,0.030914849,0.00003475284,0.00043842086,0.00012596231,0.00087125855,0.08188326],"study_design_scores_gemma":[0.0025627282,0.00032983028,0.8941218,0.00043951307,5.797565e-7,3.003058e-7,0.008124578,0.000003307273,0.0005790885,0.00061466836,0.09309552,0.00012803647],"about_ca_topic_score_codex":0.0004560071,"about_ca_topic_score_gemma":0.0031512952,"teacher_disagreement_score":0.092224255,"about_ca_system_score_codex":0.00009336408,"about_ca_system_score_gemma":0.0001414242,"threshold_uncertainty_score":0.49423012},"labels":[],"label_agreement":null},{"id":"W3200209831","doi":"10.1007/s12325-021-01878-5","title":"Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Propeller Health; Pearl Therapeutics; Allergan; Forest Laboratories; Esperion Therapeutics; AstraZeneca; Galderma; Novo Nordisk; Eisai; Brigham and Women's Hospital; Kiniksa Pharmaceuticals; Sunovion; Pfizer","keywords":"Medicine; COPD; Placebo; Internal medicine; Formoterol; Exacerbation; Maintenance therapy; Randomized controlled trial; Mace; Asthma; Conventional PCI; Myocardial infarction; Chemotherapy; Budesonide","score_opus":0.02147761966077214,"score_gpt":0.3626173923779226,"score_spread":0.34113977271715046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200209831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94904834,0.04644417,0.0005521122,0.00092981313,0.0002988235,0.0020777627,0.000073702045,0.000027888545,0.000547377],"genre_scores_gemma":[0.95866257,0.03827354,0.0016514752,0.000700322,0.00022621496,0.0001373258,0.00016490658,0.00004617672,0.00013747031],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963797,0.00077419117,0.001057898,0.0006023536,0.00075558684,0.00043027528],"domain_scores_gemma":[0.9961015,0.0019898287,0.00030826565,0.0008248295,0.0005754969,0.00020010448],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014216783,0.00028141166,0.0019661866,0.00078062905,0.00004056809,0.000013063166,0.0002942525,0.00009880125,0.0009468029],"category_scores_gemma":[0.0013638965,0.00022895978,0.0008846834,0.0026320182,0.00022951509,0.00020337536,0.00008381419,0.00025306435,0.0000056392505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77034396,0.0011887474,0.004073653,0.00007769234,0.0015252819,0.00004995469,0.00031563276,0.0005959033,0.028612798,0.00008844167,0.0000124948365,0.19311544],"study_design_scores_gemma":[0.9421406,0.00091957505,0.010237905,0.00021220237,0.0005009802,0.0000041652897,0.0006938545,0.0013329155,0.039740026,0.00022742237,0.0037011667,0.0002892273],"about_ca_topic_score_codex":0.00008013411,"about_ca_topic_score_gemma":0.000043722855,"teacher_disagreement_score":0.19282621,"about_ca_system_score_codex":0.00016131617,"about_ca_system_score_gemma":0.00045044973,"threshold_uncertainty_score":0.99996644},"labels":[],"label_agreement":null},{"id":"W3208029444","doi":"10.1007/s12325-021-01898-1","title":"Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Actelion Pharmaceuticals; Seoul St. Mary's Hospital, Catholic University of Korea; Universitaire Ziekenhuizen Leuven, KU Leuven; Guangdong Provincial People's Hospital; Universität Wien; Peking Union Medical College; Karl-Franzens-Universität Graz; University of Ottawa; Medizinische Universität Graz; Peking Union Medical College Hospital; Changi General Hospital; Royal Adelaide Hospital; Samsung; Aarhus Universitetshospital; Shanghai Pulmonary Hospital; Centre Hospitalier Universitaire de Toulouse; Universität Greifswald; Seoul National University Hospital; Renji Hospital; Seoul National University; Catholic University of Korea; Aarhus Universitet; Jewish General Hospital; Medizinische Universität Wien; University of Alberta; Rigshospitalet","keywords":"Tolerability; Medicine; Discontinuation; Internal medicine; Clinical endpoint; Adverse effect; Placebo; Pulmonary hypertension; Clinical trial; Pathology","score_opus":0.035486699790773686,"score_gpt":0.3073673866782115,"score_spread":0.27188068688743783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208029444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857843,0.012269436,0.0000035971384,0.00060828176,0.000106483785,0.0009452873,0.00009643662,0.000017844752,0.00016836463],"genre_scores_gemma":[0.9816054,0.016836299,0.00058239384,0.0003644809,0.000037421683,0.000027716434,0.00044082003,0.00002690566,0.00007854815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997846,0.00019724335,0.00037020625,0.00084496214,0.00040199776,0.00033960774],"domain_scores_gemma":[0.998799,0.0002233223,0.00008808779,0.0004366255,0.0002502753,0.0002026612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020105469,0.00026582665,0.00064326683,0.00007727427,0.000098961566,0.00003828191,0.00009667387,0.00009011765,0.000030959687],"category_scores_gemma":[0.00007925142,0.00017092211,0.000013791164,0.00031616152,0.0001234564,0.0005735983,0.000118913274,0.00023153136,0.0000022276195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08939899,0.0040526474,0.8207352,0.000033555934,0.00007058476,0.0055313264,0.00007306393,0.0000046481246,0.0026359635,0.0000039013225,0.0000050668464,0.07745505],"study_design_scores_gemma":[0.03931316,0.0017368513,0.95692354,0.0004890923,0.000016479458,0.00012485537,0.000048700393,0.0001451781,0.0005765809,0.00009123876,0.0003273571,0.0002069673],"about_ca_topic_score_codex":0.00012569797,"about_ca_topic_score_gemma":0.00040211325,"teacher_disagreement_score":0.13618833,"about_ca_system_score_codex":0.000060996543,"about_ca_system_score_gemma":0.000111353605,"threshold_uncertainty_score":0.69700015},"labels":[],"label_agreement":null},{"id":"W3209198105","doi":"10.1007/s12325-021-01934-0","title":"Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Novartis Pharma","keywords":"Medicine; Immune thrombocytopenia; Rheumatology; Quality of life (healthcare); Index (typography); Internal medicine; Health related quality of life; Immunology; Intensive care medicine; Physical therapy; Platelet; Disease; Nursing","score_opus":0.05389147020717946,"score_gpt":0.3971491396144844,"score_spread":0.34325766940730496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209198105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97846824,0.020297423,0.000031185296,0.000023460523,0.00006730082,0.00043079132,0.0000517963,0.0000036967508,0.0006261219],"genre_scores_gemma":[0.9964476,0.0031766132,0.00014941227,0.000050681596,0.0000026744324,0.00001883445,0.00014286696,0.000007016031,0.0000042707566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984562,0.0002558209,0.0004207043,0.00020096338,0.0005358609,0.00013047128],"domain_scores_gemma":[0.99900407,0.00008255068,0.00020976887,0.00024914258,0.00042370908,0.00003077385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069129746,0.00010785006,0.0005460482,0.000111233036,0.0000094649395,0.000002734803,0.00006388832,0.00005069932,0.000083813145],"category_scores_gemma":[0.00028097187,0.00008192,0.00003328387,0.0016111088,0.000049421087,0.00014764295,0.000011241769,0.00006588971,9.160113e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016105552,0.0015996407,0.89030814,0.000023633665,0.00006924682,0.0000021579604,0.00008709098,0.00012347591,0.000041297004,0.000012776804,0.0000011099584,0.10612086],"study_design_scores_gemma":[0.016513938,0.00038123046,0.9819231,0.00007443692,0.000013698584,7.395187e-7,0.00007099138,0.00004509253,0.0004215785,0.00045315543,0.000030503246,0.00007150395],"about_ca_topic_score_codex":0.0010518901,"about_ca_topic_score_gemma":0.003601283,"teacher_disagreement_score":0.10604936,"about_ca_system_score_codex":0.00009783195,"about_ca_system_score_gemma":0.00021424219,"threshold_uncertainty_score":0.33406007},"labels":[],"label_agreement":null},{"id":"W3209696856","doi":"10.1007/s12325-021-01938-w","title":"Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"SMA*; Spinal muscular atrophy; Medicine; Discontinuation; Neuromuscular disease; Retrospective cohort study; Weakness; Regimen; Internal medicine; Pediatrics; Physical therapy; Surgery; Disease","score_opus":0.029409359234226495,"score_gpt":0.36863691277718974,"score_spread":0.33922755354296324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209696856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800117,0.012609064,0.0053770076,0.0012040568,0.000042166386,0.0005925581,0.000069878944,0.000011185252,0.00008237517],"genre_scores_gemma":[0.9615861,0.03290954,0.0022307779,0.0019209731,0.000059711925,0.00015432174,0.0010690335,0.000023374356,0.000046173365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985694,0.00015688702,0.00021627371,0.00041119196,0.00035987163,0.00028634517],"domain_scores_gemma":[0.99916625,0.00013515087,0.000037654845,0.00048695694,0.00012677026,0.00004724093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026932042,0.00013913466,0.00032138207,0.00032813216,0.00005548552,0.000023863651,0.00016616823,0.00004500093,0.0001030634],"category_scores_gemma":[0.00009359391,0.00009956141,0.00018759158,0.002385135,0.000096287935,0.000092383685,0.000027424461,0.00024115945,0.0000027074882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00712886,0.0024828776,0.8927208,0.00019089301,0.0024780547,0.0019414535,0.0081159,0.0048439456,0.023631336,0.0019242908,0.00038729506,0.054154288],"study_design_scores_gemma":[0.022422483,0.0020801662,0.72251827,0.00025800077,0.0006590876,0.000028859275,0.014719745,0.012393078,0.007304209,0.012516923,0.20438945,0.0007097213],"about_ca_topic_score_codex":0.0003575711,"about_ca_topic_score_gemma":0.0006105458,"teacher_disagreement_score":0.20400216,"about_ca_system_score_codex":0.000062267514,"about_ca_system_score_gemma":0.00007166777,"threshold_uncertainty_score":0.40599966},"labels":[],"label_agreement":null},{"id":"W3210334482","doi":"10.1007/s12325-021-01957-7","title":"Economic Evaluation of Budesonide Orodispersible Tablets for the Treatment of Eosinophilic Esophagitis: A Cost–Utility Analysis","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Eosinophilic Esophagitis","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; London Health Sciences Centre; Western University; University of British Columbia; University of Calgary; McGill University; BC Children's Hospital; HEC Montréal","funders":"","keywords":"Medicine; Eosinophilic esophagitis; Budesonide; Internal medicine; Dermatology; Rheumatology; Gastroenterology; Asthma; Physical therapy; Intensive care medicine; Disease","score_opus":0.046110964182576264,"score_gpt":0.37735550063562195,"score_spread":0.3312445364530457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210334482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81910366,0.177779,0.0003325936,0.00050465926,0.00015927553,0.0014577277,0.000117100804,0.000011768349,0.0005342339],"genre_scores_gemma":[0.9581798,0.040312223,0.00082939403,0.00008409791,0.000070975155,0.0003520438,0.00007642383,0.000016257227,0.00007882669],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99848396,0.00013044679,0.0005074682,0.00036272666,0.00029912664,0.00021627947],"domain_scores_gemma":[0.9981841,0.00052700297,0.0002273028,0.0006791534,0.0003364327,0.000046000354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005862661,0.0001678026,0.0006311437,0.00016312247,0.000047112324,0.00000756497,0.00011317794,0.00006438123,0.0005061936],"category_scores_gemma":[0.00009311452,0.00012479982,0.00031367652,0.0005589237,0.00016719163,0.00015513605,0.000009860653,0.00004991093,0.0000021006203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008418757,0.0014675172,0.24065797,0.00008012228,0.0018079936,0.000008577054,0.001373568,0.010692689,0.0036156082,0.0005191873,0.000016422362,0.7389185],"study_design_scores_gemma":[0.02569101,0.0029518327,0.55819035,0.00017983011,0.004850181,0.00003409036,0.001261003,0.058309384,0.32391492,0.0069230404,0.017272921,0.00042148074],"about_ca_topic_score_codex":0.00017594076,"about_ca_topic_score_gemma":0.0014022707,"teacher_disagreement_score":0.738497,"about_ca_system_score_codex":0.00036879748,"about_ca_system_score_gemma":0.00034321038,"threshold_uncertainty_score":0.5542465},"labels":[],"label_agreement":null},{"id":"W3213116899","doi":"10.1007/s12325-021-01944-y","title":"A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar","year":2021,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nexus Clinical Research (Canada); Memorial University of Newfoundland","funders":"Amgen","keywords":"Infliximab; Medicine; Biosimilar; Rheumatoid arthritis; Pharmacology; Internal medicine; Monoclonal antibody; Tumor necrosis factor alpha; Immunology; Antibody","score_opus":0.29922630501509223,"score_gpt":0.4893622988553286,"score_spread":0.19013599384023638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213116899","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025273059,0.99794084,0.00017303323,0.00015769775,0.00023398426,0.0013895578,0.000048903632,0.0000029817327,0.000027742806],"genre_scores_gemma":[0.000026951686,0.9961267,0.0033863485,0.00027385398,0.000012352375,0.00011006448,0.000009181025,0.0000119701035,0.00004259464],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975705,0.00082305714,0.0010442606,0.00031908118,0.000060711656,0.00018238157],"domain_scores_gemma":[0.9967089,0.0017812444,0.00076749845,0.0005894878,0.00014146202,0.000011391276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018691905,0.00025171772,0.0016239175,0.000039471473,0.00004793565,0.0000030322499,0.0005775704,0.0002554163,0.000044479948],"category_scores_gemma":[0.00051357306,0.00010671003,0.0003597987,0.0003462653,0.0006414801,0.00007354793,0.00012925877,0.00027107578,1.7319667e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000396736,0.0000955978,0.00003525594,0.03013265,0.00021221398,9.7294944e-8,0.000077197656,8.9215725e-8,0.0000967455,0.00036337442,0.00003540918,0.9689117],"study_design_scores_gemma":[0.0002704224,0.00014219413,0.000040952455,0.056520198,0.0002229581,0.000008726101,0.000036094265,3.828095e-7,0.0024788422,0.000121985264,0.94002366,0.00013356804],"about_ca_topic_score_codex":0.0000039922043,"about_ca_topic_score_gemma":0.000014919157,"teacher_disagreement_score":0.96877813,"about_ca_system_score_codex":0.000020882324,"about_ca_system_score_gemma":0.00026629394,"threshold_uncertainty_score":0.43515086},"labels":[],"label_agreement":null},{"id":"W3213710096","doi":"10.1007/s12325-021-01958-6","title":"Concomitant Treatment of Hypertensive Patients with Bisoprolol and Perindopril in Routine Clinical Practice: A Post Hoc Analysis of the CONFIDENCE II, PROTECT I, and PROTECT III Observational Studies","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Trillium Health Centre","funders":"Servier","keywords":"Medicine; Perindopril; Bisoprolol; Concomitant; Observational study; Post-hoc analysis; Internal medicine; Rheumatology; Confidence interval; Intensive care medicine; Cardiology; Blood pressure","score_opus":0.07411408436144089,"score_gpt":0.3839858495488002,"score_spread":0.3098717651873593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213710096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88954854,0.10690539,0.0000023446883,0.0025566544,0.000027884089,0.0009184367,0.000014341748,0.0000035090743,0.000022924598],"genre_scores_gemma":[0.960504,0.03739948,0.00092491176,0.0010211511,0.000013125697,0.00010610475,0.0000043591335,0.0000060495377,0.000020821664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876535,0.00015919666,0.00045665228,0.00027431178,0.0002376762,0.00010682003],"domain_scores_gemma":[0.9977814,0.00079492567,0.00027729568,0.00021252559,0.0009103488,0.00002352656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022980828,0.00013706717,0.0009792071,0.000076060984,0.000060537684,0.0000033425529,0.000035175886,0.000045813398,0.0000041470544],"category_scores_gemma":[0.0005536167,0.000071241055,0.000066055654,0.00046759236,0.00035417892,0.00011740808,0.000051364557,0.00010496381,2.7439402e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069930195,0.0011475324,0.95871556,0.000051534545,0.0036399798,0.000047370166,0.003922913,0.000019824092,0.0005987236,0.00008608184,0.000003584703,0.024773857],"study_design_scores_gemma":[0.011519051,0.0057715243,0.9722547,0.00025445354,0.001268183,0.000023922332,0.0037783782,0.00006382802,0.0018573806,0.0000743408,0.0030220535,0.000112188914],"about_ca_topic_score_codex":0.00005159476,"about_ca_topic_score_gemma":0.00036312806,"teacher_disagreement_score":0.070955485,"about_ca_system_score_codex":0.0000127703815,"about_ca_system_score_gemma":0.00009764424,"threshold_uncertainty_score":0.2905126},"labels":[],"label_agreement":null},{"id":"W3214276446","doi":"10.1007/s12325-021-01936-y","title":"Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review","year":2021,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Bone health and treatments","field":"Medicine","cited_by":212,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Amgen","keywords":"Denosumab; Medicine; Osteoporosis; Discontinuation; Osteonecrosis of the jaw; Bone remodeling; Internal medicine; Bone mineral; Oncology; Bisphosphonate","score_opus":0.05126907684742239,"score_gpt":0.4286028167517308,"score_spread":0.3773337399043084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214276446","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019051232,0.996531,7.012412e-8,0.00015642111,0.00010382563,0.0025825258,0.000019184108,0.0000074509653,0.00040897288],"genre_scores_gemma":[0.000022582204,0.99780506,0.00012085811,0.00044153593,0.000029855304,0.0010840655,0.0001620474,0.000027044458,0.00030696255],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981303,0.00038090828,0.0007170403,0.0003219867,0.00021000416,0.00023976133],"domain_scores_gemma":[0.99889916,0.00020936159,0.00031487242,0.0004947192,0.000034833636,0.00004707707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001882991,0.00031289755,0.002185941,0.00011015013,0.000019814288,0.0000042969027,0.00011965979,0.00012357999,0.0001640446],"category_scores_gemma":[0.00001979986,0.00016874916,0.00034520886,0.0005496068,0.000053229924,0.000057129975,0.000006119074,0.00016397062,0.000019741872],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038970014,0.00071586354,0.00010183985,0.0076801507,0.00009973342,0.0001347945,0.0019023585,6.2981506e-8,1.4933228e-8,0.000008090713,0.000071471506,0.98924667],"study_design_scores_gemma":[0.0017015166,0.0011917934,0.00007004688,0.048050985,0.00021591267,0.000059688733,0.00015406581,4.4255916e-8,9.231315e-7,0.000024008219,0.9484264,0.00010460565],"about_ca_topic_score_codex":0.000050700604,"about_ca_topic_score_gemma":0.00015424484,"teacher_disagreement_score":0.98914206,"about_ca_system_score_codex":0.00024099252,"about_ca_system_score_gemma":0.00033288647,"threshold_uncertainty_score":0.68813914},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W3214657680","doi":"10.1007/s12325-021-01951-z","title":"The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review","year":2021,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; HEC Montréal; ABB (Canada); Université de Montréal","funders":"AbbVie Canada; AbbVie","keywords":"Biosimilar; Medicine; Systematic review; MEDLINE; Health care; Actuarial science; Business; Internal medicine","score_opus":0.020731650380400847,"score_gpt":0.41975871676771204,"score_spread":0.39902706638731117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214657680","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010059776,0.99649245,0.000009941323,0.0005619032,0.00054388994,0.0019341045,0.00004177303,0.000009697553,0.00039617706],"genre_scores_gemma":[0.000035667534,0.9982936,0.00011044261,0.0010127837,0.00007105572,0.00029565516,0.000032683085,0.00003120502,0.000116903786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99406403,0.0031975657,0.0016129136,0.00051365,0.0001113355,0.0005005005],"domain_scores_gemma":[0.99444765,0.0038377522,0.00068356737,0.00094248867,0.000047808884,0.00004075121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052185,0.00052336464,0.003027936,0.00021071982,0.000105999905,0.000048606336,0.0013789423,0.0004873948,0.00012557382],"category_scores_gemma":[0.00052448525,0.00021982174,0.00091769005,0.0010315292,0.00015332625,0.00009082206,0.00010285299,0.0014875453,0.000017535645],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000328543,0.00008373746,0.00006294113,0.1324458,0.0005901213,0.00006590406,0.00023583368,0.0000016606904,0.0000041410485,0.0014825021,0.0014895751,0.86350495],"study_design_scores_gemma":[0.00020350901,0.000101984886,0.000009362468,0.34465805,0.00013185637,0.000082175735,0.000023841756,0.0000022847805,0.0000032328057,0.00011658019,0.654458,0.00020909941],"about_ca_topic_score_codex":0.000029200335,"about_ca_topic_score_gemma":0.00016598869,"teacher_disagreement_score":0.86329585,"about_ca_system_score_codex":0.00035270682,"about_ca_system_score_gemma":0.0006184288,"threshold_uncertainty_score":0.896407},"labels":[],"label_agreement":null},{"id":"W3214922391","doi":"10.1007/s12325-021-01953-x","title":"A Qualitative Study to Characterize the Humanistic Burden of Kabuki Syndrome in the United States and Canada","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Kabuki syndrome; Medicine; Psychosocial; Quality of life (healthcare); Presentation (obstetrics); Gerontology; Psychiatry; Developmental psychology; Pediatrics; Psychology; Nursing","score_opus":0.013931039726425835,"score_gpt":0.3117162852945852,"score_spread":0.2977852455681594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214922391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932326,0.0059811636,0.000006115851,0.0004720434,0.00003335933,0.00020710706,0.00005283128,6.3366673e-7,0.000014137526],"genre_scores_gemma":[0.9948745,0.004344862,0.000013246287,0.0006158728,0.000012802092,0.000030755808,0.00008155768,0.000005319338,0.000021127942],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9993801,0.00019340926,0.00012492399,0.00013750096,0.00007175652,0.000092291186],"domain_scores_gemma":[0.99965584,0.00007303905,0.000036816356,0.0001713654,0.000046644007,0.000016300612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015468338,0.00006853987,0.00009013139,0.000018638597,0.000033182838,0.000010397203,0.0001375916,0.000010756659,0.000004380938],"category_scores_gemma":[0.000036313475,0.000041552983,0.000011009213,0.00012990268,0.000037106554,0.00000211795,0.00003187947,0.000037771202,9.5104944e-8],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002362507,0.003238967,0.054081623,0.00021620351,0.00078220695,0.0016338641,0.7012335,0.008862955,0.20524332,0.0019876943,0.00068408204,0.019673081],"study_design_scores_gemma":[0.003060464,0.002204414,0.16599235,0.0000971183,0.000024464447,0.00007478187,0.7179937,0.000051640123,0.0065727266,0.002183917,0.101188995,0.0005554792],"about_ca_topic_score_codex":0.05270427,"about_ca_topic_score_gemma":0.25407293,"teacher_disagreement_score":0.20136864,"about_ca_system_score_codex":0.000007638026,"about_ca_system_score_gemma":0.00008105537,"threshold_uncertainty_score":0.95360386},"labels":[],"label_agreement":null},{"id":"W4212819218","doi":"10.1007/s12325-015-0202-8","title":"Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users","year":2015,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Rivaroxaban; Medicine; Warfarin; Atrial fibrillation; Internal medicine; Cardiology","score_opus":0.04481134226210652,"score_gpt":0.35536020803725427,"score_spread":0.31054886577514773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212819218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9527004,0.01571442,0.00004230609,0.0015600732,0.02199288,0.0053885872,0.0003301188,0.00016652765,0.002104713],"genre_scores_gemma":[0.89024013,0.0539206,0.003664734,0.0011618843,0.014055398,0.00009191252,0.026278801,0.0006939141,0.00989261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963081,0.00038750246,0.0010155268,0.00084702275,0.0009559079,0.00048597952],"domain_scores_gemma":[0.9972213,0.000660404,0.00081720296,0.00075993204,0.0002559229,0.000285251],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044431144,0.000677645,0.0016177518,0.0005412593,0.00013166388,0.000051657345,0.00024850937,0.00047958802,0.000023810497],"category_scores_gemma":[0.00056151306,0.00059878186,0.00036288446,0.0006897199,0.00011124342,0.0004594407,0.00011493828,0.0005704667,0.000010566121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01494627,0.000021677917,0.87805736,0.0004337648,0.0005637303,0.000006631216,0.003049932,0.0024996249,0.0000150373035,0.00006253402,0.049210638,0.05113278],"study_design_scores_gemma":[0.029866612,0.007864524,0.52936304,0.0015163901,0.00030483297,2.9072876e-7,0.00070620124,0.00029363937,0.00009400476,0.00019809342,0.42883718,0.00095523143],"about_ca_topic_score_codex":0.0018199659,"about_ca_topic_score_gemma":0.0012507869,"teacher_disagreement_score":0.37962654,"about_ca_system_score_codex":0.0010843294,"about_ca_system_score_gemma":0.00023082025,"threshold_uncertainty_score":0.99964637},"labels":[],"label_agreement":null},{"id":"W4213360317","doi":"10.1007/s12325-021-02031-y","title":"A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Université de Montréal","funders":"Amryt Pharma","keywords":"Medicine; Familial hypercholesterolemia; Internal medicine; PCSK9; Intima-media thickness; Cardiology; Triglyceride; Lipoprotein; LDL receptor; Cholesterol; Gastroenterology","score_opus":0.007816532930660992,"score_gpt":0.2772037853522879,"score_spread":0.2693872524216269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213360317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99636745,0.0015393898,0.000011809036,0.0001405699,0.00026378527,0.001464653,0.00000834642,0.00001971029,0.00018429483],"genre_scores_gemma":[0.99665403,0.0017109853,0.00043635786,0.00061751134,0.00007779014,0.0004458036,0.000014874647,0.000036541624,0.0000061299274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977774,0.00060993864,0.00039817946,0.0003363184,0.0005455254,0.0003326476],"domain_scores_gemma":[0.9988493,0.00042421234,0.00014602538,0.00046323598,0.00007013769,0.0000471093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084435206,0.00019980488,0.0005086946,0.0002643361,0.00011249454,0.000013606879,0.00013591214,0.00004448832,0.0000037011555],"category_scores_gemma":[0.00013684652,0.00013477771,0.00007679569,0.00077195384,0.00010716783,0.00028712652,0.000054102828,0.00072281854,3.0738204e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014626205,0.00049802527,0.788211,0.00042476613,0.000032118558,0.002353054,0.007707503,0.00081703544,0.00026146098,0.00006308893,0.0000029403088,0.19816642],"study_design_scores_gemma":[0.020911576,0.0022504458,0.9653752,0.0017067391,0.000028891936,0.0010775207,0.005660197,0.00006150937,0.0017904055,0.00022397275,0.00051857316,0.00039500382],"about_ca_topic_score_codex":0.0017545564,"about_ca_topic_score_gemma":0.004205852,"teacher_disagreement_score":0.19777142,"about_ca_system_score_codex":0.00030543754,"about_ca_system_score_gemma":0.00013590058,"threshold_uncertainty_score":0.5496076},"labels":[],"label_agreement":null},{"id":"W4214530973","doi":"10.1007/s12325-022-02061-0","title":"Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Ticagrelor; Medicine; Clopidogrel; Cardiology; Internal medicine; Myocardial infarction; Acute coronary syndrome; Anesthesia","score_opus":0.002332707193131385,"score_gpt":0.21613047412250017,"score_spread":0.21379776692936878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214530973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909186,0.008276006,0.000038784547,0.000029834708,0.000087863205,0.00056370226,0.000005248303,0.000010653634,0.00006935303],"genre_scores_gemma":[0.99390924,0.005610386,0.00006361481,0.00028511172,0.00001939298,0.000058742466,0.000035346882,0.000012788791,0.000005384149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992933,0.000087831024,0.00012374444,0.00016450838,0.00022890921,0.000101671474],"domain_scores_gemma":[0.9997511,0.00005268329,0.00004968056,0.000104292325,0.000018535064,0.000023709907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000776597,0.000089843976,0.00021525961,0.00010622324,0.000037370144,0.0000019882177,0.000031104333,0.000024345143,0.000012714688],"category_scores_gemma":[0.000004422784,0.00007461657,0.000055224693,0.00018114963,0.000050170762,0.00009887227,0.000011608542,0.0001139302,5.146926e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009908904,0.0004647181,0.77300584,0.00003983423,0.0002672862,0.000038800703,0.00029822,0.00065025047,0.00076373987,0.000078503275,0.0000043062087,0.21447958],"study_design_scores_gemma":[0.01056963,0.0017154213,0.98477846,0.000047586935,0.00003863038,0.000010253221,0.00004378222,0.000016025995,0.000642295,0.00020341108,0.0018485704,0.00008594086],"about_ca_topic_score_codex":0.00000516286,"about_ca_topic_score_gemma":9.378021e-7,"teacher_disagreement_score":0.21439363,"about_ca_system_score_codex":0.00005101527,"about_ca_system_score_gemma":0.000021015134,"threshold_uncertainty_score":0.3042775},"labels":[],"label_agreement":null},{"id":"W4214695698","doi":"10.1007/s12325-022-02068-7","title":"Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Janssen Pharmaceuticals; EMD Serono; Genentech; H. Lundbeck A/S; Biogen; Celgene; Alexion Pharmaceuticals; Bundesministerium für Bildung und Forschung; Teva Pharmaceutical Industries; Sanofi; Deutsche Forschungsgemeinschaft; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Medicine; Glatiramer acetate; Tolerability; Discontinuation; Dimethyl fumarate; Adverse effect; Multiple sclerosis; Internal medicine; Natalizumab; Immunology","score_opus":0.034226654165303114,"score_gpt":0.3606155336236517,"score_spread":0.32638887945834855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214695698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98195285,0.0132576395,0.000032393546,0.0019320133,0.00013193114,0.0023214864,0.00021556874,0.00006336199,0.00009276724],"genre_scores_gemma":[0.98919255,0.008606291,0.00053626933,0.0007817298,0.00013029514,0.0005277201,0.000030739884,0.00004651337,0.00014789445],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99719733,0.00048451943,0.00048265918,0.00067444384,0.0007691468,0.00039188287],"domain_scores_gemma":[0.99531615,0.0037007625,0.0001820665,0.0006690699,0.000053801785,0.00007817727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007213303,0.00034039345,0.00064200733,0.000092945666,0.0004163844,0.00006343409,0.00028173314,0.00002879958,0.0002140462],"category_scores_gemma":[0.00033738618,0.00016894544,0.000059693597,0.00027416457,0.00016075697,0.00022678488,0.00018508107,0.00061464764,0.0000032663145],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14813961,0.002150708,0.31042948,0.0000064878022,0.00073212106,0.00014584446,0.06684733,0.00012384607,0.0022164593,0.000003134487,0.00003562439,0.46916935],"study_design_scores_gemma":[0.06358311,0.003734858,0.904415,0.00020557169,0.000038315935,0.0000013601726,0.013074132,0.00015602265,0.0002214749,0.00005653234,0.0142504405,0.00026317668],"about_ca_topic_score_codex":0.000641077,"about_ca_topic_score_gemma":0.0011569465,"teacher_disagreement_score":0.5939855,"about_ca_system_score_codex":0.00011144466,"about_ca_system_score_gemma":0.00003679542,"threshold_uncertainty_score":0.6889395},"labels":[],"label_agreement":null},{"id":"W4220654595","doi":"10.1007/s12325-022-02090-9","title":"Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency Department","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Bausch Health","keywords":"Medicine; Cohort; Emergency department; Emergency medicine; Opioid; Constipation; Odds ratio; Health care; Medical prescription; Internal medicine; Retrospective cohort study; Pharmacology; Psychiatry","score_opus":0.02967051343816279,"score_gpt":0.3641262994304634,"score_spread":0.3344557859923006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220654595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206465,0.0029456806,0.00024091266,0.0012456442,0.00009781319,0.0008345351,0.0000151156755,0.000010084178,0.0025455821],"genre_scores_gemma":[0.9982273,0.0009926633,0.00018673309,0.0001649727,0.000013984965,0.00034998666,0.000044517517,0.000004727347,0.000015115505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915653,0.00011369,0.00025812234,0.00012670782,0.0002165374,0.00012840478],"domain_scores_gemma":[0.9995356,0.000105160565,0.00008832616,0.00021304264,0.000030046753,0.000027781873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000298186,0.00007444521,0.00013909917,0.00007605627,0.000054193442,0.0000015176862,0.00013127766,0.0000123554055,0.0006382549],"category_scores_gemma":[0.00008554912,0.00005233408,0.00006109849,0.00039900688,0.000052384006,0.00006640748,0.000014577617,0.00016743882,0.0000011870925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070223265,0.001591702,0.9432756,0.000023998437,0.000030046938,0.0000070793294,0.0028037108,0.0017324568,0.001744227,0.00095868245,0.00027361975,0.0468567],"study_design_scores_gemma":[0.0037603443,0.0019161367,0.97697794,0.000031141753,0.000012415151,0.000040564162,0.0033804579,0.0005647627,0.00016635655,0.0047375946,0.008315158,0.000097097436],"about_ca_topic_score_codex":0.00013439309,"about_ca_topic_score_gemma":0.00017345475,"teacher_disagreement_score":0.046759605,"about_ca_system_score_codex":0.00007522636,"about_ca_system_score_gemma":0.000115598246,"threshold_uncertainty_score":0.6988444},"labels":[],"label_agreement":null},{"id":"W4220690582","doi":"10.1007/s12325-021-02030-z","title":"Beyond Response: Aiming for Quality Remission in Depression","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Treatment of Major Depression","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Servier","keywords":"Escitalopram; Agomelatine; Medicine; Mood; Depression (economics); Discontinuation; Antidepressant; Internal medicine; Quality of life (healthcare); Psychiatry; Anxiety","score_opus":0.032057109669494134,"score_gpt":0.40205237874683236,"score_spread":0.3699952690773382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220690582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737227,0.023280436,0.00016877869,0.00091867044,0.00025249948,0.0008292481,0.0000102674585,0.000050855728,0.0007665407],"genre_scores_gemma":[0.993446,0.0014373708,0.0034807199,0.00045690505,0.000042745884,0.0004409396,0.000031534684,0.000027113483,0.0006366906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984839,0.0003056813,0.0003152637,0.00034951317,0.00031766857,0.00022799657],"domain_scores_gemma":[0.99892,0.00057721155,0.000109357985,0.00032328736,0.000018863211,0.000051256324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010123688,0.00012870254,0.00025792158,0.0001857365,0.00012322562,0.000004784156,0.000115681454,0.00004865779,0.00013600157],"category_scores_gemma":[0.00019832385,0.00010599982,0.0000620078,0.0002404885,0.000024313387,0.00017725225,0.000060144554,0.00021622717,0.0000011228044],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040557217,0.0007545893,0.2770936,0.000045834586,0.0000091852735,0.00005763409,0.0010125369,0.00087498315,0.12097461,0.00009317654,0.000193255,0.5583334],"study_design_scores_gemma":[0.02938001,0.0020911002,0.41979536,0.0004211025,0.000012906759,0.000048775415,0.0010814146,0.00052962784,0.08783026,0.012825331,0.44554153,0.00044257508],"about_ca_topic_score_codex":0.000017318911,"about_ca_topic_score_gemma":0.000012971624,"teacher_disagreement_score":0.55789083,"about_ca_system_score_codex":0.00025826876,"about_ca_system_score_gemma":0.00005466051,"threshold_uncertainty_score":0.4322547},"labels":[],"label_agreement":null},{"id":"W4221019027","doi":"10.1007/s12325-022-02104-6","title":"Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Infliximab; Medicine; Biosimilar; Inflammatory bowel disease; Internal medicine; Ulcerative colitis; Observational study; Adverse effect; Disease","score_opus":0.03858910153886844,"score_gpt":0.35364014621390394,"score_spread":0.31505104467503553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221019027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974795,0.00033790251,2.6904604e-7,0.0002370916,0.00024139354,0.0013266238,0.00034770102,0.000009146944,0.000020368867],"genre_scores_gemma":[0.9989038,0.0001633106,0.000024796283,0.00069245993,0.000009332201,0.00010159857,0.00007401167,0.000014458411,0.00001624847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965223,0.0016284387,0.0008650996,0.0004947437,0.0002382909,0.00025112362],"domain_scores_gemma":[0.9977745,0.0011513783,0.0004018491,0.00055257935,0.000070209135,0.000049484213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000933407,0.0002497125,0.00043485887,0.00009688003,0.00020333484,0.000016730517,0.00031298402,0.000053649903,0.000032187712],"category_scores_gemma":[0.00021267556,0.00013137098,0.00006571795,0.00026824677,0.00035958883,0.0001596295,0.00010900717,0.0005035621,1.06057215e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00936185,0.0020775448,0.9838079,0.0000017008036,0.0002904535,0.000024534393,0.001643586,0.00014404145,0.0000062764875,0.000009274127,0.000056389275,0.0025763991],"study_design_scores_gemma":[0.013004082,0.0035687278,0.98069984,0.000012662209,0.00004873443,2.3266621e-7,0.001736967,0.0000135516775,0.000005058942,0.00010199743,0.00063735823,0.00017079929],"about_ca_topic_score_codex":0.06272872,"about_ca_topic_score_gemma":0.2815277,"teacher_disagreement_score":0.21879897,"about_ca_system_score_codex":0.00007935574,"about_ca_system_score_gemma":0.00019723119,"threshold_uncertainty_score":0.9435127},"labels":[],"label_agreement":null},{"id":"W4221029922","doi":"10.1007/s12325-022-02105-5","title":"The Economic Burden of Insulin Injection-Induced Lipohypertophy. Role of Education: The ISTERP-3 Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Management and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Advanced Micro Devices (Canada)","funders":"","keywords":"Medicine; Insulin; Hypoglycemia; Diabetes mellitus; Insulin pen; Psychological intervention; Rehabilitation; Internal medicine; Type 2 diabetes; Physical therapy; Endocrinology; Nursing","score_opus":0.014228393782122786,"score_gpt":0.32699597709322403,"score_spread":0.31276758331110127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221029922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765877,0.013227143,4.2490092e-7,0.00083120423,0.0004080686,0.00075955025,0.0000013052608,0.00000615081,0.008178422],"genre_scores_gemma":[0.9966587,0.0015774746,0.000008932342,0.00007922788,0.00012479232,0.00020414339,0.0000020173702,0.000008740533,0.0013359651],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992425,0.00012635691,0.000215835,0.000116471434,0.00019144645,0.00010737983],"domain_scores_gemma":[0.9993734,0.00015358516,0.00009913981,0.0003281184,0.00003197389,0.000013820132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047767896,0.00005982079,0.00013592895,0.00008110336,0.00012979972,0.000007739528,0.00027054962,0.000009997715,0.00013642068],"category_scores_gemma":[0.000016162876,0.000034186312,0.00004193138,0.0002153254,0.00006509232,0.00006599253,0.00008098396,0.00014813356,0.0000033027004],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005304284,0.0006139862,0.03248495,0.000016985186,0.0001060016,5.585519e-7,0.0042654555,0.0013705281,0.0016540466,0.0010436737,0.00011002793,0.95780337],"study_design_scores_gemma":[0.0057893777,0.008137463,0.072183356,0.000057115358,0.000047246038,0.0000043674213,0.13961712,0.0017552617,0.004317091,0.010201525,0.7576359,0.0002541948],"about_ca_topic_score_codex":0.00017174795,"about_ca_topic_score_gemma":0.0000453297,"teacher_disagreement_score":0.95754915,"about_ca_system_score_codex":0.00007180472,"about_ca_system_score_gemma":0.00013333886,"threshold_uncertainty_score":0.14937109},"labels":[],"label_agreement":null},{"id":"W4221036987","doi":"10.1007/s12325-022-02097-2","title":"P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Atuka (Canada); Toronto Western Hospital","funders":"Parkinsonfonden; Ipsen; H. Lundbeck A/S; Sage Therapeutics; Acorda Therapeutics; Sunovion; European Commission; Sanofi; University of South Florida; Israel Science Foundation; University of Cambridge; Boston Scientific Corporation; International Parkinson and Movement Disorder Society; Biogen; University of Oxford; Adamas Pharmaceuticals; Jazz Pharmaceuticals; National Parkinson Foundation; Teva Pharmaceutical Industries; AstraZeneca","keywords":"Rasagiline; Pramipexole; Tolerability; Levodopa; Medicine; Parkinson's disease; Selegiline; Pharmacology; Dopamine; Internal medicine; Adverse effect; Disease","score_opus":0.061359160184941836,"score_gpt":0.3735306502470583,"score_spread":0.3121714900621164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221036987","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007723488,0.99428695,0.00012865695,0.000053101547,0.00020175212,0.004337081,0.00009758973,0.00004718727,0.000075338554],"genre_scores_gemma":[0.00029034517,0.9890695,0.0035807958,0.00011525447,0.000105452,0.005029837,0.00092820666,0.00008714807,0.00079345406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976912,0.00012901126,0.0006307296,0.00086120656,0.0002620846,0.00042573444],"domain_scores_gemma":[0.9987754,0.00017188487,0.00026509495,0.00039009188,0.000016308051,0.000381177],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016431604,0.00059502135,0.0013987256,0.00036559135,0.00009413983,0.000021263304,0.00011369348,0.00011379675,0.00011240275],"category_scores_gemma":[0.000044886005,0.0004560116,0.00027966287,0.00030805782,0.000029680315,0.00014681487,0.000036424324,0.000171371,0.0000060614398],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010720338,0.0013287312,0.0003062577,0.0016976399,0.00017518933,0.00026880475,0.000112305126,0.000006602724,2.6472608e-7,0.00010076676,0.000012133084,0.9949193],"study_design_scores_gemma":[0.007537912,0.00066345604,0.0007001117,0.002400252,0.00032052153,0.000018216999,0.000028767474,0.00003445855,0.0000048068287,0.0006761278,0.9872396,0.00037575842],"about_ca_topic_score_codex":0.00003336693,"about_ca_topic_score_gemma":0.00008650715,"teacher_disagreement_score":0.9945435,"about_ca_system_score_codex":0.0011388374,"about_ca_system_score_gemma":0.0011918864,"threshold_uncertainty_score":0.9997892},"labels":[],"label_agreement":null},{"id":"W4224992031","doi":"10.1007/s12325-022-02137-x","title":"Quality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"AstraZeneca","keywords":"Medicine; COPD; Health care; Multidisciplinary approach; Position paper; Quality (philosophy); Evidence-based practice; Nursing; Intensive care medicine; Alternative medicine; Pathology","score_opus":0.03626643249394235,"score_gpt":0.4619851468467,"score_spread":0.42571871435275765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224992031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9094613,0.071098536,0.00031443956,0.010588468,0.0001322052,0.0050437883,0.0023621765,0.00003308851,0.00096598454],"genre_scores_gemma":[0.9710053,0.026617877,0.0004956605,0.00029603863,0.000030743653,0.0014838016,0.000040993364,0.000012254842,0.000017295219],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985064,0.00022117406,0.00026604175,0.00030555032,0.00041951338,0.00028127714],"domain_scores_gemma":[0.99949783,0.00006194626,0.00012958814,0.0001647914,0.00007267151,0.000073174604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005431648,0.00010874203,0.0003235992,0.00015984917,0.000079293386,0.000005505415,0.00008010377,0.000014819647,0.000025196812],"category_scores_gemma":[0.000011506567,0.00010816857,0.000036230143,0.00044008327,0.000074688294,0.00011724703,0.00007340867,0.00007966761,1.6124358e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01484908,0.0013843095,0.41100982,0.0072034937,0.00028297995,0.00009456198,0.0037899013,0.00028709578,0.000045309105,0.122303806,0.00010532612,0.43864432],"study_design_scores_gemma":[0.019467605,0.0033097407,0.88957953,0.0008294454,0.00001778588,0.000016156799,0.06119639,0.00021053731,0.0002052655,0.013569515,0.011323977,0.00027407674],"about_ca_topic_score_codex":0.0011058297,"about_ca_topic_score_gemma":0.0005178067,"teacher_disagreement_score":0.4785697,"about_ca_system_score_codex":0.0054921475,"about_ca_system_score_gemma":0.0001772389,"threshold_uncertainty_score":0.9983256},"labels":[],"label_agreement":null},{"id":"W4225103600","doi":"10.1007/s12325-022-02084-7","title":"Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Tofacitinib; Medicine; Psoriatic arthritis; Rheumatology; Health care; Database; Dermatology; Arthritis; Internal medicine; Family medicine; Rheumatoid arthritis","score_opus":0.06083006821720849,"score_gpt":0.38085236416649143,"score_spread":0.32002229594928294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225103600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9335799,0.053657033,0.00007130124,0.0005124062,0.00032869488,0.0009244367,0.010829531,0.000035591383,0.00006108296],"genre_scores_gemma":[0.8642777,0.12089929,0.002780166,0.000746542,0.00007431732,0.0007670114,0.010351848,0.000030805415,0.00007230772],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99853593,0.000075097254,0.0003927043,0.00043842473,0.0002776256,0.00028024052],"domain_scores_gemma":[0.9987234,0.00025690277,0.00015411392,0.00073848857,0.000060359,0.00006675134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013670835,0.00015656276,0.00040803832,0.00014745475,0.00016329893,0.0000073472365,0.0002524036,0.000017656428,0.00029837515],"category_scores_gemma":[0.000030693715,0.00014676014,0.00004257033,0.0005017397,0.00009390015,0.00026049922,0.00014845944,0.00013252605,0.0000012026915],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010568864,0.0021482634,0.34288293,0.0001965563,0.00043720604,0.00037298023,0.02045072,0.00013354867,0.0005710034,0.0023911444,0.0011079219,0.6187389],"study_design_scores_gemma":[0.04592823,0.0057076234,0.0481194,0.0010124581,0.000065376335,0.000022989088,0.027697373,0.001117386,0.0021910444,0.011007088,0.8564102,0.00072080636],"about_ca_topic_score_codex":0.006083839,"about_ca_topic_score_gemma":0.003960659,"teacher_disagreement_score":0.85530233,"about_ca_system_score_codex":0.00006985271,"about_ca_system_score_gemma":0.000050401,"threshold_uncertainty_score":0.91969854},"labels":[],"label_agreement":null},{"id":"W4239984345","doi":"10.1007/s12325-014-0150-8","title":"Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis","year":2014,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Exemestane; Medicine; Everolimus; Internal medicine; Oncology; Breast cancer; Postmenopausal women; Progression-free survival; Aromatase; Overall survival; Cancer","score_opus":0.007630919257924771,"score_gpt":0.2911378448630639,"score_spread":0.2835069256051391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239984345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7316745,0.2030064,0.0015831167,0.0015742499,0.042273786,0.0054913918,0.004427114,0.00020063898,0.009768816],"genre_scores_gemma":[0.8784498,0.07205095,0.0036706522,0.0037100862,0.006914992,0.0027443077,0.009903449,0.0008081926,0.021747548],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960066,0.00026089416,0.00064336834,0.0013650749,0.0008615392,0.00086253724],"domain_scores_gemma":[0.99764717,0.000042542346,0.0004772242,0.001321616,0.0003200698,0.0001913894],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003675418,0.0007749389,0.0010536236,0.00042616593,0.00008461198,0.00005607752,0.0012129146,0.00064463774,0.00008201317],"category_scores_gemma":[0.00005363806,0.0006474972,0.00016506082,0.0010750269,0.00018084866,0.000027675176,0.00022482435,0.0007537045,0.000003954552],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02963861,0.0020662616,0.5764115,0.00046818706,0.0035076167,0.00016992955,0.00063673715,0.029592317,0.004909377,0.000038193924,0.19213724,0.16042404],"study_design_scores_gemma":[0.015155523,0.006529333,0.23643059,0.001639833,0.00040837724,0.000014066535,0.00006940276,0.0002527404,0.0013026426,0.00035398346,0.7343678,0.003475711],"about_ca_topic_score_codex":0.00028678955,"about_ca_topic_score_gemma":0.0057438966,"teacher_disagreement_score":0.54223055,"about_ca_system_score_codex":0.00033424605,"about_ca_system_score_gemma":0.00063404144,"threshold_uncertainty_score":0.9995976},"labels":[],"label_agreement":null},{"id":"W4246924398","doi":"10.1007/s12325-016-0442-2","title":"Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial","year":2016,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Hôpital du Sacré-Cœur de Montréal; Royal Victoria Regional Health Centre; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Gemcitabine; Medicine; Nab-paclitaxel; Internal medicine; Oncology; Subgroup analysis; Metastatic adenocarcinoma; Paclitaxel; Adenocarcinoma; Chemotherapy; Cancer; Meta-analysis","score_opus":0.028275468941952153,"score_gpt":0.3569516600612091,"score_spread":0.32867619111925694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246924398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95758694,0.018982794,0.000042953336,0.0009547551,0.005250767,0.005844644,0.0007963261,0.00002460655,0.010516204],"genre_scores_gemma":[0.97337455,0.0070981095,0.00043184502,0.00046655466,0.00052029,0.00072302326,0.0009679245,0.00014349066,0.016274204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99496824,0.000576364,0.00119548,0.00086643687,0.0012098772,0.0011835921],"domain_scores_gemma":[0.99631685,0.0008122457,0.00055170583,0.0014162561,0.0003690074,0.00053391507],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00090744864,0.0006919507,0.0031753886,0.0022976375,0.00011300678,0.000022940432,0.0007186628,0.00039446005,0.00047805256],"category_scores_gemma":[0.00088822417,0.00039468205,0.00040277521,0.003587067,0.0004693049,0.00024035557,0.0000698405,0.0011463843,0.000013238219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28034514,0.0023468493,0.6774742,0.00036334712,0.0075455736,0.00022874551,0.0016025883,0.000079856,0.000011984494,0.000115628434,0.02154482,0.008341275],"study_design_scores_gemma":[0.3623026,0.016198577,0.57803035,0.0013431305,0.004614889,0.0000037094314,0.00035481222,0.00032536633,0.0000088732395,0.00022377413,0.035744533,0.0008493672],"about_ca_topic_score_codex":0.02156663,"about_ca_topic_score_gemma":0.18302867,"teacher_disagreement_score":0.16146204,"about_ca_system_score_codex":0.0019554244,"about_ca_system_score_gemma":0.003943477,"threshold_uncertainty_score":0.9998505},"labels":[],"label_agreement":null},{"id":"W4254619169","doi":"10.1007/s12325-015-0230-4","title":"Erratum to: Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study","year":2015,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Tolerability; Relapsing remitting; Fingolimod; Multiple sclerosis; Internal medicine; Rheumatology; Adverse effect; Immunology","score_opus":0.0726722418288143,"score_gpt":0.35049807896330554,"score_spread":0.27782583713449127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254619169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715555,0.011052391,0.000012662938,0.0011047267,0.0014087296,0.009678869,0.0001819457,0.000047042595,0.004958189],"genre_scores_gemma":[0.97715396,0.018674742,0.0016168585,0.00029264382,0.0001780042,0.0006195568,0.00009564017,0.00010962527,0.0012589917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957997,0.00044990805,0.0010521823,0.0009981092,0.0010512574,0.00064881856],"domain_scores_gemma":[0.9966563,0.00094308937,0.0006208392,0.0011045588,0.0004933494,0.00018187227],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017129794,0.0005457289,0.0017300185,0.000276975,0.00021933722,0.00006352708,0.00077660405,0.00014317487,0.000007811481],"category_scores_gemma":[0.0022316303,0.00034595473,0.000043813838,0.0012670272,0.0006442701,0.000325905,0.00070111756,0.0014122449,0.0000012828839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005405106,0.0028079876,0.90106094,0.00015832078,0.00014251044,0.0000034575833,0.007911604,0.00015018487,0.000014569203,0.0000013687322,0.006581926,0.075762026],"study_design_scores_gemma":[0.016377255,0.0039842213,0.94765013,0.002675346,0.000023415563,2.961449e-7,0.0030138062,0.00030992212,0.000008074125,0.00002324015,0.025567912,0.00036636597],"about_ca_topic_score_codex":0.002572659,"about_ca_topic_score_gemma":0.021300798,"teacher_disagreement_score":0.07539566,"about_ca_system_score_codex":0.00039422035,"about_ca_system_score_gemma":0.00026245264,"threshold_uncertainty_score":0.99989927},"labels":[],"label_agreement":null},{"id":"W4280570876","doi":"10.1007/s12325-022-02158-6","title":"Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Barrie Urology Group; Simon Fraser University","funders":"AbbVie","keywords":"Medicine; Internal medicine; Gastroenterology; Regimen; Hepatitis C; Sofosbuvir; Cirrhosis; Clinical endpoint; Adverse effect; Incidence (geometry); Hepatitis C virus; Surgery; Randomized controlled trial; Ribavirin; Immunology; Virus","score_opus":0.023043689408431274,"score_gpt":0.3430762373618999,"score_spread":0.32003254795346864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280570876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936865,0.0031381997,0.000014818876,0.000028643462,0.00004557773,0.0028715038,0.000035120738,0.000015740854,0.00016387425],"genre_scores_gemma":[0.997587,0.0020322425,0.00004349516,0.000036502155,0.000008555564,0.00023226479,0.00002820367,0.000027596778,0.0000041144285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976836,0.0010510602,0.00030750624,0.00030528568,0.00040397365,0.00024859657],"domain_scores_gemma":[0.9990329,0.00043995853,0.000109668086,0.00030909738,0.000069791844,0.00003857218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041858916,0.00017819593,0.0004615074,0.00019793055,0.00013512863,0.0000093492545,0.00012306997,0.000024758534,0.000073405325],"category_scores_gemma":[0.00003685416,0.00011415565,0.000030104828,0.00078973867,0.00014099386,0.00015509833,0.00006964436,0.00024631253,5.8586375e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003926159,0.0018758439,0.91554236,0.000025525716,0.00010478311,0.000023513056,0.0014508012,0.0007794552,0.0005202014,0.000009277154,2.183028e-7,0.075741835],"study_design_scores_gemma":[0.016911902,0.0068643643,0.97360754,0.00011163354,0.00002402489,0.0000022604534,0.00058994885,0.00043632762,0.00040122567,0.000026357045,0.00090852496,0.00011592077],"about_ca_topic_score_codex":0.0012590118,"about_ca_topic_score_gemma":0.0008857484,"teacher_disagreement_score":0.07562592,"about_ca_system_score_codex":0.0003657264,"about_ca_system_score_gemma":0.00008284438,"threshold_uncertainty_score":0.46551323},"labels":[],"label_agreement":null},{"id":"W4281298326","doi":"10.1007/s12325-022-02130-4","title":"Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Amgen (Canada); Université de Montréal; Montreal Heart Institute","funders":"Amgen Canada; Amgen","keywords":"Evolocumab; Medicine; Ezetimibe; Statin; Dyslipidemia; Internal medicine; Context (archaeology); Cohort; Quality-adjusted life year; Cardiology; Physical therapy; Cost effectiveness; Disease; Cholesterol; Apolipoprotein B","score_opus":0.010983426101665434,"score_gpt":0.255251527536024,"score_spread":0.24426810143435854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281298326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834928,0.014621137,0.00009117433,0.00001974026,0.00006961096,0.0016313377,0.00004091372,0.000005380011,0.000027934635],"genre_scores_gemma":[0.9968105,0.0022358438,0.000038738253,0.00012133414,0.000009339404,0.0007119624,0.000050961575,0.000019453963,0.0000018847239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771637,0.00044349502,0.0002901503,0.00034419823,0.00094307825,0.0002626999],"domain_scores_gemma":[0.99902797,0.00006123997,0.000070513706,0.00067788543,0.00007929459,0.000083081126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006042748,0.00014320972,0.00077236345,0.00032755322,0.000032299766,0.0000021242747,0.0001127739,0.000017730048,0.000035462675],"category_scores_gemma":[0.000035396817,0.000118372634,0.00023516806,0.0018692741,0.000032149033,0.000091020804,0.000026812562,0.000211464,1.193341e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011151034,0.00022803186,0.74242115,0.00006591146,0.0006784997,0.00005488644,0.00012719064,0.19321132,0.0000020316115,0.000010980722,1.8812285e-7,0.062084686],"study_design_scores_gemma":[0.0075738127,0.00021609795,0.9896434,0.00008840271,0.00020170017,5.304609e-7,0.00022883133,0.0009557712,0.00003191615,0.00001962954,0.00091025315,0.00012965317],"about_ca_topic_score_codex":0.6183978,"about_ca_topic_score_gemma":0.5113878,"teacher_disagreement_score":0.24722223,"about_ca_system_score_codex":0.0013057038,"about_ca_system_score_gemma":0.00069150014,"threshold_uncertainty_score":0.49752808},"labels":[],"label_agreement":null},{"id":"W4281729595","doi":"10.1007/s12325-022-02176-4","title":"Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Rheumatology; Narrative; Fibromyalgia; Internal medicine; Physical therapy","score_opus":0.024514767142040907,"score_gpt":0.34961538552925664,"score_spread":0.3251006183872157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281729595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004235658,0.99237794,0.000003878578,0.000041530395,0.000086779604,0.0030949574,0.000011650486,0.000030394433,0.00011722243],"genre_scores_gemma":[0.00039494268,0.997153,0.000026267546,0.00092759205,0.000012918238,0.0011302195,0.0002114874,0.000031913136,0.00011165097],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976818,0.00066859985,0.00066483044,0.0005225075,0.00022550159,0.00023674661],"domain_scores_gemma":[0.9989783,0.00019804633,0.0004888679,0.0002470098,0.000031365806,0.000056398225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017951714,0.0003215162,0.001082318,0.00013256243,0.00010588427,0.000009202589,0.000104484214,0.00018347913,0.00003456113],"category_scores_gemma":[0.00010865748,0.00020568738,0.00009591182,0.00079502055,0.00013854037,0.0001220275,0.000032059226,0.00076756056,8.4209114e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020129836,0.0004377223,0.007870441,0.0040943357,0.00008558596,0.000029599323,0.0005522495,0.0000028086895,1.8013347e-7,0.0000021344626,0.000021751728,0.9867019],"study_design_scores_gemma":[0.0065622525,0.012056968,0.007908958,0.044811264,0.00023857625,0.000048519963,0.000539893,0.000013824039,9.875405e-7,0.00007388514,0.92708665,0.0006582458],"about_ca_topic_score_codex":0.000035151017,"about_ca_topic_score_gemma":0.000022435035,"teacher_disagreement_score":0.98604363,"about_ca_system_score_codex":0.00016501534,"about_ca_system_score_gemma":0.000073316594,"threshold_uncertainty_score":0.8387688},"labels":[],"label_agreement":null},{"id":"W4281761508","doi":"10.1007/s12325-022-02183-5","title":"Clinical Radiofrequency Ablation Outcomes of Combined Sensory Nerve Branch and Dorsal Entry Root Zone Complex Lesions for Sacroiliac Joint Complex Pain","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Spine and Intervertebral Disc Pathology","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; McMaster University; Mount Sinai Hospital; Health Sciences Centre; The Scarborough Hospital; St. Michael's Hospital","funders":"","keywords":"Medicine; Pulsed radiofrequency; Interventional pain management; Sacroiliac joint; Radiofrequency ablation; Low back pain; Ablation; Chronic pain; Nerve root; Surgery; Radiology; Anesthesia; Physical therapy; Internal medicine; Pain relief; Pathology","score_opus":0.17937227242068968,"score_gpt":0.444489794070084,"score_spread":0.2651175216493943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281761508","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002807124,0.9922828,0.0015038385,0.00022082934,0.0004730059,0.0021391944,0.00023604611,0.000045650926,0.00029148808],"genre_scores_gemma":[0.0023650448,0.9927372,0.002594882,0.0005514501,0.00012060522,0.00027781096,0.0010336847,0.000068050475,0.00025130418],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960501,0.0009478618,0.0018362115,0.00059195445,0.00023034886,0.00034348742],"domain_scores_gemma":[0.997858,0.00073934556,0.0007387836,0.00050658116,0.00006681909,0.00009051096],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011609406,0.00044869632,0.0033193359,0.00026934678,0.00008629856,0.000007979399,0.00020119926,0.00026425708,0.0005778574],"category_scores_gemma":[0.0004291636,0.00034293524,0.0008493646,0.00024792913,0.0003098524,0.00012636269,0.000068552494,0.00054063805,0.0000030362974],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011753171,0.00048706587,0.0041949986,0.0034273413,0.00022849283,0.00002222756,0.00006626283,0.000002123714,0.000067146175,0.0004970629,0.0004338725,0.99045587],"study_design_scores_gemma":[0.005196386,0.0031285859,0.027514886,0.0018554606,0.0002648326,0.00007189996,0.00006780677,0.00015381366,0.0000054789434,0.00084735086,0.9604968,0.0003967234],"about_ca_topic_score_codex":0.000035494624,"about_ca_topic_score_gemma":0.000033119573,"teacher_disagreement_score":0.99005914,"about_ca_system_score_codex":0.000098399585,"about_ca_system_score_gemma":0.00012704654,"threshold_uncertainty_score":0.99990225},"labels":[],"label_agreement":null},{"id":"W4281933688","doi":"10.1007/s12325-022-02160-y","title":"A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Rheumatology; Internal medicine; Clinical trial; Adverse effect; Rash; Systemic lupus erythematosus; Rheumatoid arthritis; Arthritis; Lupus erythematosus; Disease; Immunology","score_opus":0.05548976719446784,"score_gpt":0.40008612301153196,"score_spread":0.3445963558170641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281933688","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019854991,0.988156,0.00004215267,0.000016878821,0.0010863135,0.010204825,0.000029376595,0.000021060576,0.00024485163],"genre_scores_gemma":[0.000035721063,0.9921006,0.00007887833,0.00001593407,0.0001472555,0.006718282,0.000046582543,0.00007045789,0.00078629586],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964152,0.0005768776,0.0017199672,0.00043840913,0.0005772107,0.00027232594],"domain_scores_gemma":[0.9953122,0.0019733915,0.0015167177,0.00096812303,0.00018274713,0.00004678288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004283995,0.00040053093,0.003249802,0.00025535724,0.000087690394,0.0000046466744,0.0003055177,0.0001292067,0.00006366102],"category_scores_gemma":[0.00016008917,0.00021827775,0.00089208566,0.000691457,0.00016384038,0.000063781794,0.00002526191,0.00021593834,0.0000012169581],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002772968,0.0003389719,0.00019926092,0.29721606,0.0005430986,0.000015156689,0.0035931405,0.0000027954227,0.0000063984653,0.000055579738,0.00009642839,0.6976558],"study_design_scores_gemma":[0.0014994192,0.0030183678,2.2153056e-7,0.21246915,0.00040986572,0.015043235,0.0024302946,0.0000050478216,0.000021495242,0.000018144561,0.7649481,0.00013661504],"about_ca_topic_score_codex":0.000031435175,"about_ca_topic_score_gemma":0.0000059959975,"teacher_disagreement_score":0.7648517,"about_ca_system_score_codex":0.00093707704,"about_ca_system_score_gemma":0.0006323464,"threshold_uncertainty_score":0.89011085},"labels":[],"label_agreement":null},{"id":"W4283785207","doi":"10.1007/s12325-022-02229-8","title":"The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"United Therapeutics Corporation","keywords":"Treprostinil; Medicine; Idiopathic pulmonary fibrosis; Pharmacology; Fibrosis; Inflammation; Pulmonary fibrosis; In vivo; Lung; Internal medicine; Pulmonary hypertension; Biology","score_opus":0.040566566312500385,"score_gpt":0.39908404381166745,"score_spread":0.35851747749916707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283785207","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001482867,0.9959081,0.00009831143,0.00002151279,0.0008383347,0.002785091,0.00004214591,0.000029034554,0.00012920704],"genre_scores_gemma":[0.00047019226,0.99754703,0.00017434855,0.00003703065,0.0002661973,0.0010917821,0.00021293592,0.00006219146,0.00013829215],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983752,0.00020355439,0.0005660153,0.0003822365,0.00021674247,0.00025629008],"domain_scores_gemma":[0.9983046,0.0007569083,0.00036674898,0.00047594795,0.000039695627,0.000056123157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035490762,0.0002725714,0.001023753,0.00012948367,0.00015725501,0.000013699979,0.00023583692,0.00009489297,0.000025252762],"category_scores_gemma":[0.00013169968,0.00017647183,0.00050340843,0.00027329856,0.000093220566,0.00015056937,0.0000326735,0.0002530643,0.000001154192],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010738727,0.00017447882,0.0000038418043,0.0159142,0.00006333819,0.000030192934,0.00006655195,0.0000045193196,0.000015039804,0.00048058335,0.000011135696,0.98216224],"study_design_scores_gemma":[0.0007693001,0.0038476104,0.000004556035,0.00920026,0.00024049164,0.000047414345,0.000050868297,0.00005860675,0.00002049671,0.000394774,0.9851857,0.00017992019],"about_ca_topic_score_codex":0.000006747657,"about_ca_topic_score_gemma":0.0000020745595,"teacher_disagreement_score":0.98517454,"about_ca_system_score_codex":0.0000971271,"about_ca_system_score_gemma":0.00013794731,"threshold_uncertainty_score":0.71963125},"labels":[],"label_agreement":null},{"id":"W4285040754","doi":"10.1007/s12325-022-02199-x","title":"Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Actelion Pharmaceuticals; Faculty of Medicine Siriraj Hospital, Mahidol University; National Taiwan University; Taichung Veterans General Hospital; Ministry of Health of the Russian Federation; National Taiwan University Hospital; NIH Clinical Center; Akademiska Sjukhuset","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Clinical endpoint; Placebo; Pulmonary hypertension; Safety profile; Clinical trial","score_opus":0.030064565627307947,"score_gpt":0.29443968968871104,"score_spread":0.26437512406140307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285040754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937062,0.0028922819,0.0000018754256,0.0010508025,0.00010159498,0.0018554408,0.00024855745,0.000024008878,0.00011922056],"genre_scores_gemma":[0.9951338,0.002890547,0.00015563049,0.00062616606,0.000029696777,0.00012483397,0.00094530685,0.000032811313,0.000061181636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974796,0.00040484467,0.00038713525,0.0007381434,0.0006250476,0.00036523916],"domain_scores_gemma":[0.99874794,0.00029905248,0.00011574347,0.00060454465,0.00010638262,0.00012634983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003499168,0.00027546767,0.00053251185,0.00010511887,0.00025136198,0.000034867462,0.00024336371,0.000046623747,0.00006504617],"category_scores_gemma":[0.00002923699,0.00014979584,0.000022669905,0.0005066029,0.0001805665,0.00040793297,0.00019727943,0.0003563381,0.0000015234439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12233069,0.0039228173,0.82843804,0.0000051502084,0.00005526774,0.0019961738,0.000071762086,0.000025654661,0.0006794235,0.0000021125625,0.000010014978,0.042462915],"study_design_scores_gemma":[0.042761635,0.0035728829,0.9523594,0.00013485702,0.000017976736,0.000091199065,0.00012022619,0.00018894176,0.00006539008,0.00009286791,0.00040999864,0.00018467364],"about_ca_topic_score_codex":0.00072967965,"about_ca_topic_score_gemma":0.00042324208,"teacher_disagreement_score":0.12392133,"about_ca_system_score_codex":0.00013419498,"about_ca_system_score_gemma":0.00006589798,"threshold_uncertainty_score":0.61084974},"labels":[],"label_agreement":null},{"id":"W4285732351","doi":"10.1007/s12325-022-02231-0","title":"Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"GlaxoSmithKline","keywords":"Medicine; Fluticasone propionate; COPD; Meta-analysis; Internal medicine; Pharmacology; Physical therapy; Corticosteroid","score_opus":0.17133879769135232,"score_gpt":0.41856365797525713,"score_spread":0.2472248602839048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285732351","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000110944915,0.9886775,0.0003663769,0.00023136479,0.00021032029,0.009243929,0.0008389975,0.00006137528,0.00025917674],"genre_scores_gemma":[0.00047476322,0.9872684,0.00071299693,0.0002531026,0.0003232079,0.009322905,0.00042764613,0.00022835293,0.0009886088],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994478,0.0010092079,0.0013339123,0.0011940054,0.0010336755,0.0009511913],"domain_scores_gemma":[0.9940252,0.0027686206,0.00096046936,0.0019049693,0.00016645831,0.00017432406],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00082192797,0.0011418785,0.0070986054,0.00054498203,0.00028693076,0.000052561743,0.0008396868,0.0001935749,0.004442455],"category_scores_gemma":[0.000019326695,0.0005682548,0.0043192473,0.002444285,0.0005206278,0.00015944938,0.000052407144,0.00047212574,0.00000651849],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048002154,0.0018858233,0.00042646143,0.0015774055,0.20115072,0.00004339859,0.0006373198,0.0005500778,0.0000013856538,0.00014347499,0.00013201265,0.7886517],"study_design_scores_gemma":[0.0053466163,0.0020440365,0.00009336118,0.00021137473,0.06128836,0.00003076051,0.0003275623,0.00020094916,0.00000651369,0.00017070159,0.9298085,0.00047127684],"about_ca_topic_score_codex":0.00013664224,"about_ca_topic_score_gemma":0.00017551411,"teacher_disagreement_score":0.9296765,"about_ca_system_score_codex":0.0006229128,"about_ca_system_score_gemma":0.000503958,"threshold_uncertainty_score":0.9996769},"labels":[],"label_agreement":null},{"id":"W4285891556","doi":"10.1007/s12325-022-02247-6","title":"Correction to: Beyond Response: Aiming for Quality Remission in Depression","year":2022,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Health Policy Implementation Science","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Depression (economics); Rheumatology; Quality (philosophy); Alternative medicine; Internal medicine; Medical physics; Physical therapy; Epistemology; Pathology","score_opus":0.3897808584831003,"score_gpt":0.6942229551170802,"score_spread":0.3044420966339799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285891556","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07820239,0.023035398,0.00978183,0.041005395,0.7198749,0.033509832,0.0014740684,0.00074701855,0.09236917],"genre_scores_gemma":[0.020893529,0.0414427,0.010830142,0.1459052,0.00683605,0.032194518,0.0011830481,0.00055046164,0.74016434],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908408,0.0047519966,0.0017595438,0.0008697227,0.0007469237,0.0010310388],"domain_scores_gemma":[0.98712736,0.010919661,0.0009459566,0.0006294736,0.00015956222,0.00021798022],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011282524,0.00031130723,0.00062753056,0.0008177792,0.0010137036,0.00001286689,0.0005755403,0.00035897954,0.0011402759],"category_scores_gemma":[0.008706157,0.000299606,0.000076835466,0.0012726452,0.00004382631,0.00045008038,0.00018370284,0.0022175352,0.000025567204],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040894053,0.000050144194,0.009678104,0.0003034966,0.0000026040354,0.0000027013912,0.015822494,0.00023071619,0.0005157125,0.000051497875,0.83374506,0.13550808],"study_design_scores_gemma":[0.001630938,0.00023407981,0.017840626,0.0007807635,0.0000012651136,6.763514e-7,0.0029050338,0.0001374466,0.00005785923,0.0010628527,0.97505236,0.00029613],"about_ca_topic_score_codex":0.0008081772,"about_ca_topic_score_gemma":0.0047424664,"teacher_disagreement_score":0.71303886,"about_ca_system_score_codex":0.0019792486,"about_ca_system_score_gemma":0.0020430651,"threshold_uncertainty_score":0.9999456},"labels":[],"label_agreement":null},{"id":"W4292470370","doi":"10.1007/s12325-022-02269-0","title":"The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of Toronto; Toronto Western Hospital; Memorial University of Newfoundland","funders":"Janssen Research and Development","keywords":"Medicine; Psoriatic arthritis; Placebo; Dermatology Life Quality Index; Visual analogue scale; Crossover study; Internal medicine; Quality of life (healthcare); EQ-5D; Physical therapy; Randomized controlled trial; Arthritis; Health related quality of life; Disease","score_opus":0.007456155231777105,"score_gpt":0.30305885108802405,"score_spread":0.29560269585624693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292470370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97370464,0.017358577,0.000010772467,0.0002639321,0.0005473886,0.007841071,0.00013973587,0.0000073360848,0.00012653135],"genre_scores_gemma":[0.9784929,0.019413603,0.00004010002,0.00015284069,0.000033519904,0.0017916868,0.000025460644,0.00001738728,0.000032488464],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99700767,0.0014133502,0.0006173045,0.0002606951,0.0004048386,0.0002961243],"domain_scores_gemma":[0.99738693,0.001671381,0.0005939924,0.00029243669,0.000031428324,0.000023856548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071477983,0.0002292927,0.0013557447,0.00005659364,0.00020884858,0.0000052001396,0.00014178274,0.000022090813,0.00001974117],"category_scores_gemma":[0.00018713667,0.00009883089,0.00021853339,0.0002845179,0.0002676332,0.00008871112,0.000042675703,0.00022410454,3.2246012e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8133754,0.0011886134,0.0023670224,0.000009507425,0.00031089387,0.000005876341,0.0011728752,0.0004423904,0.0000052077617,0.00006872483,0.0000070247725,0.18104646],"study_design_scores_gemma":[0.96455127,0.03190372,0.0010160509,0.00013637419,0.0000312447,0.000001358782,0.00023918707,0.000017460468,0.00068997993,0.00081977155,0.0005056857,0.000087884],"about_ca_topic_score_codex":0.00031487856,"about_ca_topic_score_gemma":0.0003634544,"teacher_disagreement_score":0.18095857,"about_ca_system_score_codex":0.00017873172,"about_ca_system_score_gemma":0.00008673548,"threshold_uncertainty_score":0.40302065},"labels":[],"label_agreement":null},{"id":"W4292656895","doi":"10.1007/s12325-022-02248-5","title":"Patient Preferences in the Management of Wet Age-Related Macular Degeneration: A Conjoint Analysis","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharma","keywords":"Medicine; Conjoint analysis; Macular degeneration; Preference; Demography; Physical therapy; Active listening; Family medicine; Internal medicine; Ophthalmology","score_opus":0.04598254760328476,"score_gpt":0.3677459512750403,"score_spread":0.32176340367175554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292656895","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022031926,0.9937068,0.0000051997476,0.000015474237,0.00007893527,0.0014774937,0.000036001275,0.0000067761885,0.0024701133],"genre_scores_gemma":[0.0045708646,0.99368936,0.00014172746,0.000037205846,0.000008371304,0.00085082254,0.00062031747,0.000013535001,0.00006777283],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982404,0.00030194325,0.00062361977,0.0003064436,0.0003831335,0.00014446501],"domain_scores_gemma":[0.99919295,0.000070083326,0.0003034332,0.00039101328,0.000014489397,0.000028019398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016210007,0.00023300131,0.0010109294,0.00027317414,0.000032213546,0.0000122666725,0.0001631225,0.00005158475,0.00039849355],"category_scores_gemma":[0.0000029730654,0.00013074049,0.00042326088,0.0012272109,0.00004967475,0.00004509609,0.000031034393,0.00016918758,0.0000026591758],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059938964,0.00047512693,0.00048160198,0.0016243911,0.001916558,0.00044528622,0.0001775725,0.00037136246,2.7195282e-8,0.0006411417,0.0000048151983,0.9938022],"study_design_scores_gemma":[0.0008242757,0.0004696125,0.00079480535,0.001907562,0.0028475986,0.000008531453,0.00030150753,0.000025686108,4.81987e-7,0.00033988658,0.9923346,0.00014546287],"about_ca_topic_score_codex":0.000035622532,"about_ca_topic_score_gemma":0.00001531737,"teacher_disagreement_score":0.9936567,"about_ca_system_score_codex":0.000097445176,"about_ca_system_score_gemma":0.00004013625,"threshold_uncertainty_score":0.53314424},"labels":[],"label_agreement":null},{"id":"W4293037425","doi":"10.1007/s12325-022-02241-y","title":"The Role of Interleukins in the Pathogenesis of Dermatological Immune-Mediated Diseases","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University; Université de Sherbrooke; Government of New Brunswick; University of New Brunswick","funders":"Health Canada; Bausch Health","keywords":"Medicine; Psoriasis; Pathogenesis; Atopic dermatitis; Immunology; Cytokine; Interleukin; Immune system; Tumor necrosis factor alpha; Interleukin 20; Chemokine; Interleukin 23; Interleukin 5","score_opus":0.022295024573765997,"score_gpt":0.3424399022226569,"score_spread":0.32014487764889094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293037425","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018044312,0.99658227,6.280416e-7,0.000045323646,0.00014671373,0.0007771407,0.00011855456,0.000012518743,0.000512392],"genre_scores_gemma":[0.018353749,0.9808436,0.000008315941,0.00011097785,0.000020512709,0.0004857567,0.00015171913,0.00001940544,0.0000059452445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975698,0.0008526016,0.0008658477,0.00022456965,0.00026024538,0.00022696174],"domain_scores_gemma":[0.99617904,0.0027786733,0.0004381749,0.00054698053,0.000025813477,0.000031299947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002684614,0.00024947085,0.0013798309,0.00015441701,0.00006106041,0.000004428843,0.0006464058,0.0001245742,0.00011700639],"category_scores_gemma":[0.00039080952,0.000118286436,0.00044712817,0.0005390926,0.00039600855,0.000056707013,0.000070305774,0.00034809572,0.0000027447247],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026292985,0.0005407052,0.012024565,0.0013995119,0.000094571325,0.00012565129,0.00024662243,0.0000010846128,0.0000015553954,0.00024800826,0.00003845018,0.98501635],"study_design_scores_gemma":[0.00053996744,0.00008412192,0.0037869392,0.0013225651,0.00013485929,0.00010944217,0.00078466896,0.0000029494904,0.0000051518564,0.0009211587,0.9921942,0.00011401669],"about_ca_topic_score_codex":0.0000058961587,"about_ca_topic_score_gemma":0.000011146807,"teacher_disagreement_score":0.99215573,"about_ca_system_score_codex":0.00003669565,"about_ca_system_score_gemma":0.00020210192,"threshold_uncertainty_score":0.48235807},"labels":[],"label_agreement":null},{"id":"W4294238099","doi":"10.1007/s12325-022-02250-x","title":"The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Biogen","keywords":"Medicine; Fingolimod; Teriflunomide; Adverse effect; Nausea; Qualitative research; Clinical trial; Disease; Internal medicine; Diarrhea; Multiple sclerosis; Physical therapy; Psychiatry","score_opus":0.09518329872803062,"score_gpt":0.4116198257491791,"score_spread":0.3164365270211485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294238099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938474,0.0038064015,0.000012753679,0.00029712386,0.00004596625,0.0018970792,0.00003655841,0.00002273367,0.000033953544],"genre_scores_gemma":[0.99568355,0.0029034896,0.00051093695,0.000056614863,0.0000051848433,0.00078801194,0.000013392876,0.000024360937,0.000014473303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629503,0.0015686089,0.0006050393,0.00036549542,0.0007974499,0.00036835944],"domain_scores_gemma":[0.9975059,0.0016928108,0.00033453203,0.00025771032,0.00012902003,0.00008004997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018201633,0.00020151689,0.00044314758,0.00015648273,0.00032852998,0.0000064824894,0.00015145553,0.000014424728,0.000015536296],"category_scores_gemma":[0.0006533123,0.00013123067,0.000059799186,0.0005573193,0.00029210647,0.0001637485,0.00014220926,0.00048523623,1.746731e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031576813,0.0021134806,0.94400746,0.000014435418,0.00018164984,0.000025999627,0.034477092,0.0010268474,0.00021904144,0.000015876807,0.000002168397,0.014758249],"study_design_scores_gemma":[0.009824772,0.0038316872,0.8355745,0.00038451824,0.000013253283,0.000001316,0.1482675,0.0017944111,0.0000058642577,0.00015649541,0.000035785408,0.00010989356],"about_ca_topic_score_codex":0.00014192352,"about_ca_topic_score_gemma":0.0008926035,"teacher_disagreement_score":0.1137904,"about_ca_system_score_codex":0.00028762585,"about_ca_system_score_gemma":0.0001261465,"threshold_uncertainty_score":0.53514314},"labels":[],"label_agreement":null},{"id":"W4295470189","doi":"10.1007/s12325-022-02270-7","title":"The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of Toronto; Toronto Western Hospital; Memorial University of Newfoundland","funders":"Janssen Research and Development; Janssen Scientific Affairs","keywords":"Medicine; Psoriatic arthritis; Placebo; Presenteeism; Internal medicine; Physical therapy; Absenteeism; Arthritis","score_opus":0.007089833713171946,"score_gpt":0.2797830670537712,"score_spread":0.27269323334059925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295470189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977291,0.012440019,0.0000036113186,0.00023686864,0.0006639364,0.009062384,0.000047382993,0.000008116485,0.00024668928],"genre_scores_gemma":[0.9924743,0.0046326234,0.000020537484,0.00003387546,0.000050254843,0.0027314513,0.0000115457615,0.00001592048,0.000029452212],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99730206,0.0012668065,0.00047126506,0.00030772135,0.0004092878,0.00024285135],"domain_scores_gemma":[0.9966256,0.002473853,0.00047335515,0.0003741596,0.000037519843,0.000015483269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000744657,0.00023161306,0.0012447812,0.000050991523,0.00019386031,0.000005118716,0.00015152644,0.000030314495,0.000020688916],"category_scores_gemma":[0.00057488657,0.00009843611,0.0002264208,0.00044838386,0.00036199592,0.00011190916,0.00005064287,0.0002555332,3.7802434e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83307695,0.0019126729,0.007463292,0.00000790781,0.0003454134,0.0000056433537,0.0008045416,0.00018849409,0.000008265596,0.000051125957,0.000004518114,0.15613116],"study_design_scores_gemma":[0.97507185,0.018528206,0.0028372763,0.00017924253,0.00006721998,0.0000011346843,0.00024537108,0.0000030036504,0.0019393519,0.00061305356,0.0004168331,0.000097450524],"about_ca_topic_score_codex":0.000058268302,"about_ca_topic_score_gemma":0.00010528788,"teacher_disagreement_score":0.15603371,"about_ca_system_score_codex":0.00012293101,"about_ca_system_score_gemma":0.000045016477,"threshold_uncertainty_score":0.40141082},"labels":[],"label_agreement":null},{"id":"W4296642322","doi":"10.1007/s12325-022-02303-1","title":"Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); University of Saskatchewan; Université de Montréal; University of Toronto; St. Joseph's Hospital; Mount Sinai Hospital; Western University","funders":"","keywords":"Medicine; Etanercept; Rheumatoid arthritis; Internal medicine; Rheumatology; Erythrocyte sedimentation rate; Adverse effect; Observational study; Biosimilar; Methotrexate; Concomitant; Prospective cohort study; Physical therapy","score_opus":0.01895463268009967,"score_gpt":0.3013498490173185,"score_spread":0.2823952163372188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296642322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906528,0.00704791,0.000043253604,0.00008305596,0.00032527605,0.0013718761,0.00036340303,0.000019087689,0.00009333884],"genre_scores_gemma":[0.9982787,0.00060896046,0.00038671584,0.000086423606,0.00000481113,0.00040142352,0.00016422269,0.000017470806,0.00005127947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976994,0.0010437127,0.00037555624,0.00043044033,0.00017401502,0.00027690784],"domain_scores_gemma":[0.9985875,0.0008202146,0.00016583317,0.00019645091,0.00020728687,0.000022711214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007075952,0.00020286282,0.00043051268,0.00015575049,0.00013478943,0.0000072716325,0.0001913598,0.00006253809,0.0005781001],"category_scores_gemma":[0.00014726387,0.00016746315,0.000059426133,0.0005018691,0.00020580822,0.0002132612,0.000078382815,0.00033680693,0.000001360309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019518303,0.0032591217,0.96057504,0.000016887543,0.00014000399,0.000010824423,0.0005118919,0.0002947376,0.0033825962,0.0006824629,0.0000063100006,0.011601803],"study_design_scores_gemma":[0.019156752,0.0021559054,0.97399354,0.000060329778,0.0000076025917,0.0000013177075,0.0006826776,0.000018705829,0.0013406132,0.00043552517,0.0019227741,0.00022422842],"about_ca_topic_score_codex":0.00005987763,"about_ca_topic_score_gemma":0.00015264652,"teacher_disagreement_score":0.013418511,"about_ca_system_score_codex":0.00014383183,"about_ca_system_score_gemma":0.00009963881,"threshold_uncertainty_score":0.68289495},"labels":[],"label_agreement":null},{"id":"W4296667915","doi":"10.1007/s12325-022-02277-0","title":"Educational and Emotional Needs of Patients with Myelodysplastic Syndromes: An AI Analysis of Multi-Country Social Media","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Social media; Myelodysplastic syndromes; Rheumatology; Family medicine; Psychiatry; Internal medicine; World Wide Web","score_opus":0.037495158081482065,"score_gpt":0.37385490940713384,"score_spread":0.33635975132565177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296667915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722505,0.00090447906,0.000029699338,0.0004207878,0.00095155195,0.00032141482,0.00009498648,0.0000070788874,0.000044945606],"genre_scores_gemma":[0.99857634,0.00046975465,0.0003613859,0.00008749213,0.00012975364,0.00021716149,0.00014665886,0.000007623429,0.0000038058206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857605,0.0002902272,0.0002647257,0.00013175263,0.0005742349,0.00016299923],"domain_scores_gemma":[0.9980677,0.001386627,0.00024446094,0.00007359858,0.00017163574,0.00005599904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040189555,0.00007455011,0.00022888879,0.00042513027,0.000305082,0.0000066278017,0.00015981296,0.0000394608,0.000398073],"category_scores_gemma":[0.00033589322,0.000075346004,0.00002736421,0.0020024497,0.00038155433,0.00033465945,0.000013582012,0.000116252406,1.8185281e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009562856,0.00057783094,0.87442577,0.000013850649,0.000061029794,6.263253e-8,0.10443089,0.0004260906,0.0000035093676,0.0054445327,0.0000043453106,0.014516474],"study_design_scores_gemma":[0.00060048257,0.00010134903,0.9801021,0.0000074606896,0.000032920525,5.7913407e-8,0.01665236,0.00006988229,0.0000015144893,0.0010426925,0.001306938,0.00008221721],"about_ca_topic_score_codex":0.00055487076,"about_ca_topic_score_gemma":0.002346627,"teacher_disagreement_score":0.105676375,"about_ca_system_score_codex":0.00016469296,"about_ca_system_score_gemma":0.00047066668,"threshold_uncertainty_score":0.43586203},"labels":[],"label_agreement":null},{"id":"W4304165795","doi":"10.1007/s12325-022-02329-5","title":"Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review Study","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Otsuka Pharmaceutical Development and Commercialization; Otsuka Pharmaceutical","keywords":"Medicine; Discontinuation; Pediatrics; Complication; Attention deficit hyperactivity disorder; Medical record; Psychiatry; Physical therapy; Internal medicine","score_opus":0.04816910701679069,"score_gpt":0.3875172918370127,"score_spread":0.33934818482022205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304165795","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05778253,0.9281477,0.000008610981,0.00018791734,0.00007477581,0.013624948,0.0001078858,0.000043847227,0.000021832824],"genre_scores_gemma":[0.004178529,0.98786217,0.00005297623,0.00009988186,0.000055946428,0.00713573,0.00036809646,0.00012515532,0.00012153074],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726284,0.00043105043,0.0005423425,0.0009808077,0.00036934434,0.00041364145],"domain_scores_gemma":[0.9986061,0.00020382818,0.0004609739,0.0006096425,0.000037785703,0.000081712715],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039903427,0.00067639333,0.002698982,0.00036737474,0.00012595345,0.000019716637,0.0001551273,0.00011021319,0.00009866345],"category_scores_gemma":[0.00006705241,0.0004889765,0.00026613995,0.00068525766,0.000063520136,0.00024364656,0.00005217568,0.00038297038,0.000004619442],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014518913,0.0030708918,0.3081674,0.0050075483,0.00017262335,0.000013196399,0.00003057895,6.3418713e-7,1.0614144e-7,0.0000018515013,0.0000015239551,0.6833885],"study_design_scores_gemma":[0.010751958,0.0039979666,0.087931104,0.044801127,0.001323338,0.0002837239,0.00059749343,0.000002301105,2.4135948e-8,0.0000041519997,0.84950936,0.00079747895],"about_ca_topic_score_codex":0.00010927435,"about_ca_topic_score_gemma":0.0011999131,"teacher_disagreement_score":0.8495078,"about_ca_system_score_codex":0.00034942673,"about_ca_system_score_gemma":0.00015208838,"threshold_uncertainty_score":0.9997562},"labels":[],"label_agreement":null},{"id":"W4306377497","doi":"10.1007/s12325-022-02340-w","title":"A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"AstraZeneca","keywords":"Medicine; Asthma; Charter; Referral; Intensive care medicine; Health care; Disease; Family medicine; Internal medicine","score_opus":0.008567164779409284,"score_gpt":0.27349466121056665,"score_spread":0.26492749643115737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306377497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9640348,0.033306085,0.000005577789,0.00024319145,0.0002734513,0.0007233478,0.000041018582,0.00003385758,0.0013386598],"genre_scores_gemma":[0.9959208,0.0008950469,0.0002185073,0.0022548554,0.00007375898,0.0004403766,0.000021225269,0.000022579436,0.00015284769],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988876,0.000078863406,0.00023709112,0.00030130817,0.00025795982,0.000237198],"domain_scores_gemma":[0.9995229,0.00002464961,0.00005710146,0.00026557723,0.00003173726,0.00009799408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000649287,0.00013312505,0.00022042695,0.00014852978,0.00006673873,0.0000058382816,0.000109326196,0.000025565909,0.00020350626],"category_scores_gemma":[0.000018874607,0.00011231856,0.000059433423,0.0002859926,0.00002371613,0.00009024648,0.000067818524,0.00015892851,0.0000075344346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016652159,0.00030571915,0.055756584,0.00004457972,0.000008204485,0.00016592674,0.007122166,0.0020005149,0.0018371751,0.00005764713,0.000046282126,0.93099],"study_design_scores_gemma":[0.0029585788,0.0038830976,0.028364986,0.000069622925,0.0000022102417,0.000012232304,0.0065222634,0.000036192658,0.0016663944,0.00007365735,0.9562059,0.00020488317],"about_ca_topic_score_codex":0.000018863342,"about_ca_topic_score_gemma":0.00013633404,"teacher_disagreement_score":0.9561596,"about_ca_system_score_codex":0.00018530544,"about_ca_system_score_gemma":0.000106741216,"threshold_uncertainty_score":0.4580218},"labels":[],"label_agreement":null},{"id":"W4306898284","doi":"10.1007/s12325-022-02332-w","title":"Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Exacerbation; Internal medicine; Systemic lupus erythematosus; Rheumatology; Cohort; Quality of life (healthcare); Disease","score_opus":0.05126373379941145,"score_gpt":0.3779763090322955,"score_spread":0.32671257523288405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306898284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.938636,0.053307753,0.00057290314,0.000041157648,0.0004219287,0.00652143,0.00031659188,0.000010988914,0.00017124093],"genre_scores_gemma":[0.9888236,0.007307782,0.00023795046,0.000004394812,0.000019222944,0.003488938,0.000024048622,0.00003359937,0.00006047957],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99814403,0.0003152904,0.00052270223,0.00026469238,0.0005032866,0.00024998415],"domain_scores_gemma":[0.99684215,0.0021384163,0.00019987715,0.00050723297,0.00026953526,0.00004277897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005788401,0.0001693809,0.00081436755,0.00026493886,0.000068613976,0.0000033669573,0.00022049018,0.000045383866,0.000030323052],"category_scores_gemma":[0.000083610146,0.00011849698,0.00013990393,0.0005641756,0.0000844199,0.0000733701,0.00003364091,0.0000964055,4.0208192e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3107736,0.0020508086,0.34324995,0.0108985705,0.00080756703,0.000034957342,0.08251662,0.16516046,0.016124971,0.0022044575,0.000030198442,0.06614781],"study_design_scores_gemma":[0.27192193,0.084434226,0.0032454827,0.010257443,0.00033677704,0.0028422957,0.31312415,0.006156891,0.2764843,0.0021084743,0.027855564,0.0012324393],"about_ca_topic_score_codex":0.000080967104,"about_ca_topic_score_gemma":0.0001787091,"teacher_disagreement_score":0.34000447,"about_ca_system_score_codex":0.0010121375,"about_ca_system_score_gemma":0.0002772464,"threshold_uncertainty_score":0.48321667},"labels":[],"label_agreement":null},{"id":"W4307582617","doi":"10.1007/s12325-022-02345-5","title":"Examining the Systemic Bioavailability of Cannabidiol and Tetrahydrocannabinol from a Novel Transdermal Delivery System in Healthy Adults: A Single-Arm, Open-Label, Exploratory Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BGC Engineering (Canada)","funders":"","keywords":"Cannabidiol; Cmax; Medicine; Transdermal; Pharmacokinetics; Bioavailability; Pharmacology; Area under the curve; Adverse effect; Bioequivalence; Cannabis","score_opus":0.05866162924438281,"score_gpt":0.3197853359846563,"score_spread":0.2611237067402735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307582617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9493714,0.045558017,0.000013894051,0.0006406126,0.00020971992,0.0039666323,0.00013032068,0.0000338077,0.0000755835],"genre_scores_gemma":[0.99606293,0.0013180366,0.000047227968,0.0003217926,0.000053489737,0.0020996258,0.0000135635055,0.000045508692,0.000037814596],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9964808,0.00068650465,0.0008903202,0.00075433945,0.000694878,0.00049311155],"domain_scores_gemma":[0.9987109,0.00011209399,0.00022920078,0.00068246527,0.00013119237,0.00013416154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015980063,0.0002837195,0.00078100676,0.0002851073,0.00021078838,0.00003679495,0.0005885643,0.00006717363,0.00003774349],"category_scores_gemma":[0.000054159707,0.00021940892,0.00004314042,0.0009477572,0.00025075107,0.00034393222,0.00024473562,0.000654532,6.1319275e-7],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07961801,0.0336385,0.44264233,0.0029500409,0.00041899926,0.00061677734,0.12375811,0.0011746456,0.08580468,0.0001430971,0.00042595898,0.22880886],"study_design_scores_gemma":[0.10167846,0.05993431,0.13691567,0.002290324,0.00009334114,0.00038004306,0.67790776,0.0035343815,0.0025006898,0.000053293843,0.01347814,0.0012335518],"about_ca_topic_score_codex":0.003852977,"about_ca_topic_score_gemma":0.002492254,"teacher_disagreement_score":0.5541497,"about_ca_system_score_codex":0.00068802875,"about_ca_system_score_gemma":0.00049361185,"threshold_uncertainty_score":0.8947236},"labels":[],"label_agreement":null},{"id":"W4307730286","doi":"10.1007/s12325-022-02353-5","title":"Projecting the Epidemiological and Economic Impact of Chronic Kidney Disease Using Patient-Level Microsimulation Modelling: Rationale and Methods of Inside CKD","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"AstraZeneca","keywords":"Medicine; Microsimulation; Epidemiology; Kidney disease; Rheumatology; Intensive care medicine; Internal medicine","score_opus":0.07483301571167904,"score_gpt":0.40650440792095754,"score_spread":0.3316713922092785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307730286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96090907,0.036424007,0.0019830666,0.00009332457,0.000036749265,0.00044722322,0.00008743029,0.0000048682937,0.00001424894],"genre_scores_gemma":[0.99306124,0.0024750119,0.004169683,0.00019194942,0.00003147484,0.000028288685,0.000032043008,0.00000805194,0.0000022507322],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9991511,0.00021307032,0.00028868305,0.00016886776,0.00006425197,0.00011403684],"domain_scores_gemma":[0.99910265,0.00049570267,0.00017962148,0.000121699966,0.000020193227,0.000080115125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000402517,0.000089450536,0.0002383382,0.000058873215,0.00007838177,0.0000034012846,0.000036870522,0.00001797281,0.000045090448],"category_scores_gemma":[0.00016494228,0.00005989016,0.00006565808,0.000074034906,0.00011058273,0.000119000244,0.00004188537,0.00008988966,3.5841374e-8],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009837811,0.00014507619,0.25385204,0.000110321,0.000067727226,0.0000011600584,0.0007710176,0.68803835,0.012625117,0.00024049422,0.000013481033,0.04315144],"study_design_scores_gemma":[0.0025746778,0.0006189467,0.02779598,0.00008355665,0.000041099458,0.0000053510253,0.00022514543,0.9587858,0.0020430724,0.0069532627,0.0007578766,0.00011526986],"about_ca_topic_score_codex":0.00010043323,"about_ca_topic_score_gemma":0.0000019341846,"teacher_disagreement_score":0.27074742,"about_ca_system_score_codex":0.00021609408,"about_ca_system_score_gemma":0.0005201327,"threshold_uncertainty_score":0.244225},"labels":[],"label_agreement":null},{"id":"W4307852697","doi":"10.1007/s12325-022-02322-y","title":"No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Eli Lilly and Company; Ortho Dermatologics; Galderma; Incyte; Dermira; Les Laboratories Pierre Fabre; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer","keywords":"Medicine; Dupilumab; Atopic dermatitis; Discontinuation; Incidence (geometry); Placebo; Dosing; Internal medicine; Adverse effect; Regimen; Cumulative incidence; Dermatology; Cohort","score_opus":0.005435478724070912,"score_gpt":0.25447065783412526,"score_spread":0.24903517911005435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307852697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99755496,0.0007137785,0.00016644048,0.00007551594,0.000054182117,0.0009880583,0.000053434454,0.000026118538,0.00036751037],"genre_scores_gemma":[0.99705255,0.00083961705,0.00056769646,0.0008069379,0.000012642312,0.0005413736,0.000050033275,0.000017615877,0.00011151414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992344,0.00008780221,0.00017964211,0.00020101547,0.00013462316,0.00016255086],"domain_scores_gemma":[0.9995593,0.0000847338,0.00007341681,0.00016537921,0.000057022793,0.000060186532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000062796964,0.00011177833,0.00027329818,0.00017226744,0.000047044326,0.0000035641392,0.000056530913,0.000030092895,0.000098952434],"category_scores_gemma":[0.000032169686,0.00009137067,0.000029352319,0.00029157725,0.000029249073,0.00012710286,0.000012662496,0.00010854914,0.0000028622508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017700322,0.00026057675,0.96679145,0.00007666475,0.000051450603,0.00005548984,0.0009826252,0.0073576765,0.000020596357,0.00003571885,0.0002889828,0.006378474],"study_design_scores_gemma":[0.017691782,0.0020177665,0.97077197,0.00025809294,0.000023043056,0.000058788733,0.0001234167,0.0006891191,0.0006798871,0.00032469686,0.0071797566,0.00018167727],"about_ca_topic_score_codex":0.0007245932,"about_ca_topic_score_gemma":0.0011150913,"teacher_disagreement_score":0.0068907742,"about_ca_system_score_codex":0.000067870504,"about_ca_system_score_gemma":0.00006318521,"threshold_uncertainty_score":0.37259877},"labels":[],"label_agreement":null},{"id":"W4309722656","doi":"10.1007/s12325-022-02369-x","title":"Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"Biohaven Pharmaceuticals","keywords":"Medicine; Migraine; Rheumatology; Open label; Migraine Disorders; Physical therapy; Internal medicine; Clinical trial","score_opus":0.18313469768657126,"score_gpt":0.4694301944779297,"score_spread":0.28629549679135846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309722656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79112613,0.19990416,0.00031981996,0.0031440882,0.000036208552,0.0050949887,0.00023084383,0.000009030167,0.00013471217],"genre_scores_gemma":[0.8772055,0.11923309,0.0012966933,0.00017352366,0.000026144038,0.00092143734,0.000051101128,0.000015345468,0.0010771942],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988792,0.00009488787,0.00040238784,0.00027367778,0.00014269009,0.0002071653],"domain_scores_gemma":[0.9990497,0.0003157506,0.00024846065,0.00028117586,0.00006214677,0.000042737734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000418586,0.00016034205,0.00062289357,0.0000731226,0.00019637817,0.000004182998,0.000091507936,0.000013663229,0.00003221262],"category_scores_gemma":[0.000011266819,0.000094967734,0.00008430653,0.00017816837,0.00011090226,0.00007312633,0.000054956217,0.000049627914,8.779058e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045649946,0.0076015173,0.0055827135,0.000176399,0.0006593737,0.000006797354,0.027907597,0.00004281655,0.001730765,0.00016313685,0.00039648512,0.91008246],"study_design_scores_gemma":[0.2536256,0.05257909,0.007983497,0.00024662048,0.00017121513,0.000025355206,0.014155993,0.00085640355,0.014389218,0.0029412895,0.6527229,0.0003028198],"about_ca_topic_score_codex":0.0017444558,"about_ca_topic_score_gemma":0.00088479643,"teacher_disagreement_score":0.9097796,"about_ca_system_score_codex":0.00013416242,"about_ca_system_score_gemma":0.00014343599,"threshold_uncertainty_score":0.3872672},"labels":[],"label_agreement":null},{"id":"W4311052876","doi":"10.1007/s12325-022-02360-6","title":"PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; Feinberg School of Medicine; Ipsen; Carcinoid Cancer Foundation; Neuroendocrine Tumor Research Foundation; Northwestern University","keywords":"Acromegaly; Medicine; Somatostatin; Somatostatin Analogue; Rheumatology; Internal medicine; Octreotide; Medical physics; Growth hormone; Hormone","score_opus":0.034876949359028304,"score_gpt":0.3551121762573508,"score_spread":0.3202352268983225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311052876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746096,0.00018098034,0.0006298921,0.00039397177,0.00016541342,0.0010219074,0.000024322937,0.00002566405,0.000096913216],"genre_scores_gemma":[0.99774665,0.00009967661,0.0007530654,0.0005071126,0.00003152493,0.000610142,0.00011839668,0.000018147337,0.000115268005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889016,0.00016062082,0.0002458987,0.00021880901,0.00031811206,0.00016642209],"domain_scores_gemma":[0.99912703,0.00034615208,0.00018251553,0.00018860819,0.00012501505,0.000030654985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004094049,0.000117004645,0.00016483515,0.00015327384,0.000191374,0.000023822158,0.00022300122,0.000006045227,0.0000854858],"category_scores_gemma":[0.00011173467,0.00007229686,0.000027969072,0.00045360602,0.000046963996,0.00044843787,0.000040565537,0.000087055756,3.1777276e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030590391,0.00025251973,0.94807833,0.000015743177,0.00004736101,0.0000041850794,0.013406756,0.011435851,0.00003506218,0.0000382933,0.000026463704,0.023600388],"study_design_scores_gemma":[0.0022910342,0.0030708872,0.9751301,0.00002706118,0.000009712339,0.0000030924118,0.011499457,0.0032113127,0.00024655572,0.00005796731,0.0043305825,0.00012225173],"about_ca_topic_score_codex":0.00011268881,"about_ca_topic_score_gemma":0.0014897437,"teacher_disagreement_score":0.027051749,"about_ca_system_score_codex":0.000045350782,"about_ca_system_score_gemma":0.00003852882,"threshold_uncertainty_score":0.29481804},"labels":[],"label_agreement":null},{"id":"W4311476820","doi":"10.1007/s12325-022-02379-9","title":"Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology","funders":"Eli Lilly and Company","keywords":"Medicine; Plaque psoriasis; Psoriasis; Rheumatology; Internal medicine; Dermatology; Physical therapy","score_opus":0.026024946539772983,"score_gpt":0.299438510484854,"score_spread":0.273413563945081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311476820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942229,0.002433609,0.0000053448816,0.000015319745,0.0002924714,0.0014969032,0.0013935234,0.000017139464,0.00012280402],"genre_scores_gemma":[0.9985988,0.00037286986,0.000054398246,0.000025242281,0.000009065392,0.0004168578,0.00047072928,0.000014427272,0.000037598333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664825,0.0020426426,0.00046947302,0.0004489262,0.00008612226,0.0003046085],"domain_scores_gemma":[0.99745154,0.0017829866,0.00033671848,0.00035602882,0.00006036487,0.000012354979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007612837,0.00024500236,0.0006436917,0.000094328825,0.00023848009,0.000004358904,0.0003563867,0.00006219227,0.000023653038],"category_scores_gemma":[0.000023107961,0.0001584675,0.000055517296,0.00048652876,0.00013984609,0.00011070071,0.0001571454,0.00021013002,0.0000025478764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05920292,0.001777749,0.9063263,0.000007733811,0.00031472597,0.0000050885264,0.01942586,0.005056649,0.0030882992,0.00002357559,0.000007851796,0.004763281],"study_design_scores_gemma":[0.01642218,0.0028650973,0.9541235,0.00006352239,0.000020913274,6.177208e-7,0.0053785425,0.0000041397743,0.020294428,0.00021429652,0.00041343123,0.00019932816],"about_ca_topic_score_codex":0.001310308,"about_ca_topic_score_gemma":0.011433878,"teacher_disagreement_score":0.047797237,"about_ca_system_score_codex":0.00015158701,"about_ca_system_score_gemma":0.00003324878,"threshold_uncertainty_score":0.64621174},"labels":[],"label_agreement":null},{"id":"W4317438721","doi":"10.1007/s12325-022-02422-9","title":"Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Rivaroxaban; Warfarin; Atrial fibrillation; Internal medicine; Poisson regression; Retrospective cohort study; Cohort; Population; Confidence interval; Odds ratio; Emergency medicine","score_opus":0.03983527937279056,"score_gpt":0.34376283745290837,"score_spread":0.3039275580801178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317438721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759823,0.0010575611,0.00001580944,0.00020648752,0.00014544971,0.0008707012,0.0000041994613,0.000038385213,0.000063183295],"genre_scores_gemma":[0.9978602,0.001494848,0.00012710852,0.000019268971,0.00014576745,0.0000026821215,0.00031214752,0.000018206232,0.000019803661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989788,0.00007109038,0.00031785152,0.00021155704,0.00025627812,0.00016444163],"domain_scores_gemma":[0.99945533,0.00015693277,0.0001683781,0.00013680343,0.000047966427,0.000034607714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020056553,0.000115662195,0.0002661234,0.0003092809,0.000037106336,0.000008852443,0.000032727185,0.000064463275,0.0000052612804],"category_scores_gemma":[0.00008491711,0.000098942866,0.000041534826,0.00072379486,0.000038364877,0.00030165017,0.00001961203,0.000058608977,0.0000011652762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001710081,0.0000032468872,0.9117567,0.00004345961,0.000016193899,7.0314576e-7,0.00018536774,0.0040837233,0.000011588187,0.00007879378,0.0000021727092,0.082107976],"study_design_scores_gemma":[0.007678417,0.00044391587,0.98589575,0.00016210774,0.000011420157,3.323288e-8,0.000082657636,0.0043748002,0.0000606643,0.00011387375,0.001081136,0.000095205854],"about_ca_topic_score_codex":0.0001801249,"about_ca_topic_score_gemma":0.00031360504,"teacher_disagreement_score":0.082012765,"about_ca_system_score_codex":0.0000792814,"about_ca_system_score_gemma":0.00001159563,"threshold_uncertainty_score":0.4034773},"labels":[],"label_agreement":null},{"id":"W4321169417","doi":"10.1007/s12325-023-02450-z","title":"Breast Cancer Screening Should Embrace Precision Medicine: Evidence by Reviewing Economic Evaluations in China","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China; China Medical Board","keywords":"Medicine; Breast cancer; Rheumatology; Alternative medicine; Cancer; China; Family medicine; Internal medicine; Precision medicine; Medical physics; Oncology; Traditional medicine; Intensive care medicine; Pathology","score_opus":0.2995815257093418,"score_gpt":0.5379578317870879,"score_spread":0.23837630607774607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321169417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000082879356,0.99545634,0.00017791084,0.0010147254,0.0005941511,0.0021236765,0.0000796743,0.00008322196,0.00038743264],"genre_scores_gemma":[0.00009483526,0.9971641,0.000363363,0.00035977914,0.0005919025,0.0008784785,0.00009256858,0.00010650675,0.00034849206],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956412,0.00042102407,0.0016110181,0.0010201288,0.0007047702,0.0006018751],"domain_scores_gemma":[0.99741584,0.00094994286,0.00068314216,0.0007117441,0.00008114439,0.00015818802],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025493344,0.0006337466,0.0026668236,0.00053286843,0.00010167916,0.000033627468,0.0005981396,0.00031317634,0.00050689635],"category_scores_gemma":[0.00038292437,0.0004807,0.00032814554,0.0013363699,0.00013924354,0.00095330935,0.0000969466,0.0010230142,0.00006543922],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011907939,0.000017576738,0.0007589529,0.0033069998,0.000055672936,0.000024795285,0.00014197367,0.00036443444,0.0000020356247,0.000018955989,0.0014130832,0.99377644],"study_design_scores_gemma":[0.0008379583,0.00016746078,0.00066591724,0.2873438,0.00021807829,0.00011128538,0.00006891917,0.00022320043,0.0000010986641,0.00017256744,0.70975363,0.00043610125],"about_ca_topic_score_codex":0.001499621,"about_ca_topic_score_gemma":0.0008202389,"teacher_disagreement_score":0.9933403,"about_ca_system_score_codex":0.0011323721,"about_ca_system_score_gemma":0.0006112562,"threshold_uncertainty_score":0.99976444},"labels":[],"label_agreement":null},{"id":"W4321604810","doi":"10.1007/s12325-022-02391-z","title":"Venous Thromboembolism Recurrence Among Patients Who Abandon Oral Anticoagulant Therapy in the USA: A Retrospective Longitudinal Study","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Venous thromboembolism; Anticoagulant therapy; Retrospective cohort study; Rheumatology; Internal medicine; Oral anticoagulant; Intensive care medicine; Warfarin; Atrial fibrillation; Thrombosis","score_opus":0.042814122044271576,"score_gpt":0.34948516422770154,"score_spread":0.30667104218342994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321604810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99338007,0.0019556603,0.000008991068,0.00021837525,0.0005278,0.003011954,0.0000073946917,0.00006323858,0.00082651275],"genre_scores_gemma":[0.96026134,0.038628682,0.000025793131,0.000444022,0.00011338865,0.00044548488,0.000020389956,0.000035928082,0.000024963776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973605,0.000252797,0.00046629334,0.000623514,0.00069529866,0.00060155557],"domain_scores_gemma":[0.9989647,0.00014188013,0.00016238769,0.00057736,0.000094410985,0.00005922685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087858795,0.00032521217,0.00092985877,0.00032722042,0.00015103833,0.000056011908,0.00039130443,0.00007201271,0.000058451245],"category_scores_gemma":[0.000063073945,0.00021599914,0.000106996,0.0013866192,0.00016218398,0.0003843942,0.00006620099,0.00039774607,0.000035743087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022150393,0.0048908116,0.9457688,0.000016226342,0.000091044116,0.00015001865,0.008266848,0.000056868404,0.000012531975,0.00027435977,0.00024766658,0.040003367],"study_design_scores_gemma":[0.0056090285,0.0038841283,0.9866082,0.000157845,0.000022564358,0.0000023940356,0.0010584069,0.000049999315,0.000053928812,0.0011610126,0.0011542642,0.00023822399],"about_ca_topic_score_codex":0.0010418156,"about_ca_topic_score_gemma":0.0026101747,"teacher_disagreement_score":0.040839452,"about_ca_system_score_codex":0.00013320798,"about_ca_system_score_gemma":0.00003488359,"threshold_uncertainty_score":0.88081896},"labels":[],"label_agreement":null},{"id":"W4324017399","doi":"10.1007/s12325-023-02458-5","title":"Treatment Patterns Among Patients with Attention-Deficit/Hyperactivity Disorder and Comorbid Anxiety and/or Depression in the United States: A Retrospective Claims Analysis","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Allergan; Otsuka Pharmaceutical; Neos Therapeutics; Pfizer","keywords":"Comorbidity; Anxiety; Depression (economics); Medicine; Discontinuation; Psychiatry; Attention deficit hyperactivity disorder; Odds ratio; Internal medicine","score_opus":0.01650501657985638,"score_gpt":0.3147274902662078,"score_spread":0.2982224736863514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324017399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980775,0.0003865657,0.00024741047,0.00025509726,0.00002633185,0.0008840393,0.00004580361,0.000048707585,0.000028526138],"genre_scores_gemma":[0.9815982,0.017639238,0.000036829922,0.00007593733,0.000009551072,0.00018021002,0.0003844309,0.000024866997,0.000050716153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985284,0.00020010583,0.00022896793,0.00045732292,0.0003239475,0.00026125507],"domain_scores_gemma":[0.9991841,0.00025754256,0.00012888396,0.0003080323,0.00007218873,0.00004930292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016261922,0.00023808231,0.00040670173,0.00045125725,0.00012321996,0.00003491411,0.000063211024,0.00006713759,0.00003604632],"category_scores_gemma":[0.000026228969,0.00013229658,0.00006331816,0.0018469726,0.00011484498,0.00041820997,0.000025913168,0.00021898118,0.0000019296206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075072283,0.0008029866,0.9846892,0.000015613332,0.00017932481,0.000021450021,0.0008792124,0.0007527823,0.0000106396665,0.000004394813,4.9745944e-7,0.011893211],"study_design_scores_gemma":[0.0059328927,0.00051597174,0.98401964,0.000060160477,0.00012043704,0.0000053265085,0.0056484737,0.003355766,0.0000018281082,0.000026971356,0.00014945162,0.0001630915],"about_ca_topic_score_codex":0.0013098193,"about_ca_topic_score_gemma":0.0057922225,"teacher_disagreement_score":0.017252672,"about_ca_system_score_codex":0.00009805957,"about_ca_system_score_gemma":0.000013991095,"threshold_uncertainty_score":0.5394898},"labels":[],"label_agreement":null},{"id":"W4324311138","doi":"10.1007/s12325-023-02470-9","title":"Cost-Effectiveness of Brentuximab Vedotin Versus Physician’s Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"Seagen","keywords":"Bexarotene; Medicine; Brentuximab vedotin; Methotrexate; Internal medicine; Oncology; Cutaneous T-cell lymphoma; Lymphoma; Mycosis fungoides; Dermatology; Hodgkin lymphoma","score_opus":0.08365397874228304,"score_gpt":0.4042393616517976,"score_spread":0.32058538290951455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324311138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778987,0.008598778,0.000056641235,0.00008092274,0.00017862016,0.0029969986,0.00011189494,0.000008924894,0.00017735439],"genre_scores_gemma":[0.9769131,0.022178188,0.0001299012,0.000026321655,0.000023877757,0.00057230145,0.000027526568,0.00003326984,0.00009552523],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841315,0.00021803571,0.00039445143,0.0002732942,0.00036382233,0.00033724398],"domain_scores_gemma":[0.99396557,0.0052963146,0.0001781593,0.0003476242,0.00017307955,0.000039263807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022969702,0.0001950048,0.0006835832,0.00016224483,0.00002920361,0.0000023579066,0.00018532241,0.000041022256,0.000015951091],"category_scores_gemma":[0.00015603544,0.00012636297,0.0001091796,0.00082919217,0.00014173405,0.000047330457,0.000016431768,0.00004857816,6.7185437e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059338983,0.0028423138,0.0354976,0.00085922936,0.00036109358,0.00015639541,0.001510469,0.011042494,0.056063395,0.000039050647,0.00001666752,0.8322723],"study_design_scores_gemma":[0.07165919,0.010997373,0.029155022,0.0004959138,0.00008393258,0.000031305608,0.0035150996,0.008314083,0.8645159,0.00032151636,0.010568562,0.00034210374],"about_ca_topic_score_codex":0.1940938,"about_ca_topic_score_gemma":0.39304668,"teacher_disagreement_score":0.8319302,"about_ca_system_score_codex":0.0008014243,"about_ca_system_score_gemma":0.0010803321,"threshold_uncertainty_score":0.8112728},"labels":[],"label_agreement":null},{"id":"W4327680697","doi":"10.1007/s12325-023-02457-6","title":"Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"AbbVie","keywords":"Medicine; Ustekinumab; Infliximab; Adalimumab; Vedolizumab; Certolizumab pegol; Systematic review; Golimumab; De-escalation; Internal medicine; MEDLINE; Cochrane Library; Ulcerative colitis; Guideline; Tofacitinib; Meta-analysis; Disease; Pathology","score_opus":0.013942766061465902,"score_gpt":0.3245184971234345,"score_spread":0.3105757310619686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327680697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020647782,0.99402446,0.000008675706,0.000009529812,0.000102397695,0.0035000981,0.000261967,0.000013582459,0.000014510728],"genre_scores_gemma":[0.0004141051,0.9971063,0.000037625305,0.0001168376,0.00006123097,0.0016982068,0.00041432356,0.00006373336,0.00008762658],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9974938,0.0007033338,0.00088547973,0.0005145248,0.00016941043,0.00023343116],"domain_scores_gemma":[0.99872243,0.00008778022,0.0005207219,0.0005058695,0.00008250713,0.00008069924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037588895,0.00042393742,0.0012546316,0.00016863075,0.000025824555,0.000024198845,0.00023502122,0.00017786128,0.0000061084584],"category_scores_gemma":[0.00016239897,0.00033140264,0.00023161346,0.00029600816,0.00006662036,0.0000311571,0.00005770592,0.00018111302,0.0000024717579],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032308654,0.00007551722,0.00035206098,0.77127373,0.00013357028,0.00029735744,0.00019730908,0.000012099582,0.0000037931488,0.00013072453,0.000007637602,0.22719313],"study_design_scores_gemma":[0.0011501316,0.000087388566,0.013459868,0.93932784,0.00017213385,0.000010578307,0.00006539256,0.0000046435352,0.0000029761889,0.0002811495,0.04482063,0.00061727135],"about_ca_topic_score_codex":0.0000012604038,"about_ca_topic_score_gemma":0.00011460575,"teacher_disagreement_score":0.22657585,"about_ca_system_score_codex":0.000042187978,"about_ca_system_score_gemma":0.0001309272,"threshold_uncertainty_score":0.9999138},"labels":[],"label_agreement":null},{"id":"W4353015402","doi":"10.1007/s12325-023-02483-4","title":"Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Atrial fibrillation; Internal medicine; Cardiology; Stroke (engine); Embolism; Rheumatology; Oral anticoagulant; Anticoagulant; Ischemic stroke; Rivaroxaban; Warfarin; Ischemia","score_opus":0.03123094527149826,"score_gpt":0.3188026856673539,"score_spread":0.28757174039585565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353015402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99040586,0.007235366,0.00011443806,0.0003627694,0.00023466814,0.000685646,0.0000037457125,0.00010804103,0.0008494525],"genre_scores_gemma":[0.9712328,0.02668354,0.00049369194,0.000049450624,0.00068011944,0.0000026764314,0.000025692676,0.000026250551,0.0008058053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989686,0.00004483609,0.00025151813,0.0002777733,0.00024837823,0.00020889948],"domain_scores_gemma":[0.99948716,0.00015178499,0.00010701399,0.00016150328,0.000034570778,0.00005798826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027892884,0.00015835883,0.00043343566,0.00019421017,0.0000599917,0.000028259285,0.000038726626,0.00006276055,0.000008331932],"category_scores_gemma":[0.000043979828,0.00012233485,0.00006268734,0.00032914596,0.00008407162,0.00036950523,0.000027864176,0.00007472043,0.000007360028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011663362,0.0000020552272,0.9643576,0.000095890784,0.00015226258,0.000019474559,0.000400829,0.001250373,0.003970319,0.00008242213,0.000057465633,0.028444983],"study_design_scores_gemma":[0.019936116,0.000855312,0.88707167,0.00081260403,0.00030305155,0.000046597117,0.0014386006,0.004877202,0.003038039,0.0001107869,0.08083877,0.0006712448],"about_ca_topic_score_codex":0.000049641356,"about_ca_topic_score_gemma":0.000021772388,"teacher_disagreement_score":0.0807813,"about_ca_system_score_codex":0.000026137028,"about_ca_system_score_gemma":0.00001745907,"threshold_uncertainty_score":0.49886706},"labels":[],"label_agreement":null},{"id":"W4360815487","doi":"10.1007/s12325-023-02443-y","title":"Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Genetic and Kidney Cyst Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Bardet–Biedl syndrome; Rheumatology; Quality of life (healthcare); Internal medicine; Pediatrics; Gerontology; Nursing; Phenotype; Genetics","score_opus":0.01580107757091467,"score_gpt":0.2864216264118373,"score_spread":0.2706205488409227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360815487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871359,0.012477818,0.000042004805,0.00003552826,0.000028988636,0.00023049713,0.000021087371,0.000003641367,0.00002457321],"genre_scores_gemma":[0.9962694,0.0033783158,0.00014256235,0.00006070185,0.000003773529,0.000091456146,0.000035361427,0.0000073543424,0.00001107041],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992494,0.00008023117,0.00025521917,0.00023026367,0.0000714706,0.00011340515],"domain_scores_gemma":[0.9996013,0.000025818843,0.00012646778,0.00016615802,0.000028918806,0.000051342493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008497706,0.00011017922,0.000225546,0.000051394374,0.0000115568355,0.0000030134777,0.000050252827,0.000038885457,0.000005215477],"category_scores_gemma":[0.00002887332,0.000080898055,0.0000275337,0.00010861058,0.00014986594,0.0000057255256,0.00001922895,0.00001765932,6.207499e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031721536,0.0007947966,0.4948374,0.00040263374,0.00026047716,0.000046153124,0.016999377,0.000731719,0.4043556,0.0000073990755,0.0000263191,0.07836599],"study_design_scores_gemma":[0.008479865,0.007228294,0.3165451,0.0001745493,0.000021664824,0.000009326959,0.028295761,0.00021881865,0.63638264,0.00012031091,0.0020332602,0.0004903839],"about_ca_topic_score_codex":0.000091425914,"about_ca_topic_score_gemma":0.00016635153,"teacher_disagreement_score":0.23202707,"about_ca_system_score_codex":0.00000578569,"about_ca_system_score_gemma":0.0000693464,"threshold_uncertainty_score":0.3298927},"labels":[],"label_agreement":null},{"id":"W4361303012","doi":"10.1007/s12325-023-02475-4","title":"Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Janssen Research and Development; Janssen Scientific Affairs","keywords":"Medicine; Ustekinumab; Psoriatic arthritis; Secukinumab; Sacroiliitis; Internal medicine; Axial spondyloarthritis; Ankylosing spondylitis; Human leukocyte antigen; Immunology; Oncology; Rheumatology; Adalimumab; Arthritis; Rheumatoid arthritis; Antigen","score_opus":0.10104494604942928,"score_gpt":0.4457693522950448,"score_spread":0.3447244062456155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361303012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8092478,0.18854098,0.00016596525,0.0003941092,0.00045442494,0.00067163847,0.00040688337,0.00008192039,0.000036259484],"genre_scores_gemma":[0.68979824,0.3083311,0.00088968733,0.0001412656,0.0005427607,0.00010400477,0.0001552267,0.00002946108,0.000008254212],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99721247,0.00049342454,0.000987796,0.0006309258,0.00028522845,0.00039014703],"domain_scores_gemma":[0.9979546,0.0012356126,0.00021673774,0.00030337952,0.00006547463,0.0002241744],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067741185,0.0003107526,0.0012626513,0.0003305396,0.00019372554,0.00004905026,0.00007538293,0.00014128764,0.00007464507],"category_scores_gemma":[0.00057964626,0.00027031897,0.0002701887,0.0006507264,0.00036149865,0.00016634549,0.000048873168,0.00023030012,0.000011972998],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012019373,0.00022048144,0.15661472,0.000011056416,0.00049741764,0.00077395607,0.00014130815,0.0000024718524,0.00055542233,0.000026304213,0.000033611173,0.8399213],"study_design_scores_gemma":[0.07321753,0.0062331106,0.89650375,0.0005523057,0.00054910727,0.000114996285,0.00047895947,0.000079762336,0.00031956058,0.0074434434,0.013942094,0.00056536024],"about_ca_topic_score_codex":0.00015678718,"about_ca_topic_score_gemma":0.00032739632,"teacher_disagreement_score":0.83935595,"about_ca_system_score_codex":0.000019813777,"about_ca_system_score_gemma":0.000039802344,"threshold_uncertainty_score":0.9999749},"labels":[],"label_agreement":null},{"id":"W4362507047","doi":"10.1007/s12325-023-02495-0","title":"A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”","year":2023,"lang":"en","type":"letter","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Fluticasone propionate; COPD; Meta-analysis; Internal medicine; Pharmacology; Corticosteroid","score_opus":0.0768440390173844,"score_gpt":0.3648680601505049,"score_spread":0.2880240211331205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362507047","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009082508,0.14850487,0.002409012,0.81926256,0.002692994,0.016427862,0.0013494524,0.00018405075,0.00008667026],"genre_scores_gemma":[0.030871246,0.035748024,0.0038830556,0.8236039,0.053761765,0.031262573,0.0006272632,0.001261429,0.018980736],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932787,0.001441154,0.0010280763,0.0013725245,0.0015201172,0.0013594241],"domain_scores_gemma":[0.99086297,0.00558714,0.0004966354,0.002466268,0.00040068445,0.00018629045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017668743,0.0010620584,0.0031469974,0.000694848,0.0003347869,0.00012616195,0.0011038642,0.00036465458,0.0004432872],"category_scores_gemma":[0.00009519424,0.0004978756,0.001987397,0.002451256,0.00042000052,0.0001562155,0.000076209566,0.0008950147,0.000038351493],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07235283,0.00064728403,0.0013619835,0.00014680352,0.12271715,0.00024008291,0.003977538,0.0056579392,0.00035928588,0.0000144189335,0.7831566,0.009368122],"study_design_scores_gemma":[0.0059394455,0.002669782,0.001235874,0.00009251385,0.009970069,0.000011986182,0.0003986611,0.0003078248,0.0002225064,0.000104464474,0.9785346,0.0005123153],"about_ca_topic_score_codex":0.00017540844,"about_ca_topic_score_gemma":0.00034600534,"teacher_disagreement_score":0.19537799,"about_ca_system_score_codex":0.00053758104,"about_ca_system_score_gemma":0.00027185102,"threshold_uncertainty_score":0.9997473},"labels":[],"label_agreement":null},{"id":"W4366238420","doi":"10.1007/s12325-023-02503-3","title":"The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Causal Inference Techniques","field":"Mathematics","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Defense Acquisition Program Administration; AstraZeneca","keywords":"Frequentist inference; Medicine; Bayesian probability; Expert opinion; Population; Survival analysis; Placebo; Relative survival; Statistics; Bayesian inference; Internal medicine; Intensive care medicine; Mathematics","score_opus":0.26403437545403435,"score_gpt":0.5460801964420338,"score_spread":0.2820458209879994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366238420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914762,0.0042328243,0.00062835147,0.00021635336,0.0010853141,0.0013698587,0.000004388094,0.0001210756,0.000865668],"genre_scores_gemma":[0.96181494,0.035109263,0.0024526957,0.000019249617,0.00020481915,0.00032247047,0.0000033443673,0.000037024314,0.000036214515],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9976445,0.00042642225,0.0011115688,0.00022682721,0.00032239468,0.00026829],"domain_scores_gemma":[0.9926291,0.006250185,0.0005348773,0.0005036615,0.00006392602,0.000018258823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028118445,0.00016306766,0.00054162095,0.000096872005,0.00005751079,0.000011206982,0.00050771015,0.00010112342,0.000005945339],"category_scores_gemma":[0.001523773,0.00008901344,0.00013972234,0.0004904004,0.00024411661,0.0002294949,0.00009206429,0.0003054278,9.637566e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00456308,0.00035048855,0.15939347,0.000033639564,0.00004008353,0.0000018805747,0.0021969096,0.000015744905,0.0006987372,0.04445181,0.000016480555,0.7882377],"study_design_scores_gemma":[0.013701414,0.0024230296,0.019369846,0.00025708257,0.0000044019853,0.0000012665662,0.0037152532,0.00013605425,0.014301883,0.9422119,0.003553654,0.00032419863],"about_ca_topic_score_codex":0.00003721166,"about_ca_topic_score_gemma":0.00029068036,"teacher_disagreement_score":0.8977601,"about_ca_system_score_codex":0.0000301324,"about_ca_system_score_gemma":0.00005378394,"threshold_uncertainty_score":0.36298627},"labels":[],"label_agreement":null},{"id":"W4367834624","doi":"10.1007/s12325-023-02482-5","title":"Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Seven Oaks General Hospital","funders":"AstraZeneca","keywords":"Medicine; Kidney disease; Rheumatology; Internal medicine; Stage (stratigraphy); Intensive care medicine; Disease; Disease management; Nephrology","score_opus":0.02155464134305796,"score_gpt":0.3464925788264291,"score_spread":0.32493793748337113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367834624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987882,0.009054858,0.0000011917813,0.0009953477,0.00012968134,0.0015904069,0.0000687989,0.000061062994,0.00021663212],"genre_scores_gemma":[0.96866626,0.029310072,0.000020477051,0.0010026542,0.00002880629,0.00041477403,0.00004953249,0.000023605124,0.00048384754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850434,0.00016902729,0.0004170901,0.0003217472,0.0003283177,0.00025945745],"domain_scores_gemma":[0.99861664,0.0005435702,0.00016526855,0.00042177207,0.000040818464,0.00021196049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039434177,0.00016572466,0.00040172742,0.0000905884,0.00005624887,0.000010049766,0.000100702775,0.00002921639,0.00007831651],"category_scores_gemma":[0.00032138312,0.0000949152,0.00009283564,0.00045033052,0.0001487358,0.00009483444,0.000063207786,0.00012824225,0.000004271187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043269957,0.0011759521,0.933681,0.00008077541,0.00041892668,0.000068003326,0.00023714369,0.000017029222,8.110671e-7,0.000024033612,0.0008424584,0.06302118],"study_design_scores_gemma":[0.007458429,0.0017352453,0.9777559,0.00035225638,0.00014684576,1.0753474e-7,0.00074441935,0.000059394817,0.000013632871,0.00023834805,0.011374224,0.000121171295],"about_ca_topic_score_codex":0.000023825922,"about_ca_topic_score_gemma":0.000090961454,"teacher_disagreement_score":0.06290001,"about_ca_system_score_codex":0.00009200005,"about_ca_system_score_gemma":0.00013872566,"threshold_uncertainty_score":0.38705295},"labels":[],"label_agreement":null},{"id":"W4379792157","doi":"10.1007/s12325-023-02560-8","title":"The Influence of Oral Cannabidiol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Untreated Hypertension: A Double-Blind, Placebo-Controlled, Cross-Over Pilot Study","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Cannabidiol; Medicine; Arterial stiffness; Blood pressure; Ambulatory blood pressure; Placebo; Heart rate; Cardiology; Crossover study; Ambulatory; Internal medicine; Anesthesia; Pathology","score_opus":0.033739390520634814,"score_gpt":0.34883872500381236,"score_spread":0.31509933448317756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379792157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99045885,0.0057552936,6.26923e-8,0.00063810777,0.00021494897,0.0028227514,0.000011314269,0.0000374737,0.00006117624],"genre_scores_gemma":[0.99501073,0.0026566235,0.0000016775787,0.00012296137,0.00007729233,0.00062873994,0.000004900027,0.000030312036,0.0014667643],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979672,0.00016805001,0.000476702,0.00043021323,0.0005330208,0.0004248392],"domain_scores_gemma":[0.99903506,0.000116921605,0.000115224415,0.00045533088,0.00018091108,0.00009656245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007252562,0.000233797,0.0006045353,0.00025067062,0.000121580124,0.00005343661,0.0001966321,0.00006975253,0.000024329953],"category_scores_gemma":[0.00011510216,0.00014444096,0.000049173494,0.000696608,0.00031904303,0.00017895865,0.00006130761,0.0003382453,0.0000032569453],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8019277,0.0028395832,0.14009428,0.00011933781,0.00051126437,0.00046480613,0.0013995615,0.0071173157,0.028993558,0.00012751504,0.0005034098,0.015901677],"study_design_scores_gemma":[0.24010168,0.0040206066,0.74924207,0.00011872805,0.0000694652,0.000016520062,0.00037697086,0.00019735775,0.0008890499,0.00009694916,0.004682269,0.00018836599],"about_ca_topic_score_codex":0.0007973394,"about_ca_topic_score_gemma":0.0012291615,"teacher_disagreement_score":0.6091478,"about_ca_system_score_codex":0.000025348034,"about_ca_system_score_gemma":0.00015922896,"threshold_uncertainty_score":0.5890131},"labels":[],"label_agreement":null},{"id":"W4381113775","doi":"10.1007/s12325-023-02568-0","title":"Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Sun Pharma; Sanofi Genzyme; Incyte; Eli Lilly and Company; Ortho Dermatologics; Purdue Pharma; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Purdue University","keywords":"Medicine; Adverse effect; Psoriasis; Clinical trial; Psoriatic arthritis; Internal medicine; Dermatology; Population; Intensive care medicine","score_opus":0.03196367031395327,"score_gpt":0.3203321296975279,"score_spread":0.28836845938357464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381113775","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033684584,0.9914299,0.00002216982,0.00003694221,0.0007077092,0.005771376,0.0016352277,0.00002413336,0.00003568385],"genre_scores_gemma":[0.00006259737,0.9954963,0.00010041296,0.000035269735,0.000044896646,0.0027750619,0.0009877024,0.000061472434,0.00043633915],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780464,0.0003931604,0.0009282633,0.0004790265,0.00007377167,0.00032114564],"domain_scores_gemma":[0.9974259,0.0011514223,0.000747751,0.0005134723,0.00014152964,0.000019926456],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021296441,0.00056700973,0.0023446355,0.00016164877,0.00012047814,0.0000037045645,0.00032111013,0.00026406668,0.000035127116],"category_scores_gemma":[0.00003115852,0.00028576778,0.0004969886,0.00054567034,0.00013278745,0.00008994339,0.00002066391,0.00010876596,0.000023319479],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002030217,0.00049452175,0.000055558354,0.0038218773,0.0018882175,9.957583e-7,0.0011839588,0.00002207281,0.0000010819045,0.000056838468,0.00018119096,0.99026346],"study_design_scores_gemma":[0.004210701,0.002336392,0.000032603282,0.016811403,0.0007977275,0.000001966712,0.00013574043,1.1571314e-7,0.00014391408,0.000058511123,0.97516185,0.0003090586],"about_ca_topic_score_codex":0.000017602033,"about_ca_topic_score_gemma":0.00010338895,"teacher_disagreement_score":0.9899544,"about_ca_system_score_codex":0.00014181873,"about_ca_system_score_gemma":0.00017063678,"threshold_uncertainty_score":0.99995947},"labels":[],"label_agreement":null},{"id":"W4382182642","doi":"10.1007/s12325-023-02546-6","title":"Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn’s Disease","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"AbbVie","keywords":"Medicine; Ustekinumab; Crohn's disease; Internal medicine; Confidence interval; Maintenance therapy; Gastroenterology; Crohn disease; Clinical trial; Randomized controlled trial; Surgery; Disease; Chemotherapy; Adalimumab","score_opus":0.029267054082331632,"score_gpt":0.3186003664488895,"score_spread":0.28933331236655785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382182642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968349,0.0015027284,0.0006033357,0.000055451143,0.00006875609,0.00071964366,0.0001743671,0.000016986678,0.00002387027],"genre_scores_gemma":[0.9964954,0.0026781296,0.00032073795,0.000036913796,0.000068274836,0.00019920747,0.00010828472,0.000021640048,0.00007136312],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99917203,0.000054562846,0.00018689525,0.0003219365,0.00007210811,0.00019246682],"domain_scores_gemma":[0.99958056,0.0000343899,0.00008878989,0.00016026452,0.00004279846,0.00009318587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006882355,0.00015479993,0.00021188216,0.00008027016,0.00006114167,0.000012245095,0.000060342198,0.00006272274,0.0000016299664],"category_scores_gemma":[0.0000189655,0.0001392386,0.000038346487,0.000098020646,0.00006162703,0.000019719933,0.000025899828,0.000032022388,7.623544e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058495488,0.00050337,0.1879018,0.0003049482,0.0004215373,0.00008963344,0.006607253,0.01201562,0.013908407,0.00029559445,0.0002176348,0.7192387],"study_design_scores_gemma":[0.002418941,0.00042054363,0.97903645,0.000032188404,0.000018026747,0.000001049264,0.000354503,0.00025424038,0.013117053,0.0017302545,0.00242453,0.0001922292],"about_ca_topic_score_codex":0.000017839986,"about_ca_topic_score_gemma":0.00008796207,"teacher_disagreement_score":0.79113466,"about_ca_system_score_codex":0.000037997415,"about_ca_system_score_gemma":0.000041908956,"threshold_uncertainty_score":0.56779855},"labels":[],"label_agreement":null},{"id":"W4382501551","doi":"10.1007/s12325-023-02583-1","title":"DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"Manchester Biomedical Research Centre; McMaster University; Glenmark Pharmaceuticals; CSL Behring; Gilead Sciences; Sanofi; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Genentech; AstraZeneca","keywords":"Medicine; Fluticasone propionate; COPD; Lama; Indacaterol; Exacerbation; Bronchodilator; Pharmacotherapy; Internal medicine; Obstructive lung disease; Corticosteroid; Asthma","score_opus":0.03633041686003346,"score_gpt":0.35346605408801324,"score_spread":0.31713563722797977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382501551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98268074,0.010338052,0.0037280128,0.000086824584,0.00008055542,0.0025205896,0.00006021082,0.0001109256,0.00039408784],"genre_scores_gemma":[0.9896475,0.0073471623,0.0018270247,0.000063333224,0.0001198225,0.0007164092,0.000110847184,0.00006866855,0.000099197336],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9975418,0.00020364053,0.0004770784,0.00054928835,0.0007351898,0.0004929987],"domain_scores_gemma":[0.9989886,0.0001723104,0.00018134464,0.00030077592,0.00014414277,0.00021280105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003763082,0.0002631521,0.00045526747,0.0005334517,0.00006781873,0.000015792011,0.00014697877,0.00008020443,0.00006274967],"category_scores_gemma":[0.00003640938,0.00019556214,0.00007452199,0.0015125895,0.00020484808,0.00069141004,0.000036130543,0.00036786648,0.0000039136767],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09852835,0.0027885258,0.6076996,0.0014106618,0.0002355702,0.0015387778,0.006223167,0.10514489,0.0038095377,0.00019194969,0.000030971227,0.172398],"study_design_scores_gemma":[0.04383836,0.0020244936,0.2864399,0.0019141919,0.00007173487,0.000049828486,0.0019554314,0.6560181,0.00473806,0.0013200499,0.0009184437,0.00071144185],"about_ca_topic_score_codex":0.000029057308,"about_ca_topic_score_gemma":0.000009954444,"teacher_disagreement_score":0.55087316,"about_ca_system_score_codex":0.00029997327,"about_ca_system_score_gemma":0.00044993171,"threshold_uncertainty_score":0.7974793},"labels":[],"label_agreement":null},{"id":"W4385331142","doi":"10.1007/s12325-023-02613-y","title":"Correction to: DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach","year":2023,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; Bronchodilator; COPD; Pharmacotherapy; Intensive care medicine; Disease; Rheumatology; Internal medicine; Asthma","score_opus":0.02996748469507819,"score_gpt":0.33206791315865947,"score_spread":0.30210042846358126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385331142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.759059,0.068870455,0.07660836,0.00036554178,0.055253107,0.023458939,0.00039175857,0.0011198077,0.014873053],"genre_scores_gemma":[0.900215,0.05137707,0.0045874882,0.0015507429,0.0035404193,0.003021478,0.0015301504,0.0006029234,0.033574693],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99734485,0.00023074906,0.0007366194,0.0006312025,0.0006966065,0.0003599884],"domain_scores_gemma":[0.9986892,0.00014374072,0.00046393156,0.00028408752,0.00024424234,0.00017484494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003744134,0.00040925556,0.00072538387,0.00088396884,0.00007971401,0.000022069284,0.00012282186,0.00026787975,0.00003531172],"category_scores_gemma":[0.00005980528,0.00029923292,0.000105735286,0.001238441,0.0000915209,0.0004469775,0.000021582446,0.00092914427,0.0000053649505],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18968451,0.0048482325,0.040934306,0.002942182,0.0007068968,0.0015542972,0.021907568,0.48650628,0.001456697,0.000034719462,0.043416366,0.20600794],"study_design_scores_gemma":[0.048154224,0.00849443,0.010458332,0.02088759,0.00031863796,0.00010069497,0.002440119,0.8195784,0.0039348993,0.00010322959,0.08315303,0.00237638],"about_ca_topic_score_codex":0.000031447584,"about_ca_topic_score_gemma":0.000045406174,"teacher_disagreement_score":0.33307216,"about_ca_system_score_codex":0.0003014414,"about_ca_system_score_gemma":0.000649243,"threshold_uncertainty_score":0.999946},"labels":[],"label_agreement":null},{"id":"W4385340634","doi":"10.1007/s12325-023-02611-0","title":"Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dalhousie University; University of British Columbia","funders":"","keywords":"Ustekinumab; Medicine; Persistence (discontinuity); Internal medicine; Hazard ratio; Proportional hazards model; Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; Confidence interval; Population; Retrospective cohort study; Disease; Gastroenterology; Adalimumab","score_opus":0.014665309315881551,"score_gpt":0.28743616060410565,"score_spread":0.2727708512882241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385340634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954476,0.0033119866,0.0000022210058,0.000046567166,0.00006995955,0.00031275838,0.000023698562,0.000007208911,0.0007780302],"genre_scores_gemma":[0.97224677,0.02733693,0.00003127093,0.000041708194,0.00004445057,0.0000993589,0.00003346434,0.000012380252,0.00015368279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912924,0.00011160007,0.00025111553,0.00019921597,0.00013752184,0.00017129375],"domain_scores_gemma":[0.99937594,0.00003473098,0.00010033853,0.00042343917,0.000029999563,0.000035530284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015430475,0.000119878794,0.00011923516,0.000103230195,0.000020210973,0.000003340709,0.00022628985,0.00003307828,0.000009381448],"category_scores_gemma":[0.000018022332,0.00008835744,0.000097556716,0.00020922131,0.00013872393,0.00000975789,0.000015876618,0.000030000576,0.0000029885944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002345597,0.0005572926,0.95226777,0.00012362187,0.00004343354,0.0002148327,0.0020179127,0.005049414,0.022283562,0.0007445196,0.0000676612,0.014284403],"study_design_scores_gemma":[0.0016350731,0.00025765863,0.974409,0.000039636347,0.0000072502125,4.7356227e-7,0.0005807086,0.00012498474,0.009517464,0.0005135258,0.012769779,0.00014444639],"about_ca_topic_score_codex":0.000016662714,"about_ca_topic_score_gemma":0.00042353736,"teacher_disagreement_score":0.024024945,"about_ca_system_score_codex":0.000025697098,"about_ca_system_score_gemma":0.00007898812,"threshold_uncertainty_score":0.36031118},"labels":[],"label_agreement":null},{"id":"W4385396235","doi":"10.1007/s12325-023-02622-x","title":"The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Mental Health Treatment and Access","field":"Psychology","cited_by":194,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Sage Therapeutics; Biogen","keywords":"Major depressive disorder; Medicine; Presenteeism; Absenteeism; Economic cost; Indirect costs; Economic impact analysis; Psychological intervention; Psychiatry; Demography; Environmental health; Gerontology; Psychology; Business; Economics; Mood","score_opus":0.013943775197073006,"score_gpt":0.3560974645480499,"score_spread":0.3421536893509769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385396235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986515,0.010776759,0.000003651209,0.0010610585,0.00018465836,0.0005832719,0.000018888008,0.000015889575,0.0008408192],"genre_scores_gemma":[0.9773003,0.021808134,0.000011090979,0.00016999857,0.00003176651,0.00031690352,0.00006945096,0.000012681639,0.00027966825],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991866,0.00014591355,0.0001982286,0.00016160193,0.00007090101,0.00023677551],"domain_scores_gemma":[0.9990518,0.00056601845,0.00010778191,0.00025083098,0.00000970847,0.000013853344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001793735,0.00009774349,0.00011688034,0.00008873969,0.00009358205,0.000011085487,0.00030299553,0.000027764885,0.00008575315],"category_scores_gemma":[0.000002449687,0.000046691683,0.000016901071,0.0003142368,0.0001015292,0.000103613245,0.000013526161,0.00009052626,0.0000466614],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005801544,0.00027487698,0.2784451,0.000050372793,0.00011510429,0.000055261655,0.05112355,0.009417679,0.0000066890143,0.0060812854,0.0009724111,0.64765614],"study_design_scores_gemma":[0.037550807,0.0027430377,0.4959271,0.00048008608,0.000024469686,0.000016881031,0.14260185,0.0029209566,0.00058322394,0.0328943,0.28345618,0.0008011121],"about_ca_topic_score_codex":0.00385556,"about_ca_topic_score_gemma":0.0032408417,"teacher_disagreement_score":0.646855,"about_ca_system_score_codex":0.000026606258,"about_ca_system_score_gemma":0.000009067677,"threshold_uncertainty_score":0.5828479},"labels":[],"label_agreement":null},{"id":"W4385564153","doi":"10.1007/s12325-023-02609-8","title":"Implementing an Evidence-Based COPD Hospital Discharge Protocol: A Narrative Review and Expert Recommendations","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Emergency and Acute Care Studies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; AstraZeneca","keywords":"Medicine; COPD; Exacerbation; Health care; Intensive care medicine; Pulmonary rehabilitation; Protocol (science); Population; Physical therapy; Internal medicine; Alternative medicine; Environmental health; Pathology","score_opus":0.1258795260672343,"score_gpt":0.5087637387316973,"score_spread":0.38288421266446304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385564153","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.4740655e-7,0.9332089,0.000010043102,0.00182841,0.00018222169,0.064526655,0.00004415859,0.00007436867,0.00012452896],"genre_scores_gemma":[2.2803972e-7,0.82703173,0.00042718774,0.0007831217,0.00016389803,0.17130877,0.00014629845,0.000048211205,0.00009057782],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978129,0.00026431866,0.00080893317,0.0005514032,0.00018383288,0.00037857253],"domain_scores_gemma":[0.99877995,0.0002766565,0.0004009727,0.00034780052,0.000117595766,0.00007700041],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060202775,0.0004188626,0.001604497,0.00013475816,0.00020896617,0.000015912243,0.00016015206,0.000082012186,0.00023433252],"category_scores_gemma":[0.00023577685,0.00028516236,0.00022539026,0.0005849177,0.00009143594,0.00052233646,0.00006610944,0.00032170388,0.000007521047],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014254637,0.00009837251,0.00004411219,0.030945826,0.00012370705,0.0000074199424,0.0009843339,1.3576689e-8,2.8305487e-7,0.000052810516,0.004306421,0.9634224],"study_design_scores_gemma":[0.0004520157,0.00048778398,0.000002915322,0.13355663,0.00012720714,0.0000030396893,0.0005846708,5.7681694e-7,0.0000013192903,0.000049858343,0.8644662,0.0002678131],"about_ca_topic_score_codex":0.000011667792,"about_ca_topic_score_gemma":0.000051218867,"teacher_disagreement_score":0.9631546,"about_ca_system_score_codex":0.00007605318,"about_ca_system_score_gemma":0.00016269492,"threshold_uncertainty_score":0.99996006},"labels":[],"label_agreement":null},{"id":"W4385779498","doi":"10.1007/s12325-023-02606-x","title":"Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Crizotinib; Brain metastasis; Anaplastic lymphoma kinase; Internal medicine; Oncology; ALK inhibitor; Lung cancer; Interim analysis; Tyrosine-kinase inhibitor; Progression-free survival; Metastasis; Clinical trial; Cancer; Overall survival","score_opus":0.02005702054535472,"score_gpt":0.364229775795692,"score_spread":0.34417275525033725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385779498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98688126,0.0011312315,0.00217736,0.0033361034,0.00012116834,0.0044074226,0.0003976797,0.000118611846,0.0014291842],"genre_scores_gemma":[0.9886986,0.0019318366,0.0051609417,0.00071249966,0.000048844264,0.0015296444,0.001001102,0.000057100435,0.00085945515],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9989559,0.000033137236,0.00018593454,0.00033894743,0.00023141583,0.00025466704],"domain_scores_gemma":[0.9991869,0.0003315975,0.00010529638,0.00020142345,0.000102376966,0.000072425675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006210397,0.00023342611,0.0003241724,0.00017675945,0.00010744419,0.000015179115,0.00004012016,0.000022251485,0.000030631272],"category_scores_gemma":[0.00001970369,0.0001347509,0.00006281159,0.000424265,0.000051276616,0.00020362236,0.000004101358,0.00004897427,0.000019341984],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024741182,0.00433391,0.02971336,0.00008704748,0.0022050482,0.00012483059,0.0046483655,0.008850162,0.000039237853,0.0018872172,0.00010686111,0.9232628],"study_design_scores_gemma":[0.26704964,0.2927829,0.21787418,0.0027906997,0.0027549742,0.00006805299,0.0037963716,0.0022488383,0.007856101,0.008739949,0.19204189,0.0019963859],"about_ca_topic_score_codex":0.00006683231,"about_ca_topic_score_gemma":0.00030955698,"teacher_disagreement_score":0.9212664,"about_ca_system_score_codex":0.00024511013,"about_ca_system_score_gemma":0.000082860824,"threshold_uncertainty_score":0.5494982},"labels":[],"label_agreement":null},{"id":"W4386757238","doi":"10.1007/s12325-023-02634-7","title":"Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Medicine; Prostate cancer; Concomitant; Internal medicine; Adverse effect; Urology; Population; Cancer","score_opus":0.02484750801981962,"score_gpt":0.37897592618127074,"score_spread":0.35412841816145113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386757238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92521566,0.072855644,0.0000029945868,0.000095485484,0.000047364076,0.0015976186,0.000095902,0.000024915364,0.00006442362],"genre_scores_gemma":[0.8457339,0.1539167,0.000039622835,0.000012193938,0.000019492763,0.00017368713,0.000036550857,0.000024275181,0.000043592423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980669,0.00020406515,0.0004921845,0.00045170152,0.00045526001,0.00032985967],"domain_scores_gemma":[0.998869,0.0003328913,0.00013976693,0.0004952079,0.00009430287,0.00006885822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048729643,0.00023591155,0.0011266454,0.0005440911,0.00003265584,0.0000069197695,0.00012046435,0.00005828771,0.000039698054],"category_scores_gemma":[0.000036256668,0.0001564229,0.00029066158,0.0018928358,0.00016915498,0.00015655819,0.00003134378,0.00020117262,9.898566e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020071577,0.0005665991,0.8596393,0.00003782987,0.0038558138,0.00007036846,0.0053227786,0.012392059,0.002075838,0.0000036243114,0.0000020188443,0.095962174],"study_design_scores_gemma":[0.021619905,0.002896032,0.9705652,0.0001992804,0.00017576768,4.0385973e-7,0.0012359915,0.00016549636,0.002654048,0.00014696278,0.00019867442,0.00014222277],"about_ca_topic_score_codex":0.002258021,"about_ca_topic_score_gemma":0.00071412546,"teacher_disagreement_score":0.1109259,"about_ca_system_score_codex":0.00022398622,"about_ca_system_score_gemma":0.0001203173,"threshold_uncertainty_score":0.63787407},"labels":[],"label_agreement":null},{"id":"W4386878449","doi":"10.1007/s12325-023-02658-z","title":"Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Rheumatology; Connective Tissue Disorder; Internal medicine; Pulmonary hypertension; Retrospective cohort study; Cardiology; Connective tissue; Connective tissue disease; Surgery; Pathology; Disease","score_opus":0.01531175510773769,"score_gpt":0.3036201549384517,"score_spread":0.288308399830714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386878449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971857,0.00020896974,0.000014019685,0.00055462774,0.00006276234,0.0016202083,0.00012142447,0.00008364703,0.00014865874],"genre_scores_gemma":[0.99047714,0.0059017423,0.000024507392,0.00018579939,0.00001909933,0.00037845533,0.0028503374,0.000036014768,0.00012691205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773014,0.00033150666,0.00034340395,0.00056226534,0.00054136507,0.0004913428],"domain_scores_gemma":[0.99876976,0.0003585018,0.00011931103,0.00047664886,0.00016522918,0.000110527544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017232946,0.00032166668,0.0005952633,0.0012445296,0.00012732338,0.000020925636,0.00013300925,0.000075289136,0.0000895288],"category_scores_gemma":[0.000022728644,0.00017779288,0.00010964149,0.004499333,0.00015065883,0.00019597661,0.00001735706,0.00021642697,0.000012842945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034534882,0.0024480384,0.9808564,0.0000067520946,0.0004528848,0.0025063853,0.00041551905,0.0020520191,0.000029653378,0.000007695412,0.000007545034,0.0077636247],"study_design_scores_gemma":[0.009694281,0.002769823,0.9768526,0.00010124828,0.00013900649,0.0000040571563,0.00069632597,0.008658256,0.0000942505,0.00026045702,0.0005416403,0.00018808717],"about_ca_topic_score_codex":0.0064349966,"about_ca_topic_score_gemma":0.00782495,"teacher_disagreement_score":0.0075755375,"about_ca_system_score_codex":0.00033755347,"about_ca_system_score_gemma":0.00005545764,"threshold_uncertainty_score":0.97278327},"labels":[],"label_agreement":null},{"id":"W4387033069","doi":"10.1007/s12325-023-02661-4","title":"Symptom and Treatment Satisfaction in Members of the US and Canadian GBS/CIDP Foundations with a Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Toronto General Hospital","funders":"Grifols","keywords":"Medicine; Chronic inflammatory demyelinating polyneuropathy; Rheumatology; Polyneuropathy; Internal medicine; Physical therapy; Intensive care medicine; Immunology; Antibody","score_opus":0.009068447359378649,"score_gpt":0.2634096383506164,"score_spread":0.25434119099123775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387033069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954723,0.0037007483,8.905798e-7,0.00034476782,0.00005359121,0.00028748944,0.000005413729,0.000007774784,0.00012700811],"genre_scores_gemma":[0.9675819,0.032221705,0.00002079316,0.00008958004,0.000009389859,0.000053525833,0.0000015519739,0.000009516691,0.000012007295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99949557,0.00004037309,0.0001434638,0.0001176099,0.00007502568,0.00012798203],"domain_scores_gemma":[0.9997177,0.00007329593,0.00006155903,0.0000969949,0.000014874309,0.000035540415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058931884,0.00007639621,0.00013530692,0.000118903314,0.00004095919,0.0000034735194,0.00002347526,0.000020944126,0.000009269478],"category_scores_gemma":[0.000024872383,0.000050928214,0.000015817768,0.00029496642,0.00010989897,0.00009414735,0.0000073776505,0.000055204946,1.1396135e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049696344,0.000016386879,0.8804165,0.000023885254,0.000007956291,0.0000064373166,0.0007043119,0.0005853949,0.00041857702,0.000052723703,0.0000014443975,0.11771665],"study_design_scores_gemma":[0.0017112534,0.0005001348,0.9937896,0.00012897476,0.0000073378224,0.000005697711,0.0004485559,0.00064552017,0.00045623595,0.00008690388,0.002166814,0.000052983884],"about_ca_topic_score_codex":0.02237406,"about_ca_topic_score_gemma":0.53511626,"teacher_disagreement_score":0.51274216,"about_ca_system_score_codex":0.000090775575,"about_ca_system_score_gemma":0.0001165716,"threshold_uncertainty_score":0.98413604},"labels":[],"label_agreement":null},{"id":"W4387033778","doi":"10.1007/s12325-023-02668-x","title":"Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Nintedanib; Medicine; Vital capacity; DLCO; Internal medicine; Placebo; Idiopathic pulmonary fibrosis; Interstitial lung disease; Pulmonary fibrosis; Body mass index; Diffusing capacity; Lung; Pathology; Lung function","score_opus":0.0033951741558211042,"score_gpt":0.2510020789738331,"score_spread":0.24760690481801198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387033778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974535,0.001422374,0.00001590993,0.000042209118,0.0000698819,0.0008340125,0.00004424768,0.00003578055,0.00008209539],"genre_scores_gemma":[0.9983068,0.0011449357,0.00008034862,0.00004013415,0.000045370754,0.00014745293,0.00017799223,0.000037810525,0.000019147288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867344,0.00011473994,0.00033460773,0.0002984329,0.00027325738,0.00030550826],"domain_scores_gemma":[0.9993831,0.00016004151,0.00012657706,0.00020913586,0.00006214578,0.00005903104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022702292,0.00021723437,0.0004968763,0.0002850413,0.000018140461,0.0000066327934,0.000097067394,0.000058305788,0.000019893616],"category_scores_gemma":[0.000040752562,0.00014367263,0.000047369205,0.00069939607,0.00010373828,0.00022176818,0.000025330746,0.00019773292,0.000002534244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04945434,0.00044759968,0.9032391,0.0004417885,0.000016899627,0.00032471408,0.00017296575,0.00006200288,0.00082177133,0.000007722605,0.0000011238221,0.04501],"study_design_scores_gemma":[0.005319227,0.01543813,0.9722669,0.0035097674,0.000018538007,0.000006900412,0.000073807976,0.0011676501,0.0018479978,0.000016857384,0.00012481872,0.00020936645],"about_ca_topic_score_codex":0.000032581815,"about_ca_topic_score_gemma":0.0000149437765,"teacher_disagreement_score":0.06902786,"about_ca_system_score_codex":0.000083933155,"about_ca_system_score_gemma":0.000030062289,"threshold_uncertainty_score":0.58588},"labels":[],"label_agreement":null},{"id":"W4387128991","doi":"10.1007/s12325-023-02666-z","title":"Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"","keywords":"Medicine; Rosuvastatin; Statin; Double blind; Ezetimibe; Randomized controlled trial; Internal medicine; Pill; Simvastatin; Single blind; Atorvastatin; Rheumatology; Pharmacology; Alternative medicine; Placebo","score_opus":0.0329011302102163,"score_gpt":0.36149323518587934,"score_spread":0.32859210497566305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387128991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821041,0.0038941877,0.00010220014,0.00017894413,0.0000966147,0.013460685,0.00004005514,0.000022123057,0.000101086],"genre_scores_gemma":[0.98403525,0.014388357,0.00031179708,0.000065108434,0.000039033228,0.0008785813,0.00022215418,0.00003251305,0.000027209102],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966347,0.00071736606,0.001461916,0.00042973514,0.0004807404,0.0002755428],"domain_scores_gemma":[0.99739116,0.0014266826,0.00062936224,0.00029177777,0.00014553615,0.000115465635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002261549,0.0003063756,0.0029239275,0.00026310302,0.000041324594,0.000013307673,0.00006720032,0.00012202773,0.000006166714],"category_scores_gemma":[0.0001816598,0.00018550616,0.00023445569,0.0004034761,0.0002807874,0.0002298053,0.000021241216,0.00019778512,3.2537335e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79951984,0.0047662393,0.005030103,0.00007772977,0.00042918246,0.0000069199173,0.00077677506,0.000046172845,0.00023863143,0.000016978302,9.577436e-7,0.18909049],"study_design_scores_gemma":[0.9774889,0.011445425,0.009791143,0.00018290321,0.0001459255,0.0000018446318,0.00009354905,0.00018190283,0.00032674332,0.0000922983,0.000096815245,0.0001525735],"about_ca_topic_score_codex":0.00018995441,"about_ca_topic_score_gemma":0.00008081223,"teacher_disagreement_score":0.18893792,"about_ca_system_score_codex":0.00011571163,"about_ca_system_score_gemma":0.0001399291,"threshold_uncertainty_score":0.7564722},"labels":[],"label_agreement":null},{"id":"W4387129013","doi":"10.1007/s12325-023-02678-9","title":"Emotional Journey of Patients with Eosinophilic Esophagitis","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Eosinophilic Esophagitis","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Food Allergy Canada; American Partnership for Eosinophilic Disorders","keywords":"Eosinophilic esophagitis; Medicine; Dysphagia; Feeling; Quality of life (healthcare); Qualitative research; Enthusiasm; Disease; Physical therapy; Nursing; Internal medicine; Surgery; Psychology; Social psychology","score_opus":0.013065967431209698,"score_gpt":0.2879745948451665,"score_spread":0.27490862741395683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387129013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143857,0.005870699,0.00002301486,0.0004938376,0.0001785428,0.00038229552,0.000033914857,0.00007980332,0.0014993437],"genre_scores_gemma":[0.99348325,0.005063419,0.00065337704,0.0003489408,0.00009628984,0.00002615858,0.000088332315,0.000034894452,0.00020536284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986962,0.00003564879,0.00030218164,0.00024853612,0.00045452113,0.0002629171],"domain_scores_gemma":[0.99927694,0.0001040233,0.00011619552,0.00027606738,0.00014971934,0.00007706086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012280638,0.00015118394,0.00031204434,0.00027363736,0.000034366683,0.0000054928055,0.00011447201,0.000057468314,0.00022742776],"category_scores_gemma":[0.000046897134,0.00011880878,0.000054498643,0.0008005209,0.0001645433,0.00026797128,0.00001966413,0.00015840429,0.000038222064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045756955,0.0003447729,0.9204034,0.00005424137,0.00004032086,0.00006210074,0.0003001902,0.00012405822,0.00022448749,0.00056230236,0.00015121658,0.07727532],"study_design_scores_gemma":[0.005019444,0.0008592569,0.9857743,0.00019464844,0.0000069557,0.000012087579,0.00003315321,0.000027613578,0.0018559503,0.0026658867,0.003429706,0.000121040255],"about_ca_topic_score_codex":0.000007766997,"about_ca_topic_score_gemma":0.000009166935,"teacher_disagreement_score":0.07715428,"about_ca_system_score_codex":0.000050556613,"about_ca_system_score_gemma":0.000061015613,"threshold_uncertainty_score":0.48448813},"labels":[],"label_agreement":null},{"id":"W4387435562","doi":"10.1007/s12325-023-02638-3","title":"Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Merck KGaA","keywords":"Medicine; Multiple sclerosis; Health professionals; Health care; Patient care; Nursing; Psychiatry","score_opus":0.12068137943232986,"score_gpt":0.41307197642408294,"score_spread":0.29239059699175307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387435562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98591626,0.0025756147,0.000050484745,0.008389165,0.00011420388,0.0023243371,0.00046217177,0.000039047507,0.0001287268],"genre_scores_gemma":[0.98987776,0.006667897,0.0026026834,0.0001565311,0.000034274308,0.0005411524,0.00006178587,0.000020177293,0.00003775274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972364,0.0008859306,0.0003923075,0.00028078814,0.00085318345,0.00035144258],"domain_scores_gemma":[0.9948525,0.0028427886,0.00016635086,0.00043750132,0.0015984732,0.00010239872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025568688,0.00011543438,0.00030628179,0.00022241141,0.00063153723,0.00004781239,0.0005132735,0.000088588546,0.000004981615],"category_scores_gemma":[0.001371382,0.000086339816,0.000017526805,0.0041872393,0.0003498305,0.0005193386,0.00017117229,0.00017930234,0.000002036637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007491619,0.00003327693,0.69321483,0.00010219362,0.000014810277,1.8274922e-7,0.18636885,0.00021410853,0.0015204401,0.0006772456,0.0003082791,0.116796635],"study_design_scores_gemma":[0.0010631598,0.00055416924,0.6305537,0.0009627759,0.0000031589507,2.938616e-8,0.3353806,0.000008054901,0.017421503,0.00067118136,0.013178729,0.00020291493],"about_ca_topic_score_codex":0.0037954513,"about_ca_topic_score_gemma":0.09747485,"teacher_disagreement_score":0.14901175,"about_ca_system_score_codex":0.00019326028,"about_ca_system_score_gemma":0.00062589743,"threshold_uncertainty_score":0.9189939},"labels":[],"label_agreement":null},{"id":"W4387439795","doi":"10.1007/s12325-023-02674-z","title":"Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Terlipressin; Medicine; Hepatorenal syndrome; Dialysis; Renal function; Midodrine; Internal medicine; Kidney disease; Acute kidney injury; Intensive care medicine; Cirrhosis; Surgery; Anesthesia; Blood pressure","score_opus":0.0104294428506266,"score_gpt":0.27646038003819773,"score_spread":0.26603093718757115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387439795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977596,0.001023291,0.00021760148,0.000072758645,0.000051956424,0.0007130849,0.000068495865,0.000036610847,0.000056646895],"genre_scores_gemma":[0.9943631,0.004007749,0.00011460856,0.000023761764,0.000011262509,0.00022954437,0.0011921733,0.000012529603,0.000045230838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935275,0.000027313095,0.00017554307,0.00020149339,0.00012054476,0.00012238034],"domain_scores_gemma":[0.99968415,0.000034837736,0.000078638055,0.00011413901,0.00004047858,0.00004775533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005078576,0.00010165755,0.00025127636,0.00045577064,0.000020197102,0.0000034298296,0.000022667411,0.00003649859,0.000025865387],"category_scores_gemma":[0.0000013605456,0.000067015826,0.000051329884,0.0012326292,0.000041579322,0.00023371147,7.836914e-7,0.000037491016,0.0000012065583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057459317,0.0007956864,0.8095519,0.0002997849,0.0041964687,0.00018780775,0.005539822,0.006178513,0.0029089255,0.00007504245,0.000007196611,0.11279955],"study_design_scores_gemma":[0.037783597,0.008058856,0.9345947,0.0011503318,0.0029282088,0.00006202189,0.0014434691,0.00651246,0.006540708,0.00019490422,0.00046524225,0.00026550275],"about_ca_topic_score_codex":0.00009326501,"about_ca_topic_score_gemma":0.00012402788,"teacher_disagreement_score":0.12504281,"about_ca_system_score_codex":0.00005339492,"about_ca_system_score_gemma":0.000054166314,"threshold_uncertainty_score":0.27328262},"labels":[],"label_agreement":null},{"id":"W4387765093","doi":"10.1007/s12325-023-02697-6","title":"One-Year Consistent Safety, Utilization, and Efficacy Assessment of Remote Electrical Neuromodulation (REN) for Migraine Treatment","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Safran Electronics (Canada)","funders":"","keywords":"Medicine; Migraine; Adverse effect; Chronic Migraine; Neuromodulation; Clinical trial; Incidence (geometry); Anesthesia; Physical therapy; Internal medicine","score_opus":0.08284717459902385,"score_gpt":0.40588276592387607,"score_spread":0.3230355913248522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387765093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.965866,0.021495253,0.0039431057,0.0046768147,0.00005635023,0.0022676454,0.000026113945,0.000103765036,0.0015649277],"genre_scores_gemma":[0.8903509,0.10340503,0.005418297,0.00014489995,0.00006622405,0.000030641244,0.0000876779,0.000016839276,0.0004795431],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99924237,0.000030387057,0.00025918183,0.00019279201,0.00012635336,0.0001489322],"domain_scores_gemma":[0.9994575,0.00024074325,0.00006782005,0.00012964447,0.00007127578,0.000033066284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013221356,0.000099057346,0.0002963634,0.00012258808,0.00004847044,0.0000028141778,0.000023734343,0.000031922307,0.000009316882],"category_scores_gemma":[0.000073042494,0.00008106816,0.00006404947,0.0003037594,0.00004815955,0.000044446486,0.000008756482,0.000041107032,6.899501e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016765832,0.00081286667,0.051620405,0.00017981158,0.00025227715,0.000005676439,0.0015380819,0.00018446443,0.0050842334,0.00590134,0.0005093765,0.9322349],"study_design_scores_gemma":[0.014490239,0.0048094825,0.8017893,0.00015130595,0.00008702084,0.0000048432503,0.00020028965,0.013151395,0.002213284,0.003266937,0.1596471,0.00018878817],"about_ca_topic_score_codex":0.00001890869,"about_ca_topic_score_gemma":0.000072549294,"teacher_disagreement_score":0.9320461,"about_ca_system_score_codex":0.000048200283,"about_ca_system_score_gemma":0.00004008212,"threshold_uncertainty_score":0.33058634},"labels":[],"label_agreement":null},{"id":"W4388014741","doi":"10.1007/s12325-023-02691-y","title":"Health Economic Assessments of Hyaluronic Acid Treatments for Knee Osteoarthritis: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"Ferring Pharmaceuticals","keywords":"Medicine; Osteoarthritis; Hyaluronic acid; Rheumatology; Physical therapy; Systematic review; Internal medicine; Alternative medicine; MEDLINE; Pathology","score_opus":0.05691427812644089,"score_gpt":0.43294863860138977,"score_spread":0.37603436047494887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388014741","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008604643,0.98087716,0.000009328673,0.000026958896,0.0004735782,0.018063355,0.00034559687,0.00007335298,0.00012206692],"genre_scores_gemma":[0.0000037203147,0.9882552,0.00057570176,0.00016945132,0.00007497378,0.009141098,0.0007502111,0.00015043358,0.0008791903],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9965809,0.00026011447,0.0018320507,0.00059852196,0.0002304237,0.00049801863],"domain_scores_gemma":[0.99755704,0.00026219702,0.0012861593,0.0007310192,0.000038941354,0.00012464073],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005274327,0.000607286,0.0061577368,0.0002959284,0.000049645827,0.000011615308,0.00020481033,0.00017298541,0.00003077516],"category_scores_gemma":[0.00003200682,0.00045811507,0.0008824183,0.0002585787,0.000041440224,0.00017142356,0.00002893588,0.00017166405,0.000097555116],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002529119,0.000091429676,0.0000010879046,0.43601453,0.00026794078,0.000010293334,0.000011382834,5.4452535e-8,2.1941712e-7,0.00009392148,0.000008963585,0.5634749],"study_design_scores_gemma":[0.004856132,0.01265129,1.6042144e-7,0.83851975,0.001698764,0.000077918536,0.000020531848,6.3169347e-7,0.000006538106,0.0002904909,0.14159822,0.00027953472],"about_ca_topic_score_codex":0.0000054147354,"about_ca_topic_score_gemma":0.00006124773,"teacher_disagreement_score":0.56319535,"about_ca_system_score_codex":0.0007142513,"about_ca_system_score_gemma":0.00073260395,"threshold_uncertainty_score":0.99978703},"labels":[],"label_agreement":null},{"id":"W4388538929","doi":"10.1007/s12325-023-02652-5","title":"Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Cardiorenal syndrome; Heart failure; Diabetes mellitus; Kidney disease; Intensive care medicine; Internal medicine; Renal function; Type 2 diabetes; Disease; Cardiology; Endocrinology","score_opus":0.060654851084780644,"score_gpt":0.3441065490192637,"score_spread":0.28345169793448305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388538929","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028925412,0.9964199,0.00018236497,0.000034301902,0.000808427,0.0014930271,0.000024903526,0.00007205374,0.0006757581],"genre_scores_gemma":[0.001264879,0.99733335,0.00029864992,0.00006697393,0.00017384999,0.00032563752,0.00017672447,0.000090575806,0.00026937958],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980428,0.00008090702,0.00068430335,0.00040184267,0.00042232109,0.0003678178],"domain_scores_gemma":[0.99901205,0.00013533466,0.00033146393,0.00043373523,0.00003432296,0.00005310757],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036440173,0.00041544903,0.0014846927,0.00028700742,0.000065983375,0.000017432983,0.00023829324,0.00014984063,0.000028338036],"category_scores_gemma":[0.0000073622837,0.00025118428,0.0005872085,0.00047235144,0.000082448205,0.0001396537,0.000042597283,0.0002793075,0.000018305207],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003973839,0.000074495925,0.0000139541535,0.0027469238,0.0005929813,0.00005136882,0.00016794575,0.000043818294,0.00000373453,0.0019030033,0.00001973845,0.99434227],"study_design_scores_gemma":[0.0028009657,0.0006744411,0.00006970051,0.025286905,0.001799779,0.000017021439,0.00049948227,0.0000119041,0.00020893758,0.0015005227,0.9665982,0.0005321463],"about_ca_topic_score_codex":0.000011357817,"about_ca_topic_score_gemma":0.000017727778,"teacher_disagreement_score":0.9938102,"about_ca_system_score_codex":0.00008713964,"about_ca_system_score_gemma":0.00007220782,"threshold_uncertainty_score":0.99999404},"labels":[],"label_agreement":null},{"id":"W4388598609","doi":"10.1007/s12325-023-02706-8","title":"Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Clinical Research Institute","funders":"Novartis Pharma","keywords":"Medicine; Etanercept; Discontinuation; Biosimilar; Rheumatoid arthritis; Internal medicine; Psoriatic arthritis; Clinical endpoint; Pharmacology; Clinical trial","score_opus":0.023877749858004328,"score_gpt":0.3366253561703939,"score_spread":0.31274760631238957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388598609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970449,0.0014898562,0.000018912377,0.000032041306,0.00014697388,0.00071751873,0.00046988687,0.00003376429,0.00004610301],"genre_scores_gemma":[0.9970163,0.0024512773,0.0002642381,0.000044763572,0.0000054238217,0.00001577332,0.00016501448,0.000015394371,0.000021806236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786764,0.0009333388,0.00043750802,0.000425793,0.000069252455,0.0002664416],"domain_scores_gemma":[0.99847335,0.0009982018,0.00014702516,0.00031011866,0.000041131963,0.000030205714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005635543,0.0002118866,0.00054861343,0.00019186959,0.000060857976,0.000008506969,0.00018062531,0.00010101087,0.00003513078],"category_scores_gemma":[0.000079051846,0.00014411681,0.00003156439,0.00059699203,0.00028201946,0.00018563367,0.00003392988,0.00022210702,0.0000025786587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011328021,0.0015707966,0.9533858,0.000026402773,0.00011450058,0.000006207641,0.0006941883,0.000121209596,0.0006290498,0.00001711019,0.000007265586,0.032099452],"study_design_scores_gemma":[0.015961908,0.0012441508,0.98099846,0.00020783607,0.00002331295,2.0312896e-7,0.0004231491,0.00006953888,0.0004658368,0.00020572652,0.00021321472,0.00018665272],"about_ca_topic_score_codex":0.00059333054,"about_ca_topic_score_gemma":0.0017931951,"teacher_disagreement_score":0.0319128,"about_ca_system_score_codex":0.00004015721,"about_ca_system_score_gemma":0.000023505201,"threshold_uncertainty_score":0.5876913},"labels":[],"label_agreement":null},{"id":"W4388796902","doi":"10.1007/s12325-023-02718-4","title":"Assessing the Fiscal Burden of Obesity in Canada by Applying a Public Economic Framework","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Obesity, Physical Activity, Diet","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk","keywords":"Per capita; Government revenue; Population; Revenue; Tax revenue; Obesity; Public health; Medicine; Government (linguistics); Consumption (sociology); Economics; Public economics; Environmental health; Finance","score_opus":0.021272389369096766,"score_gpt":0.32127567633950666,"score_spread":0.3000032869704099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388796902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563414,0.001329305,0.000026446327,0.0018365168,0.00018699748,0.0003251888,0.000007925587,0.000024015515,0.0006294929],"genre_scores_gemma":[0.9982622,0.001173878,0.00010318191,0.00022755002,0.0001268891,0.000059325186,0.00000866771,0.000017247836,0.00002102461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894595,0.000088503446,0.00023541768,0.00022754556,0.000202097,0.0003004654],"domain_scores_gemma":[0.99889296,0.0006670288,0.00009749487,0.00027624174,0.000013896895,0.000052383577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026593485,0.00012288579,0.00032772165,0.000067675646,0.000045743673,0.000021792785,0.00020629648,0.00005055719,0.00003794485],"category_scores_gemma":[0.00006950676,0.00009301427,0.00004318183,0.00040867232,0.000080085956,0.00037689094,0.000055625078,0.0003615157,0.0000067442766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021839749,0.00035345939,0.9437081,0.0000424978,0.000022205535,0.000014043711,0.0002680689,0.00079304393,0.0005694114,0.0007930003,0.00019956028,0.05321477],"study_design_scores_gemma":[0.0012248718,0.00009482777,0.95099086,0.00020657708,0.000006808505,0.0000030301399,0.0021566516,0.0049325465,0.0028216084,0.02439432,0.0129267,0.0002411897],"about_ca_topic_score_codex":0.1852792,"about_ca_topic_score_gemma":0.2521687,"teacher_disagreement_score":0.06688948,"about_ca_system_score_codex":0.00042840658,"about_ca_system_score_gemma":0.00030316407,"threshold_uncertainty_score":0.8201461},"labels":[],"label_agreement":null},{"id":"W4388796981","doi":"10.1007/s12325-023-02721-9","title":"Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients’ Real-World Insights for Optimizing Outcomes","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eagle Ridge Hospital","funders":"Bayer HealthCare","keywords":"Medicine; Prostate cancer; Quality of life (healthcare); Androgen deprivation therapy; Health care; Cognition; Cancer; Intensive care medicine; Internal medicine; Psychiatry; Nursing","score_opus":0.032301016615904836,"score_gpt":0.37516872691701947,"score_spread":0.3428677103011146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388796981","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018829538,0.9589127,0.0000019136255,0.000056675373,0.0006765979,0.020265767,0.00066648854,0.00018214378,0.00040820925],"genre_scores_gemma":[0.0013781388,0.98419523,0.000094703566,0.00008569126,0.00006017011,0.011327038,0.0014653602,0.0002565175,0.0011371569],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960783,0.00017175423,0.0013496216,0.001077811,0.00048649588,0.0008360204],"domain_scores_gemma":[0.997469,0.0008419834,0.0008880313,0.00030418608,0.00036316004,0.00013361246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000119699784,0.0011055734,0.00332337,0.0011671482,0.00013816632,0.000025332307,0.00014961303,0.0002227958,0.000025497538],"category_scores_gemma":[0.00005854758,0.00071098097,0.0004442698,0.0016573136,0.0001938285,0.00034006333,0.000056892695,0.00046413607,0.000017458964],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003279263,0.001943469,0.1966095,0.0029427412,0.0020055205,0.000029708517,0.001466381,0.000027845752,9.313055e-9,0.000008376028,0.000020812575,0.7916664],"study_design_scores_gemma":[0.14232832,0.023761261,0.20187996,0.13047192,0.0037506546,0.0000025614254,0.00068525557,0.000022517628,0.000007410335,0.00025771826,0.49383095,0.0030014736],"about_ca_topic_score_codex":0.00028581635,"about_ca_topic_score_gemma":0.00163905,"teacher_disagreement_score":0.7886649,"about_ca_system_score_codex":0.0026021034,"about_ca_system_score_gemma":0.00044815431,"threshold_uncertainty_score":0.99953413},"labels":[],"label_agreement":null},{"id":"W4388845145","doi":"10.1007/s12325-023-02714-8","title":"Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Neuroendocrine tumors; Reimbursement; Psychosocial; Multidisciplinary approach; Protocol (science); Intensive care medicine; Internal medicine; Health care; Alternative medicine; Pathology","score_opus":0.054524717347923246,"score_gpt":0.4142345144384069,"score_spread":0.3597097970904837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388845145","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015374105,0.97579455,0.00009840281,0.00010503421,0.00072018703,0.0072388086,0.00037874235,0.0002659093,0.00002424176],"genre_scores_gemma":[0.00030480194,0.98778784,0.0051344223,0.00014442336,0.00073687464,0.0023466228,0.002959797,0.00049978745,0.000085411455],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99469674,0.00041342876,0.0011056247,0.0016171866,0.00089332636,0.00127369],"domain_scores_gemma":[0.9967772,0.0008794919,0.0005836132,0.0011709121,0.00014998917,0.00043882796],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016436532,0.0011426149,0.0028152326,0.000717624,0.00019268012,0.00011282507,0.00075846794,0.000040433584,0.000031825835],"category_scores_gemma":[0.00012676649,0.0007992324,0.00045698034,0.0008034551,0.00026094945,0.0011125823,0.00012146988,0.00074850133,0.000013292307],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051138424,0.00175854,0.010101712,0.0031306727,0.00030619884,0.0011108272,0.00016510878,0.00003189157,0.000016010623,0.000009561919,0.00010328984,0.97815233],"study_design_scores_gemma":[0.018788604,0.015445533,0.0021450939,0.030532688,0.000102666,0.00043100087,0.00023813428,0.000094510586,0.000053187843,0.00028167354,0.93063235,0.0012545662],"about_ca_topic_score_codex":0.00007390122,"about_ca_topic_score_gemma":0.00003904793,"teacher_disagreement_score":0.9768978,"about_ca_system_score_codex":0.00026008429,"about_ca_system_score_gemma":0.00016523912,"threshold_uncertainty_score":0.99944586},"labels":[],"label_agreement":null},{"id":"W4388912340","doi":"10.1007/s12325-023-02724-6","title":"A Patient Charter for Chronic Urticaria","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University; University of British Columbia; Dalhousie University; Université Laval","funders":"","keywords":"Medicine; Angioedema; Charter; Quality of life (healthcare); Specialty; Health care; Physical therapy; Family medicine; Nursing; Dermatology","score_opus":0.013233137051226583,"score_gpt":0.31190821573193994,"score_spread":0.29867507868071336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388912340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96253055,0.019341968,0.0010404891,0.0075908834,0.0013109705,0.0018965566,0.000030471707,0.00035244037,0.0059056585],"genre_scores_gemma":[0.98675394,0.011085708,0.0003177119,0.0006314309,0.00017683751,0.00042873135,0.000060388335,0.000022464925,0.0005227716],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994288,0.000009810578,0.00013634193,0.00014089377,0.0000780089,0.00020614888],"domain_scores_gemma":[0.9997009,0.00006549904,0.000021051696,0.0001460233,0.000025574545,0.00004093609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038251146,0.000068445755,0.000117660595,0.00009147638,0.000039684026,0.0000045845777,0.000032452892,0.00005078151,0.0001234967],"category_scores_gemma":[0.000014408899,0.000051406914,0.000057097925,0.00025174677,0.0000394462,0.0000751086,0.000006041863,0.000085565596,0.000088954606],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097151124,0.00058748375,0.006731765,0.000053648717,0.0008711373,0.00011519815,0.004483702,0.0005953722,0.055724468,0.024702715,0.004677703,0.9004853],"study_design_scores_gemma":[0.012899573,0.0041149035,0.024522709,0.00025979138,0.00025086256,0.000038035538,0.0005140263,0.006986783,0.015702697,0.042167164,0.8921172,0.00042624061],"about_ca_topic_score_codex":0.0000013643004,"about_ca_topic_score_gemma":0.0000043145283,"teacher_disagreement_score":0.90005904,"about_ca_system_score_codex":0.000043317403,"about_ca_system_score_gemma":0.000039754497,"threshold_uncertainty_score":0.20963131},"labels":[],"label_agreement":null},{"id":"W4389307944","doi":"10.1007/s12325-023-02673-0","title":"The Impact of the COVID-19 Pandemic on Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; McGill University Health Centre","funders":"Pfizer","keywords":"Medicine; Ulcerative colitis; Pandemic; Medical prescription; Family medicine; Disease; Coronavirus disease 2019 (COVID-19); Anxiety; Internal medicine; Psychiatry; Nursing; Infectious disease (medical specialty)","score_opus":0.015824180247196257,"score_gpt":0.3148297700543748,"score_spread":0.2990055898071785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389307944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929926,0.00018195761,0.000012678235,0.00006118625,0.00016168664,0.0009904517,0.005277558,0.000017005446,0.00030490427],"genre_scores_gemma":[0.99786985,0.00089802704,0.000010412777,0.0003715717,0.000040544994,0.00014223375,0.000610212,0.000018559718,0.000038585324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742186,0.0011614478,0.00035463274,0.00043243982,0.00030053203,0.0003291058],"domain_scores_gemma":[0.9984765,0.0003455329,0.0003187861,0.0005104832,0.00023710668,0.000111610956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037708873,0.0002540641,0.00019826347,0.000023005468,0.00026965444,0.000027109445,0.0003295611,0.000093592025,0.00000982585],"category_scores_gemma":[0.00066417415,0.0001369758,0.000107959175,0.0003362619,0.00039655712,0.000018282793,0.00007260796,0.00012494896,0.000003755732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06576109,0.00023350283,0.9103433,0.0000051570105,0.00029759158,0.00001855558,0.0056499173,0.009105948,0.00010218016,0.00013290437,0.001653174,0.006696667],"study_design_scores_gemma":[0.0042092283,0.0010413337,0.99108124,0.000027131464,0.000003420419,6.251045e-7,0.0007120527,0.000036726993,0.00032703794,0.00092787645,0.0014455521,0.0001877859],"about_ca_topic_score_codex":0.00071751163,"about_ca_topic_score_gemma":0.020352535,"teacher_disagreement_score":0.08073791,"about_ca_system_score_codex":0.00025188067,"about_ca_system_score_gemma":0.00046432606,"threshold_uncertainty_score":0.9975235},"labels":[],"label_agreement":null},{"id":"W4389505117","doi":"10.1007/s12325-023-02745-1","title":"Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"CSL Behring","keywords":"Medicine; Confidence interval; Regimen; Internal medicine; Odds ratio; Body mass index; Surgery","score_opus":0.0883316305701726,"score_gpt":0.38474291144490447,"score_spread":0.2964112808747319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389505117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862096,0.0032086526,0.000019905712,0.0008854516,0.00072339224,0.008683723,0.00006239104,0.00011163449,0.00009526992],"genre_scores_gemma":[0.9900888,0.00395119,0.0010403388,0.000005189042,0.00007590817,0.001187102,0.00018492159,0.0000824442,0.0033840758],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99679863,0.0002236496,0.0009325269,0.00065753993,0.0006988859,0.00068877346],"domain_scores_gemma":[0.9981754,0.00036785708,0.00048195545,0.0005960662,0.00020828802,0.0001704578],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029718317,0.00047918773,0.0012941031,0.0005953873,0.00015301163,0.000015541882,0.00023504347,0.00024825672,0.00013186179],"category_scores_gemma":[0.00012171134,0.00032300505,0.00030021853,0.00096635375,0.00016031691,0.00023547262,0.000055974884,0.0002500328,0.00002824102],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026342792,0.005309008,0.014109897,0.001233914,0.00024204116,0.000058876703,0.004747873,0.000020518026,0.42057514,0.0000599539,0.000031295014,0.52726865],"study_design_scores_gemma":[0.030191835,0.042834245,0.01734719,0.0013413322,0.00006389078,0.000004933435,0.0013971351,0.0005516481,0.89583665,0.0013842621,0.008513445,0.0005334071],"about_ca_topic_score_codex":0.00023162672,"about_ca_topic_score_gemma":0.00017050466,"teacher_disagreement_score":0.52673525,"about_ca_system_score_codex":0.00045764167,"about_ca_system_score_gemma":0.00024793026,"threshold_uncertainty_score":0.9999222},"labels":[],"label_agreement":null},{"id":"W4389946153","doi":"10.1007/s12325-023-02760-2","title":"Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Long-Term Effects of COVID-19","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Brain and Cognition Discovery Foundation; University of Toronto","funders":"H. Lundbeck A/S","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Body mass index; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Rheumatology; Internal medicine; Index (typography); Cardiology; Pathology; Disease; Outbreak","score_opus":0.010795734771422812,"score_gpt":0.369300782142791,"score_spread":0.3585050473713682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389946153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522585,0.0011607865,0.00020296304,0.0018894727,0.00005372473,0.0008788503,0.00010432867,0.00012704013,0.00035696087],"genre_scores_gemma":[0.99599147,0.0012866076,0.00012927676,0.0019481137,0.000038986975,0.000110583176,0.00032218164,0.000040107174,0.00013267013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980598,0.00018554369,0.0003924827,0.00047885987,0.00044476907,0.00043851565],"domain_scores_gemma":[0.99801534,0.00090778235,0.00020809194,0.0005672707,0.00008160414,0.00021991253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044741435,0.00029515417,0.00075654854,0.0015425036,0.000048360744,0.000014701443,0.00020207142,0.00012625329,0.0006390863],"category_scores_gemma":[0.00026139035,0.0002206886,0.00024776527,0.0034431145,0.00018768621,0.00033985832,0.000018832046,0.00039393237,0.000018590248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065712826,0.00037774618,0.9575802,0.00023276907,0.0010344374,0.0007239851,0.00087969855,0.01764371,0.011902605,0.00009153298,0.00010666536,0.0028553538],"study_design_scores_gemma":[0.011866971,0.004875489,0.9776565,0.00021861598,0.0001272288,0.00002414727,0.00043701884,0.0011850705,0.0016500439,0.00057983457,0.0010420162,0.00033709066],"about_ca_topic_score_codex":0.0006737447,"about_ca_topic_score_gemma":0.00086076354,"teacher_disagreement_score":0.02007626,"about_ca_system_score_codex":0.0005588653,"about_ca_system_score_gemma":0.0007487197,"threshold_uncertainty_score":0.899942},"labels":[],"label_agreement":null},{"id":"W4390498067","doi":"10.1007/s12325-023-02732-6","title":"Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"AbbVie","keywords":"Medicine; Randomized controlled trial; Rheumatology; Systematic review; Immune system; Internal medicine; MEDLINE; Intensive care medicine; Immunology","score_opus":0.025493679472180158,"score_gpt":0.37101187627534854,"score_spread":0.34551819680316836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390498067","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000074701326,0.9796031,5.185271e-7,0.00001560906,0.00021800537,0.019010818,0.0007435849,0.000016764556,0.0003168856],"genre_scores_gemma":[0.0004277478,0.9950944,0.00005040638,0.000012232589,0.000030728716,0.0039276923,0.00035692044,0.000042648982,0.000057185112],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98977274,0.003252425,0.0060336194,0.0003815223,0.00034898942,0.00021069532],"domain_scores_gemma":[0.9878502,0.008143351,0.0033690594,0.00044486087,0.00013172989,0.0000608246],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0032691653,0.0006641174,0.037670504,0.0005975636,0.000017362905,0.000007403716,0.0001101448,0.00018092668,0.000027107795],"category_scores_gemma":[0.0028267384,0.0003217159,0.002761683,0.000731896,0.00023177371,0.00006889005,0.000029680548,0.00019595366,0.0000012212166],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03701048,0.00056717935,0.00012151631,0.8672842,0.008983398,0.000111925896,0.00037229783,2.7803765e-7,0.0000010302399,0.000046633017,0.00000851277,0.08549255],"study_design_scores_gemma":[0.19546911,0.00035608173,0.000010541222,0.7727997,0.010577648,0.000016057049,0.000042415475,0.0000019049189,0.0000036585773,0.000014798549,0.020552244,0.00015589519],"about_ca_topic_score_codex":0.000011241784,"about_ca_topic_score_gemma":0.000013341008,"teacher_disagreement_score":0.15845862,"about_ca_system_score_codex":0.00014956047,"about_ca_system_score_gemma":0.00023512916,"threshold_uncertainty_score":0.99992347},"labels":[],"label_agreement":null},{"id":"W4390637832","doi":"10.1007/s12325-023-02719-3","title":"Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Bayer","keywords":"Aflibercept; Medicine; Macular degeneration; Dosing; Randomized controlled trial; Rheumatology; Ophthalmology; Bevacizumab; Internal medicine; Oncology; Chemotherapy","score_opus":0.013967966212247036,"score_gpt":0.31497919686516135,"score_spread":0.3010112306529143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390637832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91702455,0.078979015,0.00037322615,0.00009171558,0.00016079318,0.0026538866,0.000054945314,0.000028882627,0.0006329626],"genre_scores_gemma":[0.9385076,0.05813062,0.0022556495,0.000017797813,0.00009108083,0.00031830888,0.00026560933,0.000034751753,0.00037856723],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988354,0.000107319865,0.0004597755,0.0002795617,0.00016174235,0.00015619001],"domain_scores_gemma":[0.9993824,0.00022268899,0.00010576588,0.00018291103,0.0000474776,0.000058773116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001870327,0.00019171843,0.0008077084,0.00015359155,0.000027628948,0.000018718392,0.000036318288,0.000083711166,0.000039608876],"category_scores_gemma":[0.00003151592,0.00013339614,0.00035981272,0.00018894282,0.0001520753,0.00013512459,0.000005599184,0.000050613846,8.913923e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73432195,0.001126683,0.00022536525,0.00020333275,0.0013788033,0.000053602158,0.0008946393,0.000207431,0.0053207744,0.0031959119,0.000008949438,0.25306252],"study_design_scores_gemma":[0.97007793,0.0050427844,0.0003604672,0.00036446992,0.0013019633,0.000009571588,0.00005813108,0.0021578623,0.011262207,0.007482462,0.0017072555,0.00017491473],"about_ca_topic_score_codex":0.00011614109,"about_ca_topic_score_gemma":0.00000807325,"teacher_disagreement_score":0.2528876,"about_ca_system_score_codex":0.000072922194,"about_ca_system_score_gemma":0.000059428363,"threshold_uncertainty_score":0.5439736},"labels":[],"label_agreement":null},{"id":"W4390655880","doi":"10.1007/s12325-023-02765-x","title":"Comparative Safety of Pulsed Field Ablation and Cryoballoon Ablation Technologies for Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation: A Critical Literature Review and Indirect Treatment Comparison","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Biosense Webster","keywords":"Medicine; Adverse effect; Atrial fibrillation; Internal medicine; Confidence interval; Relative risk; Clinical trial; Meta-analysis; Ablation; Catheter ablation; Surgery","score_opus":0.02859878009776757,"score_gpt":0.3633925257742418,"score_spread":0.33479374567647424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390655880","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49073485,0.49733347,0.0025143896,0.0044451905,0.00022531925,0.00430479,0.000034169138,0.00011415896,0.0002936793],"genre_scores_gemma":[0.9445442,0.053816967,0.0013353411,0.000026201255,0.00009153054,0.000011189181,0.0001482616,0.000007357435,0.000018955392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915224,0.00004815898,0.0003582529,0.00022648399,0.000114895374,0.00009996183],"domain_scores_gemma":[0.9992449,0.0005097338,0.00008362141,0.00008405958,0.00006256962,0.000015116474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013572403,0.00013543494,0.00044013027,0.00018275039,0.000034503246,0.000022349242,0.000019355313,0.000083031504,0.0000070302467],"category_scores_gemma":[0.0000778544,0.000097282435,0.00004635458,0.00035953918,0.000048486105,0.00041581137,0.000008953865,0.00006815713,1.8222464e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034319551,0.000018162093,0.82800645,0.0009074481,0.00005638596,0.0000012502163,0.00048249663,0.00044573765,0.000021075812,0.0005381676,0.000008348682,0.1660825],"study_design_scores_gemma":[0.008973313,0.0050617205,0.9196846,0.0056795976,0.0002931998,0.000004871173,0.00025963824,0.028272307,0.00051662617,0.0029882437,0.027876511,0.0003894103],"about_ca_topic_score_codex":0.0000031310742,"about_ca_topic_score_gemma":0.000017052002,"teacher_disagreement_score":0.45380935,"about_ca_system_score_codex":0.00005532776,"about_ca_system_score_gemma":0.000016083892,"threshold_uncertainty_score":0.39670625},"labels":[],"label_agreement":null},{"id":"W4390811971","doi":"10.1007/s12325-023-02730-8","title":"Real-World Management of Patients with Pulmonary Arterial Hypertension: Insights from EXPOSURE","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Actelion Pharmaceuticals","keywords":"Medicine; Rheumatology; Internal medicine; Pulmonary hypertension; Cardiology; Intensive care medicine","score_opus":0.015115327551187455,"score_gpt":0.282005116141619,"score_spread":0.26688978859043155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390811971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97394085,0.020560408,0.000006757292,0.0001452199,0.00028517196,0.0005322784,0.000029146984,0.000048757836,0.0044514104],"genre_scores_gemma":[0.97656196,0.021599963,0.00097484706,0.00010670539,0.00007289615,0.0000538598,0.000189155,0.000026419411,0.00041420312],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99877864,0.000037245532,0.00022641405,0.00034983185,0.00041340874,0.00019446356],"domain_scores_gemma":[0.99943817,0.00006337337,0.000034017154,0.00030975326,0.0000644671,0.00009019976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002863896,0.00016743214,0.00030327323,0.00018697265,0.000029594426,0.000010098926,0.000083316074,0.00003763328,0.0001388558],"category_scores_gemma":[0.000001697123,0.000101825906,0.000053509564,0.00039037352,0.00007532856,0.0002447555,0.000027569356,0.000115650786,0.000020356076],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018594688,0.005507924,0.37342513,0.00040431807,0.0011805377,0.031388707,0.00020123851,0.000023619441,0.005097003,0.001027232,0.00027911382,0.5628705],"study_design_scores_gemma":[0.005610995,0.0012204866,0.95105577,0.0010864821,0.00005600857,0.000014326842,0.00009631968,0.00014390866,0.0012148268,0.002325457,0.036984388,0.0001910151],"about_ca_topic_score_codex":0.000062427935,"about_ca_topic_score_gemma":0.000025486603,"teacher_disagreement_score":0.57763064,"about_ca_system_score_codex":0.000045470886,"about_ca_system_score_gemma":0.00003109457,"threshold_uncertainty_score":0.415234},"labels":[],"label_agreement":null},{"id":"W4391032221","doi":"10.1007/s12325-023-02773-x","title":"Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Seven Oaks General Hospital","funders":"Mitsubishi Tanabe Pharma Corporation; AstraZeneca","keywords":"Dapagliflozin; Medicine; Albuminuria; Kidney disease; Renal function; Internal medicine; Diabetes mellitus; Urology; Comorbidity; Population; Creatinine; Type 2 diabetes; Endocrinology","score_opus":0.01636351137419319,"score_gpt":0.30417992847754594,"score_spread":0.28781641710335276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391032221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99020934,0.008333285,0.0000052980704,0.00006514432,0.000063044936,0.0009878746,0.000008704137,0.000007972504,0.0003193208],"genre_scores_gemma":[0.99496514,0.0047194245,0.00000965266,0.000068332934,0.000013611567,0.000106857035,0.000020266767,0.000011815646,0.000084908424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934036,0.000074450785,0.00012933354,0.00020596148,0.0001257664,0.00012414821],"domain_scores_gemma":[0.9997222,0.00008327348,0.000028935821,0.00011166862,0.000013600466,0.00004035579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016978403,0.00011043446,0.00016619143,0.00016762762,0.000011486876,0.0000119502465,0.000040372055,0.000016703842,0.0000140636375],"category_scores_gemma":[0.000013454299,0.00006714178,0.000012689503,0.00035522602,0.000056547186,0.00026494375,0.000013207578,0.00005870105,4.443315e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000465023,0.00021359726,0.9519348,0.00035177168,0.00003456825,0.000016949223,0.00043697082,0.00004801219,0.00006262168,0.0005938256,0.0000046968516,0.04583715],"study_design_scores_gemma":[0.0033123444,0.0004539672,0.99321926,0.001128813,0.000027500733,7.078063e-8,0.000026569653,0.00042169983,0.00027024338,0.0003052544,0.0007626805,0.00007161773],"about_ca_topic_score_codex":0.00006312789,"about_ca_topic_score_gemma":0.0013997414,"teacher_disagreement_score":0.045765534,"about_ca_system_score_codex":0.0000847665,"about_ca_system_score_gemma":0.0000361002,"threshold_uncertainty_score":0.27379623},"labels":[],"label_agreement":null},{"id":"W4391137655","doi":"10.1007/s12325-023-02770-0","title":"The Cost of Seasonal Influenza: A Systematic Literature Review on the Humanistic and Economic Burden of Influenza in Older (≥ 65 Years Old) Adults","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Influenza vaccine; Seasonal influenza; Quality of life (healthcare); Gerontology; Vaccination; Demography; Environmental health; Immunology; Internal medicine; Coronavirus disease 2019 (COVID-19); Disease; Infectious disease (medical specialty)","score_opus":0.05725106847658075,"score_gpt":0.42814892708900965,"score_spread":0.3708978586124289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391137655","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044030452,0.9927656,1.1027799e-7,0.00009743811,0.00012579361,0.00622205,0.00011439627,0.000012076835,0.00022220751],"genre_scores_gemma":[0.0001530966,0.9975947,0.000010505898,0.0005988689,0.0001029323,0.001385638,0.000008835273,0.00005785799,0.000087539156],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9966137,0.00058529084,0.0015270632,0.0004486473,0.00046154196,0.0003637838],"domain_scores_gemma":[0.9962177,0.0021655571,0.0006419262,0.0007984381,0.00012220291,0.00005411837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016292131,0.0004867301,0.0026479515,0.0002883851,0.000058598645,0.000044214852,0.00048489257,0.00017128147,0.000020512098],"category_scores_gemma":[0.00075260946,0.00022993675,0.00033557424,0.000532337,0.00042831223,0.00011059658,0.0001364923,0.0009859467,0.00002803804],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020723048,0.000050058865,0.00004928681,0.7817798,0.00046904394,0.00004897646,0.0014834655,0.000007972625,3.0282808e-7,0.002598473,0.00024762316,0.21305776],"study_design_scores_gemma":[0.00060644833,0.00015960826,0.000048752692,0.60325503,0.00020689145,0.000019001582,0.00008919061,0.0000098679775,4.324394e-7,0.00014434147,0.3953239,0.00013654209],"about_ca_topic_score_codex":0.000024537168,"about_ca_topic_score_gemma":0.000046277928,"teacher_disagreement_score":0.3950763,"about_ca_system_score_codex":0.0002509,"about_ca_system_score_gemma":0.00025129813,"threshold_uncertainty_score":0.93765485},"labels":[],"label_agreement":null},{"id":"W4391482304","doi":"10.1007/s12325-023-02763-z","title":"The Evolving Role of PD-(L)1 Inhibition in Optimizing Outcomes for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Podcast","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Internal medicine; Oncology; Urology; Urothelial cancer; Cancer; Rheumatology","score_opus":0.010520303571385316,"score_gpt":0.31308453496181465,"score_spread":0.3025642313904293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391482304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86896366,0.12612486,0.0006697066,0.0011237911,0.00072567293,0.0015139369,0.000117354946,0.000051962114,0.0007090228],"genre_scores_gemma":[0.94405353,0.053454574,0.001330872,0.0002124123,0.00015424642,0.000639717,0.000011739459,0.000042094096,0.000100816615],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988104,0.00003913281,0.00035446574,0.00030711017,0.00019052152,0.00029834357],"domain_scores_gemma":[0.9990868,0.00049463037,0.00009495509,0.00021268107,0.000071221846,0.00003968939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019691058,0.00019512672,0.00033962965,0.00014479447,0.00007738673,0.000028842187,0.00007206964,0.00006907412,0.000046142846],"category_scores_gemma":[0.000050342955,0.0001260473,0.00011832528,0.0003024881,0.00007949637,0.00030799746,0.000017648399,0.00018705358,0.000002540948],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013417018,0.0003865859,0.11589731,0.00027633956,0.0004968078,0.000056407294,0.0068119434,0.0021106417,0.0139574325,0.0009731105,0.00015278788,0.85753894],"study_design_scores_gemma":[0.045406953,0.006371129,0.4682901,0.008583079,0.00067620253,0.000045102992,0.01391194,0.009637942,0.30568504,0.10184943,0.037698068,0.0018450157],"about_ca_topic_score_codex":0.00089016435,"about_ca_topic_score_gemma":0.0018570671,"teacher_disagreement_score":0.85569394,"about_ca_system_score_codex":0.00019114497,"about_ca_system_score_gemma":0.00017241013,"threshold_uncertainty_score":0.51400596},"labels":[],"label_agreement":null},{"id":"W4391521245","doi":"10.1007/s12325-023-02776-8","title":"Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"National Institute of Environmental Health Sciences; Genentech; Teva Pharmaceutical Industries; Sanofi","keywords":"Medicine; Fluticasone propionate; Exacerbation; COPD; Internal medicine; Population; Budesonide; Formoterol; Corticosteroid","score_opus":0.012597062446416042,"score_gpt":0.28700559771391027,"score_spread":0.2744085352674942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391521245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870347,0.010807112,0.000100616926,0.0001529135,0.000050088016,0.0013248363,0.00017461707,0.00004834312,0.00030678898],"genre_scores_gemma":[0.9966875,0.0023349205,0.0003990108,0.000105480074,0.000031213134,0.00013748708,0.000111207206,0.000075863485,0.00011736727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980698,0.0000904326,0.00039484713,0.00048478466,0.00060885475,0.00035127407],"domain_scores_gemma":[0.9989961,0.00013309043,0.00014781246,0.00033634395,0.00027116504,0.00011549336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001222724,0.00033281592,0.0006231642,0.00030053608,0.00003257551,0.000023080791,0.000100577054,0.00008261987,0.00015332788],"category_scores_gemma":[0.000012298584,0.00019310492,0.000059324553,0.00060343434,0.000422884,0.0005013812,0.00002260432,0.00021584111,0.0000019306888],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015006528,0.0008692746,0.9365901,0.00038564487,0.00034535505,0.00012791916,0.0007650524,0.000009881743,0.0005499134,0.000040025272,0.000004534252,0.04530579],"study_design_scores_gemma":[0.012537213,0.0052830977,0.97460485,0.0007654645,0.00007235976,0.00002555331,0.00027986543,0.00017287706,0.005334454,0.00012238156,0.00056875194,0.00023315554],"about_ca_topic_score_codex":0.000029468985,"about_ca_topic_score_gemma":0.00010412664,"teacher_disagreement_score":0.045072634,"about_ca_system_score_codex":0.00013205691,"about_ca_system_score_gemma":0.00012722854,"threshold_uncertainty_score":0.787459},"labels":[],"label_agreement":null},{"id":"W4391721467","doi":"10.1007/s12325-023-02750-4","title":"Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto","funders":"","keywords":"Medicine; Semaglutide; Type 2 diabetes; Dipeptidyl peptidase-4 inhibitor; Dipeptidyl peptidase-4; Stroke (engine); Internal medicine; Alogliptin; Type 2 Diabetes Mellitus; Sitagliptin; Diabetes mellitus; Endocrinology; Liraglutide","score_opus":0.01236021062021096,"score_gpt":0.2968267479358921,"score_spread":0.2844665373156811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391721467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98088765,0.013559294,0.0000054282004,0.00012643146,0.00018685005,0.0006882905,0.000025215604,0.00008411201,0.004436726],"genre_scores_gemma":[0.9714712,0.022524724,0.002478258,0.00012354275,0.00009329669,0.00010842031,0.00002320189,0.000042420714,0.0031349747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986233,0.00007196903,0.0003450106,0.00035130617,0.00026685483,0.0003415709],"domain_scores_gemma":[0.99922186,0.00030009967,0.00010197349,0.0002831444,0.000033414948,0.000059527247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034458397,0.00022328077,0.0004382776,0.0005045495,0.000022370632,0.000025231479,0.00009767038,0.000042189913,0.0001328369],"category_scores_gemma":[0.00004619652,0.0001431656,0.00005774871,0.0009538323,0.00008908844,0.0002627346,0.000034344575,0.00019949574,0.000012580158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004113518,0.00028607805,0.86330837,0.0002182298,0.0002457777,0.000096269156,0.0005673186,0.00013528105,0.00081769057,0.000114483606,0.00014616299,0.13365297],"study_design_scores_gemma":[0.009915228,0.0056510023,0.823994,0.006676967,0.00032586156,0.000003394028,0.0006705006,0.0005314984,0.026510846,0.0012555114,0.12376324,0.0007019854],"about_ca_topic_score_codex":0.00009799279,"about_ca_topic_score_gemma":0.0016571984,"teacher_disagreement_score":0.13295099,"about_ca_system_score_codex":0.000117107404,"about_ca_system_score_gemma":0.00006572997,"threshold_uncertainty_score":0.5838124},"labels":[],"label_agreement":null},{"id":"W4391781908","doi":"10.1007/s12325-024-02803-2","title":"Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Broadcom (Canada); Eagle Ridge Hospital; Memorial University of Newfoundland; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Asthma; Thematic analysis; Context (archaeology); Qualitative research; Family medicine; Physical therapy; Internal medicine","score_opus":0.045204862448519074,"score_gpt":0.3524703112131509,"score_spread":0.30726544876463185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391781908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98144627,0.017371088,0.00009596427,0.000056536835,0.0000835323,0.00042456042,0.000013014172,0.0000594724,0.0004495926],"genre_scores_gemma":[0.9960865,0.0033106245,0.00014324994,0.00008119194,0.00006381642,0.00018887382,0.0000027942237,0.000021798247,0.00010118495],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9990851,0.0001617731,0.00019012987,0.00024203138,0.00014365982,0.00017726271],"domain_scores_gemma":[0.9994351,0.0002494421,0.000038405436,0.00016342243,0.000042899264,0.00007072887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018489474,0.00013791956,0.00024163724,0.00018024718,0.00005196034,0.000011251761,0.00006935031,0.00002503844,0.00015630097],"category_scores_gemma":[0.000022539509,0.000086455235,0.00005524589,0.0003813286,0.00016554786,0.0003579795,0.000008546486,0.00013595598,0.000004070321],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016390235,0.0004469044,0.5664627,0.00010489251,0.00015299823,0.00011768946,0.29866418,0.00023293623,0.000359509,0.00011158726,0.000008278802,0.13317443],"study_design_scores_gemma":[0.0006201837,0.0024798166,0.4396551,0.0007806026,0.000014416091,0.000009674754,0.5535048,0.00002759215,0.000023585399,0.000080187514,0.0026373519,0.00016668887],"about_ca_topic_score_codex":0.0006907172,"about_ca_topic_score_gemma":0.005791811,"teacher_disagreement_score":0.2548406,"about_ca_system_score_codex":0.000058942034,"about_ca_system_score_gemma":0.000110436034,"threshold_uncertainty_score":0.3525542},"labels":[],"label_agreement":null},{"id":"W4391953689","doi":"10.1007/s12325-023-02778-6","title":"Correction to: Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients’ Real-World Insights for Optimizing Outcomes","year":2024,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eagle Ridge Hospital","funders":"","keywords":"Medicine; Prostate cancer; Cognitive impairment; Rheumatology; Cognition; Intensive care medicine; Internal medicine; Oncology; Cancer; Disease; Psychiatry","score_opus":0.009810852936459462,"score_gpt":0.3130978721432271,"score_spread":0.30328701920676765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391953689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7698142,0.049137484,0.000031122527,0.0013631576,0.106688246,0.048349127,0.0019540146,0.00069826475,0.02196437],"genre_scores_gemma":[0.4370575,0.24805489,0.00042753696,0.00193654,0.0011255709,0.027537204,0.008582082,0.0009563311,0.27432236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964917,0.00009194362,0.0009036706,0.0011804658,0.0005695467,0.0007627015],"domain_scores_gemma":[0.99822885,0.00035674224,0.00044027774,0.000259118,0.00056019536,0.00015480202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001014074,0.0009525181,0.0014683641,0.0012901082,0.00013702291,0.000043505883,0.00011214353,0.00023719769,0.00004502311],"category_scores_gemma":[0.00007323483,0.00068020186,0.0002334826,0.0013438208,0.0001368458,0.0003433422,0.000053142805,0.0008526677,0.000016394062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023207216,0.0037742301,0.76782393,0.00043561193,0.0022396795,0.000043689895,0.009549164,0.00046622174,9.217722e-7,0.000005860283,0.034634877,0.15781862],"study_design_scores_gemma":[0.05454224,0.024938058,0.75581783,0.017841347,0.0007824236,0.0000011151199,0.00096512225,0.00018607127,0.00011520923,0.00018412467,0.14313488,0.0014916055],"about_ca_topic_score_codex":0.000926491,"about_ca_topic_score_gemma":0.010721348,"teacher_disagreement_score":0.33275673,"about_ca_system_score_codex":0.0036753456,"about_ca_system_score_gemma":0.00047252962,"threshold_uncertainty_score":0.99956495},"labels":[],"label_agreement":null},{"id":"W4392130094","doi":"10.1007/s12325-024-02797-x","title":"Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Cilag; Janssen Research and Development; Genentech; Chugai Pharmaceutical; EUSA Pharma; Servier; Incyte; bluebird bio; Regeneron Pharmaceuticals; Universidad de Salamanca; Adaptive Biotechnologies; Karyopharm Therapeutics; Legend Biotech; Celgene; Cerecor; Janssen Pharmaceuticals; Yale University; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Hazard ratio; Confidence interval; Relative risk; Refractory (planetary science); Proportional hazards model; Multiple myeloma; Gastroenterology; Surgery","score_opus":0.059782962332057994,"score_gpt":0.3848374014435362,"score_spread":0.3250544391114782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392130094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9449859,0.052532155,0.000008048418,0.00018822389,0.000117019496,0.0020451625,0.000021540525,0.000015724308,0.00008622957],"genre_scores_gemma":[0.9861005,0.013318349,0.00012720822,0.000035375044,0.000018407487,0.0002843039,0.000079793936,0.00001571504,0.000020323956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834204,0.00024854802,0.0003823622,0.00035043366,0.00040043108,0.0002761854],"domain_scores_gemma":[0.99892354,0.00064695237,0.00008481569,0.00023348765,0.00005973771,0.000051462535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021869525,0.00023987677,0.0005084845,0.00030186897,0.000035023586,0.000014106856,0.00009216594,0.00004044091,0.000009061792],"category_scores_gemma":[0.000057330566,0.00013204134,0.00004789922,0.00046484097,0.00020344171,0.0002767511,0.000024607705,0.00027335488,0.0000038709986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070873084,0.0042885346,0.73410875,0.0001554095,0.00025539947,0.000069380025,0.010082665,0.00005214618,0.00008236702,0.000029858824,0.000025904368,0.24376225],"study_design_scores_gemma":[0.034481443,0.0036294793,0.9559836,0.0009613497,0.000023462107,0.0000022896304,0.0010606209,0.00037726745,0.0008776481,0.00009086363,0.0023871919,0.00012480865],"about_ca_topic_score_codex":0.000043220556,"about_ca_topic_score_gemma":0.00025586103,"teacher_disagreement_score":0.24363744,"about_ca_system_score_codex":0.0003073049,"about_ca_system_score_gemma":0.00004908887,"threshold_uncertainty_score":0.538449},"labels":[],"label_agreement":null},{"id":"W4392448305","doi":"10.1007/s12325-024-02794-0","title":"Patient and Clinician Perspectives: To Create a Better Future for Chronic Kidney Disease, We Need to Talk About Our Kidneys","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Seven Oaks General Hospital","funders":"AstraZeneca","keywords":"Medicine; Kidney disease; Intensive care medicine; Disease; Rheumatology; Clinical Practice; Nephrology; Disease management; MEDLINE; Health care; Physical therapy; Internal medicine","score_opus":0.00871123447423064,"score_gpt":0.32046771730716744,"score_spread":0.3117564828329368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392448305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4538471,0.40369987,0.00034227947,0.13574463,0.0014573166,0.0034261846,0.00066053006,0.00022587017,0.00059621106],"genre_scores_gemma":[0.91264474,0.04144298,0.0013942622,0.039364234,0.003250986,0.0010788762,0.000121669975,0.000113607806,0.0005886614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983557,0.000034383425,0.00029875452,0.0006437295,0.00020746059,0.0004599674],"domain_scores_gemma":[0.9983752,0.00007957598,0.000035336296,0.00034120053,0.000065242384,0.0011034547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109600594,0.00027918108,0.0003729686,0.00023335218,0.00006737872,0.000061955645,0.00009739145,0.00006976748,0.00010482359],"category_scores_gemma":[0.00016388949,0.00022074109,0.00016591998,0.0003648447,0.000037882044,0.00023230113,0.00003979005,0.00016260144,0.000032199692],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042684106,0.0007131227,0.011687058,0.0016590235,0.00038510963,0.00018552225,0.011886059,0.00006781083,0.0026384552,0.001505208,0.089001454,0.8760028],"study_design_scores_gemma":[0.0031229472,0.0015692173,0.0045858906,0.00153306,0.00007589602,0.0000027901071,0.0038648169,0.00024941095,0.0005733052,0.0016327134,0.9824466,0.00034335893],"about_ca_topic_score_codex":0.000009468052,"about_ca_topic_score_gemma":0.000015279384,"teacher_disagreement_score":0.89344513,"about_ca_system_score_codex":0.00027248173,"about_ca_system_score_gemma":0.0005321078,"threshold_uncertainty_score":0.900156},"labels":[],"label_agreement":null},{"id":"W4392614952","doi":"10.1007/s12325-024-02811-2","title":"Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Sleep and related disorders","field":"Psychology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical; Eisai; Shionogi; Meiji Seika Pharma; Boehringer Ingelheim Japan; Eisai Canada; Teijin Pharma; Takeda Pharmaceuticals U.S.A.","keywords":"Medicine; Insomnia; Drug; Psychiatry; Open label; Pharmacology; Adverse effect","score_opus":0.016436180121945188,"score_gpt":0.3523783801993804,"score_spread":0.3359422000774352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392614952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97682947,0.020950861,0.000018434199,0.00010731166,0.0004026967,0.0012790267,0.00002853501,0.000024747029,0.00035889525],"genre_scores_gemma":[0.99486053,0.004606726,0.00018605529,0.00019889793,0.000015965039,0.000065462445,0.000025507372,0.000026686033,0.000014187917],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986162,0.00023301544,0.00036633265,0.00047934864,0.00010321579,0.00020189658],"domain_scores_gemma":[0.99944186,0.00022434787,0.000042397543,0.0002106807,0.000020395426,0.000060337894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021472455,0.00016625714,0.00027339684,0.00018505391,0.000038351227,0.000043286145,0.00018153245,0.00007121657,0.00008803065],"category_scores_gemma":[0.000011424358,0.00013666536,0.000009795388,0.00032136348,0.00007667435,0.00043003075,0.00003831827,0.00020232672,0.000004959753],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069755306,0.007324179,0.24110499,0.000020621028,0.00026321178,0.000044283923,0.21177697,0.0002232286,0.00069540786,0.00016279027,0.000020265643,0.5313885],"study_design_scores_gemma":[0.08564022,0.004582458,0.85248566,0.00074389455,0.000074619325,0.0000019011695,0.04816849,0.00060264574,0.00014445146,0.00072882883,0.0061121997,0.0007146147],"about_ca_topic_score_codex":0.0015191638,"about_ca_topic_score_gemma":0.0014478132,"teacher_disagreement_score":0.6113807,"about_ca_system_score_codex":0.000022984965,"about_ca_system_score_gemma":0.000008296869,"threshold_uncertainty_score":0.55730516},"labels":[],"label_agreement":null},{"id":"W4392744020","doi":"10.1007/s12325-024-02829-6","title":"Correction to: PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly","year":2024,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences","keywords":"Acromegaly; Medicine; Somatostatin; Somatostatin Analogue; Internal medicine; Medical physics; Rheumatology; Oncology; Octreotide; Growth hormone; Hormone","score_opus":0.03755480617398558,"score_gpt":0.3943675857701895,"score_spread":0.3568127795962039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392744020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741694,0.0019499174,0.00054296106,0.0013391847,0.015311972,0.0052219066,0.0002724951,0.00016308905,0.0010291118],"genre_scores_gemma":[0.9809322,0.0015199407,0.0008948223,0.0005689767,0.00058021746,0.002333628,0.0008479748,0.00017780873,0.012144479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966516,0.0002999034,0.0007036664,0.0008360403,0.0009568755,0.00055193657],"domain_scores_gemma":[0.9970521,0.0010578844,0.00042004927,0.0005230052,0.0007798781,0.0001671071],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040201252,0.00048049827,0.0006396059,0.00070369383,0.00018600227,0.00013890829,0.0005593607,0.000022171906,0.000070349655],"category_scores_gemma":[0.0011856247,0.0002930416,0.00010252508,0.0013625587,0.00015521763,0.0010044278,0.00009512612,0.00070467725,0.000005514188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059620235,0.0031391603,0.4200295,0.0017475514,0.0012136325,0.0009609824,0.045071557,0.032820955,0.00043275286,0.00006522317,0.09404554,0.34085292],"study_design_scores_gemma":[0.0086481115,0.05157012,0.5042697,0.004956938,0.00017418966,0.0010552355,0.021218762,0.0072507174,0.0049003265,0.00027455573,0.39365098,0.0020303298],"about_ca_topic_score_codex":0.0005165239,"about_ca_topic_score_gemma":0.020583283,"teacher_disagreement_score":0.33882257,"about_ca_system_score_codex":0.00019109546,"about_ca_system_score_gemma":0.00037287374,"threshold_uncertainty_score":0.9999522},"labels":[],"label_agreement":null},{"id":"W4392923906","doi":"10.1007/s12325-024-02822-z","title":"Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada); Precision Nanosystems (Canada)","funders":"National Cancer Institute; Kite Pharma","keywords":"Mantle cell lymphoma; Medicine; Internal medicine; Hazard ratio; Population; Oncology; Progression-free survival; Confidence interval; Gastroenterology; Lymphoma; Chemotherapy","score_opus":0.01086648479791213,"score_gpt":0.2654537285972432,"score_spread":0.25458724379933106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392923906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9442793,0.053898577,0.000007823918,0.000046082627,0.00010197729,0.0011884464,0.0000387004,0.00008245108,0.00035662565],"genre_scores_gemma":[0.993356,0.005603722,0.00047430268,0.00007708412,0.00002944561,0.0001377688,0.00013481735,0.000066050176,0.000120801225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980534,0.000094286916,0.0005320675,0.0005663973,0.00039205851,0.00036182106],"domain_scores_gemma":[0.99913853,0.00015432296,0.00019857787,0.00032709213,0.000065713866,0.00011578253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012781833,0.00038813084,0.0007858702,0.0003221038,0.0000434086,0.000029164848,0.00008507823,0.00011276543,0.000027170303],"category_scores_gemma":[0.0000058263263,0.00025585137,0.000053082986,0.0006014942,0.00013661993,0.0002821391,0.000026711392,0.00014212856,0.000004446732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005108126,0.005926873,0.8595737,0.0004757833,0.00013165403,0.00023546033,0.0022922363,0.000095422896,0.0006761087,0.000029923516,0.000034551616,0.12542015],"study_design_scores_gemma":[0.03858412,0.008433924,0.8983271,0.0031001945,0.00015013352,0.000022139271,0.0003290262,0.00015906156,0.046307612,0.000031982374,0.0041366,0.0004181021],"about_ca_topic_score_codex":0.0004268269,"about_ca_topic_score_gemma":0.00037845763,"teacher_disagreement_score":0.12500206,"about_ca_system_score_codex":0.00037536738,"about_ca_system_score_gemma":0.00015648657,"threshold_uncertainty_score":0.9999894},"labels":[],"label_agreement":null},{"id":"W4393115557","doi":"10.1007/s12325-024-02826-9","title":"Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Brain and Cognition Discovery Foundation; University of Ottawa","funders":"","keywords":"Vortioxetine; Medicine; Placebo; Internal medicine; Clinical endpoint; Randomized controlled trial; Body mass index; Mood; Physical therapy; Major depressive disorder; Psychiatry; Pathology","score_opus":0.008732925826616594,"score_gpt":0.3325133837605865,"score_spread":0.32378045793396987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393115557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98472756,0.009080174,0.0008499657,0.00083944225,0.00062595174,0.0035548564,0.0000033824122,0.00004483159,0.00027385482],"genre_scores_gemma":[0.9921695,0.0058062426,0.000008328772,0.0009841127,0.000095647425,0.0008961334,0.0000037661898,0.000013724984,0.000022571487],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975613,0.0011711187,0.00047288366,0.00034026976,0.00028910983,0.00016532028],"domain_scores_gemma":[0.99124473,0.008310815,0.00022561206,0.00016070348,0.000020496569,0.000037662936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006654177,0.00017980712,0.0005912235,0.00027895797,0.00007974226,0.00011455372,0.00013439721,0.000062645995,0.000022713566],"category_scores_gemma":[0.0036994237,0.00010580747,0.00012240857,0.00037867186,0.0002632239,0.0005255207,0.00001120052,0.00019970888,0.0000021790997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77379155,0.00024240014,0.00032916182,0.00015006661,0.00007421009,0.00005217034,0.0017211796,0.0030731575,0.13648567,0.03445274,0.0000034654438,0.04962424],"study_design_scores_gemma":[0.92619395,0.0003724126,0.0015055123,0.00021205447,0.000020213856,0.00000304887,0.000108490975,0.0031135033,0.04896419,0.018745989,0.0005894235,0.00017122958],"about_ca_topic_score_codex":0.000009001898,"about_ca_topic_score_gemma":0.000009310646,"teacher_disagreement_score":0.15240239,"about_ca_system_score_codex":0.000026516567,"about_ca_system_score_gemma":0.000071427196,"threshold_uncertainty_score":0.4428823},"labels":[],"label_agreement":null},{"id":"W4393342156","doi":"10.1007/s12325-023-02766-w","title":"Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Geomechanica (Canada)","funders":"","keywords":"Medicine; Psoriatic arthritis; Rheumatology; Rheumatoid arthritis; Ankylosing spondylitis; Internal medicine; Psoriasis; Infliximab; Disease; Reimbursement; Golimumab; Quality of life (healthcare); Physical therapy; Intensive care medicine; Adalimumab; Health care; Immunology","score_opus":0.027408015565223053,"score_gpt":0.32423304761687394,"score_spread":0.2968250320516509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393342156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7208449,0.27656507,0.00011346268,0.00047440032,0.0004456326,0.0003013979,0.000004480457,0.000049175054,0.0012014615],"genre_scores_gemma":[0.8318033,0.16500719,0.002784339,0.000112128146,0.000016988079,0.00014486877,0.000007112514,0.0000143533425,0.00010969541],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991691,0.000021122622,0.00021920692,0.00026158907,0.00009461169,0.00023433208],"domain_scores_gemma":[0.9997345,0.00007863005,0.000022105749,0.0001313814,0.0000109280245,0.000022455179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000039193237,0.00015914121,0.0003051922,0.00014394148,0.00003648592,0.000013006671,0.0000348283,0.000040585524,0.00003299097],"category_scores_gemma":[0.00000331461,0.000106450214,0.000073544055,0.00019162205,0.00005147262,0.00016120127,0.000010846782,0.00008678354,0.000012752746],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041967534,0.0005936691,0.09436312,0.000023315968,0.00031995666,0.001433282,0.0055045825,0.0327735,0.00022762168,0.0011259674,0.0000049673904,0.8632103],"study_design_scores_gemma":[0.06081538,0.025787394,0.02268123,0.006729179,0.00022850018,0.00059934444,0.019684771,0.084537864,0.020151433,0.03637663,0.7196289,0.0027794326],"about_ca_topic_score_codex":0.00024365277,"about_ca_topic_score_gemma":0.00013809117,"teacher_disagreement_score":0.8604309,"about_ca_system_score_codex":0.00024238891,"about_ca_system_score_gemma":0.00003166434,"threshold_uncertainty_score":0.43409136},"labels":[],"label_agreement":null},{"id":"W4393950389","doi":"10.1007/s12325-024-02827-8","title":"Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"Fogarty International Center; Swedish Orphan Biovitrum; Apellis Pharmaceuticals","keywords":"Medicine; Paroxysmal nocturnal hemoglobinuria; Internal medicine; Adverse effect; Cutoff; Anemia; Population; Hemoglobin; Gastroenterology","score_opus":0.013220325758835647,"score_gpt":0.30904353567541964,"score_spread":0.295823209916584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393950389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97137463,0.026665162,0.000012469099,0.000029547065,0.0005111747,0.0012123294,0.000059828915,0.00002280658,0.000112079026],"genre_scores_gemma":[0.9986719,0.0010127762,0.000050551665,0.00005955649,0.00001318674,0.000040078547,0.00005222795,0.000017853969,0.00008187752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986046,0.00025298746,0.00043625294,0.00040106458,0.00006973408,0.0002353366],"domain_scores_gemma":[0.9993469,0.00021902191,0.000108158434,0.0002566609,0.00005088996,0.000018382785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020824408,0.0001943032,0.0003744089,0.00012782714,0.00007478682,0.000020150965,0.0002637846,0.000058648497,0.00020564241],"category_scores_gemma":[0.000026863081,0.0001389945,0.000019374917,0.00022160028,0.00010928245,0.00032444103,0.00014026661,0.00017564312,0.0000107574515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008728151,0.002785373,0.939239,0.00007198371,0.00017031054,0.000027120404,0.001993305,0.00004376769,0.002358968,0.00020422174,0.00016679503,0.044210963],"study_design_scores_gemma":[0.035435226,0.0019874254,0.9530215,0.0006206507,0.000026857215,0.000009507439,0.000587106,0.000019780267,0.00052938174,0.00018791374,0.0072892793,0.00028531687],"about_ca_topic_score_codex":0.00011078926,"about_ca_topic_score_gemma":0.00038647873,"teacher_disagreement_score":0.043925647,"about_ca_system_score_codex":0.000049162692,"about_ca_system_score_gemma":0.00004046364,"threshold_uncertainty_score":0.5668031},"labels":[],"label_agreement":null},{"id":"W4394818893","doi":"10.1007/s12325-024-02832-x","title":"Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Bausch Health","keywords":"Rifaximin; Medicine; Irritable bowel syndrome; Internal medicine; Diarrhea; Retrospective cohort study; Gastroenterology; Antibiotics","score_opus":0.013078550320503753,"score_gpt":0.3009737151119435,"score_spread":0.28789516479143973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394818893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946684,0.0011914194,0.0012442329,0.00006504766,0.00005117996,0.0012444805,0.00003347786,0.00007564687,0.0014260982],"genre_scores_gemma":[0.9956084,0.00033404105,0.0036296102,0.000018777866,0.000016094675,0.00025373665,0.00003227296,0.000046152512,0.000060919097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885285,0.000048613674,0.00017506331,0.0005043923,0.00010641603,0.00031268428],"domain_scores_gemma":[0.99930114,0.0001807409,0.00004316894,0.00030426987,0.000021830607,0.0001488513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090006215,0.0003124512,0.00044716182,0.00021062916,0.000052179057,0.00008629328,0.00007340485,0.000029393415,0.000008285949],"category_scores_gemma":[0.000009396567,0.00018376672,0.000061905,0.00022292844,0.00011333448,0.0005932485,0.000017142758,0.000091463815,0.000002120856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020540897,0.0008944309,0.972942,0.00012368588,0.00019103938,0.00005388669,0.0003837765,0.0022069078,0.00002462244,0.000053481494,0.0000014995337,0.021070572],"study_design_scores_gemma":[0.0076368963,0.008896292,0.980837,0.0008103317,0.000058271587,0.00010128462,0.00011959837,0.001031376,0.00008951452,0.0001399702,0.000101603575,0.00017786093],"about_ca_topic_score_codex":0.0033826975,"about_ca_topic_score_gemma":0.0019306634,"teacher_disagreement_score":0.020892711,"about_ca_system_score_codex":0.0009227468,"about_ca_system_score_gemma":0.00012071305,"threshold_uncertainty_score":0.7493789},"labels":[],"label_agreement":null},{"id":"W4395068084","doi":"10.1007/s12325-024-02825-w","title":"Stratified Patient Profiling for Vedolizumab Effectiveness in Crohn’s Disease: Identifying Optimal Subgroups for Enhanced Treatment Response in the EVOLVE Study","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"Takeda Pharmaceuticals International; Cedars-Sinai Medical Center","keywords":"Vedolizumab; Medicine; Internal medicine; Crohn's disease; Rheumatology; Profiling (computer programming); Disease","score_opus":0.01748624140895827,"score_gpt":0.34014957204818363,"score_spread":0.32266333063922537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395068084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984324,0.008179767,0.0021859088,0.000016935035,0.00022782476,0.0049811476,0.000063834355,0.00001282023,0.000007784832],"genre_scores_gemma":[0.9918833,0.00037978357,0.00032521656,0.000026735077,0.0000650818,0.0072076507,0.0000715372,0.0000308548,0.0000098730125],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983838,0.00043990146,0.00028618908,0.0004923573,0.000115419236,0.00028230192],"domain_scores_gemma":[0.99929106,0.00029337395,0.00004766352,0.00029607507,0.00003701511,0.000034804867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006723358,0.00020507503,0.00016514708,0.00009828256,0.000060367976,0.000057654695,0.00016970487,0.00005355723,0.0000016322987],"category_scores_gemma":[0.00009812262,0.00015432145,0.00010744448,0.00013056115,0.00003868333,0.0000286375,0.000018321016,0.00006345252,5.888738e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3709532,0.0055101244,0.08033584,0.0011451626,0.00034694103,0.001542951,0.017583791,0.05594629,0.3271371,0.00079932384,0.000010057299,0.13868918],"study_design_scores_gemma":[0.01451706,0.005118943,0.7944511,0.00037495015,0.000045689558,0.000002530418,0.0059699924,0.0028271922,0.17297831,0.0018783385,0.0011099572,0.0007259226],"about_ca_topic_score_codex":0.0000057710204,"about_ca_topic_score_gemma":0.00023810481,"teacher_disagreement_score":0.71411526,"about_ca_system_score_codex":0.00014202023,"about_ca_system_score_gemma":0.0001631665,"threshold_uncertainty_score":0.6293046},"labels":[],"label_agreement":null},{"id":"W4395068277","doi":"10.1007/s12325-024-02859-0","title":"Development and Application of an Attribute-Based Taxonomy on the Benefits of Oral Anticoagulant Switching in Atrial Fibrillation: A Delphi Study","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Petro-Canada; St. Paul's Hospital; Centre for Advancing Health Outcomes; Centre for Social Innovation; University of British Columbia Hospital; Vancouver General Hospital; Island Health; Royal Columbian Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Atrial fibrillation; Oral anticoagulant; Delphi; Delphi method; Internal medicine; Anticoagulant; Rheumatology; Cardiology; Warfarin; Artificial intelligence; Computer science","score_opus":0.09470546037646782,"score_gpt":0.36626309439185484,"score_spread":0.271557634015387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395068277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941487,0.002702733,0.0013698104,0.0004144762,0.00006763528,0.0012518674,0.000001411539,0.000015130836,0.000028247583],"genre_scores_gemma":[0.9978054,0.00029876074,0.0017293057,0.000028147564,0.00010787106,0.00001003861,0.000009875394,0.000007440179,0.0000031723575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920934,0.000046227284,0.00033759951,0.00016257871,0.00016764694,0.00007657489],"domain_scores_gemma":[0.99953294,0.00021318089,0.0000851287,0.00013209814,0.00002180643,0.000014871153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046624197,0.00008507889,0.00021816553,0.00015531915,0.000023702687,0.000009351252,0.00004536815,0.000023738901,0.0000049518667],"category_scores_gemma":[0.000021393704,0.000056321536,0.00003476566,0.00030020133,0.000018470642,0.000117373136,0.000011814222,0.000050408533,6.198636e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059218745,0.000018876262,0.5485989,0.00004272126,0.000033642376,0.00000144841,0.00076831295,0.009271002,0.00023117516,0.0017224598,4.603966e-7,0.43871883],"study_design_scores_gemma":[0.0066261506,0.0010306205,0.9257273,0.00032813207,0.000042901767,0.0000014396886,0.0016240544,0.026223164,0.004826797,0.0004063493,0.03294749,0.00021556557],"about_ca_topic_score_codex":0.000024209905,"about_ca_topic_score_gemma":0.000104746134,"teacher_disagreement_score":0.43850324,"about_ca_system_score_codex":0.00002773673,"about_ca_system_score_gemma":0.00003356952,"threshold_uncertainty_score":0.22967255},"labels":[],"label_agreement":null},{"id":"W4395448014","doi":"10.1007/s12325-024-02855-4","title":"Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Manchester Biomedical Research Centre; Genentech; National Institutes of Health; Sunovion; Glenmark Pharmaceuticals; AstraZeneca; CSL Behring; Sanofi; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Mylan; COPD Foundation; GlaxoSmithKline; Amgen","keywords":"Medicine; COPD; Intensive care medicine; Disease; Cause of death; Risk factor; Internal medicine","score_opus":0.0456409043811343,"score_gpt":0.43151400131990636,"score_spread":0.38587309693877203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395448014","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000025816134,0.9884558,0.00009136365,0.0003093534,0.00017059805,0.008119761,0.00069063884,0.000017171227,0.002142745],"genre_scores_gemma":[0.000026108719,0.99465483,0.00047095466,0.000052479285,0.00009684285,0.0040672743,0.00014255014,0.00006384594,0.00042513807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978043,0.0001904032,0.0008814953,0.0004978026,0.00035800633,0.0002679944],"domain_scores_gemma":[0.99780566,0.0004662322,0.00047345136,0.0010151479,0.00017807004,0.00006145169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057823793,0.00034738635,0.0018351728,0.0001748053,0.00005762651,0.00000446376,0.00045930376,0.000089737376,0.000073517476],"category_scores_gemma":[0.000032014246,0.00020202108,0.0009462034,0.0009235637,0.00030348735,0.0000756265,0.00010549888,0.0004024351,0.000007691426],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059007525,0.000097451106,0.000019899679,0.19318068,0.0010927803,0.000010067824,0.00007150488,0.0000022148386,1.456385e-7,0.001046155,0.00052026816,0.8038998],"study_design_scores_gemma":[0.00040928775,0.00010118207,0.00018446852,0.07998874,0.0022767673,0.000022460084,0.00022036639,0.000005941026,7.660011e-7,0.0018737788,0.91477156,0.0001447002],"about_ca_topic_score_codex":0.000011195244,"about_ca_topic_score_gemma":0.0000033956585,"teacher_disagreement_score":0.91425127,"about_ca_system_score_codex":0.00028206554,"about_ca_system_score_gemma":0.00031953954,"threshold_uncertainty_score":0.823818},"labels":[],"label_agreement":null},{"id":"W4395456078","doi":"10.1007/s12325-024-02860-7","title":"The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada)","funders":"","keywords":"Medicine; Epigenetics; Coronary heart disease; Health care; Disease; Intensive care medicine; Precision medicine; Internal medicine; Cardiology; Pathology","score_opus":0.048423075050866904,"score_gpt":0.40716602636033367,"score_spread":0.35874295130946676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395456078","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39164957,0.60363257,0.003677084,0.00042225939,0.00015738672,0.00041216915,0.00004426366,0.0000020136263,0.0000026578025],"genre_scores_gemma":[0.6821603,0.31260893,0.0049843416,0.00003329236,0.00002981683,0.00013823125,0.00001691466,0.000010517834,0.00001762844],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99925977,0.00016414894,0.00019946316,0.00019306326,0.00007145676,0.000112079506],"domain_scores_gemma":[0.99876404,0.0008302192,0.000054830532,0.00023053211,0.00008970949,0.000030652624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030291855,0.000081781036,0.00010288089,0.000021339305,0.00007720503,0.000019663512,0.00009883841,0.00004211674,0.0000011882861],"category_scores_gemma":[0.00013461198,0.000048560883,0.000050668776,0.00008040413,0.00011515912,0.000009225935,0.00003314797,0.00003984883,4.1416765e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030119898,0.000018301744,0.010833317,0.000068442765,0.00001785643,1.3862817e-7,0.00019174401,0.0008014573,0.053917214,0.0001275971,0.000025473846,0.9336973],"study_design_scores_gemma":[0.00028009678,0.0006406027,0.018351085,0.00011605497,0.000014941166,3.1586583e-7,0.00026290707,0.0005117105,0.5430337,0.0026839972,0.43400136,0.000103197126],"about_ca_topic_score_codex":0.00002937901,"about_ca_topic_score_gemma":0.00006378435,"teacher_disagreement_score":0.93359405,"about_ca_system_score_codex":0.000009951544,"about_ca_system_score_gemma":0.00005383677,"threshold_uncertainty_score":0.19802554},"labels":[],"label_agreement":null},{"id":"W4396552446","doi":"10.1007/s12325-024-02843-8","title":"Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Thyroid and Parathyroid Surgery","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McMaster University","funders":"Novo Nordisk; Kowa Company; Alexion Pharmaceuticals; AstraZeneca; Chugai Pharmaceutical; Amgen","keywords":"Medicine; Hypoparathyroidism; Rheumatology; Internal medicine; Renal function; Urology","score_opus":0.017247183799326063,"score_gpt":0.2944128824721473,"score_spread":0.27716569867282126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396552446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.847066,0.14945115,0.000069784255,0.00049886113,0.0007506323,0.0012453997,0.00012417337,0.00008599719,0.00070803287],"genre_scores_gemma":[0.9632105,0.033966597,0.00011318699,0.00020361542,0.0013696493,0.0003831147,0.00029759537,0.000041202147,0.00041452056],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99799746,0.00016155481,0.0005665771,0.0006303369,0.00026738888,0.0003766564],"domain_scores_gemma":[0.9987891,0.0005222549,0.00010207254,0.00048013852,0.000025836905,0.0000806192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031204073,0.00032850742,0.00044956437,0.00012745985,0.00006423162,0.00006076109,0.000109902685,0.00009782978,0.000024494675],"category_scores_gemma":[0.00003161353,0.00017862697,0.00012122935,0.00047837791,0.00010808084,0.00037948345,0.000011226772,0.00031325323,0.00004909267],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6596942,0.0013546577,0.0006085914,0.000016371241,0.00019366908,0.0006172819,0.005144996,0.0002446603,0.058413703,0.00020615662,0.0019974913,0.27150822],"study_design_scores_gemma":[0.40300515,0.02962684,0.003744893,0.00080575957,0.000066239016,0.000039652652,0.0009874052,0.0011057263,0.023511145,0.0008635091,0.53556466,0.0006790236],"about_ca_topic_score_codex":0.0002763989,"about_ca_topic_score_gemma":0.0015732554,"teacher_disagreement_score":0.5335672,"about_ca_system_score_codex":0.00025194386,"about_ca_system_score_gemma":0.0003630638,"threshold_uncertainty_score":0.7284196},"labels":[],"label_agreement":null},{"id":"W4396575375","doi":"10.1007/s12325-024-02865-2","title":"Observing the Clinical Course of Duchenne Muscular Dystrophy in Medicaid Real-World Healthcare Data","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Broadcom (Canada); Vancouver Coastal Health","funders":"Sarepta Therapeutics","keywords":"Medicine; Duchenne muscular dystrophy; Muscular dystrophy; Medicaid; Health care; Rheumatology; Physical therapy; Physical medicine and rehabilitation; Family medicine; Internal medicine","score_opus":0.05606112900153842,"score_gpt":0.42912104494120257,"score_spread":0.37305991593966414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396575375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8986156,0.098264575,0.000085763495,0.0019584454,0.00050431176,0.00018410463,0.000035440396,0.000009385814,0.00034237295],"genre_scores_gemma":[0.90795416,0.09099677,0.00017747715,0.00048022324,0.00019113682,0.000017437816,0.0001491069,0.000012093005,0.000021610756],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987285,0.00023228076,0.00038245475,0.00039303183,0.00008163279,0.00018209084],"domain_scores_gemma":[0.99901885,0.00011934741,0.00006720364,0.0007394311,0.000022165254,0.000033015116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073778303,0.0001069087,0.00020682656,0.000032559583,0.000025386385,0.0000052013525,0.00054169487,0.0000982084,0.000017087566],"category_scores_gemma":[0.00007174458,0.00007226833,0.00006182039,0.00020184329,0.0002170356,0.000014677288,0.00012546021,0.00022264982,0.0000013086756],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014882927,0.0006014239,0.16767398,0.00033122316,0.00024083813,0.0000403409,0.0005654059,0.00080451515,0.026978295,0.004577893,0.00169963,0.79499817],"study_design_scores_gemma":[0.0034812638,0.0011559344,0.27165887,0.00042522696,0.000022789962,0.000005395519,0.0011951705,0.0018752887,0.0048404075,0.015883205,0.69887567,0.00058076845],"about_ca_topic_score_codex":0.000260801,"about_ca_topic_score_gemma":0.003834077,"teacher_disagreement_score":0.7944174,"about_ca_system_score_codex":0.0000049092364,"about_ca_system_score_gemma":0.00012822959,"threshold_uncertainty_score":0.29470173},"labels":[],"label_agreement":null},{"id":"W4396662793","doi":"10.1007/s12325-024-02867-0","title":"“You Take This Day by Day, Come What May”: A Qualitative Study of the Psychosocial Impacts of Living with Duchenne Muscular Dystrophy","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Broadcom (Canada); Vancouver Coastal Health","funders":"Sarepta Therapeutics","keywords":"Psychosocial; Duchenne muscular dystrophy; Medicine; Qualitative research; Muscular dystrophy; Quality of life (healthcare); Perspective (graphical); Health related quality of life; Disease; Gerontology; Social support; Physical therapy; Psychiatry; Internal medicine; Psychology; Nursing; Psychotherapist","score_opus":0.007325064491490143,"score_gpt":0.3192542250416676,"score_spread":0.3119291605501775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396662793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619385,0.037215482,0.000094871226,0.0001089255,0.00021259807,0.00029510178,0.000017751285,0.000005733354,0.00011104479],"genre_scores_gemma":[0.99159914,0.008131324,0.000036605616,0.00010020902,0.000040565927,0.000035825196,0.0000073381248,0.000016992462,0.000032000888],"study_design_codex":"bench_or_experimental","study_design_gemma":"qualitative","domain_scores_codex":[0.9988408,0.00039809337,0.00020189238,0.00027473696,0.00012520385,0.00015923889],"domain_scores_gemma":[0.9994135,0.00012420393,0.00010811137,0.00028935756,0.000042513006,0.000022339238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003179399,0.00014311001,0.00020431829,0.000030621526,0.000043549175,0.000012757423,0.00022779198,0.000073708215,0.000024675288],"category_scores_gemma":[0.000051630566,0.000091884816,0.000074259646,0.00019354168,0.00021412353,0.000030960928,0.000037896116,0.00011538906,5.3386685e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014497155,0.0024625168,0.021485675,0.00022959716,0.0011522173,0.0000046394653,0.15262145,0.0004622019,0.7870947,0.00079215475,0.0006769592,0.03156814],"study_design_scores_gemma":[0.014548881,0.03408172,0.12372971,0.0036903394,0.00029527766,0.000011112379,0.5437064,0.00013747337,0.18291108,0.008366353,0.08556373,0.0029578896],"about_ca_topic_score_codex":0.0000921455,"about_ca_topic_score_gemma":0.00025970742,"teacher_disagreement_score":0.6041837,"about_ca_system_score_codex":0.000007763999,"about_ca_system_score_gemma":0.000037485363,"threshold_uncertainty_score":0.37469542},"labels":[],"label_agreement":null},{"id":"W4399055997","doi":"10.1007/s12325-024-02875-0","title":"Epidemiology and Treatment Patterns of Patients with Vitiligo: A Real-World Analysis","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"melanin and skin pigmentation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ABB (Canada)","funders":"AbbVie","keywords":"Vitiligo; Medicine; Comorbidity; Population; Epidemiology; Depigmentation; Internal medicine; Incidence (geometry); Psoriasis; Alopecia areata; Dermatology","score_opus":0.012129846098345042,"score_gpt":0.3232031301508689,"score_spread":0.3110732840525238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399055997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926599,0.0059840432,0.00094724144,0.000025668718,0.00004219471,0.0001039173,0.000027314381,0.000003741997,0.0002059761],"genre_scores_gemma":[0.97673976,0.02249051,0.00037446147,0.00005190108,0.000022380631,0.000023909404,0.00018004926,0.0000059128506,0.0001111306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99949366,0.0000591691,0.00013590521,0.00019213113,0.00003392106,0.000085231404],"domain_scores_gemma":[0.9997812,0.000041462885,0.00003801307,0.00010853041,0.000012575314,0.000018252951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007507965,0.00007359688,0.00014872993,0.00008250188,0.000009760293,0.0000021059382,0.00003053974,0.000026464664,0.000015862192],"category_scores_gemma":[0.0000041314615,0.000049588838,0.000034852645,0.00012684106,0.000029574507,0.000004753432,0.0000062572863,0.000016858628,2.553483e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014168852,0.000046432255,0.9503723,0.000008357668,0.00016871635,0.0000010942083,0.00007980699,0.000117080606,0.00083124987,0.00020273819,0.0000030178117,0.048027523],"study_design_scores_gemma":[0.001006213,0.0010374855,0.97173285,0.000020946232,0.000054031087,3.8068987e-7,0.00005207356,0.0001368746,0.01624175,0.00032393192,0.009276604,0.000116839],"about_ca_topic_score_codex":0.000120267265,"about_ca_topic_score_gemma":0.0015493074,"teacher_disagreement_score":0.047910683,"about_ca_system_score_codex":0.0000109587945,"about_ca_system_score_gemma":0.000008170859,"threshold_uncertainty_score":0.20221741},"labels":[],"label_agreement":null},{"id":"W4399326644","doi":"10.1007/s12325-024-02893-y","title":"Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AstraZeneca","keywords":"Medicine; Breast cancer; EconLit; Indirect costs; Health care; Health economics; MEDLINE; Disease burden; Epidemiology; Environmental health; Family medicine; Cancer; Public health; Demography; Economic growth; Population; Pathology; Accounting; Internal medicine; Business","score_opus":0.039705482735827566,"score_gpt":0.33405506546689123,"score_spread":0.29434958273106365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399326644","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017031512,0.99421483,0.0000032393555,0.00010781514,0.0002111534,0.0015079037,0.0016574631,0.000021969925,0.0022585995],"genre_scores_gemma":[0.00023872827,0.99843836,0.000013771991,0.00021704598,0.000040555275,0.00081427203,0.000021269005,0.000052111627,0.00016390163],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9978127,0.00004651371,0.0013916751,0.0004960439,0.000025903008,0.0002271636],"domain_scores_gemma":[0.99813575,0.000199437,0.0012627755,0.0003151301,0.000029744426,0.000057169276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000719455,0.00033960133,0.0035598571,0.0002885253,0.00003159851,0.00004100855,0.00021238507,0.0001790715,0.00002925574],"category_scores_gemma":[0.00013848896,0.00028999764,0.00020145519,0.00044582112,0.00009783861,0.0003062249,0.000045386132,0.00020045564,0.000017957716],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000041197686,0.000039481372,0.00035762077,0.49942875,0.00035018154,0.000001215864,0.0000686527,2.3750319e-7,3.0482333e-8,0.0103659155,0.00015686605,0.4892269],"study_design_scores_gemma":[0.0002798441,0.000045277255,0.00029226462,0.5866721,0.00036855508,0.000022465785,0.000005371496,0.000003322852,1.6930574e-7,0.005042759,0.4067309,0.0005369288],"about_ca_topic_score_codex":0.0001126508,"about_ca_topic_score_gemma":0.000098282624,"teacher_disagreement_score":0.48869,"about_ca_system_score_codex":0.00031902402,"about_ca_system_score_gemma":0.00007358285,"threshold_uncertainty_score":0.99995524},"labels":[],"label_agreement":null},{"id":"W4399543904","doi":"10.1007/s12325-024-02902-0","title":"De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Biogen","keywords":"Medicine; Fingolimod; Multiple sclerosis; Ocrelizumab; Internal medicine; Expanded Disability Status Scale; Adverse effect; Clinical trial; Immunology; Rituximab","score_opus":0.044418579673088626,"score_gpt":0.33468176764115215,"score_spread":0.2902631879680635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399543904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98054427,0.0053919633,0.0063545248,0.0041807233,0.00012187434,0.0030279953,0.0002603716,0.0000787033,0.00003956291],"genre_scores_gemma":[0.97712433,0.01266231,0.008015243,0.0006957832,0.000086193664,0.0012499727,0.00006866831,0.0000637155,0.000033754273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784404,0.00011655248,0.00056695973,0.00058950623,0.00040779728,0.0004751445],"domain_scores_gemma":[0.9973898,0.0017769099,0.00008755615,0.00038355045,0.00016784044,0.0001943608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004187802,0.0002950416,0.0008421176,0.0004012625,0.00012474894,0.00007996573,0.00012867841,0.00006500931,0.00006700674],"category_scores_gemma":[0.0006539272,0.00022955108,0.00011753763,0.0006558608,0.00004978525,0.00045312854,0.00005070553,0.00019710218,0.0000068249296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009467843,0.0004351784,0.81730556,0.0002469159,0.00023155636,0.000010679974,0.015257272,0.0019453833,0.08985792,0.00018238081,0.000055385713,0.0650039],"study_design_scores_gemma":[0.0058924374,0.0005347155,0.9780795,0.0013216395,0.000012103048,6.381553e-7,0.0007890243,0.0047056125,0.0071314713,0.00037688462,0.000896105,0.00025986813],"about_ca_topic_score_codex":0.00046398508,"about_ca_topic_score_gemma":0.0025705907,"teacher_disagreement_score":0.16077392,"about_ca_system_score_codex":0.00025907723,"about_ca_system_score_gemma":0.00016592389,"threshold_uncertainty_score":0.9360821},"labels":[],"label_agreement":null},{"id":"W4400419581","doi":"10.1007/s12325-024-02920-y","title":"Increased Risk of Severe Cardiovascular Events Following Exacerbations of Chronic Obstructive Pulmonary Disease: Results of the EXACOS-CV Study in Japan","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pulmonary disease; Internal medicine; Rheumatology; Cardiology; Disease; Intensive care medicine; Emergency medicine","score_opus":0.012654358702799186,"score_gpt":0.30352268772919216,"score_spread":0.290868329026393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400419581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87283355,0.124225505,0.000011048992,0.00003953676,0.00023874322,0.0018960871,0.00027675298,0.00001839001,0.0004603676],"genre_scores_gemma":[0.99396396,0.0055898344,0.000052505646,0.0000039982683,0.00007184697,0.00015770346,0.000028430357,0.000041391657,0.00009034102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967483,0.0006276677,0.0007425608,0.00055507664,0.0010060931,0.00032025136],"domain_scores_gemma":[0.9980748,0.00044701147,0.00021838666,0.001032152,0.00012361766,0.00010403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008289416,0.00024194532,0.0006721687,0.0003485614,0.00004998234,0.000004643327,0.0003574471,0.00006589681,0.00003359666],"category_scores_gemma":[0.00038801547,0.00018326903,0.00059436314,0.0014354044,0.00024409761,0.0003330758,0.0001247788,0.00040198286,0.0000013181154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019239254,0.0014019654,0.89208186,0.00077454123,0.00096123584,0.0001234978,0.0011892786,0.0059746075,0.0011650653,0.000058118436,0.0000031450747,0.09434274],"study_design_scores_gemma":[0.0045591863,0.00022000233,0.98825186,0.0009998454,0.00023607192,0.000005979156,0.0015729513,0.0012653808,0.00064809946,0.0017156204,0.00037306873,0.00015192032],"about_ca_topic_score_codex":0.0008616924,"about_ca_topic_score_gemma":0.00016149915,"teacher_disagreement_score":0.12113038,"about_ca_system_score_codex":0.00058138394,"about_ca_system_score_gemma":0.00068272057,"threshold_uncertainty_score":0.74734944},"labels":[],"label_agreement":null},{"id":"W4400533986","doi":"10.1007/s12325-024-02928-4","title":"Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Anemia; Post-hoc analysis; Internal medicine; Gastroenterology; Subgroup analysis; Randomized controlled trial; Surgery; Meta-analysis; Bone marrow","score_opus":0.022127148808323633,"score_gpt":0.31237314423471757,"score_spread":0.29024599542639395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400533986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98283935,0.015115685,0.000007209006,0.00012159759,0.00015054467,0.0008816673,0.000057029734,0.000034640543,0.0007922593],"genre_scores_gemma":[0.9752518,0.023439478,0.0005076354,0.00012364725,0.000040723302,0.00033770665,0.000094344585,0.00003470029,0.00016995994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810743,0.000073070376,0.00050624384,0.00059858937,0.000356457,0.00035823535],"domain_scores_gemma":[0.9987708,0.00059201464,0.00012091409,0.00029357593,0.00011931703,0.000103424194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015293015,0.00032094377,0.0008240299,0.00051846367,0.00004707758,0.000040490006,0.000087230175,0.000106521475,0.00039494716],"category_scores_gemma":[0.00004729065,0.00020360404,0.00009426741,0.0016575665,0.00019299204,0.00035487534,0.000020502732,0.00017833621,0.000006777817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010125301,0.0011724666,0.90358883,0.00008040456,0.0005681997,0.000060858645,0.0028463062,0.000050000173,0.00074677827,0.00019046773,0.00003849888,0.08053186],"study_design_scores_gemma":[0.05785365,0.022766959,0.83296144,0.0015514232,0.0005849292,0.000007134528,0.0025556346,0.0005773493,0.053150028,0.00012623591,0.026842527,0.0010227002],"about_ca_topic_score_codex":0.00013767194,"about_ca_topic_score_gemma":0.0005373243,"teacher_disagreement_score":0.07950916,"about_ca_system_score_codex":0.00012493804,"about_ca_system_score_gemma":0.00009698027,"threshold_uncertainty_score":0.83027315},"labels":[],"label_agreement":null},{"id":"W4400594797","doi":"10.1007/s12325-024-02930-w","title":"Correction: Beyond Response: Aiming for Quality Remission in Depression","year":2024,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Health Policy Implementation Science","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Rheumatology; Depression (economics); Internal medicine; Quality (philosophy); Alternative medicine; Medical physics; Family medicine; Physical therapy; Pathology; Epistemology","score_opus":0.39784102213946215,"score_gpt":0.6976135019190107,"score_spread":0.2997724797795486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400594797","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019971635,0.10556871,0.004928785,0.03948428,0.66341275,0.01829318,0.0009423217,0.00090964587,0.1464887],"genre_scores_gemma":[0.008795565,0.07449774,0.004356855,0.04200511,0.008576186,0.008941764,0.00046537168,0.00038154313,0.85197985],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926221,0.0029318344,0.0019070184,0.0009143009,0.000613069,0.001011708],"domain_scores_gemma":[0.9888593,0.009422011,0.0007617351,0.0005956225,0.00018385299,0.00017751235],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009318038,0.0003556342,0.000673875,0.00072919234,0.000562326,0.000022914355,0.00047234385,0.00074437395,0.00039339525],"category_scores_gemma":[0.0046368856,0.00030799492,0.000096461205,0.0010939835,0.0000880873,0.0005189825,0.00011641731,0.0026230044,0.00008498105],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018858308,0.00003084192,0.0038985412,0.00093948084,0.000004295292,0.0000060142606,0.010908473,0.000030767667,0.00019870095,0.00012734081,0.8654712,0.11649855],"study_design_scores_gemma":[0.0013727219,0.000117245545,0.0051427344,0.0028180338,0.0000024851315,0.0000013098642,0.0018000768,0.00028449483,0.00006209604,0.0047390754,0.9833582,0.00030150692],"about_ca_topic_score_codex":0.00033021814,"about_ca_topic_score_gemma":0.0031771646,"teacher_disagreement_score":0.7054912,"about_ca_system_score_codex":0.001225451,"about_ca_system_score_gemma":0.0024419099,"threshold_uncertainty_score":0.99993724},"labels":[],"label_agreement":null},{"id":"W4401182168","doi":"10.1007/s12325-024-02946-2","title":"Four-Strata Risk Assessment in Patients with Pulmonary Arterial Hypertension Treated with Selexipag in Real-World Settings (EXPOSURE Study)","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Rheumatology; Internal medicine; Cardiology; Pulmonary hypertension","score_opus":0.018058801456536967,"score_gpt":0.3114211555550988,"score_spread":0.2933623540985618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401182168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544203,0.001493173,0.0000023376904,0.00027872034,0.000076633216,0.0018775832,0.000032881428,0.000074397474,0.00072222296],"genre_scores_gemma":[0.99531364,0.0034137538,0.0005192667,0.00012263263,0.00004814376,0.0002173861,0.00015648069,0.00005246507,0.00015623764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997588,0.0002314327,0.0003924086,0.0006899357,0.0006141617,0.00048408395],"domain_scores_gemma":[0.9991688,0.00014281705,0.000072425486,0.00038586877,0.000099584766,0.00013049561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027448477,0.00033132388,0.00054348324,0.00056072196,0.000057179113,0.00004053246,0.00011357879,0.00006539228,0.00004630256],"category_scores_gemma":[0.000013003552,0.00019951742,0.000038728518,0.0011748502,0.00007438702,0.0005135245,0.000027582093,0.0005451059,0.000006594017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007938602,0.003981218,0.937532,0.000035177734,0.00011157938,0.012034558,0.00009237159,0.000055278822,0.00018585163,0.00000456732,0.000018266097,0.038010538],"study_design_scores_gemma":[0.013005952,0.0060061184,0.97825474,0.0006651817,0.000032946504,0.00004610582,0.00022469483,0.0005962887,0.00006532928,0.00008559611,0.00079848844,0.00021855689],"about_ca_topic_score_codex":0.0007867909,"about_ca_topic_score_gemma":0.0018291664,"teacher_disagreement_score":0.04072275,"about_ca_system_score_codex":0.00023897119,"about_ca_system_score_gemma":0.00017358125,"threshold_uncertainty_score":0.81360847},"labels":[],"label_agreement":null},{"id":"W4401404175","doi":"10.1007/s12325-024-02948-0","title":"A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AbbVie","keywords":"Medicine; Rheumatoid arthritis; Tumor necrosis factor alpha; Rheumatology; Tumor necrosis factor α; Necrosis; TNF inhibitor; Antirheumatic Agents; Internal medicine; Pharmacology; Arthritis; Oncology; Adalimumab","score_opus":0.01779634177568071,"score_gpt":0.34995272683928724,"score_spread":0.3321563850636065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401404175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771038,0.02044958,0.000039346538,0.000043086235,0.00019347314,0.0016024214,0.00038542412,0.00013477719,0.000048039397],"genre_scores_gemma":[0.9778631,0.020563994,0.00081119174,0.00009749751,0.00008706341,0.0003666473,0.0000635038,0.00014306938,0.000003932478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99599135,0.00056781556,0.001186587,0.0009527573,0.00068132504,0.0006201478],"domain_scores_gemma":[0.9978895,0.0009640772,0.00028687774,0.00043495704,0.00015590276,0.00026869169],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003468084,0.000586097,0.0015954225,0.0005128439,0.00009270595,0.00015120982,0.00016798975,0.000115234485,0.00014635125],"category_scores_gemma":[0.00006699979,0.0004080142,0.00013432544,0.00070201745,0.0005100983,0.0012635143,0.00005377188,0.0007107873,0.000003221732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020269455,0.00091322756,0.7483664,0.000086378175,0.00016790726,0.00007125969,0.0029521817,0.000005621345,0.0020650278,0.000021675689,0.0000013825186,0.22507949],"study_design_scores_gemma":[0.022064123,0.0061718686,0.9411193,0.00823916,0.0000049024634,0.000007117836,0.00059669575,0.00013425508,0.019192103,0.0003350084,0.0015407422,0.00059468515],"about_ca_topic_score_codex":0.0016090495,"about_ca_topic_score_gemma":0.0055751894,"teacher_disagreement_score":0.2244848,"about_ca_system_score_codex":0.00010010039,"about_ca_system_score_gemma":0.00017678515,"threshold_uncertainty_score":0.99983716},"labels":[],"label_agreement":null},{"id":"W4401477608","doi":"10.1007/s12325-024-02912-y","title":"Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Medizinische Universität Wien; AbbVie","keywords":"Medicine; Vedolizumab; Tofacitinib; Ustekinumab; Ulcerative colitis; Internal medicine; Gastroenterology; Oncology; Adalimumab","score_opus":0.01835251176131486,"score_gpt":0.2988069700619812,"score_spread":0.28045445830066634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401477608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845221,0.01195003,0.0020151637,0.00006412014,0.00012966791,0.0008391369,0.0003017851,0.000016748181,0.00016126042],"genre_scores_gemma":[0.994316,0.0041420315,0.0010949178,0.000081001424,0.000069918344,0.00017669324,0.00006601114,0.000020364909,0.00003308744],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99895144,0.00008785842,0.0002730316,0.0004046263,0.00007835389,0.0002047229],"domain_scores_gemma":[0.99955815,0.00009178637,0.00008422116,0.00013855062,0.00006603815,0.000061268234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016628354,0.00019987123,0.00028970663,0.00006652492,0.00006832207,0.00003645366,0.00006134015,0.000098413664,0.000008019828],"category_scores_gemma":[0.000022210716,0.00018081101,0.00003645488,0.00007806,0.00033624237,0.000040539962,0.000042271036,0.00011184013,3.539399e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22108771,0.0011012735,0.17043543,0.003891513,0.0022203824,0.00031284892,0.03633994,0.0016928512,0.06828237,0.028467916,0.0015247754,0.464643],"study_design_scores_gemma":[0.0075794472,0.00082176464,0.9433123,0.00051172427,0.000042257525,0.000052254098,0.0012839092,0.00078853854,0.01248556,0.0033399991,0.02922317,0.00055908196],"about_ca_topic_score_codex":0.00000904397,"about_ca_topic_score_gemma":0.00051899377,"teacher_disagreement_score":0.77287686,"about_ca_system_score_codex":0.000018729987,"about_ca_system_score_gemma":0.00005011081,"threshold_uncertainty_score":0.7373259},"labels":[],"label_agreement":null},{"id":"W4401590460","doi":"10.1007/s12325-024-02942-6","title":"Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Ustekinumab; Adalimumab; Internal medicine; Persistence (discontinuity); Hazard ratio; Ulcerative colitis; Psoriasis Area and Severity Index; Confidence interval; Gastroenterology; Psoriasis; Disease; Immunology","score_opus":0.020387610741738563,"score_gpt":0.30227606519998024,"score_spread":0.2818884544582417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401590460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949464,0.000971556,0.00002476778,0.000023587401,0.00026131413,0.0011533307,0.00009402898,0.00006910323,0.0024559088],"genre_scores_gemma":[0.9866411,0.010436822,0.0002704991,0.00026029474,0.00009163059,0.0007096674,0.00017746288,0.00006825109,0.0013442734],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980939,0.00017044721,0.0003035187,0.00074789143,0.00026123173,0.00042299824],"domain_scores_gemma":[0.9991375,0.000069352966,0.00010418892,0.00045111668,0.000120078264,0.00011776362],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000069951144,0.00041335725,0.0002687787,0.00012677922,0.00012721127,0.000064036125,0.00022494467,0.000095695446,0.00018805002],"category_scores_gemma":[0.000023242657,0.000256206,0.00009427581,0.00035993347,0.00025118026,0.00007053418,0.000023801924,0.000111011796,0.000009753713],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2638248,0.003284548,0.12151954,0.00016627384,0.0011334213,0.00290045,0.014125101,0.0057006697,0.0049479194,0.0008435719,0.00021370864,0.58134],"study_design_scores_gemma":[0.03682938,0.027647752,0.73841274,0.0010825456,0.000054654567,0.000016008571,0.0044221915,0.0005093384,0.10149006,0.00024269901,0.08664117,0.0026514456],"about_ca_topic_score_codex":0.000037850972,"about_ca_topic_score_gemma":0.00322946,"teacher_disagreement_score":0.61689323,"about_ca_system_score_codex":0.00022500819,"about_ca_system_score_gemma":0.00029166118,"threshold_uncertainty_score":0.99998903},"labels":[],"label_agreement":null},{"id":"W4401714924","doi":"10.1007/s12325-024-02963-1","title":"Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn’s Disease and Fistula Initiated on Ustekinumab","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Ustekinumab; Crohn's disease; Fistula; Surgery; Persistence (discontinuity); Internal medicine; Crohn disease; Complication; Inflammatory bowel disease; Disease; Gastroenterology; Adalimumab","score_opus":0.008820874744162648,"score_gpt":0.25980678888953584,"score_spread":0.2509859141453732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401714924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99347144,0.0054880725,0.0000037946731,0.00004712243,0.00007356449,0.00042449118,0.000069239504,0.000028392418,0.00039386985],"genre_scores_gemma":[0.9954016,0.0040347497,0.00003538112,0.00008328763,0.000068133326,0.000078865676,0.00011448748,0.000032696596,0.00015078968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988809,0.000058148693,0.00015804845,0.00051838416,0.00015708694,0.00022743476],"domain_scores_gemma":[0.999436,0.00001887868,0.00004473438,0.00030248627,0.00004640263,0.00015147825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000062716026,0.00022088138,0.00013373974,0.00007939281,0.00007542337,0.000072001414,0.00013747574,0.00005985935,0.000015246989],"category_scores_gemma":[0.000023595681,0.00017298924,0.00003948278,0.00011347197,0.00030017257,0.000034950383,0.000061703235,0.000103324695,0.0000013031938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028728333,0.000126125,0.9911839,0.00016076064,0.000047691297,0.0011758517,0.00015689715,0.000029432325,0.00007886417,0.00009642013,0.000023583383,0.004047666],"study_design_scores_gemma":[0.001916936,0.00023756242,0.9964403,0.00020483663,0.000016534714,0.0000052196974,0.000026805352,0.000048219154,0.00016922982,0.00007656979,0.0005959929,0.00026178575],"about_ca_topic_score_codex":0.0000041625854,"about_ca_topic_score_gemma":0.0002596773,"teacher_disagreement_score":0.005256433,"about_ca_system_score_codex":0.000027174367,"about_ca_system_score_gemma":0.000074430136,"threshold_uncertainty_score":0.7054297},"labels":[],"label_agreement":null},{"id":"W4402364275","doi":"10.1007/s12325-024-02974-y","title":"Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eli Lilly and Company","keywords":"Medicine; Atopic dermatitis; Placebo; Rheumatology; Dermatology; Internal medicine; Randomized controlled trial; Physical therapy; Double blind; Alternative medicine; Pathology","score_opus":0.03107844180460009,"score_gpt":0.3778267599319135,"score_spread":0.34674831812731344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402364275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87537485,0.118820235,0.00041969705,0.0007626044,0.0001985974,0.0042786472,0.00003347437,0.000059646765,0.000052223386],"genre_scores_gemma":[0.9502738,0.04714492,0.0002417467,0.00064175384,0.000047732796,0.0014635551,0.00003897623,0.000035723508,0.00011177337],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974767,0.00041000274,0.0010574358,0.00045061283,0.00024462928,0.00036060007],"domain_scores_gemma":[0.9975323,0.0016587744,0.0002263696,0.0003498829,0.00006345289,0.00016921794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010147715,0.00032605501,0.0017831094,0.00026613908,0.000059928618,0.00005371151,0.00010127593,0.000078692465,0.000051628536],"category_scores_gemma":[0.00017119767,0.00019000167,0.00023317001,0.00030965073,0.0004126586,0.0005825401,0.000022357683,0.00021325983,0.000003065852],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9485218,0.0009091563,0.007251374,0.00023158026,0.00053296896,0.0003894971,0.0011871953,0.0002163464,0.00032516377,0.00049107656,0.000048554753,0.039895296],"study_design_scores_gemma":[0.989685,0.00035190207,0.0006609893,0.0007483178,0.00020787978,0.00003330334,0.0002580018,0.0013353784,0.0025486634,0.0023531662,0.0015681325,0.00024927416],"about_ca_topic_score_codex":0.000114172675,"about_ca_topic_score_gemma":0.0002054025,"teacher_disagreement_score":0.07489894,"about_ca_system_score_codex":0.00004732604,"about_ca_system_score_gemma":0.0002026799,"threshold_uncertainty_score":0.7748043},"labels":[],"label_agreement":null},{"id":"W4402640848","doi":"10.1007/s12325-024-02961-3","title":"Summary of Research: Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seven Oaks General Hospital","funders":"AstraZeneca","keywords":"Medicine; Albuminuria; Dapagliflozin; Kidney disease; Internal medicine; Intensive care medicine; Disease; Urology; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.04193459373356344,"score_gpt":0.35978972029929357,"score_spread":0.3178551265657301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402640848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98678035,0.011520209,0.0000018789808,0.000061391824,0.00004222295,0.0011194529,0.000013434533,0.0000050861845,0.00045600548],"genre_scores_gemma":[0.99127865,0.008444158,0.0000089970845,0.000024171784,0.000011620678,0.00009827588,0.000021460848,0.000011419529,0.00010125927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990821,0.00017841657,0.00015854159,0.00020700831,0.00022459868,0.00014932331],"domain_scores_gemma":[0.99953973,0.00021257134,0.00003150071,0.00013922204,0.000034074226,0.000042882708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049129035,0.00009477405,0.0001853912,0.0003142129,0.000013028186,0.000008546992,0.00005591236,0.000018984216,0.000011064937],"category_scores_gemma":[0.00003381188,0.00005858937,0.000013391003,0.00060488755,0.0001338089,0.00025251697,0.000023715838,0.00009043247,2.3530315e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008969128,0.00030729835,0.9653691,0.0007885422,0.000039561648,0.000018003282,0.0005673526,0.000032908218,0.00015437548,0.00075465016,0.0000109734665,0.031060291],"study_design_scores_gemma":[0.002954552,0.0007067767,0.9919013,0.002299602,0.000017786371,4.7759414e-8,0.00005721258,0.00026630732,0.00068860856,0.0005149175,0.0005366613,0.000056238907],"about_ca_topic_score_codex":0.00012814983,"about_ca_topic_score_gemma":0.0016573574,"teacher_disagreement_score":0.031004053,"about_ca_system_score_codex":0.00009056887,"about_ca_system_score_gemma":0.0000615359,"threshold_uncertainty_score":0.23892051},"labels":[],"label_agreement":null},{"id":"W4403566765","doi":"10.1007/s12325-024-02985-9","title":"Differences Between Intravenous and Subcutaneous Modes of Administration in Oncology from the Patient, Healthcare Provider, and Healthcare System Perspectives: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Health care; Rheumatology; Administration (probate law); Internal medicine; Intensive care medicine","score_opus":0.06060773984211042,"score_gpt":0.4284270474126201,"score_spread":0.3678193075705097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403566765","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022147663,0.9899502,9.975537e-7,0.0012225135,0.000118008735,0.006235696,0.0002104768,0.000021975502,0.000025394838],"genre_scores_gemma":[0.117311895,0.8813689,0.000028162884,0.00013822752,0.00008574208,0.0009618715,0.000073333795,0.000025317582,0.0000065737154],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9971824,0.0009024972,0.0010612649,0.00048135294,0.00016577072,0.00020670216],"domain_scores_gemma":[0.99803114,0.0010296853,0.00056745386,0.00024300902,0.000057354257,0.00007137233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025610364,0.00035850418,0.0031840121,0.00012721264,0.000038389306,0.000012564379,0.00011136641,0.00020022968,0.0000034009352],"category_scores_gemma":[0.000035037985,0.00019683778,0.00012022029,0.0002775333,0.0001447079,0.000056619618,0.000027594942,0.0004485498,8.393446e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010181497,0.00007605362,0.0002771138,0.62824565,0.00020253299,0.0001132989,0.0028544147,1.8562304e-8,1.5313677e-7,0.00021145558,0.0000032716212,0.36791423],"study_design_scores_gemma":[0.0008803297,0.0062894523,0.00004505236,0.96880364,0.0025780075,0.0005858176,0.006373858,0.0000064902056,0.0000011291519,0.00032992486,0.013827269,0.0002790467],"about_ca_topic_score_codex":0.00064452796,"about_ca_topic_score_gemma":0.0014895273,"teacher_disagreement_score":0.3676352,"about_ca_system_score_codex":0.0005131879,"about_ca_system_score_gemma":0.0005600327,"threshold_uncertainty_score":0.80268115},"labels":[],"label_agreement":null},{"id":"W4403771038","doi":"10.1007/s12325-024-02999-3","title":"Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; Fluticasone propionate; COPD; Exacerbation; Copd exacerbation; Internal medicine; Fluticasone; Physical therapy; Rheumatology; Intensive care medicine; Corticosteroid; Acute exacerbation of chronic obstructive pulmonary disease","score_opus":0.033166634943709035,"score_gpt":0.3519477026347077,"score_spread":0.3187810676909987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403771038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9556712,0.03714066,0.00020127463,0.0012555488,0.00068448833,0.0012667794,0.00006493665,0.00013128217,0.0035838129],"genre_scores_gemma":[0.99305785,0.0055181496,0.00030987425,0.00037534212,0.00017784887,0.00019400081,0.00014573566,0.000054752807,0.00016644597],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977222,0.00013261473,0.00054835936,0.00049493765,0.0007425841,0.00035929255],"domain_scores_gemma":[0.99884844,0.00045179832,0.00012147202,0.0003569327,0.00011874777,0.00010263072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038301168,0.00025912566,0.00046175462,0.00041035583,0.00006466243,0.000039635845,0.00014455656,0.000111875815,0.0002627509],"category_scores_gemma":[0.0001556412,0.00022367566,0.00018010785,0.0006030275,0.00008567511,0.00069903256,0.000034792414,0.00031421642,0.000053515327],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034320322,0.0016879397,0.46636277,0.0022384038,0.00062367826,0.0004958081,0.0034970962,0.0015551522,0.00782255,0.01361387,0.0002921394,0.49837855],"study_design_scores_gemma":[0.010231359,0.0016226663,0.9422013,0.0031296927,0.00013535822,0.000058293535,0.0007021833,0.005602818,0.017453529,0.0044848444,0.013711069,0.0006668838],"about_ca_topic_score_codex":0.000015867907,"about_ca_topic_score_gemma":0.000017030594,"teacher_disagreement_score":0.49771166,"about_ca_system_score_codex":0.00035900238,"about_ca_system_score_gemma":0.00017962148,"threshold_uncertainty_score":0.91212285},"labels":[],"label_agreement":null},{"id":"W4403876789","doi":"10.1007/s12325-024-02996-6","title":"Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Barrie Urology Group; Simon Fraser University","funders":"AbbVie","keywords":"Medicine; Internal medicine; Retrospective cohort study; Cirrhosis; Rheumatology; Hepatitis C; Crest; Hepatology; Gastroenterology; Surgery","score_opus":0.022229306867654595,"score_gpt":0.3242751436532075,"score_spread":0.30204583678555286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403876789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99297583,0.002152815,0.000006678242,0.00023778806,0.000074700605,0.0034102506,0.00037527425,0.000041590036,0.0007250589],"genre_scores_gemma":[0.9959167,0.003591549,0.000013280014,0.00005519804,0.000021140104,0.00015518865,0.00020137243,0.000035895,0.000009626747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716693,0.0012040553,0.0003954113,0.0005276251,0.00044693722,0.00025903067],"domain_scores_gemma":[0.99598724,0.0032545163,0.000088462446,0.0005065651,0.00011478643,0.00004843715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062861276,0.0002568703,0.000506634,0.0001502914,0.000080466656,0.00003472339,0.000159422,0.000058392932,0.000037583082],"category_scores_gemma":[0.00024490213,0.00012295616,0.00004349917,0.0010621597,0.00024098392,0.00018089029,0.000037375135,0.00037655668,0.000007495566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013443816,0.0014883348,0.95328665,0.000015862417,0.0002733637,0.000040347808,0.0026832526,0.00003544977,0.0002540619,0.00008835001,0.0000070563215,0.028383445],"study_design_scores_gemma":[0.012530019,0.006448029,0.97745526,0.00066684413,0.00003113411,3.9621204e-7,0.00031969222,0.00013734744,0.0011189048,0.00016149208,0.0010088377,0.00012204509],"about_ca_topic_score_codex":0.0022997272,"about_ca_topic_score_gemma":0.0020184468,"teacher_disagreement_score":0.0282614,"about_ca_system_score_codex":0.00038451282,"about_ca_system_score_gemma":0.000076036195,"threshold_uncertainty_score":0.5014007},"labels":[],"label_agreement":null},{"id":"W4404184100","doi":"10.1007/s12325-024-03009-2","title":"Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Treatment of Major Depression","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"AbbVie","keywords":"Medicine; Post-hoc analysis; Anhedonia; Randomized controlled trial; Post hoc; Placebo; Internal medicine; Depression (economics); Physical therapy; Bipolar disorder; Psychiatry; Clinical psychology; Mood; Schizophrenia (object-oriented programming); Alternative medicine; Pathology","score_opus":0.01749421252127073,"score_gpt":0.39051661970359763,"score_spread":0.37302240718232693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404184100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9312328,0.06476995,0.00007177395,0.00006770369,0.00023307616,0.0034262633,0.000025874126,0.00003045065,0.0001421027],"genre_scores_gemma":[0.9934699,0.0058529996,0.00027098542,0.000041875017,0.00004272139,0.00021853519,0.000057580753,0.00002725276,0.000018151035],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99500895,0.0023626303,0.001474635,0.00043553728,0.00053362845,0.0001846284],"domain_scores_gemma":[0.98685163,0.012043215,0.00049740804,0.00046137764,0.00008188399,0.00006446281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005986946,0.00027506868,0.0039382125,0.0008278359,0.000014199406,0.000007872475,0.00012115245,0.00014696627,0.000077912686],"category_scores_gemma":[0.0016959242,0.00013308428,0.0007174461,0.0008706477,0.0001484216,0.00014887306,0.000018358462,0.00025950902,0.0000021688193],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50044227,0.00048534607,0.31761762,0.0000487806,0.0017151574,0.000015108306,0.00004677069,0.00029023347,0.00012606126,0.00000790476,0.0000023413854,0.17920244],"study_design_scores_gemma":[0.81957835,0.009938526,0.16273545,0.0011228798,0.002627767,4.806007e-7,0.000004870801,0.0012674109,0.0023676779,0.00004734162,0.00017593635,0.00013328179],"about_ca_topic_score_codex":0.00004846397,"about_ca_topic_score_gemma":0.0001371981,"teacher_disagreement_score":0.31913614,"about_ca_system_score_codex":0.000051644187,"about_ca_system_score_gemma":0.000054449345,"threshold_uncertainty_score":0.54270196},"labels":[],"label_agreement":null},{"id":"W4404252364","doi":"10.1007/s12325-024-03013-6","title":"Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021–2023","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Ottawa Hospital","funders":"Novo Nordisk","keywords":"Reimbursement; Medicine; Drug approval; Health care; Oncology; Internal medicine; Intensive care medicine; Family medicine; Medical physics; Pharmacology; Drug","score_opus":0.364190534098096,"score_gpt":0.5518524548868433,"score_spread":0.18766192078874733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404252364","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008114735,0.9869046,0.00019629383,0.00600182,0.0007474735,0.005179394,0.00056243927,0.000015217483,0.00031160485],"genre_scores_gemma":[0.00008676339,0.98738766,0.008727904,0.0012473009,0.000094563715,0.0021177435,0.0002339936,0.00005477376,0.00004929482],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99079293,0.00088539015,0.0068269153,0.00095640856,0.00009466042,0.000443714],"domain_scores_gemma":[0.9932566,0.0026148292,0.0034660087,0.0005372965,0.000048189067,0.000077073986],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0126426695,0.0004302403,0.0045844787,0.0011941667,0.00006244747,0.00002702619,0.00032195475,0.0003140603,0.00005316392],"category_scores_gemma":[0.000816911,0.00044558966,0.00028141477,0.0009920589,0.000065788096,0.00027417115,0.000060404214,0.00034302849,0.000029982244],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032289856,0.00022016559,0.0009872516,0.049522586,0.00009472479,0.0000014088357,0.0006724754,0.000017624732,1.022887e-8,0.0055129873,0.0029187438,0.9400197],"study_design_scores_gemma":[0.0008558655,0.00026418502,0.0001535156,0.080958225,0.000028391165,0.0000032971093,0.00021222487,0.00014922932,5.984826e-8,0.0058158343,0.9112545,0.0003046145],"about_ca_topic_score_codex":0.000475058,"about_ca_topic_score_gemma":0.0020240606,"teacher_disagreement_score":0.93971515,"about_ca_system_score_codex":0.003792374,"about_ca_system_score_gemma":0.0007574036,"threshold_uncertainty_score":0.9997996},"labels":[],"label_agreement":null},{"id":"W4404601188","doi":"10.1007/s12325-024-03047-w","title":"Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Biogen","keywords":"Medicine; Discontinuation; Dimethyl fumarate; Adverse effect; Incidence (geometry); Internal medicine; Multiple sclerosis; Observational study; Immunology","score_opus":0.02427547317549341,"score_gpt":0.37583402119553233,"score_spread":0.35155854802003894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404601188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852983,0.011938904,0.000011880728,0.00017621917,0.0000488677,0.0021331839,0.00020799797,0.00002040027,0.0001642411],"genre_scores_gemma":[0.96952903,0.030029463,0.0001393403,0.000030709845,0.000021961674,0.00017095549,0.00004094285,0.000025423178,0.000012179799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982274,0.0002947815,0.00032904028,0.0004929833,0.00041429716,0.00024147391],"domain_scores_gemma":[0.9969773,0.0024638665,0.000096604286,0.00025566845,0.00015538369,0.00005114237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005206723,0.00024091847,0.0005291488,0.00016255412,0.00007112135,0.000017149721,0.00007179095,0.000029143557,0.0000023766186],"category_scores_gemma":[0.0002122893,0.00011688179,0.000020492713,0.00050860277,0.00041093,0.0002349225,0.000048677895,0.00024234981,3.88917e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10192624,0.0019602263,0.5695089,0.00036252014,0.00045047823,0.000019448715,0.0064375447,0.000037272064,0.00023187422,0.000035340472,0.000011216969,0.31901893],"study_design_scores_gemma":[0.06845398,0.0076610725,0.9157922,0.004520367,0.000028812261,1.7669281e-7,0.00030439626,0.00007903871,0.0022761875,0.0001734948,0.0005477334,0.00016253932],"about_ca_topic_score_codex":0.000303294,"about_ca_topic_score_gemma":0.0011204641,"teacher_disagreement_score":0.3462833,"about_ca_system_score_codex":0.000106047504,"about_ca_system_score_gemma":0.000037885427,"threshold_uncertainty_score":0.47663012},"labels":[],"label_agreement":null},{"id":"W4404932315","doi":"10.1007/s12325-024-03042-1","title":"Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Health Authority","funders":"Janssen Scientific Affairs","keywords":"Medicine; Secukinumab; Psoriatic arthritis; Discontinuation; Ixekizumab; Internal medicine; Cohort; Arthritis","score_opus":0.035536215093915684,"score_gpt":0.34500213515231065,"score_spread":0.30946592005839496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404932315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9623717,0.033993457,0.000001257471,0.00011469353,0.00078985223,0.000631638,0.000018935652,0.00004679564,0.0020316634],"genre_scores_gemma":[0.96182245,0.037500974,0.00035273336,0.000021122458,0.000052006362,0.00009895295,0.000027418431,0.000033745848,0.00009059342],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99850535,0.000044489683,0.0004382366,0.0004126074,0.00029611142,0.00030322722],"domain_scores_gemma":[0.99926865,0.00028629784,0.000098744174,0.00024463807,0.00004677106,0.000054916218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005390686,0.000267974,0.00060193246,0.00028857798,0.000046770536,0.000015618598,0.00006881527,0.000045158482,0.00004006995],"category_scores_gemma":[0.000019217625,0.00019782645,0.000071480936,0.000539425,0.00010448192,0.00014629477,0.00001478339,0.00015154187,0.000009736138],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065403013,0.0019286853,0.33527148,0.000054126136,0.00021813822,0.00037761073,0.003671844,0.00008024068,0.00002531027,0.00012599911,0.000015631282,0.6516906],"study_design_scores_gemma":[0.24875253,0.20629844,0.4425592,0.03543406,0.000499269,0.0001012291,0.0130013,0.0012873524,0.013126614,0.00095270807,0.035376914,0.0026103603],"about_ca_topic_score_codex":0.0002905569,"about_ca_topic_score_gemma":0.007210138,"teacher_disagreement_score":0.6490803,"about_ca_system_score_codex":0.0006167982,"about_ca_system_score_gemma":0.0000512115,"threshold_uncertainty_score":0.80671287},"labels":[],"label_agreement":null},{"id":"W4405079672","doi":"10.1007/s12325-024-03066-7","title":"Genetic Etiologies and Outcomes in Malignancy and Mortality in Activated Phosphoinositide 3-Kinase Delta Syndrome: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Etiology; Malignancy; Internal medicine; Rheumatology; Phosphoinositide 3-kinase; Oncology; Intensive care medicine; Bioinformatics; PI3K/AKT/mTOR pathway; Genetics; Signal transduction","score_opus":0.018689562186398008,"score_gpt":0.3274944721667329,"score_spread":0.3088049099803349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405079672","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025255708,0.9719071,0.000001098399,0.000019978488,0.00029703797,0.002408116,0.00004245639,0.000042472435,0.000026063035],"genre_scores_gemma":[0.016623523,0.9821918,0.000009024038,0.00011629334,5.792634e-7,0.0008883512,0.00006702431,0.00003460275,0.00006879655],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9967165,0.0008288449,0.001324967,0.0006422868,0.00004562798,0.00044180144],"domain_scores_gemma":[0.9987492,0.0004155814,0.00034957516,0.00046478925,0.000014470906,0.000006415432],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061213877,0.00058207975,0.0033457945,0.00034197123,0.000050159433,0.000022190423,0.0003442302,0.00037244114,0.000022203456],"category_scores_gemma":[0.00015666074,0.0003995009,0.0001864865,0.0005827816,0.00028418977,0.00017426752,0.00011519208,0.0006909335,0.000022669537],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019326833,0.00020854494,0.0019433975,0.68672377,0.0003409514,0.00024198937,0.00032178054,0.0000018483059,0.000036506724,0.00017124451,0.0000026306068,0.30998802],"study_design_scores_gemma":[0.0013741298,0.00021700763,0.0058037965,0.9519332,0.00068675843,0.0005531475,0.000291777,9.215792e-7,0.000022760536,0.0011225054,0.03689048,0.0011035076],"about_ca_topic_score_codex":0.00018096129,"about_ca_topic_score_gemma":0.00006429369,"teacher_disagreement_score":0.3088845,"about_ca_system_score_codex":0.00007841417,"about_ca_system_score_gemma":0.00008064075,"threshold_uncertainty_score":0.9998457},"labels":[],"label_agreement":null},{"id":"W4405079951","doi":"10.1007/s12325-024-03055-w","title":"Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; COPD; Inhaler; Medicare Advantage; Persistence (discontinuity); Health plan; Physical therapy; Rheumatology; Intensive care medicine; Internal medicine; Family medicine; Asthma; Health care","score_opus":0.057697442291397866,"score_gpt":0.3470230347695473,"score_spread":0.2893255924781495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405079951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9175669,0.08022092,0.0001232922,0.00029474057,0.00014181633,0.0011554677,0.00023039473,0.000050970535,0.0002154783],"genre_scores_gemma":[0.9809689,0.017074108,0.0011037684,0.00036779587,0.00010680255,0.000031469783,0.00025254395,0.000055421126,0.000039175276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761534,0.00014134355,0.00030736634,0.00080976845,0.0006511631,0.00047499652],"domain_scores_gemma":[0.99878037,0.00017029612,0.000108938475,0.0005585525,0.00008633309,0.0002955233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027483108,0.0002938182,0.00049353443,0.00015889865,0.00015839773,0.00006455932,0.0002487505,0.00006883609,0.00008686954],"category_scores_gemma":[0.000020634652,0.0001997084,0.000025012376,0.00040658776,0.0007819274,0.0008937303,0.000099084915,0.0004204056,9.685411e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002188827,0.00021344166,0.68795985,0.00032733887,0.00007222521,0.00014411323,0.0009544078,0.000007589282,0.000038662478,0.000015433954,0.000028279106,0.30804986],"study_design_scores_gemma":[0.011892401,0.0032479947,0.9627097,0.002467094,0.000035669815,0.00011006931,0.0023738346,0.0035650178,0.00006911593,0.00009488089,0.0129457135,0.00048846117],"about_ca_topic_score_codex":0.00027440462,"about_ca_topic_score_gemma":0.00068903656,"teacher_disagreement_score":0.3075614,"about_ca_system_score_codex":0.00020858661,"about_ca_system_score_gemma":0.00040668924,"threshold_uncertainty_score":0.81438726},"labels":[],"label_agreement":null},{"id":"W4405179396","doi":"10.1007/s12325-024-03051-0","title":"Baseline Characteristics of Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Medicine; Dupilumab; Asthma; Exhaled nitric oxide; Bronchodilator; Internal medicine; Eosinophil; Quality of life (healthcare); Clinical trial; Allergy; Immunology; Spirometry","score_opus":0.007122883553507687,"score_gpt":0.2871591282762942,"score_spread":0.2800362447227865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405179396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851904,0.011424587,0.000026187858,0.00046784696,0.00012968318,0.00044844972,0.000083367995,0.000028791146,0.0022007136],"genre_scores_gemma":[0.99521303,0.0038167832,0.000045123066,0.00060675875,0.00012214667,0.000034011122,0.000060687205,0.000013657142,0.00008780935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894756,0.00013713325,0.00027537404,0.00019540972,0.000275326,0.00016919369],"domain_scores_gemma":[0.99934244,0.00015669962,0.00008052487,0.000328293,0.000058062535,0.00003398142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022012404,0.00014233416,0.00021806813,0.000065195585,0.00003221003,0.000016706565,0.00016137172,0.00003385849,0.00007387491],"category_scores_gemma":[0.00003410905,0.000063031795,0.000052205094,0.0006915799,0.00018817715,0.000108877684,0.000011396135,0.00016395788,0.0000037947418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013158718,0.00031512775,0.6262492,0.00006170311,0.000021872513,0.00010176718,0.00021784255,0.000010779149,0.000015706348,0.00022095838,0.00014103216,0.37132818],"study_design_scores_gemma":[0.0016289937,0.0004934547,0.8802762,0.00036574257,0.000014080251,0.0000041889,0.00020254748,0.00007338576,0.000051046452,0.00008739031,0.11671258,0.00009036291],"about_ca_topic_score_codex":0.00003893337,"about_ca_topic_score_gemma":0.00013222221,"teacher_disagreement_score":0.3712378,"about_ca_system_score_codex":0.000049167764,"about_ca_system_score_gemma":0.00008796772,"threshold_uncertainty_score":0.2570362},"labels":[],"label_agreement":null},{"id":"W4405448205","doi":"10.1007/s12325-024-03043-0","title":"Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"COVID-19 and Mental Health","field":"Psychology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Technische Universität München; AstraZeneca United States","keywords":"Medicine; Pandemic; Population; Anxiety; Health care; Vaccination; Depression (economics); Economic impact analysis; Mental health; Disease; Intensive care medicine; Coronavirus disease 2019 (COVID-19); Psychiatry; Environmental health; Immunology; Internal medicine; Infectious disease (medical specialty)","score_opus":0.24668512617302282,"score_gpt":0.5680260971119089,"score_spread":0.32134097093888603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405448205","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013639946,0.9814931,0.0000038536323,0.008429314,0.0019940936,0.0071994495,0.0002772198,0.00010388614,0.00048545696],"genre_scores_gemma":[0.00001890558,0.95656884,0.000033207474,0.037915945,0.00040576202,0.004372574,0.00028178332,0.00011703993,0.00028596705],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994062,0.002171839,0.0014218224,0.0012272112,0.00039826665,0.00071883295],"domain_scores_gemma":[0.9965641,0.0011657345,0.0005654657,0.001438369,0.000028676015,0.00023769122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018998217,0.0007758289,0.002298284,0.0003858559,0.00010521289,0.000044608925,0.0010946859,0.00040539276,0.0008928921],"category_scores_gemma":[0.00007622481,0.00047991204,0.0004251607,0.00097547733,0.00013783913,0.00015625678,0.00008519177,0.001251318,0.0002638747],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001061733,0.00017539637,0.000021616066,0.022318916,0.00007115281,0.00002993873,0.0067612645,2.0944317e-7,1.11412696e-7,0.0018817668,0.0021423348,0.9664911],"study_design_scores_gemma":[0.0010903076,0.0005244725,0.000010847036,0.057594057,0.000025286488,0.000021926475,0.00043993583,5.036638e-7,2.2727804e-7,0.0015491975,0.93831336,0.00042984495],"about_ca_topic_score_codex":0.0027716616,"about_ca_topic_score_gemma":0.00036864635,"teacher_disagreement_score":0.9660613,"about_ca_system_score_codex":0.0012458356,"about_ca_system_score_gemma":0.0011545199,"threshold_uncertainty_score":0.9997653},"labels":[],"label_agreement":null},{"id":"W4405701066","doi":"10.1007/s12325-024-03083-6","title":"Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact; Group for Research in Decision Analysis","funders":"","keywords":"Fluticasone propionate; Medicine; Asthma; Corticosteroid; Internal medicine; Population; Rate ratio; Fluticasone; Pediatrics","score_opus":0.006048360401840431,"score_gpt":0.27489551670097284,"score_spread":0.2688471562991324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405701066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961887,0.0025371474,0.00011916479,0.00021144756,0.000026577107,0.0007378993,0.00010100887,0.000040775456,0.000037286463],"genre_scores_gemma":[0.9975945,0.00097002403,0.000111999434,0.00058285624,0.00002094716,0.00009407572,0.00057892915,0.00003568529,0.000010990543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986963,0.00011081211,0.0002950238,0.00028571658,0.0004054904,0.00020661282],"domain_scores_gemma":[0.99944025,0.0001148465,0.00010123885,0.00019077993,0.00009024334,0.0000626274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116071045,0.00023316666,0.00033167837,0.0002914982,0.000033614615,0.000022120103,0.00006539993,0.000059187427,0.00002677181],"category_scores_gemma":[0.0000120421655,0.000107273576,0.000026526157,0.00062536285,0.00014988416,0.0003664064,0.000009476617,0.00017668349,7.8127766e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003490415,0.00023038339,0.9772957,0.00014593358,0.000058206544,0.00016132773,0.0019257349,0.00008410043,0.0000053095714,0.000024291865,0.000002270305,0.016576307],"study_design_scores_gemma":[0.004460669,0.002850661,0.98800343,0.0007721355,0.000048574606,0.000013132075,0.0020797756,0.0003497261,0.00005129216,0.000050181818,0.0011773526,0.00014306657],"about_ca_topic_score_codex":0.000044462005,"about_ca_topic_score_gemma":0.00045259707,"teacher_disagreement_score":0.01643324,"about_ca_system_score_codex":0.000041340343,"about_ca_system_score_gemma":0.00003587612,"threshold_uncertainty_score":0.43744895},"labels":[],"label_agreement":null},{"id":"W4405869080","doi":"10.1007/s12325-024-03088-1","title":"Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; Fluticasone propionate; COPD; Formoterol; Hazard ratio; Internal medicine; Formoterol Fumarate; Population; Physical therapy; Budesonide; Asthma; Confidence interval; Environmental health","score_opus":0.009763335949859092,"score_gpt":0.29664554877652494,"score_spread":0.2868822128266658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405869080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9473324,0.049267195,0.00012114762,0.00003072102,0.00020292848,0.0022270759,0.00018048285,0.00007822236,0.0005598606],"genre_scores_gemma":[0.9952977,0.0039882576,0.00008844622,0.000023104234,0.00008029476,0.00027611686,0.00012652646,0.00007319451,0.00004637427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971867,0.00032207125,0.00044635413,0.00089035503,0.00054314284,0.00061138486],"domain_scores_gemma":[0.9983792,0.00046912907,0.0001280501,0.00046623734,0.00020747635,0.00034990927],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027761477,0.00048165492,0.00084505463,0.00036334796,0.00009167778,0.000047870722,0.00019869348,0.00010002896,0.000094141375],"category_scores_gemma":[0.000024128649,0.00036454844,0.00012565343,0.000650113,0.00090250076,0.0010077766,0.000096085874,0.00050184596,0.000012134047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016873468,0.00065192394,0.94978446,0.0028883328,0.0003369847,0.0005698783,0.00040538295,0.0003475088,0.0021477898,0.00025067056,0.0000028883985,0.025740707],"study_design_scores_gemma":[0.0043589594,0.00097237545,0.9823582,0.0018796542,0.00009064115,0.000030124811,0.0001082907,0.0058997204,0.002434568,0.0012133559,0.00030704789,0.00034704138],"about_ca_topic_score_codex":0.000061932464,"about_ca_topic_score_gemma":0.000037428537,"teacher_disagreement_score":0.047965318,"about_ca_system_score_codex":0.0005596759,"about_ca_system_score_gemma":0.00029441284,"threshold_uncertainty_score":0.9998807},"labels":[],"label_agreement":null},{"id":"W4405869081","doi":"10.1007/s12325-024-03091-6","title":"Simplified Approach to Managing Newly Diagnosed Patients with Mild-to-Moderate Hypertension in Routine Clinical Practice","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"Servier","keywords":"Medicine; Rheumatology; Clinical Practice; Internal medicine; Intensive care medicine; Cardiology; Physical therapy","score_opus":0.044435892856641866,"score_gpt":0.3547103765645311,"score_spread":0.31027448370788924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405869081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89666337,0.07439741,0.0022120345,0.0137755135,0.0008125808,0.0024425553,0.0000076532315,0.00020342013,0.009485469],"genre_scores_gemma":[0.94832134,0.007841873,0.014597957,0.028789395,0.00017656918,0.000106898086,0.000013974859,0.000044238077,0.00010772492],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819887,0.00011921588,0.00044572057,0.0005924891,0.0003274913,0.00031622424],"domain_scores_gemma":[0.9987024,0.0006505148,0.00004721798,0.0003126105,0.00016036931,0.00012686598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004887904,0.00021450258,0.0006159697,0.00022661334,0.000050950624,0.000033564844,0.00009660673,0.000072471856,0.0000050339654],"category_scores_gemma":[0.00021063616,0.00014337162,0.00005215806,0.0006347758,0.000038511527,0.00032452412,0.00005796864,0.00035252827,0.000027093502],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015926806,0.004101372,0.16446935,0.00022298768,0.0006395673,0.0010780985,0.0048474763,0.0028254373,0.00016525091,0.00058982335,0.0076424805,0.7974914],"study_design_scores_gemma":[0.018696807,0.0026931101,0.26819316,0.0014561946,0.0003283319,0.00005044031,0.0015854294,0.0027183674,0.00016847857,0.0005448591,0.7028007,0.00076412613],"about_ca_topic_score_codex":0.00006299518,"about_ca_topic_score_gemma":0.000043897468,"teacher_disagreement_score":0.79672724,"about_ca_system_score_codex":0.000020241347,"about_ca_system_score_gemma":0.000035976183,"threshold_uncertainty_score":0.58465254},"labels":[],"label_agreement":null},{"id":"W4406081463","doi":"10.1007/s12325-024-03087-2","title":"Correction to: Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021–2023","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Ottawa Hospital","funders":"","keywords":"Medicine; Reimbursement; Health care; Intensive care medicine; Oncology; Internal medicine; Drug approval; Family medicine; Pharmacology; Drug","score_opus":0.27687616858635417,"score_gpt":0.5382367545615118,"score_spread":0.2613605859751576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406081463","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005634134,0.9856125,0.0009165436,0.0046486943,0.0017146391,0.0062383185,0.00032437855,0.00001263448,0.00047594018],"genre_scores_gemma":[0.00006774764,0.9863821,0.008780739,0.0018644006,0.00006955667,0.002493924,0.00020019895,0.00003044417,0.00011084907],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918427,0.0009671701,0.005854975,0.0008619202,0.00008250677,0.0003907375],"domain_scores_gemma":[0.9914306,0.0046702907,0.0032636982,0.00049245084,0.000067915054,0.000075077776],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010512762,0.0003660393,0.004024794,0.0013604251,0.00007960719,0.000019475412,0.0002822713,0.00024685793,0.00003890381],"category_scores_gemma":[0.0021019487,0.000412623,0.00021582392,0.0012286945,0.000038461752,0.00023774276,0.000052393167,0.0002718669,0.000011842009],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004922658,0.00021081616,0.0017208458,0.023866938,0.00004757755,3.664274e-7,0.00045395366,0.00006322325,1.1403657e-8,0.001338543,0.005718842,0.96652967],"study_design_scores_gemma":[0.0008936423,0.0003172947,0.0004888007,0.098453365,0.000015474308,0.0000016703806,0.00021118637,0.00016346108,1.359702e-7,0.0014989862,0.89768624,0.00026976038],"about_ca_topic_score_codex":0.00083500985,"about_ca_topic_score_gemma":0.00428455,"teacher_disagreement_score":0.9662599,"about_ca_system_score_codex":0.0042660404,"about_ca_system_score_gemma":0.0008664628,"threshold_uncertainty_score":0.9998326},"labels":[],"label_agreement":null},{"id":"W4408003689","doi":"10.1007/s12325-025-03125-7","title":"Astaxanthin (AstaReal®) Improved Acute and Chronic Digital Eye Strain in Children: A Randomized Double-Blind Placebo-Controlled Trial","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Ocular Surface and Contact Lens","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Medicine; Placebo; Randomized controlled trial; Rheumatology; Astaxanthin; Double blind; Internal medicine; Physical therapy; Pathology; Alternative medicine","score_opus":0.006855111473456546,"score_gpt":0.30166445913405454,"score_spread":0.294809347660598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408003689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654281,0.02330111,0.00031708894,0.00069907855,0.00024722642,0.008415192,0.000021555414,0.000045964276,0.0015246498],"genre_scores_gemma":[0.9854418,0.012547171,0.00013466459,0.00028751657,0.0001168715,0.00065645576,0.000048528436,0.000023759238,0.00074323843],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982621,0.00013160624,0.0006244649,0.00042437774,0.00017458142,0.00038286205],"domain_scores_gemma":[0.99918723,0.00026086345,0.00015252063,0.0002942295,0.000035256053,0.00006989783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006150066,0.0002931343,0.0012939236,0.00028050374,0.000044652483,0.00006903411,0.00012506195,0.0001406037,0.00003953357],"category_scores_gemma":[0.00007442587,0.00021895068,0.00022162496,0.00030877345,0.00013946198,0.00043747126,0.00003080223,0.00036729197,0.0000025670213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9498385,0.00026187292,0.0030809678,0.000015643234,0.00048713147,0.000020162535,0.00021668356,0.000021471105,0.0011365715,0.00034451945,0.0000011878097,0.04457525],"study_design_scores_gemma":[0.9959648,0.0007276401,0.0003132798,0.00014078726,0.000087247645,0.000002741799,0.00009109115,0.00048436815,0.00062236225,0.00076331745,0.0006086202,0.00019373893],"about_ca_topic_score_codex":0.00004463669,"about_ca_topic_score_gemma":0.00022934079,"teacher_disagreement_score":0.04612627,"about_ca_system_score_codex":0.000117300864,"about_ca_system_score_gemma":0.00027084487,"threshold_uncertainty_score":0.892855},"labels":[],"label_agreement":null},{"id":"W4408010209","doi":"10.1007/s12325-024-03078-3","title":"Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Mitsubishi Tanabe Pharma Corporation; Celltrion; Eli Lilly Japan; EA Pharma Co., Ltd.; Gilead Sciences; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ulcerative colitis; Disease; Rheumatology; Crohn's disease; Internal medicine; Health care; Crohn disease; Inflammatory bowel disease; Burden of disease; Alternative medicine; Physical therapy; Family medicine; Pathology","score_opus":0.00803733676803766,"score_gpt":0.31974431467879477,"score_spread":0.31170697791075713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408010209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682188,0.029281875,6.4210997e-7,0.0011665326,0.000040417995,0.00084169296,0.00037388867,0.000002676611,0.000073442476],"genre_scores_gemma":[0.99537796,0.004042146,0.0000061978044,0.00038940425,0.00005511867,0.00007053499,0.000028768021,0.0000061082274,0.000023757479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905074,0.0003097636,0.0001645277,0.00027620982,0.0000919514,0.00010678688],"domain_scores_gemma":[0.99940985,0.00012367876,0.00011037271,0.00022941873,0.00006660971,0.00006009524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014187774,0.00011998102,0.000118991935,0.000016938202,0.00013760476,0.000017757075,0.00007580484,0.000026353096,0.0000036534698],"category_scores_gemma":[0.00013456492,0.00006526055,0.000025263746,0.000038073318,0.00021718303,0.000007884633,0.000057485795,0.00007490152,5.776823e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054392736,0.00065409276,0.48467916,0.00008990265,0.0007546482,0.00006587492,0.41758764,0.0005476408,0.0009716618,0.0011039493,0.0017027969,0.0374499],"study_design_scores_gemma":[0.0016610353,0.00037682106,0.9212895,0.00005700442,0.0000053631516,1.6737695e-7,0.07599102,0.000011057266,0.000052098745,0.00014303005,0.00034635927,0.00006651657],"about_ca_topic_score_codex":0.00032281817,"about_ca_topic_score_gemma":0.00033598437,"teacher_disagreement_score":0.43661037,"about_ca_system_score_codex":0.000024043935,"about_ca_system_score_gemma":0.00019718369,"threshold_uncertainty_score":0.2661248},"labels":[],"label_agreement":null},{"id":"W4408081825","doi":"10.1007/s12325-025-03132-8","title":"Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Astellas Pharma US; Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Abiraterone; Internal medicine; Oncology; Docetaxel; Chemotherapy; Cancer; Abiraterone acetate; Urology; Androgen deprivation therapy; Androgen receptor","score_opus":0.03130694606278112,"score_gpt":0.3684111111346669,"score_spread":0.3371041650718858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408081825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91350317,0.083521925,0.000015547124,0.00045870285,0.00007369088,0.0021271233,0.000013470073,0.000017250728,0.00026914748],"genre_scores_gemma":[0.9497854,0.048860703,0.00014150003,0.00010810956,0.000020070844,0.0007229447,0.0000066871735,0.000026580527,0.0003280219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982421,0.00021344016,0.00034760617,0.00047142783,0.00034638253,0.0003790604],"domain_scores_gemma":[0.99944043,0.00008749806,0.000053450276,0.00029865353,0.00006538745,0.000054593038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005927443,0.00024288055,0.00062862545,0.00033298242,0.000044607514,0.000029268189,0.000082952356,0.000040033774,0.000029491068],"category_scores_gemma":[0.000009515151,0.00016992017,0.000048877228,0.00069392554,0.00013235863,0.0002371732,0.000017903783,0.0002794691,8.794066e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011487008,0.0010241288,0.8483075,0.00022733618,0.0007680847,0.0007112183,0.0060418136,0.0020258576,0.0028182932,0.00003162199,0.0000027883266,0.12655436],"study_design_scores_gemma":[0.02946915,0.0012585558,0.9599841,0.00048428014,0.00006640364,0.000004860441,0.0027589975,0.00014369939,0.0032806762,0.00034689822,0.0019514967,0.00025088122],"about_ca_topic_score_codex":0.0017153149,"about_ca_topic_score_gemma":0.00821438,"teacher_disagreement_score":0.12630348,"about_ca_system_score_codex":0.0002956213,"about_ca_system_score_gemma":0.00024733148,"threshold_uncertainty_score":0.6929143},"labels":[],"label_agreement":null},{"id":"W4408206616","doi":"10.1007/s12325-025-03138-2","title":"A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Biosimilar; Randomized controlled trial; Internal medicine; Clinical endpoint; Adverse effect; Psoriasis; Dermatology; Infliximab; Disease","score_opus":0.021678752856792344,"score_gpt":0.3021284946839793,"score_spread":0.28044974182718696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408206616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906574,0.0031060644,0.00032027383,0.0014059803,0.00028001453,0.0034552864,0.000058029804,0.000013379479,0.000703612],"genre_scores_gemma":[0.9976778,0.00082885136,0.00042768245,0.0007843172,0.000009492265,0.0001149528,0.000008857792,0.000013497541,0.00013452198],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979854,0.0005669252,0.0005427911,0.00045239445,0.0001034379,0.00034900673],"domain_scores_gemma":[0.99849796,0.00065628183,0.00016705785,0.000536644,0.00011561247,0.000026427613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053712295,0.00028994321,0.00066433725,0.00013957966,0.00017765014,0.000024347464,0.00054831547,0.00014953285,0.000044521727],"category_scores_gemma":[0.00006032979,0.00013671965,0.00007000412,0.00083917,0.00035608822,0.000097911434,0.0001465379,0.00044263463,0.000001550127],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97035635,0.00043885648,0.012421772,0.000016411102,0.00021764074,7.6870094e-7,0.00040283724,0.00081815297,0.00034650989,0.0005695457,0.000034490215,0.014376674],"study_design_scores_gemma":[0.901688,0.0020031915,0.056564484,0.0005160558,0.00009710499,0.0000043600717,0.0003405991,0.000018473982,0.017720735,0.00036354933,0.020204274,0.00047922484],"about_ca_topic_score_codex":0.00012343311,"about_ca_topic_score_gemma":0.0010660919,"teacher_disagreement_score":0.06866839,"about_ca_system_score_codex":0.0000659921,"about_ca_system_score_gemma":0.00010348873,"threshold_uncertainty_score":0.5575265},"labels":[],"label_agreement":null},{"id":"W4408730910","doi":"10.1007/s12325-025-03158-y","title":"Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Eli Lilly and Company","keywords":"Medicine; Comparability; Pharmacokinetics; Clinical trial; Rheumatology; Pharmacology; Intensive care medicine; Internal medicine; Medical physics","score_opus":0.12910321262455474,"score_gpt":0.47651952724574037,"score_spread":0.3474163146211856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408730910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8922382,0.066019595,0.031481393,0.004100392,0.0013747041,0.0019469068,0.0019324125,0.000074888725,0.0008315225],"genre_scores_gemma":[0.9693259,0.016277468,0.013500601,0.00043941007,0.000117231175,0.000054150038,0.000106160056,0.000009368702,0.00016972287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759996,0.00073832326,0.0009915662,0.0004327313,0.000024870396,0.00021256699],"domain_scores_gemma":[0.98946065,0.01001554,0.00017085319,0.0002715896,0.00005499951,0.000026343892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002343508,0.00016132115,0.0006727364,0.00007509229,0.0001642871,0.000017602999,0.00016443261,0.00024019176,0.000046516318],"category_scores_gemma":[0.0011396045,0.00012078597,0.00010583693,0.00016650991,0.00044291254,0.00009777631,0.000045562778,0.00029410238,0.0000010166646],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020280961,0.00021010346,0.09083763,0.000023109922,0.00041384672,0.0000013898006,0.00007617779,0.000012089532,0.0016554534,0.0032938328,0.00043422417,0.8827612],"study_design_scores_gemma":[0.026989348,0.001154019,0.25084183,0.00009642168,0.00025444455,0.000009298402,0.000060597522,0.00032140134,0.0041372725,0.31186083,0.4039071,0.00036745847],"about_ca_topic_score_codex":0.00005278074,"about_ca_topic_score_gemma":0.00031186943,"teacher_disagreement_score":0.8823937,"about_ca_system_score_codex":0.000023800281,"about_ca_system_score_gemma":0.000041088017,"threshold_uncertainty_score":0.49255088},"labels":[],"label_agreement":null},{"id":"W4409209212","doi":"10.1007/s12325-025-03145-3","title":"Assessment of Access Barriers to Rifaximin Among Patients with Hepatic Encephalopathy Using Adjudicated Claims Data","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Bausch Health","keywords":"Rifaximin; Medicine; Hepatic encephalopathy; Internal medicine; Rheumatology; Encephalopathy; Intensive care medicine; Cirrhosis","score_opus":0.02347803123815045,"score_gpt":0.3655692152713887,"score_spread":0.34209118403323824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409209212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994196,0.00066187425,0.003867719,0.000035352827,0.00010005121,0.0006312548,0.000063775595,0.000015678534,0.00042831685],"genre_scores_gemma":[0.99675107,0.00094982615,0.0016827508,0.00034524107,0.000010217913,0.00002363631,0.00022236998,0.0000093299595,0.000005574219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990457,0.000047142552,0.00025934336,0.0002717362,0.00023995174,0.00013607644],"domain_scores_gemma":[0.9992912,0.000052826254,0.00009296242,0.00038488206,0.000080594706,0.00009753522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001143511,0.00010540251,0.0002398212,0.00016316115,0.000036831116,0.000010052912,0.00024411432,0.000029800516,0.000045653418],"category_scores_gemma":[0.000011209718,0.0000809765,0.00001829517,0.00049283204,0.00006384421,0.0006109926,0.000029569135,0.000078346064,3.3297547e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056430546,0.00013614898,0.98872966,0.000101648555,0.000093780625,0.000007824718,0.000231745,0.0005492062,0.00018377884,0.000035407393,0.0000027432063,0.009363743],"study_design_scores_gemma":[0.0032130934,0.00018659777,0.992194,0.00055943447,0.00010852374,1.8575781e-7,0.00010290518,0.0018628761,0.0014613786,0.00015525898,0.00006951126,0.00008620939],"about_ca_topic_score_codex":0.00015693017,"about_ca_topic_score_gemma":0.00009170366,"teacher_disagreement_score":0.009277534,"about_ca_system_score_codex":0.000040489558,"about_ca_system_score_gemma":0.00023557195,"threshold_uncertainty_score":0.33021256},"labels":[],"label_agreement":null},{"id":"W4409772562","doi":"10.1007/s12325-025-03144-4","title":"Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer: An Indirect Treatment Comparison","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Carboplatin; Head and neck cancer; Paclitaxel; Internal medicine; Oncology; First line treatment; Cancer; Chemotherapy; Cisplatin; Immunotherapy","score_opus":0.13731959727465098,"score_gpt":0.46446788718191817,"score_spread":0.3271482899072672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409772562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0139600765,0.9798023,0.000009538512,0.000103965314,0.00036600186,0.005141927,0.0005068061,0.000020493339,0.00008888312],"genre_scores_gemma":[0.0064504268,0.9882361,0.00029721984,0.000016755188,0.00008839316,0.004644069,0.00012931993,0.000042020187,0.00009569142],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811125,0.00015459233,0.00066625106,0.0005929094,0.00016200409,0.00031299496],"domain_scores_gemma":[0.99761665,0.0013828693,0.00049075886,0.00036404314,0.0000639547,0.00008170979],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008826368,0.000649513,0.0031373887,0.00018788197,0.00014205968,0.000014863374,0.00009020649,0.00008050232,0.000003996459],"category_scores_gemma":[0.000015843792,0.00032592437,0.00017854545,0.00026492262,0.00012207596,0.000086405715,0.00001538668,0.00010346384,1.4732827e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005246839,0.00076656125,0.0015674562,0.004838522,0.002597231,0.000008891443,0.0021599864,0.000012456868,1.2655607e-7,0.000011552059,0.0000051406696,0.9827852],"study_design_scores_gemma":[0.07532375,0.08205785,0.00064941857,0.05309261,0.006887554,0.00006176357,0.0010553258,0.00030832892,0.000055816734,0.00006241186,0.77970314,0.00074205286],"about_ca_topic_score_codex":0.00065301015,"about_ca_topic_score_gemma":0.005446268,"teacher_disagreement_score":0.9820432,"about_ca_system_score_codex":0.00093037175,"about_ca_system_score_gemma":0.00030265457,"threshold_uncertainty_score":0.9999193},"labels":[],"label_agreement":null},{"id":"W4409951695","doi":"10.1007/s12325-025-03198-4","title":"The Limitations of Artificial Intelligence in Head and Neck Oncology","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Rheumatology; Head and neck; Internal medicine; Radiation oncology; Oncology; Medical physics; Head and neck cancer; Radiation therapy; Surgery","score_opus":0.3660024584419,"score_gpt":0.5541710030371777,"score_spread":0.1881685445952777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409951695","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020914756,0.9965017,0.0001340234,0.0006546432,0.00058594096,0.00090351154,0.0000027871654,0.000006934452,0.0010013559],"genre_scores_gemma":[0.0003820866,0.9985283,0.0005603874,0.00011007926,0.000103751925,0.00022546286,0.000012907836,0.000009764391,0.00006726381],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983954,0.0001773494,0.0009193636,0.00022407807,0.00009230707,0.0001915324],"domain_scores_gemma":[0.9959416,0.0034934427,0.00021854193,0.00023286388,0.00007912515,0.00003444877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004351876,0.00014650768,0.00072548795,0.00024436755,0.00005885026,0.000007760747,0.00012595554,0.00018344341,0.000006031292],"category_scores_gemma":[0.0006236367,0.00009859716,0.00008110594,0.0006593187,0.0001994241,0.00006884524,0.000016625982,0.0003743815,0.0000050588974],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006232281,0.00011209483,0.00008808847,0.0012119269,0.000008675225,0.0000023303426,0.00063929695,0.000005336007,2.0307044e-7,0.0040789144,0.0000061477185,0.99378467],"study_design_scores_gemma":[0.00001643288,0.00032404176,0.000021296488,0.0059999675,0.000020846055,0.0000060348534,0.0009018794,0.000026018397,0.000018611878,0.017039364,0.97554886,0.00007665222],"about_ca_topic_score_codex":0.00012983795,"about_ca_topic_score_gemma":0.002683427,"teacher_disagreement_score":0.993708,"about_ca_system_score_codex":0.00014252216,"about_ca_system_score_gemma":0.0007982998,"threshold_uncertainty_score":0.4020675},"labels":[],"label_agreement":null},{"id":"W4410136066","doi":"10.1007/s12325-025-03183-x","title":"One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn’s Disease: A Network Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Johnson and Johnson","keywords":"Medicine; Crohn's disease; Internal medicine; Rheumatology; Disease; Meta-analysis; Oncology","score_opus":0.07057943722818513,"score_gpt":0.3817224484559923,"score_spread":0.3111430112278072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410136066","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000850001,0.9942491,0.0007232937,0.000020764717,0.0001665735,0.0031058458,0.0008187484,0.000008402978,0.000057243833],"genre_scores_gemma":[0.0018127721,0.9941364,0.0010041357,0.000041364707,0.000106006526,0.002377701,0.0002700426,0.00004740814,0.00020416807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99789673,0.00029077101,0.0006633681,0.00063136645,0.00019789602,0.00031988823],"domain_scores_gemma":[0.99753916,0.00064395915,0.00051088305,0.0010575771,0.00016891015,0.00007948094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015581137,0.0005043951,0.0020973121,0.00015105006,0.00007740735,0.000014079332,0.00051234907,0.00015663062,0.000031053554],"category_scores_gemma":[0.00007669612,0.00033210954,0.0027608725,0.0005194414,0.00011183219,0.000011601335,0.000045344736,0.00006907953,9.71509e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028577073,0.0005739836,0.0000058749088,0.001185263,0.11983529,0.000004931354,0.00015722305,0.029532233,0.0000033014348,0.00022384617,0.00002137086,0.8198796],"study_design_scores_gemma":[0.00348064,0.0008481796,0.0012637341,0.0003149702,0.09382194,9.0446115e-8,0.000046688438,0.000017129638,0.00015529316,0.00023684712,0.8992312,0.0005832691],"about_ca_topic_score_codex":0.000005198663,"about_ca_topic_score_gemma":0.000103741964,"teacher_disagreement_score":0.89920986,"about_ca_system_score_codex":0.00007356065,"about_ca_system_score_gemma":0.00036414625,"threshold_uncertainty_score":0.9999131},"labels":[],"label_agreement":null},{"id":"W4410586462","doi":"10.1007/s12325-025-03232-5","title":"Real-World Insights on Satisfaction and Experience with Acthar Gel via SelfJect (RISE™): A Cross-Sectional Patient Survey","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Cross-sectional study; Medicine; Rheumatology; Patient satisfaction; Family medicine; Internal medicine; Nursing; Pathology","score_opus":0.016034298690402283,"score_gpt":0.3461847020189336,"score_spread":0.3301504033285313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410586462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876477,0.010092534,0.000103667735,0.000045980454,0.0001485847,0.00040736573,0.0000063513367,0.00004172964,0.0015060785],"genre_scores_gemma":[0.908608,0.09079422,0.00016718886,0.00016668,0.000018456512,0.00011314052,0.000010870945,0.000011948574,0.00010945064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882126,0.00011941363,0.00021449503,0.0003284691,0.0002985522,0.00021783693],"domain_scores_gemma":[0.99937016,0.0002169506,0.000055217402,0.00019360747,0.000094379495,0.00006966267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013680174,0.00014808158,0.00020764025,0.00024508187,0.00014314758,0.00004576367,0.00004776432,0.00004084397,0.000058518017],"category_scores_gemma":[0.00003408561,0.00010703923,0.000024042556,0.0003979655,0.00021396861,0.0003424012,0.000014217433,0.00019948007,0.0000036973643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030971179,0.00010208049,0.890391,0.000009830006,0.000030133768,0.000012934194,0.0008895913,0.000037105896,0.0012714652,0.00035108032,0.000009335902,0.10379834],"study_design_scores_gemma":[0.0024723937,0.0008814293,0.98157597,0.00013559448,2.656753e-7,0.000010923613,0.00007134729,0.00006915713,0.0042965524,0.0007635082,0.009614836,0.00010803932],"about_ca_topic_score_codex":0.001173438,"about_ca_topic_score_gemma":0.006444642,"teacher_disagreement_score":0.1036903,"about_ca_system_score_codex":0.000095151074,"about_ca_system_score_gemma":0.00007266307,"threshold_uncertainty_score":0.43649334},"labels":[],"label_agreement":null},{"id":"W4410586982","doi":"10.1007/s12325-025-03195-7","title":"Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"EMD Serono","keywords":"Medicine; Rheumatology; Internal medicine; Oncology; Family medicine; General surgery; Intensive care medicine","score_opus":0.020835090550126657,"score_gpt":0.40953198234919574,"score_spread":0.3886968917990691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410586982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90156376,0.020313183,0.016434526,0.034688357,0.00092359853,0.010686021,0.000084596526,0.00012522866,0.015180735],"genre_scores_gemma":[0.97616124,0.009350012,0.006279567,0.00062009064,0.00011170263,0.0016260723,0.00011601298,0.000025504507,0.005709801],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993486,0.000025538571,0.00013843692,0.00020495562,0.00013115737,0.00015130162],"domain_scores_gemma":[0.99933463,0.00016759666,0.00016545893,0.0001980857,0.0001067154,0.000027520822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004194382,0.00013473612,0.00015327029,0.000061023347,0.00028542895,0.0000463916,0.00004763965,0.000022470156,0.000016105469],"category_scores_gemma":[0.000021521559,0.000050359347,0.00003293439,0.00021347025,0.00004917683,0.0005360517,0.0000038152675,0.0000602253,0.0000013644145],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034396045,0.0040945024,0.46441042,0.000042384312,0.0006845769,0.0000052142786,0.0035790235,0.000993747,0.00006102453,0.0012717133,0.00014372855,0.52127403],"study_design_scores_gemma":[0.026093906,0.008977651,0.063909136,0.0010107355,0.0004979125,0.000009519959,0.0045703673,0.00024191453,0.0009083524,0.0012951078,0.89222187,0.0002635098],"about_ca_topic_score_codex":0.00007462674,"about_ca_topic_score_gemma":0.0006482648,"teacher_disagreement_score":0.89207816,"about_ca_system_score_codex":0.00023131802,"about_ca_system_score_gemma":0.00017875158,"threshold_uncertainty_score":0.21953174},"labels":[],"label_agreement":null},{"id":"W4410872297","doi":"10.1007/s12325-025-03239-y","title":"Economic Burden and Provider Referral Patterns Among Patients with Unresectable Stage III EGFR-Mutated NSCLC Receiving Chemoradiotherapy in the United States","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Referral; Stage (stratigraphy); Chemoradiotherapy; Internal medicine; Rheumatology; Oncology; Family medicine; Overall survival","score_opus":0.007839728466091026,"score_gpt":0.31028360856865783,"score_spread":0.3024438801025668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410872297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949162,0.0022122096,0.000081725244,0.00083746214,0.000074168376,0.0010483946,0.00002384622,0.000026974165,0.00077900523],"genre_scores_gemma":[0.9919342,0.0062668594,0.00012814009,0.0007034604,0.000028191258,0.00018412377,0.00020222629,0.00002101916,0.0005317884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990899,0.00006778897,0.00022318064,0.0002719731,0.00011210404,0.00023508025],"domain_scores_gemma":[0.9995022,0.00012455361,0.00008031829,0.00022351043,0.00003773083,0.000031696516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012367904,0.00016834537,0.00025191717,0.00020933498,0.000071734845,0.000046564597,0.000103746934,0.00004170939,0.00005556503],"category_scores_gemma":[0.0000066693965,0.00010329496,0.000019287756,0.00032611765,0.000081091595,0.0003171911,0.000010809466,0.00015329443,5.551169e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085493206,0.00011855467,0.9658357,0.000042847107,0.00010818326,0.000011288676,0.004511377,0.0020012169,0.000019740544,0.000060837792,0.00002528945,0.026410013],"study_design_scores_gemma":[0.019824574,0.0006216664,0.95928943,0.00048875157,0.00003254925,0.0000016849763,0.003570194,0.001068337,0.00026648087,0.00033886987,0.014284804,0.00021265616],"about_ca_topic_score_codex":0.003925533,"about_ca_topic_score_gemma":0.0029195272,"teacher_disagreement_score":0.026197357,"about_ca_system_score_codex":0.0002623611,"about_ca_system_score_gemma":0.00008523544,"threshold_uncertainty_score":0.59342575},"labels":[],"label_agreement":null},{"id":"W4411223753","doi":"10.1007/s12325-025-03226-3","title":"Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Sanofi Genzyme; Grifols; BioCryst; Regeneron Pharmaceuticals; Moderna; Takeda Pharmaceuticals U.S.A.; BioMarin Pharmaceutical; AstraZeneca; CSL Behring; Amgen; Sanofi; GlaxoSmithKline","keywords":"Medicine; Tolerability; Hereditary angioedema; Angioedema; Rheumatology; Internal medicine; Adverse effect; Intensive care medicine; Physical therapy; Dermatology","score_opus":0.009382766756255299,"score_gpt":0.33892470648832074,"score_spread":0.3295419397320654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411223753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865524,0.00951984,0.00016406826,0.0002465827,0.00011593563,0.0025863722,0.000010530582,0.00002521515,0.00077905034],"genre_scores_gemma":[0.9987265,0.0006204543,0.000058947662,0.000042700995,0.000043783966,0.00018777253,0.00001760031,0.000015975464,0.0002862535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984971,0.00020442247,0.0004591238,0.00039041086,0.00023607894,0.00021283451],"domain_scores_gemma":[0.9990609,0.00034217344,0.0001210463,0.0003071492,0.0001333101,0.000035388075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060797646,0.0002023294,0.0004988566,0.00021896957,0.000076296405,0.000012740318,0.00011542431,0.000045157463,0.00004493672],"category_scores_gemma":[0.0000391151,0.00013098701,0.00007994781,0.00070206536,0.00026637025,0.00022472593,0.000052021413,0.00017786412,2.4685122e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008295837,0.0023281665,0.95170116,0.00022642082,0.0001320087,0.000071122,0.0008549673,0.00005201901,0.000044772798,0.00065707415,0.000003120347,0.035633355],"study_design_scores_gemma":[0.01465617,0.0026142201,0.9789051,0.0005594061,0.000026882155,0.000007306884,0.0005640622,0.000041901778,0.000618043,0.0018341036,0.000050196988,0.00012262884],"about_ca_topic_score_codex":0.00044794026,"about_ca_topic_score_gemma":0.007146957,"teacher_disagreement_score":0.035510726,"about_ca_system_score_codex":0.00015959611,"about_ca_system_score_gemma":0.0001439935,"threshold_uncertainty_score":0.5341495},"labels":[],"label_agreement":null},{"id":"W4412063527","doi":"10.1007/s12325-025-03295-4","title":"Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact; Group for Research in Decision Analysis; GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; COPD; Internal medicine; Dual (grammatical number); Rheumatology; Physical therapy","score_opus":0.012974904815215123,"score_gpt":0.32779301825035484,"score_spread":0.3148181134351397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412063527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733864,0.02347515,0.00008550193,0.00004331984,0.00014395746,0.0015736219,0.000051136634,0.00001774714,0.0012231556],"genre_scores_gemma":[0.99617827,0.0033167829,0.00015570584,0.00007565632,0.000022960243,0.00012010005,0.000065002634,0.000019197523,0.000046295718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983361,0.00024601465,0.0003039677,0.00044138537,0.0003634102,0.00030914968],"domain_scores_gemma":[0.9987722,0.00059743266,0.000099789206,0.0003007539,0.00015850802,0.00007133248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023961806,0.00023672149,0.0006635554,0.0002622668,0.000046812977,0.000011852133,0.00012276796,0.000070023554,0.000054046082],"category_scores_gemma":[0.00001937631,0.00018142666,0.00004326863,0.00055693794,0.0003410687,0.00034194055,0.0000473799,0.0002765967,0.0000015583612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015728783,0.00065833307,0.8915459,0.00022458317,0.0001728546,0.000016006072,0.0010821921,0.000085860156,0.0010413941,0.0003431599,0.000004247107,0.08909671],"study_design_scores_gemma":[0.019633703,0.0006337931,0.9686013,0.0009328537,0.0000093873205,6.454695e-7,0.00058616005,0.00014238643,0.0066418485,0.001887988,0.0007658526,0.00016408341],"about_ca_topic_score_codex":0.0002286075,"about_ca_topic_score_gemma":0.00011285179,"teacher_disagreement_score":0.088932626,"about_ca_system_score_codex":0.00028185928,"about_ca_system_score_gemma":0.00018892465,"threshold_uncertainty_score":0.73983645},"labels":[],"label_agreement":null},{"id":"W4412187101","doi":"10.1007/s12325-025-03296-3","title":"Broad Impact of Bowel Urgency in Ulcerative Colitis and Crohn’s Disease: US, European, and Japanese Patient and Healthcare Professional Perspectives from the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Eli Lilly and Company","keywords":"Medicine; Ulcerative colitis; Inflammatory bowel disease; Crohn's disease; Health care; Disease; Internal medicine; Rheumatology; Family medicine; Health professionals; Crohn disease; Gastroenterology","score_opus":0.008744103949303722,"score_gpt":0.3129416128593667,"score_spread":0.30419750891006303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412187101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8955892,0.10381306,6.7237926e-7,0.00007510989,0.000025462161,0.0002982451,0.00012259603,0.0000016892427,0.00007400997],"genre_scores_gemma":[0.9765471,0.023244306,0.000032723245,0.00008664938,0.000009054287,0.000036050256,0.000027240156,0.000006381676,0.000010466889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987268,0.00069954526,0.00020184582,0.00019869707,0.000063983054,0.000109155364],"domain_scores_gemma":[0.9994368,0.00013862932,0.000109539425,0.00019212913,0.00007192943,0.000050956955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022196071,0.00011884486,0.000145876,0.000038488317,0.00007889168,0.000012817111,0.0001005289,0.000034804107,0.00000303464],"category_scores_gemma":[0.00012319785,0.00008295885,0.000020260788,0.00007472883,0.00044948806,0.000019170824,0.000114063136,0.00008348882,9.09641e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018965779,0.000066470464,0.94676447,0.000042191554,0.00003138646,0.0000053994813,0.04066232,0.000008110978,0.0022834158,0.0001369804,0.000011739859,0.008090954],"study_design_scores_gemma":[0.0006042686,0.0000930744,0.9756385,0.00012663059,0.0000023468644,6.502583e-7,0.022901349,0.000010534978,0.000365676,0.0001277217,0.00004991274,0.00007933999],"about_ca_topic_score_codex":0.0011067417,"about_ca_topic_score_gemma":0.0030294724,"teacher_disagreement_score":0.08095797,"about_ca_system_score_codex":0.00001000598,"about_ca_system_score_gemma":0.00007502018,"threshold_uncertainty_score":0.33829638},"labels":[],"label_agreement":null},{"id":"W4412462061","doi":"10.1007/s12325-025-03274-9","title":"Efficacy and Safety of TV-46000 and Second-Generation Long-Acting Injectable Antipsychotics for Schizophrenia: A Systematic Literature Review and Network Meta-Analysis of Randomized Controlled Trials","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre; EVERSANA (Canada); Global Affairs Canada","funders":"","keywords":"Medicine; Meta-analysis; Randomized controlled trial; Schizophrenia (object-oriented programming); MEDLINE; Systematic review; Internal medicine; Psychiatry","score_opus":0.08478789504659646,"score_gpt":0.422756095169057,"score_spread":0.33796820012246054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412462061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037871727,0.97666353,0.00031536588,0.00006216968,0.0000662169,0.022670435,0.00015562795,0.000008205513,0.000020602942],"genre_scores_gemma":[0.00020952296,0.993149,0.0035422465,0.000054852993,0.00006844244,0.002591274,0.0002470712,0.000023991688,0.00011362193],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9921907,0.0033409141,0.0034433657,0.00051383954,0.00027350156,0.0002376677],"domain_scores_gemma":[0.9797277,0.017087769,0.0023951866,0.0004442905,0.0002580975,0.00008694653],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.009498526,0.00052772457,0.036454026,0.0006558986,0.00006602717,0.000048837068,0.000093384224,0.00020568771,0.000040760464],"category_scores_gemma":[0.0042784815,0.0002650104,0.003040823,0.0012421666,0.000115258794,0.00012246978,0.000025378586,0.00024997033,5.3098383e-8],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18683597,0.000113078815,0.0000025564952,0.46069112,0.24767324,0.00000505478,0.000053014086,0.000012693222,9.0377995e-7,0.0004199216,0.000010048237,0.1041824],"study_design_scores_gemma":[0.23740514,0.00030363534,0.0000024007506,0.14566076,0.6150289,0.000018622779,0.0000051331444,0.00010145884,0.000002897987,0.00019275032,0.0010782446,0.00020003413],"about_ca_topic_score_codex":0.000001729633,"about_ca_topic_score_gemma":0.000045459616,"teacher_disagreement_score":0.36735567,"about_ca_system_score_codex":0.000030459445,"about_ca_system_score_gemma":0.00019621075,"threshold_uncertainty_score":0.9999802},"labels":[],"label_agreement":null},{"id":"W4412493533","doi":"10.1007/s12325-025-03258-9","title":"Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022–2023","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Novartis Pharma; Samsung; LEO Pharma; Swedish Orphan Biovitrum; Chugai Pharmaceutical; Celltrion; UCB Pharma; Regeneron Pharmaceuticals; Baxalta; Biogen; Celgene; Cilag; Mylan; Gilead Sciences; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ixekizumab; Medicine; Secukinumab; Psoriatic arthritis; Psoriasis; Dermatology; Ustekinumab; Quality of life (healthcare); Internal medicine; Physical therapy; Adalimumab; Rheumatoid arthritis","score_opus":0.042011582688675476,"score_gpt":0.3994908874577577,"score_spread":0.3574793047690822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412493533","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014758871,0.9855891,0.0000016818009,0.00013873889,0.00063743524,0.012926682,0.00030774876,0.000020046124,0.0003637996],"genre_scores_gemma":[0.00001937242,0.99097,0.00022758184,0.00019059543,0.00022241504,0.007782751,0.0002371917,0.000047067035,0.00030298694],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99619246,0.00058965397,0.0016724949,0.00072869536,0.000377848,0.00043886405],"domain_scores_gemma":[0.99585706,0.0024980337,0.0006347121,0.00084014115,0.00011006357,0.000060010276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006462998,0.00072615204,0.0048763305,0.0004066117,0.00011001367,0.000041339907,0.00026107786,0.00019599023,0.000019550918],"category_scores_gemma":[0.00027385715,0.000436177,0.0006892419,0.0014211948,0.00014405452,0.0002153876,0.000026566679,0.0002536756,0.0000028410489],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016113868,0.00032055183,0.000009743354,0.3279064,0.00020500859,0.0001784111,0.00025702236,5.795746e-8,3.0979095e-8,0.0007984765,0.000061021758,0.6701021],"study_design_scores_gemma":[0.003511603,0.0012976706,0.00001483959,0.6396896,0.0006942766,0.00011962386,0.0000495942,2.9635024e-7,5.605957e-7,0.00029286352,0.35412958,0.0001994396],"about_ca_topic_score_codex":0.00007996391,"about_ca_topic_score_gemma":0.0017216483,"teacher_disagreement_score":0.6699027,"about_ca_system_score_codex":0.00030471123,"about_ca_system_score_gemma":0.00017982187,"threshold_uncertainty_score":0.999809},"labels":[],"label_agreement":null},{"id":"W4412552202","doi":"10.1007/s12325-025-03305-5","title":"Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Rheumatology; Axial spondyloarthritis; Quality of life (healthcare); Duration (music); Internal medicine; Signs and symptoms; Physical therapy; Arthritis; Psoriatic arthritis; Sacroiliitis; Secukinumab","score_opus":0.007269823551129115,"score_gpt":0.2827602829955768,"score_spread":0.2754904594444477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412552202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762434,0.022438087,0.000020188814,0.00006144158,0.000082440296,0.00062584586,0.00003359152,0.000009153358,0.00048589555],"genre_scores_gemma":[0.99301785,0.006636058,0.00018503178,0.00006556421,0.0000123875825,0.000034108525,0.00001983295,0.000008543658,0.000020610954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891454,0.00006412135,0.000452767,0.00023664004,0.00018539568,0.00014652431],"domain_scores_gemma":[0.9993856,0.00013356775,0.00017782794,0.00015946577,0.00011484724,0.000028715533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110056404,0.0001386763,0.00049972965,0.0001629422,0.000028183527,0.0000037684993,0.000041169442,0.00005158448,0.000009932761],"category_scores_gemma":[0.00008492219,0.00011020103,0.00003389661,0.00030913483,0.00017146635,0.0001758418,0.000019927696,0.00008143747,2.2238193e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055839974,0.00054873904,0.8545843,0.000070593924,0.00008834346,0.000002662558,0.00056382996,0.000003736164,0.00052579684,0.0008651115,0.0000015229405,0.1371614],"study_design_scores_gemma":[0.020472404,0.002042935,0.97421706,0.00036803907,0.0000099644585,3.3820373e-7,0.00035123163,0.0000026067385,0.0016936427,0.0005880596,0.00016395749,0.00008979282],"about_ca_topic_score_codex":0.00024447023,"about_ca_topic_score_gemma":0.00072084967,"teacher_disagreement_score":0.13707161,"about_ca_system_score_codex":0.000059629194,"about_ca_system_score_gemma":0.00006081361,"threshold_uncertainty_score":0.44938675},"labels":[],"label_agreement":null},{"id":"W4412695394","doi":"10.1007/s12325-025-03310-8","title":"Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Swedish Orphan Biovitrum; Apellis Pharmaceuticals","keywords":"Paroxysmal nocturnal hemoglobinuria; Medicine; Rheumatology; Internal medicine; Nocturnal; Hemoglobinuria; Pediatrics; Anemia","score_opus":0.0051057788509720516,"score_gpt":0.267746939681555,"score_spread":0.2626411608305829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412695394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830848,0.014846385,0.00013206815,0.00026118368,0.00044557298,0.000644738,0.000016344598,0.000033786342,0.000535102],"genre_scores_gemma":[0.99788153,0.0012546288,0.00016714039,0.00027561025,0.00001552374,0.000058464975,0.000022628723,0.000009838184,0.0003146214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988999,0.00016838737,0.00028274165,0.0003163569,0.00003231476,0.000300345],"domain_scores_gemma":[0.99946725,0.000226853,0.000059622475,0.00020641329,0.000018899475,0.000020985433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018542752,0.00015286011,0.0002619336,0.0001765012,0.00005515929,0.000012112374,0.0001884695,0.000060251205,0.00016958873],"category_scores_gemma":[0.000040766463,0.00012987906,0.000020821975,0.00027775043,0.00007916184,0.000107841,0.000051600062,0.00015220557,0.000015857673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034228146,0.00028156678,0.7040502,0.00014187212,0.00017199924,0.00005527571,0.00525233,0.000761882,0.0074781845,0.0018914741,0.00068317406,0.24500391],"study_design_scores_gemma":[0.022355631,0.0005696689,0.89374286,0.0014641917,0.000009965447,0.000031090745,0.0016810646,0.000007625303,0.0019076042,0.0007554504,0.07709749,0.00037735043],"about_ca_topic_score_codex":0.00006118903,"about_ca_topic_score_gemma":0.0007756954,"teacher_disagreement_score":0.24462657,"about_ca_system_score_codex":0.00007862782,"about_ca_system_score_gemma":0.000046180838,"threshold_uncertainty_score":0.52963144},"labels":[],"label_agreement":null},{"id":"W4412717873","doi":"10.1007/s12325-025-03309-1","title":"Key Learnings from Clinical Research and Real-World Evidence on Asfotase Alfa Effectiveness in Hypophosphatasia: 10 Years Post-Approval","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Alkaline Phosphatase Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Hypophosphatasia; Rheumatology; Key (lock); Internal medicine; Intensive care medicine; Medical physics; Family medicine; Alkaline phosphatase","score_opus":0.20057118062795315,"score_gpt":0.5627583183409461,"score_spread":0.362187137712993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412717873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028963217,0.9925352,0.0000013695776,0.00019967672,0.000263801,0.0034926606,0.00022875928,0.000045486853,0.00033673312],"genre_scores_gemma":[0.00017058529,0.99720305,0.00029810597,0.0000889692,0.00027894825,0.0008878804,0.0003806431,0.00008067741,0.0006111585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99234,0.0028591536,0.001215855,0.001611994,0.0011018066,0.00087113515],"domain_scores_gemma":[0.9729105,0.025235496,0.0002906845,0.0010270583,0.0003075292,0.00022869639],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006550491,0.00061872293,0.003243568,0.0011296305,0.00011965219,0.00004309426,0.00058290403,0.00037464596,0.000087029286],"category_scores_gemma":[0.0067158877,0.00048947835,0.0003075775,0.0022412995,0.00091711094,0.00033634398,0.00046654278,0.003220954,0.00009340649],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003051136,0.00046415857,0.0040597306,0.007044139,0.00021051241,0.0008810841,0.0000828087,0.0000010006709,7.956478e-7,0.00023045653,0.00028349087,0.9836907],"study_design_scores_gemma":[0.0028558567,0.002129566,0.017241944,0.10042037,0.00009131798,0.000007718452,0.0000872225,0.0000027232081,0.000012878904,0.0017317677,0.87498415,0.00043448855],"about_ca_topic_score_codex":0.0018851426,"about_ca_topic_score_gemma":0.0007914412,"teacher_disagreement_score":0.9832562,"about_ca_system_score_codex":0.0005973368,"about_ca_system_score_gemma":0.0010861064,"threshold_uncertainty_score":0.9997557},"labels":[],"label_agreement":null},{"id":"W4413792153","doi":"10.1007/s12325-025-03328-y","title":"Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Charité – Universitätsmedizin Berlin; AbbVie","keywords":"Medicine; Psoriatic arthritis; Rheumatoid arthritis; Inflammatory bowel disease; Dermatology; Atopic dermatitis; Rheumatology; Psoriasis; Ankylosing spondylitis; Internal medicine; Disease","score_opus":0.0049820408310046966,"score_gpt":0.26221983043281205,"score_spread":0.2572377896018074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413792153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7500203,0.24776049,0.000032432486,0.000077107936,0.0003258307,0.0009794701,0.00045186913,0.000037825856,0.00031465906],"genre_scores_gemma":[0.6870866,0.31204292,0.00030933917,0.00017613212,0.000023085739,0.00018891801,0.00011843067,0.00002302839,0.000031562944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701625,0.00016797689,0.0011300468,0.0006490601,0.00040670222,0.00062997174],"domain_scores_gemma":[0.9988156,0.00016677233,0.00027816283,0.00045922797,0.000106819425,0.00017340685],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021917994,0.00040142323,0.0010671777,0.00048739664,0.00013930225,0.000038231068,0.0001287009,0.00013932385,0.00019248136],"category_scores_gemma":[0.000119312266,0.00042127963,0.00022529415,0.001073729,0.0004291878,0.000516714,0.000103762686,0.00028169344,0.0000047055682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010162018,0.0004313663,0.65413016,0.0001018632,0.00037686672,0.00047484643,0.002005311,0.000046257912,0.000030327528,0.00087726227,0.000040269457,0.34046924],"study_design_scores_gemma":[0.018362332,0.00033423633,0.96405905,0.0022151698,0.0000496947,0.000019082125,0.0015390135,0.00008739661,0.00033600937,0.0014714601,0.01117345,0.00035311995],"about_ca_topic_score_codex":0.0003062236,"about_ca_topic_score_gemma":0.003635539,"teacher_disagreement_score":0.34011614,"about_ca_system_score_codex":0.00017822416,"about_ca_system_score_gemma":0.00013662108,"threshold_uncertainty_score":0.9998239},"labels":[],"label_agreement":null},{"id":"W4414132918","doi":"10.1007/s12325-025-03345-x","title":"Healthcare Costs Associated with Adverse Events in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Claims-Based Study","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Adverse effect; Health care; Rheumatology; Patient safety; MEDLINE; Adverse drug event; Healthcare system","score_opus":0.014235280551496279,"score_gpt":0.3298150909744432,"score_spread":0.31557981042294697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414132918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947394,0.0010471474,0.00022124166,0.0005989235,0.00016214432,0.0029852071,0.000019193258,0.00008476216,0.00014199341],"genre_scores_gemma":[0.998663,0.0002637899,0.000098396624,0.00027864016,0.000019993908,0.00037321687,0.00010877989,0.000052696756,0.00014150688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728125,0.00040148728,0.00047745527,0.00069701753,0.0006632465,0.00047956064],"domain_scores_gemma":[0.99850947,0.00033719558,0.0002889708,0.00047192266,0.0003090872,0.00008333166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031634516,0.00037743486,0.0006369183,0.0005968038,0.0001244432,0.000007856781,0.00014649563,0.00012706901,0.000038411155],"category_scores_gemma":[0.0001315273,0.00029891785,0.000079384314,0.0019883201,0.000051803825,0.00059967383,0.000027033419,0.0005798634,0.000008966105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027435834,0.0101246545,0.9793253,0.000060965333,0.0000804362,0.000024921887,0.00011573275,0.0009659942,0.000004207019,0.000008576308,0.0000012203393,0.0065444103],"study_design_scores_gemma":[0.0279709,0.0015195828,0.96760494,0.00031897656,0.00006579929,5.2159606e-7,0.0020153197,0.00013047902,8.321942e-7,0.00002399247,0.00005961598,0.00028905924],"about_ca_topic_score_codex":0.0002406114,"about_ca_topic_score_gemma":0.0067826635,"teacher_disagreement_score":0.025227318,"about_ca_system_score_codex":0.00054980145,"about_ca_system_score_gemma":0.00029024057,"threshold_uncertainty_score":0.9999463},"labels":[],"label_agreement":null},{"id":"W4414167020","doi":"10.1007/s12325-025-03359-5","title":"A Narrative Review of the Immunomodulatory Effects of Acthar® Gel Beyond Its Steroidogenic Properties","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Immune system; Narrative review; Rheumatoid arthritis; Adverse effect; Receptor; Melanocortin; Rheumatology; Adrenocorticotropic hormone","score_opus":0.005476303432366392,"score_gpt":0.25526784872908204,"score_spread":0.24979154529671566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414167020","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4938832,0.5049893,0.0000046489868,0.000117104064,0.0003169279,0.00037659414,7.2380124e-7,0.00000446156,0.00030702047],"genre_scores_gemma":[0.8113586,0.18748799,0.000005336983,0.00030676078,0.0000030391889,0.000059803362,0.0000028295228,0.000004345911,0.0007713246],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989573,0.00042689196,0.0003515705,0.00011357763,0.000030496603,0.00012021241],"domain_scores_gemma":[0.9992898,0.00013573674,0.00020825896,0.00028157886,0.000082395454,0.000002194159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023614548,0.00010696237,0.00029459532,0.00006800054,0.00005337782,0.0000014900379,0.00025582817,0.00007316051,0.00003549],"category_scores_gemma":[0.00012114135,0.00006500381,0.00009613798,0.00021777482,0.00016925149,0.00018090068,0.0000429273,0.0001354704,0.00000604718],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039937196,0.00006245763,0.00021402033,0.0014379353,0.00010864101,1.7817268e-7,0.0024280467,0.000003911342,0.9586222,0.00042307714,0.00007015419,0.03623],"study_design_scores_gemma":[0.000937462,0.0001309709,0.0030301197,0.004616285,0.000011312821,0.0000017641195,0.00018310074,6.101943e-7,0.9715616,0.00022416806,0.019240266,0.000062307],"about_ca_topic_score_codex":0.0000058485552,"about_ca_topic_score_gemma":0.0000036611964,"teacher_disagreement_score":0.31750134,"about_ca_system_score_codex":0.000024742261,"about_ca_system_score_gemma":0.00008370472,"threshold_uncertainty_score":0.26507783},"labels":[],"label_agreement":null},{"id":"W4414416604","doi":"10.1007/s12325-025-03373-7","title":"The IMPACT Survey: The Economic Impact of Caring for an Individual with Osteogenesis Imperfecta","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Connective tissue disorders research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Mereo BioPharma","keywords":"Economic impact analysis; Osteogenesis imperfecta; Rheumatology; Productivity; Social impact; Health care; Impact assessment; Health economics","score_opus":0.02189328852987421,"score_gpt":0.393577280307019,"score_spread":0.3716839917771448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414416604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798776,0.01915029,0.00017272416,0.000028309678,0.00003350631,0.0004925142,0.00010532805,0.0000023899813,0.00013733018],"genre_scores_gemma":[0.99520326,0.0045347493,0.00001880719,0.000013402003,0.000025676027,0.000098307486,0.000059911312,0.000013947903,0.00003193119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920696,0.00017551534,0.00012510372,0.00020962137,0.000055606302,0.00022717264],"domain_scores_gemma":[0.9992079,0.00027191645,0.000056539742,0.00037710342,0.00006603268,0.00002049122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006106627,0.00011619406,0.00012740771,0.00003945094,0.00011223989,0.000028300045,0.00040432398,0.000043576445,0.0000060363686],"category_scores_gemma":[0.00007233862,0.0000585986,0.00008708886,0.000114633265,0.00014098677,0.000010557688,0.000047801124,0.000057605626,2.1409733e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037250298,0.000053242584,0.68173945,0.000008493392,0.0004899913,1.922538e-7,0.00026774657,0.012705377,0.0586011,0.00007185765,0.00013497242,0.24220257],"study_design_scores_gemma":[0.0027982178,0.004501986,0.86398894,0.000017255195,0.000010376504,0.0000029071139,0.0006040764,0.0005930856,0.122659266,0.00081785745,0.0037543336,0.0002516993],"about_ca_topic_score_codex":0.0019140275,"about_ca_topic_score_gemma":0.009111554,"teacher_disagreement_score":0.24195087,"about_ca_system_score_codex":0.00006583971,"about_ca_system_score_gemma":0.00033978088,"threshold_uncertainty_score":0.5084461},"labels":[],"label_agreement":null},{"id":"W4414418254","doi":"10.1007/s12325-025-03363-9","title":"IL-17C as a Driver of Inflammation in Psoriasis","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health","keywords":"Psoriasis; Autocrine signalling; Inflammation; Rheumatology; Psoriatic arthritis; Mechanism of action; Ustekinumab; Cytokine","score_opus":0.019473864995041102,"score_gpt":0.3204962230484371,"score_spread":0.301022358053396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414418254","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011111641,0.99520296,0.000004592462,0.000008696896,0.00093381177,0.00067706575,0.00006177553,0.000020617676,0.0019793033],"genre_scores_gemma":[0.00018719798,0.9980718,0.000059213653,0.000011956506,0.000036783058,0.00028379058,0.00026242682,0.000016942753,0.0010698985],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983345,0.00042335212,0.0006410459,0.00033471143,0.000033599747,0.0002327874],"domain_scores_gemma":[0.9988222,0.0004860404,0.00033551207,0.00032112823,0.000027838623,0.0000072904495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020095201,0.00032171552,0.001284963,0.00050241046,0.000028124437,0.000003833082,0.00028749648,0.00047356618,0.00020431685],"category_scores_gemma":[0.000052098112,0.00025450863,0.00026025926,0.0005383715,0.00008130538,0.00014410744,0.00003382934,0.00021125226,0.00010550092],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009459895,0.000085806314,0.00014901745,0.0012327833,0.00017418728,0.000005960707,0.00018811866,0.0000023481102,0.00005825012,0.0005812001,0.000016812943,0.9974109],"study_design_scores_gemma":[0.0014421409,0.0001007812,0.00006135047,0.004728458,0.00010651919,0.0000056341705,0.000024747033,5.148998e-8,0.00085231144,0.00084702356,0.99162334,0.0002076512],"about_ca_topic_score_codex":0.000042729513,"about_ca_topic_score_gemma":0.00011810727,"teacher_disagreement_score":0.9972033,"about_ca_system_score_codex":0.000086172986,"about_ca_system_score_gemma":0.00016518423,"threshold_uncertainty_score":0.9999907},"labels":[],"label_agreement":null},{"id":"W4414519113","doi":"10.1007/s12325-025-03351-z","title":"Meta-analysis to Investigate the Correlation Between Event-Free Survival and Overall Survival in Patients with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Overall survival; Head and neck squamous-cell carcinoma; Correlation; Head and neck; Neoadjuvant therapy; Rheumatology; Adjuvant; Radiation therapy; Head and neck cancer","score_opus":0.030650267883544483,"score_gpt":0.30389759177776005,"score_spread":0.2732473238942156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414519113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744729,0.021850104,0.0002734775,0.0015054764,0.000081852464,0.0007866552,0.000022135531,0.000014556798,0.0009928806],"genre_scores_gemma":[0.9975094,0.0009761481,0.0004822582,0.00056344946,0.000018874696,0.00008502681,0.000017352162,0.000015046323,0.00033239496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842894,0.00017355433,0.00036247916,0.0004271681,0.000314389,0.00029349356],"domain_scores_gemma":[0.99892265,0.00039611335,0.00008713133,0.00040862133,0.00009889528,0.000086577274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003911964,0.0002273472,0.00093546964,0.00023241802,0.00009963941,0.000019261675,0.00011613021,0.00005447332,0.000009890517],"category_scores_gemma":[0.000077611,0.00014061877,0.00008387071,0.00093448604,0.00011441209,0.00021023904,0.00008101701,0.00021815403,5.386218e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013697979,0.00008101546,0.9916273,0.00003493178,0.0012418113,0.0000038555268,0.000618575,0.0016549255,0.00002045635,0.0000915421,0.000016528473,0.003239296],"study_design_scores_gemma":[0.008001949,0.0010082542,0.98623335,0.000026486301,0.0021645916,1.4190715e-7,0.0001531209,0.00011824422,0.00016350247,0.00071664946,0.0012525875,0.00016112928],"about_ca_topic_score_codex":0.0005676016,"about_ca_topic_score_gemma":0.005949087,"teacher_disagreement_score":0.023036588,"about_ca_system_score_codex":0.00007188418,"about_ca_system_score_gemma":0.00006777597,"threshold_uncertainty_score":0.57342666},"labels":[],"label_agreement":null},{"id":"W4414542678","doi":"10.1007/s12325-025-03372-8","title":"The IMPACT Survey: The Humanistic Impact of Caring for an Individual with Osteogenesis Imperfecta","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Connective tissue disorders research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Mereo BioPharma","keywords":"Osteogenesis imperfecta; Rheumatology; Quality of life (healthcare); MEDLINE; Health care; Empathy; Alternative medicine","score_opus":0.02815782071704819,"score_gpt":0.4085189092588146,"score_spread":0.3803610885417664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414542678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743779,0.024314497,0.0004834618,0.000027521226,0.000027663085,0.0005447172,0.00008320358,0.000002959345,0.00013808052],"genre_scores_gemma":[0.99682194,0.0028805658,0.000022336786,0.00001527416,0.000023871109,0.00010718466,0.000071596965,0.000015184664,0.00004206715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991026,0.00021029917,0.0001284172,0.00021463998,0.000098176286,0.00024588138],"domain_scores_gemma":[0.99906284,0.00032966677,0.000056597084,0.0003983108,0.00013163687,0.000020962736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062709354,0.00012531917,0.00013118054,0.00004105361,0.00016354333,0.000032169828,0.00042511447,0.000043872293,0.000005537375],"category_scores_gemma":[0.0001680267,0.00006180974,0.00008307765,0.00020710536,0.00017449172,0.000008452869,0.00005024751,0.000068772424,1.305201e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004282975,0.00016399327,0.6741096,0.000018285922,0.0005667136,5.2402146e-7,0.0004358851,0.0032500215,0.1267864,0.00016425265,0.00014891622,0.19007243],"study_design_scores_gemma":[0.0023345123,0.0052362974,0.91927606,0.000023525728,0.000013284301,0.000002843748,0.00058337266,0.00020153262,0.06849816,0.001109281,0.0024916076,0.00022952093],"about_ca_topic_score_codex":0.00097593846,"about_ca_topic_score_gemma":0.005860338,"teacher_disagreement_score":0.24516647,"about_ca_system_score_codex":0.000027692802,"about_ca_system_score_gemma":0.0001802737,"threshold_uncertainty_score":0.32702062},"labels":[],"label_agreement":null},{"id":"W4414571303","doi":"10.1007/s12325-025-03378-2","title":"Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 Studies","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Sinusitis and nasal conditions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation; Université de Montréal","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Rheumatology; Nose; Rhinomanometry; Pathophysiology; Breathing","score_opus":0.007289450487137565,"score_gpt":0.26146575807545963,"score_spread":0.25417630758832205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414571303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851693,0.0128189735,0.000026403997,0.00072681793,0.00026927394,0.0005242117,0.00002318215,0.000021164487,0.0004206792],"genre_scores_gemma":[0.99598956,0.0017395113,0.00020223534,0.0017985037,0.000078242505,0.00007285534,0.0000293645,0.000010982371,0.00007875006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991077,0.00013099333,0.00018321563,0.00019975804,0.0002381745,0.00014016248],"domain_scores_gemma":[0.99906665,0.0005089366,0.0001074759,0.00017082493,0.00013021615,0.000015889567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019072175,0.00013096494,0.0002469179,0.00006129229,0.00014570385,0.000021214275,0.00006662427,0.000053702857,0.000008961224],"category_scores_gemma":[0.00009422185,0.00006367299,0.000022737893,0.00034638937,0.00018458691,0.00024740506,0.000017736918,0.00024483912,8.8698755e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020871481,0.00007726461,0.9752667,0.000008066785,0.0001396209,0.0000044167655,0.0014845765,0.00008005205,0.000011662024,0.0003807652,0.00014450158,0.020315217],"study_design_scores_gemma":[0.01282661,0.00028097484,0.9816683,0.00021283321,0.00003461614,0.0000015462521,0.001265859,0.000030719777,0.000049323342,0.0012341763,0.0023036567,0.000091378846],"about_ca_topic_score_codex":0.00008778395,"about_ca_topic_score_gemma":0.0015709591,"teacher_disagreement_score":0.020223837,"about_ca_system_score_codex":0.00017284925,"about_ca_system_score_gemma":0.00005750605,"threshold_uncertainty_score":0.25965092},"labels":[],"label_agreement":null},{"id":"W4414948117","doi":"10.1007/s12325-025-03377-3","title":"Real-World Health Care Resource Utilization and Costs Among Patients with Activated Phosphoinositide 3-Kinase Delta (PI3Kδ) Syndrome in the United States","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Health care; Managed care; Delta; Rheumatology; MEDLINE; Patient care; Public health","score_opus":0.0062765451594935,"score_gpt":0.2638679887652232,"score_spread":0.2575914436057297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414948117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9259131,0.07278329,0.000018554887,0.0002492043,0.00007639563,0.0005426523,0.000022434868,0.00003177354,0.0003625933],"genre_scores_gemma":[0.9855213,0.012265992,0.000007031085,0.00089187734,3.348142e-7,0.000048261772,0.0011763739,0.000011040464,0.00007776448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875575,0.00037513376,0.00026502108,0.00025473486,0.00004273335,0.0003066475],"domain_scores_gemma":[0.99938256,0.00020901683,0.00012110037,0.00023660056,0.000046446687,0.0000042532074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001838278,0.00017069068,0.00022085391,0.00029369027,0.0002497235,0.000017523114,0.00020626787,0.000066513036,0.000010336475],"category_scores_gemma":[0.000016097762,0.00011956357,0.000017919194,0.0010679233,0.00022222278,0.00018852092,0.000025122457,0.00026580284,0.0000010842072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029964736,0.00086946785,0.60309494,0.00009662919,0.00011077064,0.000014752729,0.022975642,0.0019590184,0.0006224082,0.0019856612,0.000118646945,0.36515558],"study_design_scores_gemma":[0.006280496,0.00056178024,0.9032627,0.00052774884,0.0000074112095,0.0000024734559,0.012525182,0.0000251504,0.0036089537,0.0001929448,0.0727258,0.00027938036],"about_ca_topic_score_codex":0.0045275595,"about_ca_topic_score_gemma":0.0016540644,"teacher_disagreement_score":0.3648762,"about_ca_system_score_codex":0.00012185927,"about_ca_system_score_gemma":0.00004661995,"threshold_uncertainty_score":0.6844346},"labels":[],"label_agreement":null},{"id":"W4415063955","doi":"10.1007/s12325-025-03382-6","title":"Therapeutic Advances in Hereditary Angioedema: A Focus on Present and Future Options","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary","funders":"","keywords":"Hereditary angioedema; Narrative review; Personalized medicine; Quality of life (healthcare); Genome editing; Autonomy; Precision medicine; Bradykinin","score_opus":0.024453131652032663,"score_gpt":0.36171896063001835,"score_spread":0.3372658289779857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415063955","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024813544,0.9935089,0.000021041591,0.0011344876,0.0008838832,0.0017471208,0.000039535058,0.00007139985,0.0025688463],"genre_scores_gemma":[0.00012823787,0.9965594,0.00024057263,0.0003737233,0.0015252464,0.0004549298,0.00010220995,0.0000592005,0.0005565105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99754596,0.00020412778,0.00076256326,0.0007318155,0.00031104434,0.0004444751],"domain_scores_gemma":[0.9984654,0.0006155232,0.00024692412,0.00052604434,0.000043342105,0.00010273483],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023711391,0.0006018392,0.001745886,0.00058777013,0.00008589313,0.000025940084,0.00022350221,0.00034829875,0.00008418382],"category_scores_gemma":[0.000019102119,0.00045049487,0.00035933484,0.0008649337,0.00013890474,0.0003802247,0.000041886233,0.0005138681,0.000008171695],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013041592,0.00023798377,0.0003484654,0.003198214,0.00007779265,0.000056304467,0.00015498132,0.000014332397,1.04588004e-7,0.00218193,0.00008630734,0.99351317],"study_design_scores_gemma":[0.0014741737,0.00033060688,0.0005114777,0.012041394,0.00012764099,0.000038712347,0.0001063941,0.000012284282,0.0000030537026,0.005363775,0.9796117,0.0003787751],"about_ca_topic_score_codex":0.000024605304,"about_ca_topic_score_gemma":0.00013004357,"teacher_disagreement_score":0.9931344,"about_ca_system_score_codex":0.00014701324,"about_ca_system_score_gemma":0.0002433062,"threshold_uncertainty_score":0.99979466},"labels":[],"label_agreement":null},{"id":"W4415323057","doi":"10.1007/s12325-025-03388-0","title":"Fetal Surgery for Congenital Heart Diseases: A Systematic Review and Single-Arm Meta-analysis","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Congenital Heart Disease Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cardiac surgery; Heart disease; Rheumatology; MEDLINE; Multicenter study; Fetus; Orthopedic surgery","score_opus":0.09142833783795772,"score_gpt":0.4022150068843841,"score_spread":0.3107866690464264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415323057","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.969908e-7,0.9901634,0.000024801899,0.0001534961,0.00011322211,0.008640455,0.0007435717,0.00005546408,0.00010469617],"genre_scores_gemma":[0.000031619187,0.99132615,0.00013204078,0.00089016365,0.000049722268,0.006519898,0.00021965503,0.000050643463,0.0007801219],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9966666,0.00040485922,0.0014914428,0.00074777484,0.00030981953,0.00037947248],"domain_scores_gemma":[0.9946957,0.0038681522,0.00034404575,0.00074582954,0.00017692444,0.00016932675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005094296,0.0006917717,0.014515834,0.0006500656,0.000081772574,0.000032650918,0.00013399552,0.00011460389,0.00010728789],"category_scores_gemma":[0.0008925576,0.00044775064,0.006256553,0.0013967823,0.00015123664,0.00016883905,0.00006451103,0.0001774354,0.0000073658352],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029914992,0.00026271644,0.00001770319,0.8256157,0.1002103,0.000018413642,0.000009621269,2.8122352e-8,8.879941e-9,0.000007081345,0.00011925379,0.073709235],"study_design_scores_gemma":[0.00022170866,0.00011592185,0.000001782827,0.078764305,0.7076506,0.00002438313,0.000016271902,0.0000015459445,5.7343133e-8,0.000050694856,0.21281779,0.00033494015],"about_ca_topic_score_codex":0.000003843133,"about_ca_topic_score_gemma":0.00003684018,"teacher_disagreement_score":0.74685144,"about_ca_system_score_codex":0.00011071746,"about_ca_system_score_gemma":0.0002807346,"threshold_uncertainty_score":0.9997974},"labels":[],"label_agreement":null},{"id":"W4415500029","doi":"10.1007/s12325-025-03392-4","title":"Visualizing Improvements in Airway Dysfunction After Inhaled Therapy in Patients With Uncontrolled Asthma: A Narrative Review","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Asthma; Airway; Spirometry; Narrative review; Bronchodilator; Clinical trial; Magnetic resonance imaging; Fluticasone","score_opus":0.004408364618635577,"score_gpt":0.2930193637082804,"score_spread":0.2886109990896448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415500029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8742488,0.1229085,0.00004602196,0.00021559183,0.00013200565,0.002022357,0.000002677352,0.00002042496,0.00040363547],"genre_scores_gemma":[0.9616158,0.031686988,0.00005463405,0.0057052295,0.000026869997,0.00073749083,0.00001579031,0.000019040552,0.00013815214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849236,0.00017908074,0.0004610638,0.00036218777,0.00024184327,0.00026349237],"domain_scores_gemma":[0.9994568,0.000055117212,0.00012417563,0.00022347056,0.000093989205,0.000046417415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022137747,0.00023538282,0.0005535184,0.00029179844,0.00003241718,0.00000864339,0.000075361764,0.0000619967,0.000091114554],"category_scores_gemma":[0.00004018507,0.0001551851,0.000067133464,0.00075226347,0.00006049364,0.00032290345,0.000013683119,0.00020069107,0.0000029365042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011643206,0.0010720604,0.60455877,0.00022764583,0.000042167485,0.00004278028,0.0005822433,0.000024169962,0.00010805474,0.000011509572,0.000027021382,0.38166037],"study_design_scores_gemma":[0.06889337,0.004101538,0.88752645,0.009015819,0.000015970407,8.761074e-7,0.0007179583,0.000042852316,0.00046255198,0.00021104954,0.028612657,0.00039890184],"about_ca_topic_score_codex":0.000019048368,"about_ca_topic_score_gemma":0.00019519993,"teacher_disagreement_score":0.38126147,"about_ca_system_score_codex":0.00017297936,"about_ca_system_score_gemma":0.00012414693,"threshold_uncertainty_score":0.63282645},"labels":[],"label_agreement":null},{"id":"W4416502533","doi":"10.1007/s12325-025-03411-4","title":"Clinical Complications, Mortality, and Healthcare Resource Utilization of Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Ontario, Canada: A Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Government of Ontario; Institute for Clinical Evaluative Sciences; Vertex Pharmaceuticals","keywords":"Retrospective cohort study; Disease; Health care; Cohort study; Resource use; Rheumatology; MEDLINE","score_opus":0.02118208301244729,"score_gpt":0.33648017140864156,"score_spread":0.3152980883961943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416502533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99178296,0.0054285577,0.000026593385,0.0002771728,0.000047674308,0.0018843621,0.00002230423,0.00000820465,0.0005221695],"genre_scores_gemma":[0.9968003,0.002621328,0.000051500592,0.00034657834,0.000003620834,0.00006694766,0.00006977348,0.000008692193,0.00003128461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988113,0.00010805744,0.00036501882,0.00032425282,0.00025680734,0.00013453502],"domain_scores_gemma":[0.9992998,0.000067397996,0.00013949895,0.00024942975,0.00016635751,0.00007747855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014345172,0.00012219006,0.0003458113,0.000074297175,0.000050575174,0.0000037093846,0.00005729604,0.000036670182,0.000007237971],"category_scores_gemma":[0.000028949917,0.00008681436,0.00001596319,0.00032330267,0.00011286115,0.000058999518,0.000021444117,0.00024251315,4.376906e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015482943,0.0013794319,0.9934562,0.000059634207,0.000047115893,0.00000872021,0.0005694667,0.00009202925,1.1959159e-7,0.000056623918,0.000034211098,0.00274817],"study_design_scores_gemma":[0.004488586,0.0010013629,0.9913785,0.00028095738,0.000044915872,1.5044367e-7,0.0013144095,0.000031508447,0.0000022823683,0.00011834164,0.0012542035,0.00008476778],"about_ca_topic_score_codex":0.36840522,"about_ca_topic_score_gemma":0.9489983,"teacher_disagreement_score":0.58059305,"about_ca_system_score_codex":0.0003388995,"about_ca_system_score_gemma":0.0007962758,"threshold_uncertainty_score":0.6358006},"labels":[],"label_agreement":null},{"id":"W4416775922","doi":"10.1007/s12325-025-03409-y","title":"Comparative Efficacy of Talquetamab vs. Real-World Physician’s Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Johnson and Johnson; Universidad de Salamanca; Regeneron Pharmaceuticals; Genentech; Celgene; Adaptive Biotechnologies; Karyopharm Therapeutics; Gilead Sciences; Sanofi; Pfizer; Amgen","keywords":"Identifier; Rheumatology; MEDLINE; Comparative effectiveness research; Identification (biology)","score_opus":0.058499155964655956,"score_gpt":0.41023446096345717,"score_spread":0.35173530499880123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416775922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98982555,0.0044082557,0.000034789544,0.00019187013,0.000092667506,0.0021280309,0.00009433205,0.00002471855,0.0031997596],"genre_scores_gemma":[0.99162,0.0067109233,0.0005513925,0.00008521463,0.000020227337,0.00016564876,0.00031960037,0.000021483225,0.0005055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743474,0.0003178221,0.00103417,0.00045121196,0.00038873858,0.0003733125],"domain_scores_gemma":[0.99782777,0.000827697,0.0004984981,0.0005845866,0.00016974338,0.00009170019],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016401095,0.00036134347,0.0014130234,0.0008327211,0.00003834938,0.000005716258,0.00021165807,0.00008331401,0.00007311311],"category_scores_gemma":[0.000065796055,0.00028201702,0.00024651355,0.0013708427,0.00027906956,0.00025165212,0.00004431285,0.00020375903,0.0000037268412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025545077,0.0208816,0.71152127,0.0002992401,0.0020138712,0.0000460018,0.0020053117,0.002054109,0.15736087,0.00021356963,0.00019614589,0.07786294],"study_design_scores_gemma":[0.037844107,0.0027555143,0.48719892,0.00044754127,0.000070789596,3.7448916e-7,0.00034145545,0.0010674151,0.46711028,0.00007416663,0.0029418238,0.00014764264],"about_ca_topic_score_codex":0.0029757398,"about_ca_topic_score_gemma":0.003234748,"teacher_disagreement_score":0.3097494,"about_ca_system_score_codex":0.00083516975,"about_ca_system_score_gemma":0.00022728025,"threshold_uncertainty_score":0.9999632},"labels":[],"label_agreement":null},{"id":"W4416939994","doi":"10.1007/s12325-025-03440-z","title":"Efficacy of Lebrikizumab on Pruritus: A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Narrative review; Quality of life (healthcare); Atopic dermatitis; Disease; Clinical trial; Rheumatology; Alternative medicine; Clinical efficacy","score_opus":0.027435745872139178,"score_gpt":0.4247709164721386,"score_spread":0.39733517059999945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416939994","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003587328,0.9890597,0.0000020269165,0.00015534255,0.00020937067,0.001976379,0.000019328745,0.000027079042,0.008547187],"genre_scores_gemma":[0.000008967772,0.99781036,0.000064024265,0.0012015994,0.000042998607,0.0002936685,0.000091110844,0.000019265011,0.00046800773],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982555,0.00028123613,0.000757867,0.00035170626,0.00017128763,0.00018241318],"domain_scores_gemma":[0.99824613,0.00078047096,0.000361095,0.00051395973,0.000051120838,0.000047191763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001445035,0.00033085828,0.0026050606,0.00022043819,0.00002562472,0.0000021085878,0.00021285578,0.00017119061,0.00014141182],"category_scores_gemma":[0.00039783705,0.00022467377,0.0004945756,0.0005046233,0.00014338022,0.000062437284,0.000019708354,0.00035566583,0.000020473757],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001823363,0.0003568294,0.000012036352,0.088797346,0.00012720298,0.000058730762,0.000060337523,1.6715236e-7,1.2745236e-8,0.00017035165,0.00319403,0.9070406],"study_design_scores_gemma":[0.0008907376,0.00010638734,0.000011888833,0.26973972,0.00020170542,0.0000316165,0.000008195765,4.3497806e-8,0.0000017899853,0.00014023753,0.72875226,0.00011545481],"about_ca_topic_score_codex":7.235849e-7,"about_ca_topic_score_gemma":0.0000011758574,"teacher_disagreement_score":0.90692514,"about_ca_system_score_codex":0.000050446197,"about_ca_system_score_gemma":0.00042435352,"threshold_uncertainty_score":0.916193},"labels":[],"label_agreement":null},{"id":"W4416940022","doi":"10.1007/s12325-025-03424-z","title":"Clinical Characteristics and Patient Burden of Cluster Headache in Brazil: A Real-World Study","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Brock University","funders":"Eli Lilly Canada","keywords":"Cluster (spacecraft); Psychological intervention; Rheumatology; Cluster headache; Socioeconomic status; Disease; Burden of disease","score_opus":0.02685882319281423,"score_gpt":0.41750712691110603,"score_spread":0.3906483037182918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416940022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98569405,0.007695904,0.0000075858816,0.0013267341,0.00004906934,0.0006420654,0.0000027914487,0.000010049292,0.0045717782],"genre_scores_gemma":[0.97429055,0.02365894,0.00025071108,0.0009289297,0.00005181116,0.00003751656,0.0000023716375,0.0000073547885,0.0007717988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988536,0.000100153375,0.00058028236,0.00021442951,0.00011009441,0.00014141489],"domain_scores_gemma":[0.9993681,0.00027532797,0.000087787834,0.00019785517,0.000043781678,0.00002720299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003181902,0.00010912882,0.0005111591,0.00016916811,0.000019230163,0.0000032214546,0.000049940758,0.00003804871,0.000012697782],"category_scores_gemma":[0.00008912266,0.000083644365,0.000043561584,0.00027942564,0.00010086004,0.000053146938,0.00004639303,0.0001992337,6.029593e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079288415,0.0005734327,0.8879874,0.000053874803,0.000044951357,0.000012126799,0.004034278,0.0000016987327,0.00003095716,0.00011367917,0.00035302676,0.106001705],"study_design_scores_gemma":[0.0038940879,0.0011042594,0.94310814,0.00023930785,0.00001621769,7.3555105e-7,0.0023724264,0.000059317033,0.000034722252,0.00041745606,0.048675247,0.00007808297],"about_ca_topic_score_codex":0.00031256728,"about_ca_topic_score_gemma":0.0024104752,"teacher_disagreement_score":0.10592362,"about_ca_system_score_codex":0.000023981025,"about_ca_system_score_gemma":0.000039345035,"threshold_uncertainty_score":0.34109184},"labels":[],"label_agreement":null},{"id":"W4417148083","doi":"10.1007/s12325-025-03435-w","title":"Therapeutic and Preventive Role of Integrated Moderate-to-Vigorous Recreational Activity Programs in Type 2 Diabetes Care: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Physical Activity and Health","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Biotech (Canada)","funders":"","keywords":"Type 2 diabetes; Recreation; Rheumatology; Diabetes mellitus; MEDLINE; Physical activity","score_opus":0.04341038760262197,"score_gpt":0.3634356148806266,"score_spread":0.32002522727800464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417148083","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48490492,0.512406,0.00008303361,0.0005107948,0.0000068480717,0.0019468268,0.000011227651,0.000010559742,0.00011982577],"genre_scores_gemma":[0.9619853,0.036972605,0.00018330068,0.0004976684,0.0000020899454,0.00031194833,0.000011181903,0.00000500147,0.000030933865],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9990417,0.0002465166,0.00025511958,0.00022322699,0.00010891165,0.00012456298],"domain_scores_gemma":[0.9994202,0.00018633844,0.000100329824,0.00015723465,0.000098879726,0.000037021015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024814132,0.00012481384,0.0014887747,0.00014957259,0.000021426173,0.000007525982,0.000045642075,0.000037261354,0.000008846593],"category_scores_gemma":[0.000049622176,0.00008208991,0.000102631064,0.0010080457,0.000050782786,0.00014157064,0.000013709643,0.00012944179,4.8135405e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048856437,0.008798755,0.13572924,0.40358198,0.12705751,0.000009169278,0.012021398,0.0003833854,0.006877216,0.0062548807,0.000004873134,0.29439598],"study_design_scores_gemma":[0.012698304,0.013146074,0.16748597,0.06672544,0.5706002,0.0000091529355,0.00540132,0.011364167,0.031224322,0.11745634,0.0014375309,0.0024511523],"about_ca_topic_score_codex":0.00007152441,"about_ca_topic_score_gemma":0.00027167317,"teacher_disagreement_score":0.47708035,"about_ca_system_score_codex":0.00005452511,"about_ca_system_score_gemma":0.000065391534,"threshold_uncertainty_score":0.33475292},"labels":[],"label_agreement":null},{"id":"W7117101903","doi":"10.1007/s12325-025-03442-x","title":"Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Asthma; Post-hoc analysis; Rheumatology; Post hoc; MEDLINE","score_opus":0.08155075590346315,"score_gpt":0.5017766244504785,"score_spread":0.4202258685470154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117101903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92545,0.07231804,0.00018224407,0.00028668073,0.0000888108,0.00037818088,0.000003852396,0.00002995244,0.001262201],"genre_scores_gemma":[0.98180497,0.014501322,0.00200708,0.0013104947,0.00008401337,0.000024442892,0.00001190505,0.000017183778,0.00023860007],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99847806,0.00025197872,0.0005095763,0.00030054324,0.00028226146,0.00017757817],"domain_scores_gemma":[0.99891394,0.0002927279,0.00018670676,0.00033531786,0.00019687801,0.00007444573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005129808,0.0001607853,0.00046839452,0.00016740373,0.00004985254,0.0000060797324,0.000114947165,0.00008229417,0.000099365105],"category_scores_gemma":[0.000195368,0.00009699825,0.00012862973,0.00047067186,0.00019400993,0.00012264792,0.000017106779,0.00018143535,0.0000017199194],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065352907,0.00046680812,0.10578475,0.000050096725,0.0000814923,0.000046517802,0.000118015654,0.00022751851,0.020315412,0.00004003947,0.000024884333,0.86630917],"study_design_scores_gemma":[0.056196276,0.029103445,0.62074643,0.005043242,0.0001838738,0.000059287275,0.0044584973,0.0022511133,0.10041738,0.0020300683,0.17845654,0.0010538218],"about_ca_topic_score_codex":0.000014223949,"about_ca_topic_score_gemma":0.00001277846,"teacher_disagreement_score":0.86525536,"about_ca_system_score_codex":0.000027914522,"about_ca_system_score_gemma":0.00033123058,"threshold_uncertainty_score":0.3955474},"labels":[],"label_agreement":null},{"id":"W7117129385","doi":"10.1007/s12325-025-03444-9","title":"Correction to: Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 Studies","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Sinusitis and nasal conditions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation; Université de Montréal","funders":"","keywords":"Rheumatology; Peak flow meter; Breathing; Airway obstruction; Bronchial obstruction","score_opus":0.006677489225963944,"score_gpt":0.263541801161339,"score_spread":0.25686431193537507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117129385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99216133,0.0049436823,0.0000623233,0.0007035498,0.0010099233,0.00064481184,0.000015462487,0.000025311465,0.0004336112],"genre_scores_gemma":[0.9965782,0.00084658165,0.00017380506,0.0019986068,0.00009582443,0.00009638899,0.000026015394,0.000010982829,0.00017358182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911624,0.00012895517,0.00017972707,0.0002104751,0.0002300769,0.00013450245],"domain_scores_gemma":[0.998998,0.00057843945,0.000096766315,0.00015454929,0.00015292033,0.00001935929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019267906,0.00012747604,0.00022817183,0.000078303485,0.00015698194,0.000023183306,0.00005649002,0.0000456964,0.000007421347],"category_scores_gemma":[0.0001640684,0.000065506705,0.000021353297,0.00045672574,0.00011083279,0.00023360836,0.000016596778,0.0002454765,0.000001253906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029207042,0.00007779526,0.956754,0.0000056885187,0.00010705962,0.0000026447444,0.0018570983,0.00027511088,0.000019435825,0.000106243024,0.00064565276,0.03722856],"study_design_scores_gemma":[0.008725305,0.00041158745,0.98589796,0.00027760683,0.000030337023,0.0000019652018,0.0015490863,0.00007054961,0.00008075499,0.00036169103,0.0025012738,0.00009191273],"about_ca_topic_score_codex":0.00016681787,"about_ca_topic_score_gemma":0.0034871607,"teacher_disagreement_score":0.037136648,"about_ca_system_score_codex":0.0002457838,"about_ca_system_score_gemma":0.000055213946,"threshold_uncertainty_score":0.2671286},"labels":[],"label_agreement":null},{"id":"W7117517214","doi":"10.1007/s12325-025-03471-6","title":"The Balancing Act of Paid Work and Caregiving in Duchenne Muscular Dystrophy (DMD): Results from a Cross-sectional Survey","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Broadcom (Canada)","funders":"Sarepta Therapeutics; Parent Project Muscular Dystrophy","keywords":"Duchenne muscular dystrophy; Work (physics); Paid work; Muscular dystrophy; Rheumatology; Work hours; MEDLINE","score_opus":0.007792480871328333,"score_gpt":0.28594667277196484,"score_spread":0.2781541919006365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117517214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819307,0.017497009,0.00011287033,0.000035300254,0.00016421876,0.000091116875,0.000024137495,0.0000027641508,0.00014191247],"genre_scores_gemma":[0.99333066,0.006397304,0.00006425106,0.00006785542,0.000028420267,0.0000144007845,0.000066500885,0.000004961207,0.000025620635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991921,0.00014759284,0.00021193695,0.00026091296,0.000047156853,0.00014028809],"domain_scores_gemma":[0.99943966,0.0002347575,0.000067570814,0.00021106291,0.000034333647,0.000012595864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037019525,0.00008804891,0.000114389564,0.000028892768,0.000063136074,0.0000113633,0.00013225069,0.00008763803,0.0000017178755],"category_scores_gemma":[0.00022040686,0.00006842516,0.000033546534,0.00014191058,0.00015272401,0.000007932581,0.000040791183,0.000092408336,1.2038637e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020762766,0.000031740474,0.95489025,0.0000051213797,0.000027817652,5.9932853e-7,0.00006585418,0.0010503256,0.031812537,0.000055966404,0.0000089519735,0.009974582],"study_design_scores_gemma":[0.0013468999,0.000063985135,0.98923266,0.000017427632,6.156902e-7,1.10873096e-7,0.000038088227,0.000013671731,0.005047565,0.0010937491,0.0030758497,0.00006938697],"about_ca_topic_score_codex":0.00025450776,"about_ca_topic_score_gemma":0.001247878,"teacher_disagreement_score":0.034342423,"about_ca_system_score_codex":0.000008689712,"about_ca_system_score_gemma":0.000033922795,"threshold_uncertainty_score":0.2790297},"labels":[],"label_agreement":null}]}